
<html lang="en"     class="pb-page"  data-request-id="69a02d66-8fc9-49ce-b950-42c47791ed67"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2017.60.issue-12;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.7b00468;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFRα) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs)" /></meta><meta name="dc.Creator" content="Yanli  Lu" /></meta><meta name="dc.Creator" content="Fei  Mao" /></meta><meta name="dc.Creator" content="Xiaokang  Li" /></meta><meta name="dc.Creator" content="Xinyu  Zheng" /></meta><meta name="dc.Creator" content="Manjiong  Wang" /></meta><meta name="dc.Creator" content="Qing  Xu" /></meta><meta name="dc.Creator" content="Jin  Zhu" /></meta><meta name="dc.Creator" content="Jian  Li" /></meta><meta name="dc.Description" content="Stem cell factor receptor (c-KIT) and platelet derived growth factor receptor alpha (PDGFRα) kinases play an important role in gastrointestinal stromal tumors (GISTs). Here, we have discovered an c..." /></meta><meta name="Description" content="Stem cell factor receptor (c-KIT) and platelet derived growth factor receptor alpha (PDGFRα) kinases play an important role in gastrointestinal stromal tumors (GISTs). Here, we have discovered an c..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 7, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00468" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00468" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00468" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00468" /></link>
        
    
    

<title>Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFRα) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00468" /></meta><meta property="og:title" content="Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFRα) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0018.jpeg" /></meta><meta property="og:description" content="Stem cell factor receptor (c-KIT) and platelet derived growth factor receptor alpha (PDGFRα) kinases play an important role in gastrointestinal stromal tumors (GISTs). Here, we have discovered an c-KIT/PDGFRα dual inhibitor, compound 31, with single-digit nanomolar potency against c-KIT and PDGFRα. Compared to Imatinib (1), 31 showed better antiproliferative efficacy against various TEL-c-KIT/PDGFRα-BaF3 isogenic cells, including three 1-resistant BaF3 cell lines, as well as against GIST-T1 and GIST-882 cell lines. Furthermore, compound 31 showed a good KinomeScan selectivity (468 kinases) (S score (1) = 0.01 at 1 μM concentration), good metabolic stability in liver microsomes, and no hERG inhibitory activity. It was worth noting that 31 inhibited GIST-T1 tumor growth (TGI = 81.5%) and even the BaF3-TEL-cKIT-T670I tumor progression (TGI = 41.9%, 1-resistant GISTs) at a dosage of 100 mg/kg/day without exhibiting apparent toxicity." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00468"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00468">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00468&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00468&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00468&amp;href=/doi/10.1021/acs.jmedchem.7b00468" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 5099-5119</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00437" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00475" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFRα) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs)</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yanli++Lu">Yanli Lu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fei++Mao">Fei Mao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaokang++Li">Xiaokang Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xinyu++Zheng">Xinyu Zheng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Manjiong++Wang">Manjiong Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qing++Xu">Qing Xu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jin++Zhu">Jin Zhu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jian++Li">Jian Li</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-7521-8798" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China</span></div><div class="corresp-info"><strong>*</strong>Phone: 86-21-64252584. Fax: 86-21-64252584. E-mail: <a href="/cdn-cgi/l/email-protection#1f75767e7173765f7a7c6a6c6b317a7b6a317c71"><span class="__cf_email__" data-cfemail="91fbf8f0fffdf8d1f4f2e4e2e5bff4f5e4bff2ff">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00468&amp;href=/doi/10.1021%2Facs.jmedchem.7b00468" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 5099–5119</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 25, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>27 March 2017</li><li><span class="item_label"><b>Published</b> online</span>7 June 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 June 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00468" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00468</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5099%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYanli%2BLu%252C%2BFei%2BMao%252C%2BXiaokang%2BLi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D12%26contentID%3Dacs.jmedchem.7b00468%26title%3DDiscovery%2Bof%2BPotent%252C%2BSelective%2BStem%2BCell%2BFactor%2BReceptor%252FPlatelet%2BDerived%2BGrowth%2BFactor%2BReceptor%2BAlpha%2B%2528c-KIT%252FPDGFR%25CE%25B1%2529%2BDual%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BImatinib-Resistant%2BGastrointestinal%2BStromal%2BTumors%2B%2528GISTs%2529%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5119%26publicationDate%3DJune%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00468"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2331</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">6</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00468" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFRα) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yanli&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Fei&quot;,&quot;last_name&quot;:&quot;Mao&quot;},{&quot;first_name&quot;:&quot;Xiaokang&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Xinyu&quot;,&quot;last_name&quot;:&quot;Zheng&quot;},{&quot;first_name&quot;:&quot;Manjiong&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Qing&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Jin&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Jian&quot;,&quot;last_name&quot;:&quot;Li&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;5099-5119&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00468&quot;},&quot;abstract&quot;:&quot;Stem cell factor receptor (c-KIT) and platelet derived growth factor receptor alpha (PDGFRα) kinases play an important role in gastrointestinal stromal tumors (GISTs). Here, we have discovered an c-KIT/PDGFRα dual inhibitor, compound 31, with single-digit nanomolar potency against c-KIT and PDGFRα. Compared to Imatinib (1), 31 showed better antiproliferative efficacy against various TEL-c-KIT/PDGFRα-BaF3 isogenic cells, including three 1-resistant BaF3 cell lines, as well as against GIST-T1 and GIST-882 cell lines. Furthermore, compound 31 showed a good KinomeScan selectivity (468 kinases) (S score (1) = 0.01 at 1 μM concentration), good metabolic stability in liver microsomes, and no hERG inhibitory activity. It was worth noting that 31 inhibited GIST-T1 tumor growth (TGI = 81.5%) and even the BaF3-TEL-cKIT-T670I tumor progression (TGI = 41.9%, 1-resistant GISTs) at a dosage of 100 mg/kg/day without exhibiting apparent toxicity.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00468&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00468" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00468&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00468" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00468&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00468" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00468&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00468&amp;href=/doi/10.1021/acs.jmedchem.7b00468" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00468" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00468" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (8 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00468%26sid%3Dliteratum%253Aachs%26pmid%3D28541695%26genre%3Darticle%26aulast%3DLu%26date%3D2017%26atitle%3DDiscovery%2Bof%2BPotent%252C%2BSelective%2BStem%2BCell%2BFactor%2BReceptor%252FPlatelet%2BDerived%2BGrowth%2BFactor%2BReceptor%2BAlpha%2B%2528c-KIT%252FPDGFR%25CE%25B1%2529%2BDual%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BImatinib-Resistant%2BGastrointestinal%2BStromal%2BTumors%2B%2528GISTs%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D12%26spage%3D5099%26epage%3D5119%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/jmcmar.2017.60.issue-12/20170622/jmcmar.2017.60.issue-12.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00468&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Stem cell factor receptor (c-KIT) and platelet derived growth factor receptor alpha (PDGFRα) kinases play an important role in gastrointestinal stromal tumors (GISTs). Here, we have discovered an c-KIT/PDGFRα dual inhibitor, compound <b>31</b>, with single-digit nanomolar potency against c-KIT and PDGFRα. Compared to Imatinib (<b>1</b>), <b>31</b> showed better antiproliferative efficacy against various TEL-c-KIT/PDGFRα-BaF3 isogenic cells, including three <b>1</b>-resistant BaF3 cell lines, as well as against GIST-T1 and GIST-882 cell lines. Furthermore, compound <b>31</b> showed a good KinomeScan selectivity (468 kinases) (<i>S</i> score (1) = 0.01 at 1 μM concentration), good metabolic stability in liver microsomes, and no hERG inhibitory activity. It was worth noting that <b>31</b> inhibited GIST-T1 tumor growth (TGI = 81.5%) and even the BaF3-TEL-cKIT-T670I tumor progression (TGI = 41.9%, <b>1</b>-resistant GISTs) at a dosage of 100 mg/kg/day without exhibiting apparent toxicity.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74760" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74760" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms originating from the intestitial cells of Cajal, the pacemaker cells of the gut and pervading the entire area of the gastrointestinal tract.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Epidemiological data shows that the annual incidence of GISTs is about 1–2/100000, and approximately 30% of GISTs are malignant.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The treatment of GISTs faces great challenges due to its complex etiology. Prior to 2010,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> surgical resection appeared to be the only available treatment for GISTs, resulting in five-year survival rates of 48–54% for resectable cases,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> while the median survival period was only 19 months, and just 5–10% of irresectable or metastasized GISTs patients have a five-year survival rate.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> In addition, over one-third of patients will suffer tumor metastases after macroscopically complete surgery.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Unfortunately, GISTs respond poorly to conventional cytotoxic chemotherapy, and radiation therapy has not been shown to be effective.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div class="NLM_p">The year 1998 witnessed a critical breakthrough for GISTs, which began with the discovery of the proto-oncogene stem cell factor receptor (c-KIT). Approximately 90% of GISTs are positive for c-KIT expression,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> which has facilitated the diagnosis of GISTs. About 80%–85% of GISTs arise from gain-of-function mutations in c-KIT or the platelet derived growth factor receptor-α (PDGFRα) gene,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> both of which encode type III receptor tyrosine kinases (RTK). The common sites of mutations are usually located in c-KIT exon 11 (∼70%), c-KIT exon 9 (∼10%), or PDGFRα exons 12 or 18 (∼10%),<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> which cause sustained activation of the tyrosine kinase resulting in uncontrolled cellular proliferation and resistance to apoptosis.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Because of the critical role of c-KIT and PDGFRα kinases in cellular transformation and differentiation to the tumorigenesis of GISTs, c-KIT and PDGFRα kinases have been extensively evaluated as important drug discovery targets for anti-GIST therapy.</div><div class="NLM_p">Currently, there are three nonselective c-KIT/PDGFRα kinase inhibitors approved for clinical use (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). Imatinib (<b>1</b>),<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> a small molecule tyrosine kinase inhibitor (TKI) with activity against ABL/c-KIT/PDGFR kinases, was the first TKI approved by the U.S. Food and Drug Administration (FDA) as frontline therapy for metastatic or unresectable GISTs. Compound <b>1</b> binds competitively to the adenosine triphosphate (ATP) binding site of the target kinases, preventing substrate phosphorylation and signaling, thereby inhibiting tumor proliferation.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> However, approximately 14% patients are initially insensitive to <b>1,</b><a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and one-half of the responding patients can acquire secondary c-KIT mutations within 2 year of <b>1</b> treatment, which contains a T670I substitution within the ATP binding pocket.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The T670 residue is situated at the gatekeeper position of c-KIT kinase and provides one of the key hydrogen bonds for the binding to <b>1</b>.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> This mutation prevents the full access of <b>1</b> to the ATP binding pocket due to steric hindrance in the drug binding site.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> In addition, experimental evidence showed that c-KIT/T670I mutant will contribute to an early, more aggressive metastasis and shorter progression-free survival.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Additionally, nearly 5%–7% of patients with GISTs who have PDGFRα mutations are generally <b>1</b>-resistant.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Sunitinib (<b>2</b>),<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> a VEGFR/PDGFR/c-KIT/FLT3 TKI, is approved as second-line therapy for patients with advanced GISTs who are <b>1</b> resistant or intolerant. Regorafenib (<b>3</b>),<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> a VEGFR/PDGFR/FGFR/c-KIT/RET/Raf-1 TKI, is a third-line therapy for GISTs that progressed on <b>1</b> and <b>2</b>. Moreover, a number of multitarget inhibitors (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) are undergoing clinical investigation such as nilotinib (<b>4</b>),<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> masitinib (<b>5</b>),<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and dovitinib (<b>6</b>).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0001.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of representative nonselective c-KIT/PDGFRα kinase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00468&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although the above agents for the treatment of GISTs have achieved some success stories, the clinical resistance still demand close attention for the heterogeneity of patterns of mutations in the c-KIT and PDGFRα proteins. In addition, nonselective profiles targeting c-KIT and PDGFRα frequently induced different and more side effects. The patients occurring serious adverse events (grade 3 or 4) with <b>1</b> treatment were 21.1% and suffering mild or moderate edema, and fatigue was frequently seen with <b>1</b> treatment, while 61% patients suffered the drug-related adverse events of grade 3 or higher with <b>3</b> treatment.<a onclick="showRef(event, 'ref12 ref21 ref25'); return false;" href="javascript:void(0);" class="ref ref12 ref21 ref25">(12, 21, 25)</a> Hypertension, diarrhea, palmar plantar erythrodysesthesia, and fatigue were commonly observed in therapy with <b>2</b> or <b>3</b>.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Moreover, skin discoloration (up to 30%, yellow color) and hair discoloration were more representative with <b>2</b> treatment,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> while weight loss, hypophosphatemia, and hyperlipasemia were more often observed with <b>3</b> treatment.</div><div class="NLM_p last">In this text, we planned to design and synthesize a series of novel, potent, and selective dual-target c-KIT/PDGFRα inhibitors, with powerful efficacy against c-KIT/PDGFRα kinase and mutants, and anticipated finding a good lead compound for the treatment of GISTs, especially <b>1</b>-resistant GISTs.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Design of c-KIT/PDGFRα Dual Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21186" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21186" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Linifanib (<b>7</b>) (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>),<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> a 3-aminoindazole-based orally active drug containing an <i>N</i>,<i>N</i>′-diaryl urea moiety (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>), is a novel available multitarget inhibitor of the vascular endothelial growth factor receptor (VEGFR) and PDGFR family members with minimal activity against unrelated RTKs. Inhibitor <b>7</b> has demonstrated potent antitumor efficacy in a broad range of clinical trials.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> At the beginning of our efforts to discover new antitumor chemotypes targeting VEGFR2 and PDGFRα, <b>7</b> was selected as a hit compound (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>; PDGFRα, IC<sub>50</sub> = 15 nM; VEGFR2, IC<sub>50</sub> = 250 nM). With the aid of a well-documented structure–activity relationship (SAR) as well as the synthetic accessibility of <b>7</b>, we modified three regions (R<sup>1</sup>–R<sup>3</sup>, <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>) of this molecule to obtain new SAR information and improve TKI activity.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic illustration of the discovery of selective potent dual c-KIT/PDGFRα inhibitor <b>31</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00468&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structures and Kinase Inhibitory Activities of Compounds <b>7</b>–<b>17</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0011.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0012.gif" alt="" id="fx2" /></img><div></div></div><div class="NLM_p last">To obtain novel analogues and clarify the SARs under the premise of minimizing the structural changes, we designed and synthesized compounds <b>8</b>–<b>15</b> (R<sup>1</sup>, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) to determine if the 3-aminoindazole moiety is necessary for VEGFR2 and PDGFRα inhibitory activities, compounds <b>16</b>,<b>17</b> (R<sup>3</sup>, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) to demonstrate the significance of the oxygen atom in the urea group as a key linker, and compounds <b>18</b>–<b>22</b> (R<sup>1</sup>, <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>) to examine the influence of different substituents on the 3-position of pyrazolo[3,4-<i>b</i>]pyridine scaffold. Furthermore, compounds <b>23</b>–<b>65</b> (R<sup>2</sup>, <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>) were prepared to determine if the type of <i>N</i>-substitutions would affect c-KIT/PDGFRα inhibitory activities.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56288" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56288" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, ethyl trifluoroacetate was selected as the starting material and was reacted with acetonitrile by like-nucleophilic substitution to produce 4,4,4-trifluoro-3-oxobutanenitrile (<b>66</b>), which was not further purified because of its difficult detection by TLC and low boiling point. Then, <b>66</b> was cyclized in the presence of hydrazine hydrate to yield the intermediate <b>67a</b>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0007.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Intermediate <b>67a</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00468&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaH, THF, reflux, 15 h; (b) N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O, CH<sub>3</sub>HSO<sub>3</sub>, 80 °C, overnight.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> depicts the synthetic route for the preparation of target compounds <b>8</b>–<b>17</b> and <b>20</b>–<b>27</b>. Intermediate <b>68a</b>,<b>b</b> was synthesized by coupling <b>67a</b> and <b>67b</b> (commercially available) with 4-nitro benzaldehyde and 2,2-dimethyl-1,3-dioxane-4,6-dione through an effective one-container three-component approach. The reduction of <b>68b</b> by catalytic hydrogenation of Pd/C yielded the key intermediate <b>69</b>, followed by treatment with two substituted phenyl isocyanates to produce target compounds <b>8</b>,<b>9</b>. <b>68a</b>,<b>b</b> was treated with 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) and <i>N</i>,<i>O</i>-bis(trimethylsilyl) trifluoroacetamide (BSTFA) to provide aromatic intermediates <b>70a</b>,<b>b</b> via oxidative dehydrogenation. The nitro group of <b>70b</b> was reduced using SnCl<sub>2</sub> to form another key intermediate <b>71</b>, followed by treatment with isocyanates to produce target compounds <b>10</b>,<b>11</b>. The chlorination of <b>70a</b>,<b>b</b> with phenylphosphonic dichloride (BPOD) gave intermediates <b>72a</b>,<b>b</b>, and a reductive elimination reaction with zinc and hydrazine hydrate then produced the last key intermediates <b>73a</b>,<b>b</b>, followed by coupling with various commercially available substituted isocyanates and isothiocyanates to achieve target compounds <b>12</b>–<b>17</b> and <b>20</b>–<b>27</b>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0008.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>8</b>–<b>17</b> and <b>20</b>–<b>27<sup>a</sup></b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00468&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) for <b>68a</b>, EtOH, reflux, 4 h; (b) for <b>68b</b>, DMF, reflux, 4 h; (c) Pd/C, H<sub>2</sub>, MeOH, rt, 5 h; (d) R<sup>2</sup>NCO or R<sup>2</sup>NSO, Et<sub>3</sub>N, DMSO, rt, overnight; (e) for <b>70a</b>, DDQ, BSTFA, chlorobenzene, reflux, overnight; (f) for <b>70b</b>, DDQ, BSTFA, 1,4-dioxane, reflux, overnight; (g) SnCl<sub>2</sub>, EtOH, reflux, overnight; (h) BPOD, 110 °C, overnight; (i) N<sub>2</sub>, Zn, N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O, THF, reflux, 5 h.</p></p></figure><div class="NLM_p">The synthetic route for the preparation of target compounds <b>18</b>,<b>19</b> and <b>41</b>–<b>65</b> is shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Boc protection of <b>73b</b> gave trisubstitued intermediate <b>74</b>, followed by bromination to provide <b>75</b>, which was hydrolyzed to produce <b>76</b>. The nucleophilic addition of substituted isocyanates with <b>76</b> generated target compounds <b>18</b>,<b>19</b>. Different isocyanates were in situ synthesized using <i>N</i>,<i>N</i>′-carbonyl diimidazole (CDI) from various commercially available aliphatic amines, aryl amines, and aralkyl amines. Nucleophilic addition of these isocyanates with <b>73b</b> gave target compounds <b>41</b>–<b>65</b>.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0009.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>18</b>,<b>19</b> and <b>41</b>–<b>65</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00468&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (Boc)<sub>2</sub>O, DMPA, THF, rt, 1 h; (b) N<sub>2</sub>, NBS, BPO, CCl<sub>4</sub>, reflux, 20 h; (c) H<sub>2</sub>O, 1,4-dioxane, reflux, overnight; (d) R<sup>2</sup>NCO, Et<sub>3</sub>N, DMSO, rt, overnight; (e) R<sup>2</sup>NH<sub>2</sub>, CDI, Et<sub>3</sub>N, DMSO, rt, overnight.</p></p></figure><div class="NLM_p">Intermediates <b>77a</b>–<b>m</b> were reduced by the catalytic hydrogenation of Pd/C to provide the corresponding amines <b>78a</b>–<b>m</b>, respectively, then reacted with phenyl chloroformate and <b>73b</b> to generate target compounds <b>28</b>–<b>40</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). The details of the synthetic procedures and structural characterizations of target compounds <b>8</b>–<b>65</b> are described in the <a class="ref internalNav" href="#sec6" aria-label="Experimental Section">Experimental Section</a>. The purities of all targeted compounds were determined by HPLC (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00468/suppl_file/jm7b00468_si_001.pdf" class="ext-link">Table S1</a>, Supporting Information). The details of the synthetic procedures and structural characterizations of intermediates <b>66</b>–<b>78</b> are shown in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b00468/suppl_file/jm7b00468_si_001.pdf" class="ext-link">Supporting Information</a>.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0010.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>28</b>–<b>40</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00468&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Pd/C, H<sub>2</sub>, MeOH, rt, overnight; (b) (1) pyridine, DMF, phenyl chloroformate, rt, 3 h, (2) 1,4-dioxane, reflux, overnight.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08245" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08245" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Kinase Enzymatic Assay</h3><div class="NLM_p">On the basis of our initial investigations of <b>7</b>, the novel designed analogues were first optimized according to the potencies (IC<sub>50</sub>) against PDGFRα, VEGFR2, and fibroblast growth factor receptor 1 (FGFR1). From <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, we could see that compounds <b>8</b>–<b>15</b> caused a distinct loss of activity against VEGFR2 (IC<sub>50</sub> > 1000 nM) compared to <b>7</b> (IC<sub>50</sub> = 250 nM) and weak inhibitory activity against FGFR1 (IC<sub>50</sub> > 1000 nM), similar to <b>7</b> (IC<sub>50</sub> = 5479 nM). This finding indicated that the potencies against VEGFR2 and FGFR1 may not tolerate the change of the core scaffold. Furthermore, in the studied set of three new core scaffolds (R<sup>1</sup>), the potency (especially PDGFRα) was increased in the order 3-methyl-pyrazolo[3,4-<i>b</i>]pyridine (<b>12</b>,<b>13</b>) > 3-methyl-6-hydroxy- pyrazolo[3,4-<i>b</i>]pyridine (<b>10</b>,<b>11</b>) > 3-methyl-6-hydroxy-4,5-dihydro-pyrazolo[3,4-<i>b</i>] pyridine (<b>8</b>,<b>9</b>). A small set of analogues with various <i>N</i>-aryl substituents (<b>12</b>–<b>15</b>, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, R<sup>2</sup>) showed that R<sup>2</sup> substituent enabled good variability for potent PDGFRα inhibitory activity. With the novel good core scaffold retained, we turned our attention to the “urea linker” (R<sup>3</sup>) and prepared thiourea compounds (<b>16</b>,<b>17</b>). Unfortunately, these two compounds both obviously lost activity against all three kinases (IC<sub>50</sub> > 1000 nM). Considering the multitargeted profiles of <b>7</b>, we decided to select compound <b>13</b>, the most potent PDGFRα inhibitor among compounds <b>8</b>–<b>17</b>, as the lead compound (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>) to preliminarily explore its spectrum of activity against other RTKs (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Surprisingly, compound <b>13</b> showed very potent inhibitory activity against c-KIT at the single-digit nanomolar concentration (IC<sub>50</sub> = 2.1 nM). It is interesting that compound <b>13</b> seemed to be a selective c-KIT/PDGFRα dual inhibitor. On the basis of this result, the subsequent work was aimed to developing a dual-targeted compound against c-KIT and PDGFRα, and VEGFR2 was used as a typical kinase to monitor the selective profile.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Kinase Spectrum of <b>13</b> against RTK</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" colspan="8" align="center" char=".">IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">PDGFRα</th><th class="colsep0 rowsep0" align="center" char=".">VEGFR2</th><th class="colsep0 rowsep0" align="center" char=".">FGFR1</th><th class="colsep0 rowsep0" align="center" char=".">c-KIT</th><th class="colsep0 rowsep0" align="center" char=".">PDGFRβ</th><th class="colsep0 rowsep0" align="center" char=".">FLT3</th><th class="colsep0 rowsep0" align="center" char=".">VEGFR1</th><th class="colsep0 rowsep0" align="center" char=".">VEGFR3</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="char" char=".">40</td><td class="colsep0 rowsep0" align="char" char=".">1225</td><td class="colsep0 rowsep0" align="char" char=".">>50000</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">197</td><td class="colsep0 rowsep0" align="char" char=".">1880</td><td class="colsep0 rowsep0" align="char" char=".">3493</td><td class="colsep0 rowsep0" align="char" char=".">376</td></tr></tbody></table></div></div><div class="NLM_p">To examine the influence of different substituents on the 3-position of pyrazolo[3,4-<i>b</i>]pyridine scoffold, we replaced the 3-methyl substituent with hydroxymethyl (<b>18</b>,<b>19</b>) and trifluoromethyl (<b>20</b>,<b>21</b>). The results in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a> showed that replacement of the 3-methyl group with a hydroxymethyl group (<b>18</b> vs <b>13</b>) maintained fairly potent c-KIT inhibition (IC<sub>50</sub> = 2.4 vs 2.1 nM) but led to a 2-fold loss of PDGFRα activity (IC<sub>50</sub> = 87 vs 40 nM). Changing the 3-methyl group to the trifluoromethyl group (<b>20</b> vs <b>13</b>) could not be tolerated, leading to a complete loss of all kinase activities (IC<sub>50</sub> > 50,000 nM). Therefore, the 3-methyl-pyrazolo[3,4-<i>b</i>] pyridine moiety represented seemingly the best pharmacophore for inhibiting both c-KIT and PDGFRα.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Structures and Kinase Inhibitory Activities of Compounds <b>18</b>–<b>22</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0013.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0014.gif" alt="" id="fx4" /></img><div></div></div><div class="NLM_p">Considering the 3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine scaffold and urea linker as a promising novel template for a dual-targeted c-KIT/PDGFRα inhibitor, we next focused SAR exploration on substituent (R<sup>2</sup>, <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>) at the terminal nitrogen of urea. Shifting the methyl group from 3-position (<b>13</b>) to 2-position (<b>23</b>) or 4-position (<b>24</b>) both led to significant loss of activity against c-KIT/PDGFRα (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Among various 3-substituents (<b>13</b>–<b>15</b> and <b>25</b>–<b>28</b>), 3-methyl group was the best one for c-KIT/PDGFRα inhibition. Surprisingly, a <i>N</i>-methyl piperazinyl group at 3-position (<b>28</b>) only moderately decreased the c-KIT/PDGFRα inhibitory activities compared to <b>13</b> (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Inspired by this result, a combination of 3-methyl and <i>N</i>-methyl piperazinyl or morpholinyl group on the terminal phenyl obtained compounds <b>29</b>–<b>31</b>, of which <b>31</b> displayed more potent inhibitory activities than lead compound <b>13</b> against c-KIT/PDGFRα kinases (IC<sub>50</sub> = 2.4 and 7.2 nM, respectively) and also retained the selectivity over VEGFR2. However, when we changed the combined type or position of methyl, <i>N</i>-methyl piperazinyl, or morpholinyl group on the terminal phenyl (<b>32</b>–<b>35</b>), it caused a significant loss of activities against all three kinases. Furthermore, introducing diethylamino group (<b>36</b>,<b>37</b>) or dimethylamino group (<b>38</b>,<b>39</b>) on the terminal phenyl started to gain back the c-KIT/PDGFRα activities but inferior to <b>31</b>. Replacement of 3-dimethylamino group with 3-dimethylaminomethyl group (<b>40</b>) also led to complete loss of activities to all three kinases.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Structures and Kinase Inhibitory Activities of Compounds <b>23</b>–<b>65</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0015.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0016.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0017.gif" alt="" id="GRAPHIC-d46e1299-autogenerated" /></img><div></div></div><div class="NLM_p">To explore more effective compounds, further screening of R<sup>2</sup> group (<b>41</b>–<b>65</b>) was implemented (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). For the linear alkyl groups (<b>41</b>–<b>45</b>), the c-KIT/PDGFRα inhibitory activity was substantially improved with an increasing length of alkyl groups. Changing linear alkyl (<b>43</b>) into branched alkyl (<b>46</b>,<b>47</b>) or cycloalky (<b>48</b>–<b>51</b>) groups could not enhance the c-KIT/PDGFRα inhibitory activity compared to <b>13</b>. For the aralkyl groups (<b>52</b>–<b>59</b>), the heteroarylmethyl groups (<b>52</b>–<b>54</b>) were favorable for c-KIT/PDGFRα inhibition compared to the phenylmethyl group (<b>55</b>) but inferior to <b>13</b>. With the different length set of phenylalkyl groups (<b>55</b>–<b>59</b>), the potency against c-KIT/PDGFRα was increased in the order phenylpropyl (<b>57</b>) > phenylethyl (<b>56</b>) > 2,3-dihydro-indene (<b>59</b>) > phenylbutyl (<b>58</b>). Although the c-KIT inhibitory activity of <b>57</b> was slightly better than that of <b>13</b> and <b>31</b>, the PDGFRα inhibitory activity of <b>57</b> was weaker than that of <b>31</b> (IC<sub>50</sub> = 24 nM vs 7.2 nM). Additionally, replacement of the aryl group (R<sup>2</sup>) with heteroaryl groups (<b>60</b>–<b>62</b>) all led to a reduction of kinase potency greater than 6-fold, but introduction of large fused aryl groups (<b>63</b>–<b>65</b>) seemingly was beneficial, leading to a visible increase of c-KIT/PDGFRα inhibition compared to <b>13</b> but still not improving PDGFRα inhibition at the single-digit nanomolar concentration.</div><div class="NLM_p last">Collectively, the structural optimization and SAR studies led to the discovery of a number of novel compounds, such as <b>31</b>, <b>45</b>, <b>57</b>, and <b>63</b> that exhibited a higher dual-target potency against c-KIT (IC<sub>50</sub> < 3 nM) and PDGFRα (IC<sub>50</sub> < 30 nM) as well as maintained the appropriate selective window against VEGFR2 (IC<sub>50</sub> > 1800 nM). Especially, <b>31</b> had the most surprising single-digit nanomolar potency against PDGFRα, similar to the launched compound <b>1</b> (IC<sub>50</sub>= 7.2 vs 4.6 nM, <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>), and had powerful c-KIT activity (IC<sub>50</sub> = 2.4 nM), providing a 17-fold improvement compared to <b>1</b> (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Cellular Property and Biochemical Evaluation</h3><div class="NLM_p">In light of the previous research of kinase inhibitory activities, compound <b>31</b> was the best c-KIT/PDGFRα dual inhibitor. To further evaluate whether <b>31</b> was the optimal compound, we selected 11 compounds to examine the inhibitory activities against cellular c-KIT and PDGFRα, including four BaF3 cells,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> whose viability were KIT-dependent or PDGFRα-dependent. As shown in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>, the 3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine scaffold was favorable for the antiproliferation against c-KIT/PDGFRα cell lines. Moreover, the inhibitory activities of cellular level were consistent with the kinase inhibitory activities in vitro. Excitingly, compound <b>31</b> showed the best antiproliferation activities against the four BaF3 cell lines, which was superior to the hit compound <b>7</b>, with a 5-fold increase of Tel-c-KIT-BaF3 inhibitory potency (GI<sub>50</sub> = 0.0181 vs 0.0887 μM, <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Therefore, <b>31</b> was chosen for further in-depth studies of antitumor potencies.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Antiproliferative Effect of 11 Compounds against Four TEL-c-KIT/PDGFRα-BaF3 Isogenic Cells</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">kinases in vitro: IC<sub>50</sub> (nM)</th><th class="rowsep1 colsep0" colspan="4" align="center">BaF3 isogenic cells: GI<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">c-KIT</th><th class="colsep0 rowsep0" align="center">PDGFRα</th><th class="colsep0 rowsep0" align="center">c-KIT</th><th class="colsep0 rowsep0" align="center">c-KIT/T670I</th><th class="colsep0 rowsep0" align="center">PDGFRα</th><th class="colsep0 rowsep0" align="center">PDGFRα/T674I</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="center">35</td><td class="colsep0 rowsep0" align="center">15</td><td class="colsep0 rowsep0" align="center">0.0887</td><td class="colsep0 rowsep0" align="center">0.0371</td><td class="colsep0 rowsep0" align="center">0.0104</td><td class="colsep0 rowsep0" align="center">0.1041</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="center">>50000</td><td class="colsep0 rowsep0" align="center">>50000</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">4.254</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="center">367</td><td class="colsep0 rowsep0" align="center">1179</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">0.2045</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="center">2.1</td><td class="colsep0 rowsep0" align="center">40</td><td class="colsep0 rowsep0" align="center">0.2480</td><td class="colsep0 rowsep0" align="center">0.3176</td><td class="colsep0 rowsep0" align="center">0.0104</td><td class="colsep0 rowsep0" align="center">1.171</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="center">2.4</td><td class="colsep0 rowsep0" align="center">87</td><td class="colsep0 rowsep0" align="center">1.068</td><td class="colsep0 rowsep0" align="center">1.841</td><td class="colsep0 rowsep0" align="center">0.0104</td><td class="colsep0 rowsep0" align="center">4.996</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="center">>50000</td><td class="colsep0 rowsep0" align="center">>50000</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">0.4652</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="center">2.4</td><td class="colsep0 rowsep0" align="center">7.2</td><td class="colsep0 rowsep0" align="center">0.0181</td><td class="colsep0 rowsep0" align="center">0.0392</td><td class="colsep0 rowsep0" align="center">0.0104</td><td class="colsep0 rowsep0" align="center">0.1348</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="center">1.4</td><td class="colsep0 rowsep0" align="center">27</td><td class="colsep0 rowsep0" align="center">3.028</td><td class="colsep0 rowsep0" align="center">1.779</td><td class="colsep0 rowsep0" align="center">0.0104</td><td class="colsep0 rowsep0" align="center">3.178</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50</b></td><td class="colsep0 rowsep0" align="center">144</td><td class="colsep0 rowsep0" align="center">576</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">0.0133</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>57</b></td><td class="colsep0 rowsep0" align="center">1.7</td><td class="colsep0 rowsep0" align="center">24</td><td class="colsep0 rowsep0" align="center">3.025</td><td class="colsep0 rowsep0" align="center">1.669</td><td class="colsep0 rowsep0" align="center">0.0104</td><td class="colsep0 rowsep0" align="center">2.054</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>63</b></td><td class="colsep0 rowsep0" align="center">1.9</td><td class="colsep0 rowsep0" align="center">22</td><td class="colsep0 rowsep0" align="center">0.0833</td><td class="colsep0 rowsep0" align="center">0.2173</td><td class="colsep0 rowsep0" align="center">0.0104</td><td class="colsep0 rowsep0" align="center">1.513</td></tr></tbody></table></div></div><div class="NLM_p">First, the inhibitory activities of optimal compound <b>31</b> against c-KIT/PDGFRα-BaF3 cell lines were comprehensively evaluated. The results are exhibited in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a> and <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>, including the four cell lines examined above. According to the data, <b>31</b> was more potent against all of the mutations except Tel-c-KIT/V559D-BaF3 (GI<sub>50</sub> = 0.0965 vs 0.0310 μM) mutation compared to <b>1</b>. On the basis of exhibiting a similar trend to <b>1</b> in the parental BaF3, <b>31</b> improved the antiproliferative activity more than 21-fold toward the native c-KIT (GI<sub>50</sub> = 0.0181 vs 0.3819 μM). The inhibitory activity of Tel-c-KIT/C674S-BaF3 mutation (GI<sub>50</sub> = 0.0105 μM) was consistent with a point mutation<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Tel-c-KIT/L576P-BaF3 (GI<sub>50</sub> = 0.0106 μM) in exon 11, which showed poor sensitivity for <b>1</b> (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). In addition, <b>31</b> was an effective inhibitor of all four ATP pocket mutations (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>)<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> and brought approximately more than 250-fold activity improvement in the <b>1</b>-resistance mutations of Tel-c-KIT/T670I-BaF3 (GI<sub>50</sub> = 0.0392 vs >10 μM) and Tel-c-KIT/V559D/T670I-BaF3 (GI<sub>50</sub> = 0.0364 vs >10 μM) compared to <b>1</b>. With four A-loop mutations (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>), <b>31</b> exhibited a highly inhibitory activity of Tel-c-KIT/N822 K-BaF3 mutation (GI<sub>50</sub> = 0.0111 μM) and Tel-c-KIT/N829 K-BaF3 mutation (GI<sub>50</sub> = 0.0116 μM) in contrast to Tel-c-KIT/D816 V-BaF3 mutation (GI<sub>50</sub> > 10 μM) but showed a moderate activity (GI<sub>50</sub> = 0.1341 μM) against Tel-c-KIT/D816H-BaF3 mutation. More excitingly (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>), <b>31</b> improved the antiproliferation activity of Tel-PDGFRα/T674I-BaF3 mutation (GI<sub>50</sub> = 0.1348 μM), which was insensitive to <b>1</b> (GI<sub>50</sub> > 10 μM), while retaining activity against the native PDGFRα (GI<sub>50</sub> = 0.0104 μM). Combining the results from all of these different BaF3 cell lines, we concluded that <b>31</b> is promising as a powerful dual-targeted c-KIT/PDGFRα kinase inhibitor that is even superior to <b>1</b>.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Antiproliferative Effect of <b>31</b> against a Variety of TEL-c-KIT/PDGFRα -BaF3 Isogenic Cells</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell lines</th><th class="colsep0 rowsep0" align="center"><b>1</b>, GI<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center"><b>31</b>, GI<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">parental BaF3</td><td class="colsep0 rowsep0" align="center">4.6860</td><td class="colsep0 rowsep0" align="center">4.0310</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-c-KIT-BaF3</td><td class="colsep0 rowsep0" align="center">0.3819</td><td class="colsep0 rowsep0" align="center">0.0181</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-c-KIT/C674S-BaF3</td><td class="colsep0 rowsep0" align="center">0.0249</td><td class="colsep0 rowsep0" align="center">0.0105</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-c-KIT/L576P-BaF3</td><td class="colsep0 rowsep0" align="center">0.0451</td><td class="colsep0 rowsep0" align="center">0.0106</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-c-KIT/V559D-BaF3</td><td class="colsep0 rowsep0" align="center">0.0360</td><td class="colsep0 rowsep0" align="center">0.0965</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-c-KIT/V654A-BaF3</td><td class="colsep0 rowsep0" align="center">0.8031</td><td class="colsep0 rowsep0" align="center">0.1365</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-c-KIT/T670I-BaF3</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">0.0392</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-c-KIT/V559D/V654A-BaF3</td><td class="colsep0 rowsep0" align="center">0.8030</td><td class="colsep0 rowsep0" align="center">0.3303</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-c-KIT/V559D/T670I-BaF3</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">0.0364</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-c-KIT/A829P-BaF3</td><td class="colsep0 rowsep0" align="center">0.1482</td><td class="colsep0 rowsep0" align="center">0.0116</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-c-KIT/D816H-BaF3</td><td class="colsep0 rowsep0" align="center">1.2450</td><td class="colsep0 rowsep0" align="center">0.1341</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-c-KIT/D816 V-BaF3</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-c-KIT/N822 K-BaF3</td><td class="colsep0 rowsep0" align="center">1.4660</td><td class="colsep0 rowsep0" align="center">0.0111</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-PDGFRα-BaF3</td><td class="colsep0 rowsep0" align="center">0.0107</td><td class="colsep0 rowsep0" align="center">0.0104</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Tel-PDGFRα/T674I-BaF3</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">0.1348</td></tr></tbody></table></div></div><figure id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Antiproliferative effect of <b>31</b> against a variety of TEL-c-KIT/PDGFRα -BaF3 isogenic cells. (Note: no comparison for GI<sub>50</sub> > 10 μM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00468&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, the inhibitory effects of compound <b>31</b> against a variety of intact cancer cell lines were investigated (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). The results showed that the inhibitory effect of <b>31</b> against proliferation was more potent than <b>1</b> against the GIST-T1<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> cell line; these cells expressed the characteristics of GISTs that were strongly positive for CD34 and c-KIT but not for desmin, S-100 protein, or α-smooth muscle actin. Most interestingly, <b>31</b> exhibited powerful antiproliferative activity against the GIST-882<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> cell line with single c-KIT mutation and gained significant improvement of antiproliferation activity compared to <b>1</b> (GI<sub>50</sub> < 0.003 μM vs 0.020 μM). For the GIST 48B<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> cell line harboring the activating c-KIT mutation but expressing no detectable c-KIT transcript or c-KIT protein, <b>31</b> showed the same drug resistance as <b>1</b>. In addition, <b>31</b> completely abolished the inhibitory activity against the BCR-ABL driven CML cell lines, such as K562 (GI<sub>50</sub> > 10 μM), KU812 (GI<sub>50</sub> > 10 μM), and MEG-01 (GI<sub>50</sub> = 9.092 μM) cells in contrast with <b>1</b>. Moreover, <b>31</b> had no antiproliferative activity against normal Chinese hamster ovary CHL and CHO cells, implying a good safety profile.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Antiproliferative Effect of <b>31</b> against a Variety of Intact Cancer Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell lines</th><th class="colsep0 rowsep0" align="center"><b>1</b>, GI<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center"><b>31</b>, GI<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CHL</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">7.036</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CHO</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GIST-T1</td><td class="colsep0 rowsep0" align="center">0.003</td><td class="colsep0 rowsep0" align="center"><0.003</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GIST-882</td><td class="colsep0 rowsep0" align="center">0.020</td><td class="colsep0 rowsep0" align="center"><0.003</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GIST-48B</td><td class="colsep0 rowsep0" align="center">6.986</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">K562</td><td class="colsep0 rowsep0" align="center">0.147</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KU812</td><td class="colsep0 rowsep0" align="center">0.110</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MEG-01</td><td class="colsep0 rowsep0" align="center">0.045</td><td class="colsep0 rowsep0" align="center">9.092</td></tr></tbody></table></div></div><div class="NLM_p">To understand kinase spectrum selective of <b>31</b> comprehensively, we then examined its kinome wide selectivity profile with DiscoveRx’s KinomeScan technology.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The results are shown in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.7b00468/suppl_file/jm7b00468_si_001.pdf" class="ext-link">Table S2</a> (Supporting Information). We were delighted to find that <b>31</b> possessed a good selectivity (<i>S</i> score (1) = 0.01) in a panel of 468 kinases and mutants at 1 μM concentration. Besides high binding against c-KIT and PDGFRα kinases, it also exhibited strong binding affinity to PDGFRβ, CSF1R kinases and mutant kinases including c-KIT/V559D/T670I, c-KIT/L576P, c-KIT/V559D, and FLT3/N841I (percent activity remaining <1% at 1 μM) (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A,B). We further calculated the values of <i>S</i> score (10) and <i>S</i> score (35), and the results also (<i>S</i> score (10) = 0.03 at 1 μM, <i>S</i> score (35) = 0.04 at 1 μM) illustrated that <b>31</b> exhibited a good selectivity at 1 μM concentration (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00468/suppl_file/jm7b00468_si_001.pdf" class="ext-link">Table S3</a>). Furthermore, considering the fact that KinomeScan is a competitive binding assay and may not fully reflect the inhibitory activity, <b>31</b>’s inhibitory activities against six kinds of available kinases (CSF1R, PDGFRβ, FLT1, FLT3, FLT4, and RET kinases) with POC < 10 at 1 μM were further tested by using Invitrogen’s Z′-LYTE assay and enzyme-linked immunosorbent assay (ELISA),<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> and the results were shown in <a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>. The Z′-LYTE assay demonstrated that <b>31</b> inhibited CSF1R kinase with an IC<sub>50</sub> of 160 nM. The ELISA showed that <b>31</b> inhibited PDGFRβ kinase with an IC<sub>50</sub> below 1 nM, FLT1 with an IC<sub>50</sub> of 159 nM, FLT3 with an IC<sub>50</sub> of 2.0 nM, FLT4 with an IC<sub>50</sub> of 72 nM, and RET with an IC<sub>50</sub> above 1000 nM (<a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>). The good inhibitory activity against PDGFRβ and FLT3 kinases was understandable because c-KIT, CSF1R, PDGFRα, PDGFRβ, and FLT3 kinases are members of the type III receptor tyrosine kinase family. In addition, compound <b>31</b> showed high percent of control values (POC > 35%) against all kinds of ABL kinases and mutants (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00468/suppl_file/jm7b00468_si_001.pdf" class="ext-link">Table S4</a>), indicating weak binding and consistent with the results that compound <b>31</b> showed almost no inhibitory activity against the BCR-ABL driven CML cell lines which had been evaluated in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>.</div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Kinome wide selectivity profiling of <b>31</b>. (A) KinomeScan profiling of compound <b>31</b> at a concentration of 1 μM against 468 kinases and mutants. (B) Kinases mutants that remained activity less than 1% of control in the presence of 1 μM <b>31</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00468&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Compound <b>31</b>’s Inhibitory Activities against CSF1R, PDGFRβ, FLT1, FLT3, FLT4, and RET Kinases</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center">targets</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">CSF1R</th><th class="colsep0 rowsep0" align="center">PDGFRβ</th><th class="colsep0 rowsep0" align="center">FLT1</th><th class="colsep0 rowsep0" align="center">FLT3</th><th class="colsep0 rowsep0" align="center">FLT4</th><th class="colsep0 rowsep0" align="center">RET</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">% activity remaining</td><td class="colsep0 rowsep0" align="center">0</td><td class="colsep0 rowsep0" align="center">0</td><td class="colsep0 rowsep0" align="center">1.4</td><td class="colsep0 rowsep0" align="center">3.5</td><td class="colsep0 rowsep0" align="center">7.8</td><td class="colsep0 rowsep0" align="center">8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="center">160</td><td class="colsep0 rowsep0" align="center"><1</td><td class="colsep0 rowsep0" align="center">159</td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="center">72</td><td class="colsep0 rowsep0" align="center">>1000</td></tr></tbody></table></div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Pharmacokinetic and in Vitro Safety Properties</h3><div class="NLM_p">Because of its potency and attractive selectivity profile, compound <b>31</b> was evaluated in an in vivo rat pharmacokinetic (PK) model following intravenous (IV), oral, and intraperitoneal (IP) administration. As shown in <a class="ref internalNav" href="#tbl9" aria-label="Table 9">Table 9</a>, <b>31</b> demonstrated a short half-life (<i>T</i><sub>1/2</sub> = 0.69 h), a moderate plasma clearance (CL<sub><i>z</i></sub> = 0.95 L/h/kg), small volume distribution (Vss = 0.97 L/kg), and a good plasma exposure in Sprague–Dawley rats (AUC<sub>(0–<i>t</i>)</sub> = 2243.82 ng/mL·h) with intravenous (IV) injection at a dose of 2 mg/kg. However, there was no absorption in the oral administration with a dose of 10 mg/kg, which prevented <b>31</b> from the oral application in the animal model. And then, pharmacokinetic characterization of <b>31</b> with IP injection was tested with two dosages of 25 and 100 mg/kg (<a class="ref internalNav" href="#tbl10" aria-label="Table 10">Table 10</a>). At the dosage of 100 mg/kg, <b>31</b> showed a good half-life (<i>T</i><sub>1/2</sub> = 10.97 h) and a better plasma exposure in Sprague–Dawley rats (AUC<sub>(0–t)</sub> = 4245.24 ng/mL·h), which was much better than the plasma level at the dosage of 25 mg/kg (AUC<sub>(0–<i>t</i>)</sub> = 691.08 ng/mL·h).</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Pharmacokinetic Characterization of <b>31</b> with IV Injection in Intact Rats</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>31</b></th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>(0–<i>t</i>)</sub> (ng·h/mL)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>(0–∞)</sub> (ng·h/mL)</th><th class="colsep0 rowsep0" align="center" char=".">MRT<sub>(0–<i>t</i>)</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">Vss (L/kg)</th><th class="colsep0 rowsep0" align="center" char=".">CL<sub><i>z</i></sub> (L/h/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IV (2 mg/kg)<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">2243.82</td><td class="colsep0 rowsep0" align="char" char=".">2253.60</td><td class="colsep0 rowsep0" align="char" char=".">1.13</td><td class="colsep0 rowsep0" align="char" char=".">0.69</td><td class="colsep0 rowsep0" align="char" char=".">0.083</td><td class="colsep0 rowsep0" align="char" char=".">0.97</td><td class="colsep0 rowsep0" align="char" char=".">0.95</td><td class="colsep0 rowsep0" align="char" char=".">1889.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SD (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="char" char=".">773.33</td><td class="colsep0 rowsep0" align="char" char=".">786.16</td><td class="colsep0 rowsep0" align="char" char=".">0.56</td><td class="colsep0 rowsep0" align="char" char=".">0.32</td><td class="colsep0 rowsep0" align="char" char=".">0.000</td><td class="colsep0 rowsep0" align="char" char=".">0.13</td><td class="colsep0 rowsep0" align="char" char=".">0.28</td><td class="colsep0 rowsep0" align="char" char=".">118.37</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup>a</sup><p class="last">Formulation: 5% DMSO, 40% PEG400, and 55% (30%-HP-β-CD).</p></div></div></div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Pharmacokinetic Characterization of <b>31</b> with IP Injection in Intact Rats</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="7" align="center" char="."><b>31</b></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>(0–<i>t</i>)</sub> (ng·h/mL)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>(0–∞)</sub> (ng·h/mL)</th><th class="colsep0 rowsep0" align="center" char=".">MRT<sub>(0–<i>t</i>)</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">MRT<sub>(0–∞)</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IP (25 mg/kg)<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">691.08</td><td class="colsep0 rowsep0" align="char" char=".">713.00</td><td class="colsep0 rowsep0" align="char" char=".">5.67</td><td class="colsep0 rowsep0" align="char" char=".">6.48</td><td class="colsep0 rowsep0" align="char" char=".">5.09</td><td class="colsep0 rowsep0" align="char" char=".">4.00</td><td class="colsep0 rowsep0" align="char" char=".">116.96</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SD (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="char" char=".">205.32</td><td class="colsep0 rowsep0" align="char" char=".">210.66</td><td class="colsep0 rowsep0" align="char" char=".">0.40</td><td class="colsep0 rowsep0" align="char" char=".">0.32</td><td class="colsep0 rowsep0" align="char" char=".">0.68</td><td class="colsep0 rowsep0" align="char" char=".">0.00</td><td class="colsep0 rowsep0" align="char" char=".">23.78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IP (100 mg/kg)<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">4245.24</td><td class="colsep0 rowsep0" align="char" char=".">5388.11</td><td class="colsep0 rowsep0" align="char" char=".">7.99</td><td class="colsep0 rowsep0" align="char" char=".">14.80</td><td class="colsep0 rowsep0" align="char" char=".">10.97</td><td class="colsep0 rowsep0" align="char" char=".">4.00</td><td class="colsep0 rowsep0" align="char" char=".">656.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SD (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="char" char=".">1288.30</td><td class="colsep0 rowsep0" align="char" char=".">1621.92</td><td class="colsep0 rowsep0" align="char" char=".">0.89</td><td class="colsep0 rowsep0" align="char" char=".">3.65</td><td class="colsep0 rowsep0" align="char" char=".">1.94</td><td class="colsep0 rowsep0" align="char" char=".">0.00</td><td class="colsep0 rowsep0" align="char" char=".">338.05</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup>a</sup><p class="last">Formulation: HKI solution (0.5% methocellulose and 0.4% Tween 80 in ddH<sub>2</sub>O)</p></div></div></div><div class="NLM_p last">Moreover, the metabolic stability of compound <b>31</b> in rat liver microsomes was further tested in vitro and the result showed that its half-life was 46.76 min, indicating <b>31</b> was metabolically stable (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00468/suppl_file/jm7b00468_si_001.pdf" class="ext-link">Supporting Information</a>). What is more, the safety evaluation experiment (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00468/suppl_file/jm7b00468_si_001.pdf" class="ext-link">Supporting Information</a>) displayed that <b>31</b> possessed almost no hERG inhibitory activity (IC<sub>50</sub> > 40 μM).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> In Vivo Evaluation of <b>31</b> in Inoculated Xenograft Mouse Model with GIST-T1 Cell</h3><div class="NLM_p">To assess the potential of <b>31</b> for further medicinal chemistry development, we investigated its antitumor efficacy using the GIST-T1 cell inoculated xenograft mouse model. Intraperitoneal (IP) injection was selected based upon the PK data (<a class="ref internalNav" href="#tbl10" aria-label="Table 10">Table 10</a>). It was noteworthy that the PK profile obtained from rats cannot be transformed into mice due to the differences of species. <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A showed that no animal lethality or obvious weight loss was observed by the administration of 25 or 100 mg/kg of <b>31</b> during 28 consecutive treatment days. Furthermore, <b>31</b> showed a high inhibition of tumor growth (TGI = 81.5%) which was slightly weaker than <b>1</b> (TGI = 87.3%) at the dosage of 100 mg/kg. When the dosage of <b>31</b> was decreased to 25 mg/kg, the treatment also resulted in a modest suppression against tumor progression (TGI = 20.2%) (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B–D). Immunohistochemistry staining demonstrated that <b>31</b> could strongly suppress the cellular proliferation marker (Ki-67 stain) and induce the apoptosis effect (TUNEL stain) in the tumor tissues (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>E).</div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Antitumor efficacy of compound <b>31</b> in GIST-T1 xenograft model. Female nu/nu mice harboring established GIST-T1 tumor xenografts were treated with <b>31</b> at 25 and 100 mg/kg/d or vehicle or with <b>1</b> at 100 mg/kg/d. Daily IP injection was initiated when GIST-T1 tumors had reached a volume of 100–200 mm<sup>3</sup>. Each group contained five animals. The data are expressed as the mean ± SEM (A) body weight and (B) tumor size measurements from GIST-T1 xenograft mice after <b>31</b> or <b>1</b> administration. Initial body weight and tumor size were set as 100%. (C) Comparison of the final tumor volume in each group after 28-day treatment period with <b>31</b> or <b>1</b>; ns, <i>p</i> > 0.05, *<i>p</i> < 0.05, ***<i>p</i> < 0.001. (D) Representative photographs of tumors in each group after <b>31</b> or <b>1</b> treatment. (E) Immunohistochemical staining assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00468&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> In Vivo Evaluation of <b>31</b> in Inoculated Xenograft Mouse Model with BaF3-TEL-cKIT-T670I Cell</h3><div class="NLM_p">Considering <b>31</b> with a strong suppression against GIST-T1 progression, we next wished to determine the antiproliferation efficacy in BaF3-TEL-cKIT-T670I cells inoculated xenograft mouse model. We also chose the IP injection administration with the dosage of 25 and 100 mg/kg/day for 11 days of continuous treatment, and the results were shown in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>. The changes of all mice body weights were in a reasonable range as shown in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A. As expected, <b>1</b> could not suppress the c-KIT T670I tumor growth while compound <b>31</b> demonstrated moderate tumor growth inhibition (TGI = 41.9%) at 100 mg/kg/day dosage (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>B,C) without obvious toxicity. In addition, The <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>D showed that <b>31</b> affected c-KIT pY719, pY703, and pY823 autophosphorylation sites of c-KIT at the dosage of 100 mg/kg/day. The results of immunohistochemistry staining also indicated the proliferation of tumor cells was greatly inhibited, and apoptosis was well induced (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>E).</div><figure id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0006.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Antitumor efficacy of compound <b>31</b> in BaF3-TEL-cKIT-T670I xenograft model. Female nu/nu mice harboring established BaF3-TEL-cKIT-T670I tumor xenografts were treated with <b>31</b> at 25 and 100 mg/kg/d or vehicle or with <b>1</b> at 100 mg/kg/d. Daily IP injection was initiated when BaF3-TEL-cKIT-T670I tumors had reached a volume of 100–200 mm<sup>3</sup>. Each group contained five animals. The data are expressed as the mean ± SEM (A) body weight and (B) tumor size measurements from BaF3-TEL-cKIT-T670I xenograft mice after <b>31</b> or <b>1</b> administration. Initial body weight and tumor size were set as 100%. (C) Comparison of the final tumor volume in each group after 11-day treatment period with <b>31</b> or <b>1</b>; ns, <i>p</i> > 0.05, *<i>p</i> < 0.05. (D) Western blot analysis with antibodies specific to the indicated proteins from tumor lysates prepared from the BaF3-TEL-cKIT-T670I tumor xenografts upon the completion of the indicated treatments. (E) Immunohistochemical staining assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00468&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06242" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06242" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In conclusion, the application of lead optimization based on multitargeted RTK inhibitor <b>7</b> contributed to the design and synthesis of 58 new compounds (<b>8</b>–<b>65</b>), and the novel 3-substituted-pyrazolo[3,4-<i>b</i>]pyridine scaffold shifted the kinase inhibitory spectrum from VEGFR/PDGFR to c-KIT/PDGFRα. Using kinase inhibitory assays provided an integrated assessment of kinase selectivity and potency of all compounds. Preliminary SARs were obtained, which showed that the 3-methyl-pyrazolo[3,4-<i>b</i>] pyridine core scaffold of new compounds was an important pharmacophore of the c-KIT/PDGFRα dual inhibitor; the urea linker and terminal <i>N</i>-substituents, e.g., 3-methyl-4-(morpholin-4-yl)phenyl, long linear alkyl, aralkyl, and large fused heteroaryl, substantially improved the potency.</div><div class="NLM_p">The preferred compound <b>31</b>, harboring single-digit nanomolar potency against c-KIT (IC<sub>50</sub> = 2.4 nM) and PDGFRα (IC<sub>50</sub> = 7.2 nM), also exhibited better inhibition activity against four TEL-c-KIT/PDGFRα cell lines compared to the tested compounds. So its further in-depth anti-GISTs investigations in vitro and in vivo were performed. In vitro, broad antiproliferative efficacy of <b>31</b> was found across a range of TEL-c-KIT/PDGFRα -BaF3 isogenic cells, which were almost suppressed except for the TEL-c-KIT/D816 V-BaF3 cells that were also insensitive to <b>1</b>. In particular, <b>31</b> showed more potent inhibitory activities against the c-KIT/T670I-BaF3, c-KIT/V559D/T670I-BaF3, and PDGFRα/T674I-BaF3 cell lines, which were all <b>1</b>-resistant. In parallel, the potency of <b>31</b> against a variety of intact cancer cell lines was observed and improved almost 10 times or more against GIST-882 cells and completely abolished the inhibitory activity against BCR-ABL driven CML cell lines compared to <b>1</b>. Moreover, <b>31</b> showed a good selectivity (<i>S</i> score (1) = 0.01 at 1 μM) among 468 kinases and mutants tested with DiscoveRx’s KinomeScan technology and exhibited almost no effects on the growth of two normal cells (CHL, GI<sub>50</sub> = 7.036 μM; CHO, GI<sub>50</sub> > 10 μM) as well as possessing almost no hERG inhibitory activity (IC<sub>50</sub> > 40 μM), indicating a good therapeutic window. <b>31</b> also displayed a high metabolic stability in rat liver microsomes with good half-life (<i>T</i><sub>1/2</sub> = 46.76 min). Furthermore, <b>31</b> was assessed in a GIST-T1 xenograft mouse model and showed significant in vivo antitumor activities, suppressing tumor growth (TGI = 81.5%) and inducing apoptosis. More excitingly, <b>31</b> demonstrated 41.9% tumor growth inhibition in the BaF3-TEL-cKIT-T670I isogenic cell inoculated xenograft mouse model (insensitive to <b>1</b>) and blocked cKIT pY703, pY719, and pY823 autophosphorylation sites at the dosage of 100 mg/kg/day.</div><div class="NLM_p last">In general, the favorable in vitro and in vivo potency of <b>31</b> makes it possible for serving as a dual-targeted compound against c-KIT and PDGFRα for the treatment of GISTs, especially <b>1</b>-resistant GISTs, as well as a useful prototype for medicinal chemistry programs to further study the GISTs.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63510" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63510" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> General Chemistry</h3><div class="NLM_p last">Synthetic starting materials, reagents, and solvents were purchased from Energy Chemical, J&K, Adamas-beta, TCI, Shanghai Shaoyuan Co. Ltd., and Alfa Aesar and were used without further purification. Analytical thin-layer chromatography (TLC) was performed on an HSGF 254 (150–200 μm thickness; Yantai Huiyou Co., China), and the peak purity was verified with UV spectroscopy (254 and 365 nm). Melting points were measured in capillary tubes on an SGW X-4 melting point apparatus without correction. Nuclear magnetic resonance (NMR) spectroscopy was performed on a Bruker AMX-400 NMR (IS as TMS). Chemical shifts were reported in parts per million (ppm, δ) downfield from tetramethylsilane. Proton coupling patterns were described as singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), and broad (br). High-resolution mass spectra (LRMS and HRMS) were obtained with electric ionization (EI) and electrospray ionization (ESI) produced by a Waters GCT Premie and Waters LCT. HPLC data analysis of compounds <b>8</b>–<b>65</b> were performed on an Agilent 1100 with a quaternary pump and diode array detector (DAD). All compounds were confirmed to have a purity ≥95%.</div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> General Procedure for the Preparation of Compounds <b>8</b>–<b>27</b></h3><div class="NLM_p">To a solution of <b>69</b>/<b>71</b>/<b>73</b>/<b>76</b> (0.5 mmol) in DMSO (5 mL) was added Et<sub>3</sub>N (50 μL) and corresponding isocyanates or isothiocyanates (0.6 mmol). The reaction mixture was stirred at room temperature for 12 h. Water (15 mL) was added, and the mixture was extracted with EtOAc (3 × 50 mL). The organic layer was separated and dried over Na<sub>2</sub>SO<sub>4</sub>. Removal of the solvents produced a residue, which was purified by column chromatography eluted with a mixture of MeOH/DCM to yield corresponding target compounds <b>8</b>–<b>27</b>.</div><div id="sec6_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>N</i>-(2-Fluoro-5-methylphenyl)-<i>N</i>′-(4-(3-methyl-6-hydroxy-4,5-dihydro-2<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>8</b>)</h4><div class="NLM_p last">Yellow solid; yield = 21%; mp 163–166 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.81 (s, 1H), 10.29 (s, 1H), 9.04 (s, 1H), 8.45 (d, <i>J</i> = 2.5 Hz, 1H), 7.98 (dd, <i>J</i> = 8.0, 2.0 Hz, 1H), 7.38 (d, <i>J</i> = 8.4 Hz, 2H), 7.13–7.05 (m, 3H), 6.81–6.76 (m, 1H), 4.49–4.43 (m, 1H), 3.39 (d, <i>J</i> = 5.2 Hz, 1H), 3.17 (d, <i>J</i> = 5.2 Hz, 1H), 2.26 (s, 3H), 1.84 (s, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>20</sub>FN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 394.1679, found 394.1679.</div></div><div id="sec6_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>N</i>-(3-Methylphenyl)-<i>N</i>′-(4-(3-methyl-6-hydroxy-4,5-dihydro-2<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>9</b>)</h4><div class="NLM_p last">Yellow solid; yield = 43%; mp 231–233 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.81 (s, 1H), 10.29 (s, 1H), 8.62 (s, 1H), 8.56 (s, 1H), 7.37 (d, <i>J</i> = 8.4 Hz, 2H), 7.29 (s, 1H), 7.21 (d, <i>J</i> = 8.4 Hz, 1H), 7.14 (t, <i>J</i> = 7.6 Hz, 1H), 7.07 (d, <i>J</i> = 8.4 Hz, 2H), 6.78 (d, <i>J</i> = 7.2 Hz, 1H), 4.08 (t, <i>J</i> = 6.4 Hz, 1H), 2.76 (dd, <i>J</i> = 15.6, 6.8 Hz, 1H), 2.54 (dd, <i>J</i> = 15.6, 6.4 Hz, 1H), 2.27 (s, 3H), 1.85 (s, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 376.1772, found 376.1773.</div></div><div id="sec6_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>N</i>-(2-Fluoro-5-methylphenyl)-<i>N</i>′-(4-(3-methyl-6-hydroxy-2<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>10</b>)</h4><div class="NLM_p last">Light-yellow solid; yield = 11%; mp 131–134 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.89 (s, 1H), 11.56 (s, 1H), 9.38 (s, 1H), 8.60 (s, 1H), 7.99 (d, <i>J</i> = 7.6 Hz, 1H), 7.58 (d, <i>J</i> = 8.8 Hz, 2H), 7.43 (d, <i>J</i> = 8.8 Hz, 2H), 7.12 (dd, <i>J</i> = 11.2, 8.4 Hz, 1H), 6.82 (m, 1H), 5.85 (s, 1H), 2.28 (s, 3H), 2.09 (s, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>18</sub>FN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 392.1524, found 392.1523.</div></div><div id="sec6_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> <i>N</i>-(3-Methylphenyl)-<i>N</i>′-(4-(3-methyl-6-hydroxy-2<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>11</b>)</h4><div class="NLM_p last">Yellow solid; yield = 18%; mp 173–175 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.87 (s, 1H), 11.57 (s, 1H), 8.91 (s, 1H), 8.71 (s, 1H), 7.58 (d, <i>J</i> = 8.4 Hz, 2H), 7.41 (d, <i>J</i> = 8.4 Hz, 2H), 7.31 (s, 1H), 7.26 (d, <i>J</i> = 8.4 Hz, 1H), 7.17 (t, <i>J</i> = 7.6 Hz, 1H), 6.80 (d, <i>J</i> = 7.6 Hz, 1H), 5.87 (s, 1H), 2.29 (s, 3H), 2.10 (s, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>19</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 374.1618, found 374.1617.</div></div><div id="sec6_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> <i>N</i>-(2-Fluoro-5-methylphenyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>12</b>)</h4><div class="NLM_p last">White solid; yield = 62%; mp 215–222 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.34 (s, 1H), 9.41 (s, 1H), 8.64 (s, 1H), 8.47 (d, <i>J</i> = 4.7 Hz, 1H), 8.09–7.94 (m, 1H), 7.65 (d, <i>J</i> = 8.6 Hz, 2H), 7.51 (d, <i>J</i> = 8.5 Hz, 2H), 7.12 (dd, <i>J</i> = 11.3, 8.4 Hz, 1H), 7.03 (d, <i>J</i> = 4.7 Hz, 1H), 6.82 (s, 1H), 2.27 (d, <i>J</i> = 13.8 Hz, 6H). HRMS (EI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>18</sub>FN<sub>5</sub>O (M<sup>+</sup>) 375.1495, found 375.1499.</div></div><div id="sec6_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>N</i>-(3-Methylphenyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>13</b>)</h4><div class="NLM_p last">White solid; yield = 52%; mp 225–229 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.34 (s, 1H), 9.16 (s, 1H), 8.92 (s, 1H), 8.47 (d, <i>J</i> = 4.6 Hz, 1H), 7.65 (d, <i>J</i> = 8.5 Hz, 2H), 7.49 (d, <i>J</i> = 8.4 Hz, 2H), 7.34 (s, 1H), 7.29 (d, <i>J</i> = 7.9 Hz, 1H), 7.18 (t, <i>J</i> = 7.7 Hz, 1H), 7.03 (d, <i>J</i> = 4.6 Hz, 1H), 6.81 (d, <i>J</i> = 7.2 Hz, 1H), 2.28 (d, <i>J</i> = 13.5 Hz, 6H). HRMS (EI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>19</sub>N<sub>5</sub>O (M<sup>+</sup>) 357.1590, found 357.1593.</div></div><div id="sec6_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>N</i>-(3-Bromophenyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>14</b>)</h4><div class="NLM_p last">White solid; yield = 86%; mp 232–235 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.34 (s, 1H), 9.19 (s, 2H), 8.47 (d, <i>J</i> = 4.3 Hz, 1H), 7.89 (s, 1H), 7.65 (d, <i>J</i> = 8.0 Hz, 2H), 7.51 (d, <i>J</i> = 7.9 Hz, 2H), 7.36 (d, <i>J</i> = 7.8 Hz, 1H), 7.26 (t, <i>J</i> = 7.9 Hz, 1H), 7.17 (d, <i>J</i> = 7.6 Hz, 1H), 7.03 (d, <i>J</i> = 4.2 Hz, 1H), 2.25 (s, 3H). HRMS (EI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>16</sub>BrN<sub>5</sub>O (M<sup>+</sup>) 423.0518, found 423.0523.</div></div><div id="sec6_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> <i>N</i>-(3-(Trifluoromethyl)phenyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine-4-yl)phenyl)urea (<b>15</b>)</h4><div class="NLM_p last">White solid; yield = 82%; mp 234–237 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.35 (s, 1H), 9.41 (d, <i>J</i> = 50.8 Hz, 2H), 8.47 (d, <i>J</i> = 4.7 Hz, 1H), 8.06 (s, 1H), 7.65 (dd, <i>J</i> = 16.5, 8.5 Hz, 3H), 7.53 (dd, <i>J</i> = 13.4, 8.3 Hz, 3H), 7.33 (d, <i>J</i> = 7.6 Hz, 1H), 7.03 (d, <i>J</i> = 4.7 Hz, 1H), 2.25 (s, 3H). HRMS (EI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>16</sub>F<sub>3</sub>N<sub>5</sub>O (M<sup>+</sup>) 411.1307, found 411.1306.</div></div><div id="sec6_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> <i>N</i>-(3-Bromophenyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)thiourea (<b>16</b>)</h4><div class="NLM_p last">Light-yellow solid; yield = 60%; mp 93–101 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.36 (s, 1H), 10.17 (s, 1H), 10.06 (s, 1H), 8.49 (d, <i>J</i> = 4.7 Hz, 1H), 7.83 (s, 1H), 7.67 (d, <i>J</i> = 8.5 Hz, 2H), 7.54 (d, <i>J</i> = 8.5 Hz, 2H), 7.46 (d, <i>J</i> = 6.7 Hz, 1H), 7.32 (s, 2H), 7.05 (d, <i>J</i> = 4.7 Hz, 1H), 2.23 (s, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>17</sub>BrN<sub>5</sub>S [M + H]<sup>+</sup> 438.0368, found 438.0383.</div></div><div id="sec6_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>N</i>-(3-(Trifluoromethyl)phenyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine-4-yl)phenyl)thiourea (<b>17</b>)</h4><div class="NLM_p last">Light-yellow solid; yield = 64%; mp 86–95 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.37 (s, 1H), 10.25 (s, 1H), 10.18 (s, 1H), 8.50 (dd, <i>J</i> = 9.1, 4.7 Hz, 1H), 7.97 (s, 1H), 7.78 (d, <i>J</i> = 8.2 Hz, 1H), 7.68 (d, <i>J</i> = 8.5 Hz, 2H), 7.63–7.52 (m, 3H), 7.48 (d, <i>J</i> = 7.8 Hz, 1H), 7.05 (d, <i>J</i> = 4.7 Hz, 1H), 2.24 (s, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>17</sub>F<sub>3</sub>N<sub>5</sub>S [M + H]<sup>+</sup> 428.1151, found 428.1151.</div></div><div id="sec6_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>N</i>-(3-Methylphenyl)-<i>N</i>′-(4-(3-hydroxymethyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>18</b>)</h4><div class="NLM_p last">White solid; yield = 59%; mp 211–214 °C. <sup>1</sup>H NMR (400 MHz, MeOD): δ 8.52 (d, <i>J</i> = 4.7 Hz, 1H), 8.45 (d, <i>J</i> = 4.9 Hz, 1H), 7.46 (d, <i>J</i> = 8.4 Hz, 2H), 7.31 (s, 1H), 7.27 (d, <i>J</i> = 8.2 Hz, 1H), 7.19 (dd, <i>J</i> = 16.4, 6.2 Hz, 2H), 7.10 (d, <i>J</i> = 4.9 Hz, 1H), 6.88 (t, <i>J</i> = 9.5 Hz, 3H), 4.70 (d, <i>J</i> = 8.4 Hz, 2H), 2.36 (s, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>19</sub>N<sub>5</sub>NaO<sub>2</sub> [M + Na]<sup>+</sup> 396.1434, found 396.1431.</div></div><div id="sec6_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>N</i>-(3-Ethylphenyl)-<i>N</i>′-(4-(3-hydroxymethyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>19</b>)</h4><div class="NLM_p last">White solid; yield = 34%; mp 209–213 °C. <sup>1</sup>H NMR (400 MHz, MeOD): δ 8.40 (d, <i>J</i> = 4.8 Hz, 1H), 8.33 (d, <i>J</i> = 4.8 Hz, 1H), 7.33 (d, <i>J</i> = 8.4 Hz, 2H), 7.22 (s, 1H), 7.19–7.08 (m, 2H), 7.05 (d, <i>J</i> = 4.8 Hz, 1H), 6.98 (d, <i>J</i> = 4.8 Hz, 1H), 6.80 (d, <i>J</i> = 7.3 Hz, 1H), 6.75 (d, <i>J</i> = 8.4 Hz, 2H), 4.58 (d, <i>J</i> = 8.0 Hz, 2H), 2.54 (q, <i>J</i> = 7.6 Hz, 2H), 1.15 (t, <i>J</i> = 7.6 Hz, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>21</sub>N<sub>5</sub>NaO<sub>2</sub> [M + Na]<sup>+</sup> 410.1588, found 410.1588.</div></div><div id="sec6_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> <i>N</i>-(3-Methylphenyl)-<i>N</i>′-(4-(3-trifluoromethyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>20</b>)</h4><div class="NLM_p last">White solid; yield = 46%; mp 294–298 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.71 (s, 1H), 8.88 (s, 1H), 8.68 (d, <i>J</i> = 4.4 Hz, 2H), 7.60 (d, <i>J</i> = 8.4 Hz, 2H), 7.41 (d, <i>J</i> = 8.4 Hz, 2H), 7.33 (s, 1H), 7.28–7.23 (m, 2H), 7.18 (t, <i>J</i> = 8.0 Hz, 1H), 6.81 (d, <i>J</i> = 7.6 Hz, 1H), 2.29 (s, 3H). HRMS (EI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>16</sub>F<sub>3</sub>N<sub>5</sub>O (M<sup>+</sup>) 411.1307, found 411.1305.</div></div><div id="sec6_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>N</i>-(3-Ethylphenyl)-<i>N</i>′-(4-(3-trifluoromethyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>21</b>)</h4><div class="NLM_p last">White solid; yield = 65%; mp 297–299 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.71 (s, 1H), 8.87 (s, 1H), 8.71–8.67 (m, 2H), 7.60 (d, <i>J</i> = 8.4 Hz, 2H), 7.41 (d, <i>J</i> = 8.4 Hz, 2H), 7.35 (s, 1H), 7.30–7.24 (m, 2H), 7.20 (t, <i>J</i> = 7.6 Hz, 1H), 6.84 (d, <i>J</i> = 7.6 Hz, 1H), 2.59 (q, <i>J</i> = 7.6 Hz, 1H), 1.19 (t, <i>J</i> = 7.6 Hz, 1H). HRMS (EI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>18</sub>F<sub>3</sub>N<sub>5</sub>O (M<sup>+</sup>) 425.1463, found 425.1464.</div></div><div id="sec6_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>N</i>-(3-Ethylphenyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>22</b>)</h4><div class="NLM_p last">White solid; yield = 48%; mp 165–170 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.34 (s, 1H), 9.07 (s, 1H), 8.86 (s, 1H), 8.47 (d, <i>J</i> = 4.6 Hz, 1H), 7.65 (d, <i>J</i> = 8.5 Hz, 2H), 7.50 (d, <i>J</i> = 8.5 Hz, 2H), 7.36 (s, 1H), 7.30 (d, <i>J</i> = 8.0 Hz, 1H), 7.20 (t, <i>J</i> = 7.8 Hz, 1H), 7.03 (d, <i>J</i> = 4.6 Hz, 1H), 6.84 (d, <i>J</i> = 7.4 Hz, 1H), 2.59 (q, <i>J</i> = 7.5 Hz, 2H), 2.26 (s, 3H), 1.19 (s, 3H). HRMS (EI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>21</sub>N<sub>5</sub>O (M<sup>+</sup>) 371.1746, found 371.1744.</div></div><div id="sec6_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>N</i>-(2-Methylphenyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>23</b>)</h4><div class="NLM_p last">White solid; yield = 45%; mp 222–226 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.34 (s, 1H), 9.54 (s, 1H), 8.47 (d, <i>J</i> = 4.7 Hz, 1H), 8.20 (s, 1H), 7.85 (d, <i>J</i> = 8.0 Hz, 1H), 7.67 (d, <i>J</i> = 8.6 Hz, 2H), 7.50 (d, <i>J</i> = 8.6 Hz, 2H), 7.18 (dd, <i>J</i> = 15.0, 7.5 Hz, 2H), 7.03 (d, <i>J</i> = 4.7 Hz, 1H), 6.97 (dd, <i>J</i> = 10.6, 4.1 Hz, 1H), 2.27 (d, <i>J</i> = 11.0 Hz, 6H). HRMS (EI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>19</sub>N<sub>5</sub>O (M<sup>+</sup>) 357.1590, found 357.1595.</div></div><div id="sec6_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> <i>N</i>-(4-Methylphenyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>24</b>)</h4><div class="NLM_p last">White solid; yield = 25%; mp 234–238 °C, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.33 (s, 1H), 9.30 (s, 1H), 9.05 (s, 1H), 8.47 (d, <i>J</i> = 4.7 Hz, 1H), 7.64 (d, <i>J</i> = 8.6 Hz, 2H), 7.49 (d, <i>J</i> = 8.6 Hz, 2H), 7.38 (d, <i>J</i> = 8.4 Hz, 2H), 7.10 (d, <i>J</i> = 8.2 Hz, 2H), 7.03 (d, <i>J</i> = 4.7 Hz, 1H), 2.26 (s, 6H). HRMS (EI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>19</sub>N<sub>5</sub>O (M<sup>+</sup>) 357.1590, found 357.1595.</div></div><div id="sec6_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>N</i>-(3-Fluorophenyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>25</b>)</h4><div class="NLM_p last">White solid; yield = 65%; mp 263–266 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.34 (s, 1H), 9.26 (d, <i>J</i> = 11.4 Hz, 2H), 8.47 (d, <i>J</i> = 4.7 Hz, 1H), 7.66 (d, <i>J</i> = 8.6 Hz, 2H), 7.60–7.46 (m, 3H), 7.32 (dd, <i>J</i> = 15.2, 8.1 Hz, 1H), 7.22–7.11 (m, 1H), 7.03 (d, <i>J</i> = 4.7 Hz, 1H), 6.80 (td, <i>J</i> = 8.4, 2.0 Hz, 1H), 2.26 (s, 3H). HRMS (EI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>16</sub>FN<sub>5</sub>O (M<sup>+</sup>) 361.1339, found 361.1344.</div></div><div id="sec6_2_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>N</i>-(3-Chlorphenyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>26</b>)</h4><div class="NLM_p last">White solid; yield = 84%; mp 238–245 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.34 (s, 1H), 9.56 (d, <i>J</i> = 7.9 Hz, 2H), 8.47 (d, <i>J</i> = 4.7 Hz, 1H), 7.75 (d, <i>J</i> = 0.9 Hz, 1H), 7.66 (d, <i>J</i> = 8.6 Hz, 2H), 7.51 (d, <i>J</i> = 8.6 Hz, 2H), 7.33 (d, <i>J</i> = 1.0 Hz, 2H), 7.17–6.89 (m, 2H), 2.25 (s, 3H). HRMS (EI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>16</sub>ClN<sub>5</sub>O (M<sup>+</sup>) 377.1043, found 377.1042.</div></div><div id="sec6_2_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> <i>N</i>-(3-Cyanophenyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>27</b>)</h4><div class="NLM_p last">White solid; yield = 53%; mp 173–177 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.35 (s, 1H), 9.54 (d, <i>J</i> = 37.3 Hz, 2H), 8.47 (d, <i>J</i> = 4.7 Hz, 1H), 8.02 (s, 1H), 7.72 (d, <i>J</i> = 8.1 Hz, 1H), 7.66 (d, <i>J</i> = 8.5 Hz, 2H), 7.58–7.48 (m, 3H), 7.44 (d, <i>J</i> = 7.6 Hz, 1H), 7.04 (d, <i>J</i> = 4.7 Hz, 1H), 2.25 (s, 3H). HRMS (EI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>16</sub>N<sub>6</sub>O (M<sup>+</sup>) 368.1386, found 368.1395.</div></div></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> General Procedure for the Preparation of Compounds <b>28</b>–<b>40</b></h3><div class="NLM_p">Under ice cooling, after a solution of phenyl chloroformate (0.5 mL, 4 mmol) in THF (0.5 mL) was added dropwise to a solution of the intermediate <b>78</b>/<b>80</b> (3.2 mmol) and pyridine (1.2 mL) in DMF (5 mL), the mixture was stirred at room temperature for 3 h. Ethyl acetate (40 mL) was added thereto, and the whole mixture was washed with water (40 mL) twice and brine (40 mL) twice. The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and the solvent was evaporated under reduced pressure. The resulting solid was collected by filtration with diethyl ether and dried under reduced pressure without further purification. This product was dissolved in 1,4-dioxane (10 mL) with <b>73b</b> (0.5 mmol) and 1-methyl pyrrolidine (20 μL). The mixture was stirred at 80 °C for 12 h and then cooled to room temperature and concentrated. The residue was purified by column chromatography eluting with a mixture of MeOH/DCM to afford corresponding target compounds <b>28</b>–<b>40</b>.</div><div id="sec6_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> <i>N</i>-(3-(4-Methylpiperazin-1-yl)phenyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>28</b>)</h4><div class="NLM_p last">Yellow solid; yield = 27%; mp 108–109 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.33 (s, 1H), 8.91 (s, 1H), 8.68 (s, 1H), 8.46 (d, <i>J</i> = 4.8 Hz, 1H), 7.63 (d, <i>J</i> = 8.4 Hz, 2H), 7.49 (d, <i>J</i> = 8.4 Hz, 2H), 7.20 (s, 1H), 7.12 (t, <i>J</i> = 8.0 Hz, 1H), 7.02 (d, <i>J</i> = 4.8 Hz, 1H), 6.81 (d, <i>J</i> = 7.6 Hz, 1H), 6.59 (d, <i>J</i> = 8.0 Hz, 1H), 3.13 (brs, 4H), 2.50 (brs, 4H), 2.25 (d, 6H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>28</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 442.2350, found 442.2348.</div></div><div id="sec6_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>N</i>-(5-Methyl-2-(4-methylpiperazin-1-yl)phenyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>29</b>)</h4><div class="NLM_p last">White solid; yield = 19%; mp 247–250 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.33 (s, 1H), 9.81 (s, 1H), 8.47 (d, <i>J</i> = 4.8 Hz, 1H), 8.08 (s, 1H), 7.89 (s, 1H), 7.68 (d, <i>J</i> = 8.4 Hz, 2H), 7.50 (d, <i>J</i> = 8.4 Hz, 2H), 7.07 (d, <i>J</i> = 8.0 Hz, 1H), 7.03 (d, <i>J</i> = 4.8 Hz, 1H), 6.79 (d, <i>J</i> = 8.0 Hz, 1H), 2.79 (t, <i>J</i> = 4.0 Hz, 4H), 2.64 (brs, 4H), 2.31 (s, 3H), 2.25 (s, 6H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>30</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 456.2506, found 456.2504.</div></div><div id="sec6_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>N</i>-(3-Methyl-4-(4-methylpiperazin-1-yl)phenyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>30</b>)</h4><div class="NLM_p last">White solid; yield = 20%; mp 236- 238 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.34 (s, 1H), 8.87 (s, 1H), 8.58 (s, 1H), 8.46 (d, <i>J</i> = 4.8 Hz, 1H), 7.62 (d, <i>J</i> = 8.6 Hz, 2H), 7.48 (d, <i>J</i> = 8.6 Hz, 2H), 7.27 (s, 1H), 7.24 (d, <i>J</i> = 8.4 Hz, 1H), 7.02 (d, <i>J</i> = 4.8 Hz, 1H), 6.97 (d, <i>J</i> = 8.8 Hz, 1H), 2.79 (t, <i>J</i> = 4.4 Hz, 4H), 2.45 (brs, 4H), 2.24 (t, 9H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>30</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 456.2506, found 456.2506.</div></div><div id="sec6_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>N</i>-(3-Methyl-4-(morpholin-4-yl)phenyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>31</b>)</h4><div class="NLM_p last">White solid; yield = 18%; mp 253–255 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.32 (s, 1H), 8.85 (s, 1H), 8.57 (s, 1H), 8.46 (d, <i>J</i> = 4.8 Hz, 1H), 7.62 (d, <i>J</i> = 8.4 Hz, 2H), 7.48 (d, <i>J</i> = 8.4 Hz, 2H), 7.28 (s, 1H), 7.26 (d, <i>J</i> = 8.4 Hz,1H), 7.03 (d, <i>J</i> = 4.8 Hz, 1H), 6.98 (d, <i>J</i> = 8.4 Hz, 1H), 3.73 (t, <i>J</i> = 4.4 Hz, 4H), 2.79 (t, <i>J</i> = 4.4 Hz, 4H), 2.25 (s, 6H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>27</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> 443.2190, found 443.2188.</div></div><div id="sec6_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> <i>N</i>-(2-Methyl-4-(4-methylpiperazin-1-yl)phenyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>32</b>)</h4><div class="NLM_p last">Pink solid; yield = 24%; mp 263–264 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.33 (s, 1H), 9.09 (s, 1H), 8.46 (d, <i>J</i> = 4.8 Hz, 1H), 7.86 (s, 1H), 7.62 (d, <i>J</i> = 8.4 Hz, 1H), 7.48 (d, <i>J</i> = 8.4 Hz, 3H), 7.02 (d, <i>J</i> = 4.8 Hz, 1H), 6.81 (s, 1H), 6.75 (d, <i>J</i> = 8.8 Hz, 1H), 3.07 (t, <i>J</i> = 4.4 Hz, 4H), 2.45 (t, <i>J</i> = 4.4 Hz, 4H), 2.25 (s, 3H), 2.21 (s, 6H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>30</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 456.2506, found 456.2504.</div></div><div id="sec6_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> <i>N</i>-(2-(4-Methylpiperazin-1-yl)phenyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>33</b>)</h4><div class="NLM_p last">White solid; yield = 89%; mp 253–253 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.33 (s, 1H), 8.91 (s, 1H), 8.68 (s, 1H), 8.46 (d, <i>J</i> = 4.8 Hz, 1H), 7.63 (d, <i>J</i> = 8.4 Hz, 3H), 7.49 (d, <i>J</i> = 8.4 Hz, 2H), 7.20 (s, 1H), 7.12 (t, <i>J</i> = 8.0 Hz, 1H), 7.02 (d, <i>J</i> = 4.8 Hz, 1H), 6.81 (d, <i>J</i> = 7.6 Hz, 1H), 6.59 (d, <i>J</i> = 8.0 Hz, 1H), 3.13 (brs, 4H), 2.50 (brs, 4H), 2.25 (d, 6H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>28</sub>N<sub>7</sub>O [M + H]<sup>+</sup> 442.2350, found 442.2346.</div></div><div id="sec6_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>N</i>-(5-Methyl-2-(morpholin-4-yl)phenyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>34</b>)</h4><div class="NLM_p last">Yellow solid; yield = 48%; mp 268–270 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.34 (s, 1H), 9.76 (s, 1H), 8.47 (d, <i>J</i> = 4.4 Hz, 1H), 8.19 (s, 1H), 7.94 (s, 1H), 7.68 (d, <i>J</i> = 8.4 Hz, 2H), 7.51 (d, <i>J</i> = 8.4 Hz, 2H), 7.09 (d, <i>J</i> = 8.0 Hz, 1H), 7.03 (d, <i>J</i> = 4.4 Hz, 1H), 6.81 (d, <i>J</i> = 8.0 Hz, 1H), 3.86 (t, <i>J</i> = 3.6 Hz, 4H), 2.79 (t, <i>J</i> = 3.6 Hz, 4H), 2.26 (d, 6H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>27</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> 443.2190, found 443.2188.</div></div><div id="sec6_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> <i>N</i>-(2-(Morpholin-4-yl)phenyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>35</b>)</h4><div class="NLM_p last">White solid; yield = 39%; mp 225–228 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.33 (s, 1H), 9.76 (s, 1H), 8.47 (d, <i>J</i> = 4.4 Hz, 1H), 8.20 (s, 1H), 8.08 (d, <i>J</i> = 8.0 Hz, 1H), 7.68 (d, <i>J</i> = 8.4 Hz, 2H), 7.51 (d, <i>J</i> = 8.4 Hz, 2H), 7.20 (d, <i>J</i> = 7.2 Hz, 1H), 7.10 (t, <i>J</i> = 7.2 Hz, 1H), 7.03 (d, <i>J</i> = 4.4 Hz, 1H), 6.99 (d, <i>J</i> = 8.0 Hz, 1H), 3.87 (brs, 4H), 2.83 (brs, 4H), 2.25 (s, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>25</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> 429.2034, found 429.2033.</div></div><div id="sec6_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> <i>N</i>-((3-Diethylamino)phenyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>36</b>)</h4><div class="NLM_p last">Green-brown solid; yield = 26%; mp 125–128 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.34 (s, 1H), 8.84 (s, 1H), 8.59 (s, 1H), 8.47 (d, <i>J</i> = 4.8 Hz, 1H), 7.63 (d, <i>J</i> = 8.4 Hz, 2H), 7.49 (d, <i>J</i> = 8.4 Hz, 2H), 7.03 (t, <i>J</i> = 4.8 Hz,8.4 Hz, 2H), 6.92 (s, 1H), 6.63 (d, <i>J</i> = 8.4 Hz, 1H), 6.31 (d, <i>J</i> = 8.4 Hz, 1H), 3.31 (q, <i>J</i> = 7.2 Hz, 4H), 2.25 (s, 3H), 1.10 (t, <i>J</i> = 7.2 Hz, 6H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>27</sub>N<sub>6</sub>O [M + H]<sup>+</sup> 415.2241, found 415.2241.</div></div><div id="sec6_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> <i>N</i>-((4-Diethylamino)phenyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>37</b>)</h4><div class="NLM_p last">Brown solid; yield = 73%; mp 242–246 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.32 (s, 1H), 8.76 (s, 1H), 8.46 (d, <i>J</i> = 4.8 Hz, 1H), 8.33 (s, 1H), 7.63 (d, <i>J</i> = 8.4 Hz, 2H), 7.47 (d, <i>J</i> = 8.4 Hz, 2H), 7.25 (d, <i>J</i> = 8.8 Hz, 2H), 7.00 (d, <i>J</i> = 4.8 Hz, 1H), 6.64 (d, <i>J</i> = 8.8 Hz, 2H), 3.27 (q, <i>J</i> = 6.8 Hz, 4H), 2.26 (s, 3H), 1.07 (t, <i>J</i> = 6.8 Hz, 6H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>27</sub>N<sub>6</sub>O [M + H]<sup>+</sup> 415.2241, found 415.2238.</div></div><div id="sec6_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> <i>N</i>-((3-Dimethylamino)phenyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>38</b>)</h4><div class="NLM_p last">Light-yellow solid; yield = 19%; mp 226–228 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.33 (s, 1H), 8.84 (s, 1H), 8.61 (s, 1H), 8.46 (d, <i>J</i> = 4.8 Hz, 1H), 7.63 (d, <i>J</i> = 8.4 Hz, 2H), 7.49 (d, <i>J</i> = 8.4 Hz, 2H), 7.08 (t, <i>J</i> = 8.0 Hz, 1H), 7.03 (d, <i>J</i> = 4.8 Hz, 1H), 6.95 (s, 1H), 6.74 (d, <i>J</i> = 8.0 Hz, 1H), 6.38 (d, <i>J</i> = 8.0 Hz, 1H), 2.89 (s, 7H), 2.25 (s, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>23</sub>N<sub>6</sub>O [M + H]<sup>+</sup> 387.1928, found 387.1925.</div></div><div id="sec6_3_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> <i>N</i>-((4-Dimethylamino)phenyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>39</b>)</h4><div class="NLM_p last">Brown solid; yield = 10%; mp 218–221 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.33 (s, 1H), 8.78 (s, 1H), 8.46 (d, <i>J</i> = 4.4 Hz, 1H), 8.41 (s, 1H), 7.61 (d, <i>J</i> = 8.4 Hz, 2H), 7.48 (d, <i>J</i> = 8.4 Hz, 2H), 7.29 (d, <i>J</i> = 8.8 Hz, 2H), 7.02 (d, <i>J</i> = 4.4 Hz, 1H), 6.72 (d, <i>J</i> = 8.8 Hz, 2H), 2.82 (d, 6H), 2.23 (s, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>23</sub>N<sub>6</sub>O [M + H]<sup>+</sup> 387.1928, found 387.1928.</div></div><div id="sec6_3_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> <i>N</i>-((3-((Dimethylamino)methyl)phenyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>40</b>)</h4><div class="NLM_p last">Yellow solid; yield = 23%; mp 185–186 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.39 (s, 1H), 9.64 (s, 1H), 9.25 (s, 1H), 8.52 (d, <i>J</i> = 2.8 Hz, 1H), 7.95 (d, <i>J</i> = 7.6 Hz, 1H), 7.73 (d, <i>J</i> = 7.2 Hz, 2H), 7.55 (d, <i>J</i> = 7.2 Hz, 2H), 7.31 (t, <i>J</i> = 6.4 Hz, 1H), 7.23 (d, <i>J</i> = 6.4 Hz, 1H), 7.08 (d, <i>J</i> = 2.8 Hz, 1H), 7.04 (t, <i>J</i> = 6.4 Hz, 1H), 3.50 (s, 2H), 2.30 (s, 3H), 2.24 (s, 6H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>25</sub>N<sub>6</sub>O [M + H]<sup>+</sup> 401.2084, found 401.2082.</div></div></div><div id="sec6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> General Procedure for the Preparation of Compounds <b>41</b>–<b>65</b></h3><div class="NLM_p">A solution of corresponding substituted amine (37.4 mmol) in DMSO was added: Et<sub>3</sub>N (5.73 mL, 41.1 mmol), CDI (3.64 g, 22.4 mmol), and <b>73b</b>. After stirring overnight at room temperature, the mixture was partitioned between EtOAc and water. Upon separation of the layers, the organic layer was washed with brine and then dried over Na<sub>2</sub>SO<sub>4</sub>. The desiccant was filtered and the solvent removed under vacuum to provide raw products, which were purified by column chromatography eluted with a mixture of MeOH/DCM to obtain the corresponding target compounds.</div><div id="sec6_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> <i>N</i>-Ethyl-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>41</b>)</h4><div class="NLM_p last">Yellow solid; yield = 69%; mp 211–213 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.17 (s, 1H), 8.49 (d, <i>J</i> = 4.8 Hz, 1H), 7.30 (d, <i>J</i> = 8.0 Hz, 2H), 7.12 (d, <i>J</i> = 4.8 Hz, 1H), 6.83 (d, <i>J</i> = 8.0 Hz, 2H), 3.62 (q, 2H), 2.36 (s, 3H), 1.35 (t, <i>J</i> = 7.2 Hz, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>18</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 296.1511, found 296.1506.</div></div><div id="sec6_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> <i>N</i>-Propyl-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>42</b>)</h4><div class="NLM_p last">Yellow solid; yield = 64%; mp 208–210 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.15 (t, <i>J</i> = 5.6 Hz, 1H), 8.56 (d, <i>J</i> = 4.8 Hz, 1H), 7.28 (d, <i>J</i> = 8.4 Hz, 2H), 7.22 (d, <i>J</i> = 4.8 Hz, 1H), 6.72 (d, <i>J</i> = 8.4 Hz, 2H), 3.42–3.35 (t, 2H), 2.30 (s, 3H), 1.68–1.55 (m, 2H), 0.95 (t, <i>J</i> = 7.6 Hz, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>20</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 310.1668, found 310.1662.</div></div><div id="sec6_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> <i>N</i>-Butyl-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>43</b>)</h4><div class="NLM_p last">Yellow solid; yield = 72%; mp 177–180 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.20 (s, 1H), 8.49 (d, <i>J</i> = 4.8 Hz, 1H), 7.27 (d, <i>J</i> = 7.6 Hz, 2H), 7.12 (d, <i>J</i> = 4.8 Hz, 1H), 6.81 (d, <i>J</i> = 7.6 Hz, 2H), 3.58 (dd, <i>J</i> = 13.2, 6.4 Hz, 2H), 2.38 (s, 3H), 1.81–1.64 (m, 2H), 1.48 (m, 2H), 0.99 (t, <i>J</i> = 7.2 Hz, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>22</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 324.1824, found 324.1819.</div></div><div id="sec6_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> <i>N</i>-<i>n</i>-Pentyl-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>44</b>)</h4><div class="NLM_p last">Yellow solid; yield = 68%; mp 233–236 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.31 (s, 1H), 8.64 (s, 1H), 8.45 (d, <i>J</i> = 4.4 Hz, 1H), 7.56 (d, <i>J</i> = 8.4 Hz, 2H), 7.43 (d, <i>J</i> = 8.4 Hz, 2H), 7.00 (d, <i>J</i> = 4.8 Hz, 1H), 6.22 (t, <i>J</i> = 5.6 Hz, 1H), 3.10 (dd, <i>J</i> = 12.4 Hz, 6.4 Hz, 2H), 2.24 (s, 3H), 1.45 (m, 2H), 1.30 (m, 4H), 0.89 (t, <i>J</i> = 6.4 Hz, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>24</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 338.1981, found 338.1975.</div></div><div id="sec6_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> <i>N</i>-<i>n</i>-Hexyl-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>45</b>)</h4><div class="NLM_p last">Light-yellow solid; yield = 68%; mp 233–236 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.30 (s, 1H), 8.63 (s, 1H), 8.44 (d, <i>J</i> = 4.8 Hz, 1H), 7.56 (d, <i>J</i> = 8.4 Hz, 2H), 7.42 (d, <i>J</i> = 8.4 Hz, 2H), 7.00 (d, <i>J</i> = 4.8 Hz, 1H), 6.21 (t, <i>J</i> = 5.6 Hz, 1H), 3.10 (dd, <i>J</i> = 12.8, 6.4 Hz, 2H), 2.23 (s, 3H), 1.43 (m, 2H), 1.29 (m, 6H), 0.88 (t, <i>J</i> = 6.4 Hz, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>25</sub>N<sub>5</sub>NaO [M + Na]<sup>+</sup> 374.1957, found 374.1951.</div></div><div id="sec6_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> <i>N</i>-Isobutyl-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>46</b>)</h4><div class="NLM_p last">White solid; yield = 69%; mp 262–265 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.30 (s, 1H), 8.64 (s, 1H), 8.44 (d, <i>J</i> = 4.8 Hz, 1H), 7.56 (d, <i>J</i> = 8.4 Hz, 2H), 7.43 (d, <i>J</i> = 8.4 Hz, 2H), 7.00 (d, <i>J</i> = 4.8 Hz, 1H), 6.27 (t, <i>J</i> = 6.0 Hz, 1H), 2.95 (t, <i>J</i> = 6.4 Hz, 2H), 2.23 (s, 3H), 1.71 (dt, <i>J</i> = 13.6, 6.8 Hz, 1H), 0.89 (d, <i>J</i> = 6.8 Hz, 6H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>22</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 324.1825, found 324.1819.</div></div><div id="sec6_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> <i>N</i>-<i>tert</i>-Butyl-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>47</b>)</h4><div class="NLM_p last">Yellow solid; yield = 56%; mp 244–251 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.30 (s, 1H), 8.47 (s, 1H), 8.44 (d, <i>J</i> = 4.4 Hz, 1H), 7.52 (d, <i>J</i> = 8.4 Hz, 2H), 7.42 (d, <i>J</i> = 8.4 Hz, 2H), 6.99 (d, <i>J</i> = 4.4 Hz, 1H), 6.08 (s, 1H), 2.23 (s, 3H), 1.31 (s, 9H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>21</sub>N<sub>5</sub>NaO [M + Na]<sup>+</sup> 346.1644, found 346.1638.</div></div><div id="sec6_4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> <i>N</i>-Cyclopropyl-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>48</b>)</h4><div class="NLM_p last">White solid; yield = 63%; mp 247–250 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.30 (s, 1H), 8.53 (s, 1H), 8.45 (d, <i>J</i> = 4.4 Hz, 1H), 7.58 (d, <i>J</i> = 8.4 Hz, 2H), 7.43 (d, <i>J</i> = 8.4 Hz, 2H), 7.00 (d, <i>J</i> = 4.4 Hz, 1H), 6.49 (d, <i>J</i> = 2.0 Hz, 1H), 2.60–2.55 (m, 1H), 2.23 (s, 3H), 0.65 (q, <i>J</i> = 6.8 Hz, 2H), 0.46–0.39 (m, 2H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>18</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 308.1511, found 308.1506.</div></div><div id="sec6_4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> <i>N</i>-Cyclobutyl-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>49</b>)</h4><div class="NLM_p last">White solid; yield = 67%; mp 240–243 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.30 (s, 1H), 8.56 (s, 1H), 8.44 (d, <i>J</i> = 4.8 Hz, 1H), 7.55 (d, <i>J</i> = 8.4 Hz, 2H), 7.42 (d, <i>J</i> = 8.4 Hz, 2H), 7.00 (d, <i>J</i> = 4.8 Hz, 1H), 6.50 (d, <i>J</i> = 8.0 Hz, 1H), 4.15 (dd, <i>J</i> = 16.4, 8.4 Hz, 1H), 2.23 (s, 3H), 2.19 (dd, 2H), 1.86 (dd, <i>J</i> = 19.6, 10.4 Hz, 2H), 1.70–1.55 (m, 2H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>20</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 322.1668, found 322.1662.</div></div><div id="sec6_4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> <i>N</i>-Cyclopentyl-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>50</b>)</h4><div class="NLM_p last">White solid; yield = 89%; mp 258–262 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.30 (s, 1H), 8.49 (s, 1H), 8.44 (d, <i>J</i> = 4.8 Hz, 1H), 7.55 (d, <i>J</i> = 8.4 Hz, 2H), 7.42 (d, <i>J</i> = 8.4 Hz, 2H), 7.00 (d, <i>J</i> = 4.8 Hz, 1H), 6.25 (d, <i>J</i> = 7.2 Hz, 1H), 3.96 (dq, <i>J</i> = 13.2, 6.8 Hz, 1H), 2.23 (s, 3H), 1.85 (dt, <i>J</i> = 12.2, 6.0 Hz, 2H), 1.62 (dd, <i>J</i> = 16.4, 6.0 Hz, 2H), 1.56 (dd, <i>J</i> = 14.2, 7.2 Hz, 2H), 1.39 (dt, <i>J</i> = 12.2, 6.4 Hz, 2H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>22</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 336.1824, found 336.1819.</div></div><div id="sec6_4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> <i>N</i>-Cyclohexyl-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>51</b>)</h4><div class="NLM_p last">Light-yellow solid; yield = 52%; mp 233–237 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.30 (s, 1H), 8.53 (s, 1H), 8.44 (d, <i>J</i> = 4.4 Hz, 1H), 7.54 (d, <i>J</i> = 8.4 Hz, 2H), 7.42 (d, <i>J</i> = 8.4 Hz, 2H), 7.00 (d, <i>J</i> = 4.8 Hz, 1H), 6.17 (d, <i>J</i> = 7.6 Hz, 1H), 3.54–3.41 (m, 1H), 2.23 (s, 3H), 1.82 (d, <i>J</i> = 8.8 Hz, 2H), 1.67 (d, <i>J</i> = 12.8 Hz, 2H), 1.55 (d, <i>J</i> = 12.0 Hz, 1H), 1.32 (dd, <i>J</i> = 23.6, 11.6 Hz, 2H), 1.18 (dd, <i>J</i> = 21.8, 12.0 Hz, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>24</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 350.1981, found 350.1975.</div></div><div id="sec6_4_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> <i>N</i>-(Furan-2-ylmethyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>52</b>)</h4><div class="NLM_p last">White solid; yield = 70%; mp 232–234 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.31 (s, 1H), 8.77 (s, 1H), 8.45 (d, <i>J</i> = 4.8 Hz, 1H), 7.60 (s, 1H), 7.57 (d, <i>J</i> = 8.4 Hz, 2H), 7.44 (d, <i>J</i> = 8.4 Hz, 2H), 7.00 (d, <i>J</i> = 4.8 Hz, 1H), 6.65 (t, <i>J</i> = 5.6 Hz, 1H), 6.41 (s, 1H), 6.28 (s, 1H), 4.32 (d, <i>J</i> = 5.6 Hz, 2H), 2.23 (s, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>18</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 348.1460, found 348.1455.</div></div><div id="sec6_4_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> <i>N</i>-(Thiophen-2-ylmethyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>53</b>)</h4><div class="NLM_p last">White solid; yield = 67%; mp 233–235 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.31 (s, 1H), 8.81 (s, 1H), 8.45 (d, <i>J</i> = 4.8 Hz, 1H), 7.58 (d, <i>J</i> = 8.4 Hz, 2H), 7.44 (d, <i>J</i> = 8.4 Hz, 2H), 7.40 (d, <i>J</i> = 4.8 Hz, 1H), 7.04–6.94 (m, 3H), 6.77 (t, <i>J</i> = 5.6 Hz, 1H), 4.49 (d, <i>J</i> = 5.6 Hz, 2H), 2.23 (s, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>17</sub>N<sub>5</sub>NaOS [M + Na]<sup>+</sup> 386.1052, found 386.1046.</div></div><div id="sec6_4_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> <i>N</i>-(Pyridin-2-ylmethyl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>54</b>)</h4><div class="NLM_p last">Light-yellow solid; yield = 68%; mp 218–222 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.31 (s, 1H), 8.97 (s, 1H), 8.52 (d, <i>J</i> = 4.4 Hz, 2H), 8.45 (d, <i>J</i> = 4.4 Hz, 1H), 7.59 (d, <i>J</i> = 8.4 Hz, 2H), 7.44 (d, <i>J</i> = 8.4 Hz, 2H), 7.32 (d, <i>J</i> = 4.8 Hz, 2H), 7.00 (d, <i>J</i> = 4.8 Hz, 1H), 6.85 (t, <i>J</i> = 6.0 Hz, 1H), 4.36 (d, <i>J</i> = 6.0 Hz, 2H), 2.23 (s, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>19</sub>N<sub>6</sub>O [M + H]<sup>+</sup> 359.1620, found 359.1615.</div></div><div id="sec6_4_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> <i>N</i>-Benzyl-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>55</b>)</h4><div class="NLM_p last">Light-yellow solid; yield = 50%; mp 91–97 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.56 (t, <i>J</i> = 6.0 Hz, 1H), 8.55 (d, <i>J</i> = 4.8 Hz, 1H), 7.37 (m,4H), 7.27 (t, <i>J</i> = 7.8 Hz, 3H), 7.23 (d, <i>J</i> = 5.2 Hz, 1H), 6.71 (d, <i>J</i> = 8.4 Hz, 2H), 4.63 (d, <i>J</i> = 6.0 Hz, 2H), 2.32 (s, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>20</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 358.1668, found 358.1662.</div></div><div id="sec6_4_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> <i>N</i>-Phenylethyl-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>56</b>)</h4><div class="NLM_p last">White solid; yield = 82%; mp 221–224 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.31 (s, 1H), 8.73 (s, 1H), 8.45 (d, <i>J</i> = 4.8 Hz, 1H), 7.56 (d, <i>J</i> = 8.4 Hz, 2H), 7.43 (d, <i>J</i> = 8.4 Hz, 2H), 7.32 (d, <i>J</i> = 7.6 Hz, 2H), 7.24 (dd, <i>J</i> = 18.6, 7.2 Hz, 3H), 7.00 (d, <i>J</i> = 4.8 Hz, 1H), 6.22 (t, <i>J</i> = 5.6 Hz, 1H), 3.37 (t, 2H), 2.78 (t, <i>J</i> = 7.2 Hz, 2H), 2.23 (s, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>22</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 372.1824, found 372.1819.</div></div><div id="sec6_4_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> <i>N</i>-Phenylpropyl-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>57</b>)</h4><div class="NLM_p last">Yellow solid; yield = 70%; mp 223–225 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.31 (s, 1H), 8.68 (s, 1H), 8.45 (d, <i>J</i> = 4.8 Hz, 1H), 7.57 (d, <i>J</i> = 8.4 Hz, 2H), 7.43 (d, <i>J</i> = 8.4 Hz, 2H), 7.30 (t, <i>J</i> = 7.2 Hz, 2H), 7.23 (d, <i>J</i> = 7.2 Hz, 2H), 7.19 (t, <i>J</i> = 7.2 Hz, 1H), 7.00 (d, <i>J</i> = 4.8 Hz, 1H), 6.31 (t, <i>J</i> = 5.6 Hz, 1H), 3.13 (dd, <i>J</i> = 12.8, 6.4 Hz, 2H), 2.63 (t, <i>J</i> = 7.6 Hz, 2H), 2.24 (s, 3H), 1.83–1.67 (m, 2H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>23</sub>N<sub>5</sub>NaO [M + Na]<sup>+</sup> 408.1800, found 408.1795.</div></div><div id="sec6_4_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> <i>N</i>-Phenylbutyl-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>58</b>)</h4><div class="NLM_p last">White solid; yield = 92%; mp 224–227 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.30 (s, 1H), 8.63 (s, 1H), 8.44 (d, <i>J</i> = 4.8 Hz, 1H), 7.55 (d, <i>J</i> = 8.4 Hz, 2H), 7.42 (d, <i>J</i> = 8.4 Hz, 2H), 7.28 (t, <i>J</i> = 7.2 Hz, 2H), 7.24–7.13 (m, 3H), 6.99 (d, <i>J</i> = 4.4 Hz, 1H), 6.24 (t, <i>J</i> = 5.6 Hz, 1H), 3.13 (dd, <i>J</i> = 12.6, 6.4 Hz, 2H), 2.61 (t, <i>J</i> = 7.2 Hz, 2H), 2.23 (s, 3H), 1.60 (dd, <i>J</i> = 14.8, 7.2 Hz, 2H), 1.47 (dd, <i>J</i> = 14.5, 7.0 Hz, 2H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>25</sub>N<sub>5</sub>NaO [M + Na]<sup>+</sup> 422.1957, found 422.1951.</div></div><div id="sec6_4_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> <i>N</i>-(2,3-Dihydro-1<i>H</i>-inden-2-yl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>59</b>)</h4><div class="NLM_p last">White solid; yield = 20%; mp 249–251 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.30 (s, 1H), 8.55 (s, 1H), 8.44 (d, <i>J</i> = 4.8 Hz, 1H), 7.55 (d, <i>J</i> = 8.4 Hz, 2H), 7.43 (d, <i>J</i> = 8.4 Hz, 2H), 7.30–7.22 (m, 2H), 7.21–7.14 (m, 2H), 7.00 (d, <i>J</i> = 4.8 Hz, 1H), 6.55 (d, <i>J</i> = 7.2 Hz, 1H), 4.45 (m, 1H), 3.23 (d, <i>J</i> = 7.2 Hz, 1H), 3.19 (d, <i>J</i> = 6.8 Hz, 1H), 2.82 (d, <i>J</i> = 5.2 Hz, 1H), 2.78 (d, <i>J</i> = 4.8 Hz, 1H), 2.22 (s, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>22</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 384.1824, found 384.1819.</div></div><div id="sec6_4_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> <i>N</i>-(1<i>H</i>-Pyrazol-5-yl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>60</b>)</h4><div class="NLM_p last">White solid; yield = 30%; mp 260–263 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.33 (s, 1H), 12.28 (s, 1H), 9.26 (s, 1H), 9.06 (s, 1H), 8.46 (d, <i>J</i> = 4.8 Hz, 1H), 7.63 (d, <i>J</i> = 8.4 Hz, 3H), 7.49 (d, <i>J</i> = 8.4 Hz, 2H), 7.03 (d, <i>J</i> = 4.8 Hz, 1H), 6.29 (s, 1H), 2.24 (s, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>15</sub>N<sub>7</sub>NaO [M + Na]<sup>+</sup> 356.1236, found 356.1230.</div></div><div id="sec6_4_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> <i>N</i>-(Pyridin-2-yl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>61</b>)</h4><div class="NLM_p last">Yellow solid; yield = 30%; mp 244–248 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.32 (s, 1H), 10.74 (s, 1H), 9.53 (s, 1H), 8.46 (d, <i>J</i> = 4.7 Hz, 1H), 8.30 (d, <i>J</i> = 4.9 Hz, 1H), 7.76 (t, <i>J</i> = 7.8 Hz, 1H), 7.70 (d, <i>J</i> = 8.4 Hz, 2H), 7.51 (t, <i>J</i> = 8.0 Hz, 3H), 7.02 (dd, <i>J</i> = 8.1, 4.0 Hz, 2H), 2.23 (s, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>16</sub>N<sub>6</sub>NaO [M + Na]<sup>+</sup> 367.1283, found 367.1278.</div></div><div id="sec6_4_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> <i>N</i>-(Pyridin-3-yl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>62</b>)</h4><div class="NLM_p last">White solid; yield = 52%; mp 245–247 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.33 (s, 1H), 9.06 (s, 1H), 8.64 (s, 1H), 8.47 (d, <i>J</i> = 4.8 Hz, 1H), 8.21 (d, <i>J</i> = 4.0 Hz, 1H), 7.97 (d, <i>J</i> = 8.4 Hz, 1H), 7.65 (d, <i>J</i> = 8.4 Hz, 2H), 7.51 (d, <i>J</i> = 8.4 Hz, 2H), 7.34 (dd, <i>J</i> = 8.4, 4.8 Hz, 1H), 7.03 (d, <i>J</i> = 4.4 Hz, 1H), 6.66 (s, 1H), 2.25 (s, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>16</sub>N<sub>6</sub>NaO [M + Na]<sup>+</sup> 367.1283, found 367.1278.</div></div><div id="sec6_4_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> <i>N</i>-(Quinolin-3-yl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>63</b>)</h4><div class="NLM_p last">Yellow solid; yield = 30%; mp 226–229 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.33 (s, 1H), 9.23 (s, 1H), 9.15 (s, 1H), 8.87 (d, <i>J</i> = 2.4 Hz, 1H), 8.56 (d, <i>J</i> = 2.4 Hz, 1H), 8.47 (d, <i>J</i> = 4.7 Hz, 1H), 7.93 (dd, <i>J</i> = 13.8, 8.3 Hz, 2H), 7.69 (d, <i>J</i> = 8.4 Hz, 2H), 7.64–7.55 (m, 2H), 7.53 (d, <i>J</i> = 8.4 Hz, 2H), 7.04 (d, <i>J</i> = 4.8 Hz, 1H), 2.26 (s, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>19</sub>N<sub>6</sub>O [M + H]<sup>+</sup> 395.1620, found 395.1615.</div></div><div id="sec6_4_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> <i>N</i>-(Naphthalen-2-yl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>64</b>)</h4><div class="NLM_p last">White solid; yield = 34%; mp 232–235 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.32 (s, 1H), 8.99 (d, <i>J</i> = 5.6 Hz, 2H), 8.47 (d, <i>J</i> = 4.8 Hz, 1H), 8.14 (s, 1H), 7.89–7.78 (m, 3H), 7.68 (d, <i>J</i> = 8.8 Hz, 2H), 7.55–7.49 (m, 3H), 7.49–7.43 (m, 1H), 7.37 (t, <i>J</i> = 7.6 Hz, 1H), 7.04 (d, <i>J</i> = 4.8 Hz, 1H), 2.25 (s, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>20</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 394.1668, found 394.1662.</div></div><div id="sec6_4_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> <i>N</i>-(Naphthalen-1-yl)-<i>N</i>′-(4-(3-methyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-4-yl)phenyl)urea (<b>65</b>)</h4><div class="NLM_p last">Yellow solid; yield = 69%; mp 225–228 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.34 (s, 1H), 8.87 (s, 1H), 8.48 (d, <i>J</i> = 4.4 Hz, 1H), 8.15 (d, <i>J</i> = 8.4 Hz, 1H), 8.03 (d, <i>J</i> = 7.2 Hz, 1H), 7.96 (d, <i>J</i> = 8.0 Hz, 1H), 7.75–7.47 (m, 9H), 7.04 (d, <i>J</i> = 4.4 Hz, 1H), 2.26 (s, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>20</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 394.1668, found 394.1662.</div></div></div><div id="sec6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> Kinase Enzyme Assays</h3><div class="NLM_p last">Enzyme inhibition assays were carried by mobility shift assay under the condition of ATP at km concentration. c-KIT, PDGFRα–β, VEGFR1–3, FLT3, and FGFR-1 kinase activities were tested in vitro, with staurosporine and <b>1</b> serving as a reference and positive control compound, respectively. An excess (2.5×) of corresponding enzyme was added into the plate except to control wells (no enzyme), where the buffer (1×) (50 mM HEPES pH 7.5, 0.01% Brij-35, 10 mM MgCl<sub>2</sub>, 2 mM DTT) was added instead. FAM-labeled peptide and ATP were simultaneously added to the 1× kinase base buffer to prepare 2.5× peptide solution. The initial concentration of each compound was prepared at 50 μM in 100% DMSO solution and then diluted 5-fold to eight different concentrations; a 5 μL volume was added for dose response in 384-well reaction plates. A 10 μL volume of the above diluted enzyme solution was sequentially added, and the assay plates were incubated at room temperature for 10 min. A 10 μL volume of the above 2.5× peptide solution was added and incubated at 28 °C for the specified period of time. The reaction was stopped with the addition of 50 mM EDTA containing 25 mL of 100 mM HEPES, pH 7.5, 0.015% Brij-35, and 0.2% Coating Reagent no. 3. After detection by a single span, the conversion values were read with a caliper and converted into inhibition values according to the following formula: percent inhibition = (max-conversion)/(max – min) × 100 (“max” stands for DMSO control; “min” stands for low control with no kinase control). Finally, the data were fitted in XLfit excel add-in version 4.3.1 to obtain IC<sub>50</sub> values. The equation used is <i>Y</i> = Bottom + (Top – Bottom)/(1 + (LogIC<sub>50</sub>/<i>X</i>) × HillSlope)).</div></div><div id="sec6_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> Cellular Antiproliferation Assays</h3><div id="sec6_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> TEL-Isogenic Cell Generation</h4><div class="NLM_p last">On the basis of the pMSCVpuro (Clontech) backbone, retroviral constructs for BaF3-c-KIT and BaF3-PDGFRα mutants were prepared according to published procedures. For the TEL-c-KIT/PDGFRα vector, the first 1 kb of human TEL gene with an artificial myristoylation site sequence (MGCGCSSHPEDD) was cloned into the pMSCVpuro retroviral vector, followed by a 3xFLAG tag sequence and 3976a stop codon. Thereafter, the kinase domain coding sequence of c-KIT/PDGFRα was inserted in-frame between TEL and 3xFLAG sequences. For full-length expression vectors, the coding sequences of c-KIT/PDGFRα variants were directly cloned in pMSCVpuro vector with a 3xFLAG tag at the C-terminal end. All mutagenesis was performed using the QuikChange site-directed mutagenesis kit (Stratagene) following the manufacturer’s instructions. Retrovirus was packaged in HEK293T cells by transfecting c-KIT/PDGFRα-containing MSCV vectors together with two helper plasmids. Virus supernatants were harvested 48 h after transfection and filtered before infection. BaF3 cells were then infected with harvested virus supernatants using an inoculation protocol, and stable cell lines were obtained after puromycin selection for 48 h. The IL-3 concentrations in the culture medium were gradually withdrawn until cells were able to grow in the absence of IL-3.</div></div><div id="sec6_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> Cell Lines and Cell Culture</h4><div class="NLM_p last">All of the cells were obtained and maintained as described. All the isogenic BaF3 cells were grown in RPMI 1640 medium supplemented with 10% FBS and 1% penicillin/streptomycin. The human GIST-T1 cell line was purchased from Cosmo Bio Co., Ltd. (Tokyo, Japan). GIST-882 and GIST-48B cell lines were kindly provided by the group of Professor Jonathan A. Fletcher, Brigham and Women’s Hospital, Boston (USA). K562 (CML), KU812 (CML), MEG-01 (CML), CHL (hamster lung cell), and CHO (hamster ovary cell) were obtained from American Type Culture Collection (Manassas, VA). GIST-T1 and CHO cells were maintained in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. GIST-882 and GIST-48B cells were grown in IMDM supplemented with 10% FBS and 1% penicillin/streptomycin.</div></div><div id="sec6_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> General Procedure for Antiproliferation Study</h4><div class="NLM_p last">A series of concentrations of compound <b>31</b> were added into the 96-well culture plates (3000/well) seeded with cells and treated for 72 h to observe the cell proliferation. According to the manufacturer’s instructions, cell viability was detected using the CellTiter-Glo assay (Promega, USA), and luminescence was measured using a multilabel reader (Envision, PerkinElmer, USA). The data were normalized to control groups (DMSO) and represented as the mean of three independent measurements with standard error of <20%. GI<sub>50</sub> values were calculated using Prism 5.0 (GraphPad Software, San Diego, CA).</div></div></div><div id="sec6_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> Rat Pharmacokinetics Assay in Vivo</h3><div class="NLM_p last">Male Sprague–Dawley rats (<i>n</i> = 3, 210–220 g, Shanghai Sippr-BK Laboratory Animal Co. Ltd.) injected intraveneously via the jugular vein were used in the pharmacokinetic studies of compound <b>31</b>. This drug was dissolved and vortexed in 5% DMSO, 40% PEG400, and 55% (30%-HP-β-CD) for a dosing volume of 2 mL/kg. The rats were housed in a room with controlled temperature and humidity and allowed free access to food and water. Serial blood samples were collected from the jugular vein cannulae of all animals at 0 (predose) and at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 h postdose. These samples were centrifuged at 4 °C to obtain plasma, which was stored at −80 °C until analysis by LC/MS/MS for each analyte within a week. The plasma concentration versus time data were analyzed, and the pharmacokinetic parameters were calculated. At last, all surviving animals were transferred to the repository or euthanized after completing the test.</div></div><div id="sec6_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> GIST-T1 Xenograft Model</h3><div class="NLM_p last">The in vivo anti-GIST activity of compound <b>31</b> was evaluated using a GIST-T1 xenograft model in five-week-old female nu/nu mice purchased from the Shanghai Experimental Center, Chinese Academy of Sciences (Shanghai, China). Animal facilities and experiments were in accordance with local institutional guidelines for animal welfare and were approved by Hefei Institutes of Physical Science, Chinese Academy of Sciences (Hefei, China). All efforts were made to minimize animal suffering. Briefly, animals were randomly divided into three groups (A, vehicle (<i>n</i> = 5); B, <b>31</b> at 25 mg/kg/day (<i>n</i> = 5); C, <b>31</b> at 100 mg/kg/day (<i>n</i> = 5)). Five million GIST-T1 cells harvested during exponential growth in PBS were suspended in a 1:1 mixture with Matrigel (BD Biosciences) and injected into the subcutaneous space on the right flank of the nu/nu mice. A range of doses of <b>31</b> or its vehicle was delivered daily in an HKI solution (0.5% methocellulose/0.4% Tween 80 in ddH<sub>2</sub>O) by intraperitoneal injection when GIST-T1 tumors had reached a volume of 100–200 mm<sup>3</sup>. As indicated in the legend of <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>, body weight and tumor growth were measured daily after treatment with <b>31</b>, and the growth tumor curves were determined by measuring the tumor volume using the following equation: <i>V</i>(mm<sup>3</sup>) = (<i>L</i> × <i>W</i><sup>2</sup>)/2, where length (<i>L</i>) is defined as the larger of the two measurements, and width (<i>W</i>) is defined as the smaller of the two measurements.</div></div><div id="sec6_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> HE Staining</h3><div class="NLM_p last">HE staining was performed as previously reported.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The tissue sections on a slide were hydrated and dipped into a Coplin jar containing Mayer’s hematoxylin and agitated for 30 s. The slide was stained with 1% eosin Y solution for 10–30 s with agitation after rinsing it in H<sub>2</sub>O for 1 min. The sections were dehydrated with two changes of 95% alcohol and two changes of 100% alcohol for 30 s each, followed by removal of alcohol with two changes of xylene. Eventually, one or two drops of mounting medium were added, and the slides were covered with coverslips.</div></div><div id="sec6_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> <i>K</i>i-67 Staining</h3><div class="NLM_p last">For IHC demonstration of <i>K</i>i-67, the tissue sections were quenched for endogenous peroxides and placed in an antigen retrieval solution (0.01 M citrate buffer, pH 6.0) for 15 min in a microwave oven at 100 °C at 600 W. After incubation in the casein block, the slides were incubated in mouse mAb anti-<i>K</i>i-67 (ZSGB-BIO, China) solution at a 1:50 dilution overnight at 4 °C, followed by the secondary detection system to visualize antibody binding. Staining was developed with 3,3′-diaminobenzidine (DAB), and slides were counterstained with hematoxylin, dehydrated, and mounted.</div></div><div id="sec6_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> TUNEL Staining</h3><div class="NLM_p last">TUNEL staining was carried out using the POD In Situ Cell Death Detection Kit (Roche, USA). Briefly, the sections were deparaffinized in xylene and rehydrated in decreasing concentrations of ethanol. Subsequently, the sections were treated by nuclease-free Proteinase K at room temperature for 15 min before the endogenous peroxidase was blocked with 3% H<sub>2</sub>O<sub>2</sub> in methanol. Terminal deoxynucleotidyl transferase in a reaction buffer was applied to sections at 37 °C for 1 h. Following washes, the slides were covered with converter–POD solution for 30 min at 37 °C. Finally, apoptotic cells were tested after incubation in 3,3′-diaminobenzidine (DAB) chromogen (Beyotime Biotechnology, China) for nearly 8 min, and slides were counterstained with hematoxylin.</div></div><div id="sec6_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> BaF3-TEL-cKIT-T670I Xenograft Model</h3><div class="NLM_p last">The in vivo anti-<b>1</b>-resistant GIST activity of compound <b>31</b> was tested in BaF3-TEL-cKIT-T670I xenograft model. The experimental conditions and methods were similar as the GIST-T1 xenograft model. Differently, to obtain orthotopic xenograft of human mammary tumor in the mice, one million BaF3-TEL-cKIT-T670I cells which were harvested during exponential growth in PBS were suspended in a 1:1 mixture with Matrigel (BD Biosciences).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i99"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00468">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66232" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66232" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00468" class="ext-link">10.1021/acs.jmedchem.7b00468</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">HPLC reports for the purity check of compounds <b>8</b>–<b>65</b>, details of the synthetic procedures and structural characterizations of intermediates <b>66</b>–<b>78</b>, KinomeScan selectivity profiling data of compound <b>31</b>, in vitro metabolic stability assay, and methods of the hERG inhibition assay (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00468/suppl_file/jm7b00468_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of compounds <b>8</b>–<b>65</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00468/suppl_file/jm7b00468_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00468/suppl_file/jm7b00468_si_001.pdf">jm7b00468_si_001.pdf (307.13 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00468/suppl_file/jm7b00468_si_002.csv">jm7b00468_si_002.csv (3.43 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00468" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57653" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57653" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jian Li</span> - <span class="hlFld-Affiliation affiliation">Shanghai Key Laboratory
of New Drug Design, School of Pharmacy,
East China University of Science and Technology, Shanghai 200237, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7521-8798" title="Orcid link">http://orcid.org/0000-0002-7521-8798</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#deb4b7bfb0b2b79ebbbdabadaaf0bbbaabf0bdb0"><span class="__cf_email__" data-cfemail="4b21222a2527220b2e283e383f652e2f3e652825">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yanli Lu</span> - <span class="hlFld-Affiliation affiliation">Shanghai Key Laboratory
of New Drug Design, School of Pharmacy,
East China University of Science and Technology, Shanghai 200237, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fei Mao</span> - <span class="hlFld-Affiliation affiliation">Shanghai Key Laboratory
of New Drug Design, School of Pharmacy,
East China University of Science and Technology, Shanghai 200237, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaokang Li</span> - <span class="hlFld-Affiliation affiliation">Shanghai Key Laboratory
of New Drug Design, School of Pharmacy,
East China University of Science and Technology, Shanghai 200237, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xinyu Zheng</span> - <span class="hlFld-Affiliation affiliation">Shanghai Key Laboratory
of New Drug Design, School of Pharmacy,
East China University of Science and Technology, Shanghai 200237, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Manjiong Wang</span> - <span class="hlFld-Affiliation affiliation">Shanghai Key Laboratory
of New Drug Design, School of Pharmacy,
East China University of Science and Technology, Shanghai 200237, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qing Xu</span> - <span class="hlFld-Affiliation affiliation">Shanghai Key Laboratory
of New Drug Design, School of Pharmacy,
East China University of Science and Technology, Shanghai 200237, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jin Zhu</span> - <span class="hlFld-Affiliation affiliation">Shanghai Key Laboratory
of New Drug Design, School of Pharmacy,
East China University of Science and Technology, Shanghai 200237, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>These authors contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d46e7285-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i101">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22313" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22313" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Financial support for this research was provided by the National Natural Science Foundation of China (grants 21672064 and 21372001), the “Shu Guang” project supported by the Shanghai Municipal Education Commission and the Shanghai Education Development Foundation (grant 14SG28), and the Fundamental Research Funds for the Central Universities. We sincerely thank the group of Professor Jonathan A. Fletcher, Brigham and Women’s Hospital, Boston, USA, for providing GIST-882 and GIST-48B cells. We gratefully acknowledge Hefei PreceDo Pharmaceuticals Co., Ltd. for the pharmacological evaluation of compound <b>31</b>.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i102" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i102"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i103" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i103"> Abbreviations Used</h2><tr><td class="NLM_term">GISTs</td><td class="NLM_def"><p class="first last">gastrointestinal stromal tumors</p></td></tr><tr><td class="NLM_term">c-KIT</td><td class="NLM_def"><p class="first last">stem cell factor receptor</p></td></tr><tr><td class="NLM_term">PDGFRα</td><td class="NLM_def"><p class="first last">platelet derived growth factor receptor α</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term">ABL kinase</td><td class="NLM_def"><p class="first last">Abelson kinase</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">VEGFR</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor</p></td></tr><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">FMS-related tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">DDQ</td><td class="NLM_def"><p class="first last">2,3-dichloro-5,6-dicyano-1,4-benzoquinone</p></td></tr><tr><td class="NLM_term">BSTFA</td><td class="NLM_def"><p class="first last">bis(trimethylsilyl)trifluoroacetamide</p></td></tr><tr><td class="NLM_term">BPOD</td><td class="NLM_def"><p class="first last">phenylphosphonic dichloride</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>′-carbonyl diimidazole</p></td></tr><tr><td class="NLM_term">FGFR1</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor 1</p></td></tr><tr><td class="NLM_term">CML</td><td class="NLM_def"><p class="first last">chronic myelogenous leukemia</p></td></tr><tr><td class="NLM_term">CHL</td><td class="NLM_def"><p class="first last">hamster lung cells</p></td></tr><tr><td class="NLM_term">CHO</td><td class="NLM_def"><p class="first last">hamster ovary cells</p></td></tr><tr><td class="NLM_term">POC</td><td class="NLM_def"><p class="first last">percent of control</p></td></tr><tr><td class="NLM_term">ELISA</td><td class="NLM_def"><p class="first last">enzyme-linked immunosorbent assay</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">IV injection</td><td class="NLM_def"><p class="first last">intravenous injection</p></td></tr><tr><td class="NLM_term">IP injection</td><td class="NLM_def"><p class="first last">intraperitoneal injection</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-dimethyl aminopyridine</p></td></tr><tr><td class="NLM_term">NBS</td><td class="NLM_def"><p class="first last"><i>N</i>-bromosuccinimide</p></td></tr><tr><td class="NLM_term">BPO</td><td class="NLM_def"><p class="first last">benzoyl peroxide</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">(Boc)<sub>2</sub>O</td><td class="NLM_def"><p class="first last">di<i>tert</i>-butyl decarbonate</p></td></tr><tr><td class="NLM_term">EI</td><td class="NLM_def"><p class="first last">electric ionization</p></td></tr><tr><td class="NLM_term">ESI</td><td class="NLM_def"><p class="first last">electrospray ionization</p></td></tr><tr><td class="NLM_term">DAD</td><td class="NLM_def"><p class="first last">diode-array detector</p></td></tr><tr><td class="NLM_term">DAB</td><td class="NLM_def"><p class="first last">3,3′-diaminobenzidine</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i104">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26460" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26460" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 38 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Kindblom, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remotti, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldenborg, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meis-Kindblom, J. M.</span><span> </span><span class="NLM_article-title">Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">152</span><span class="NLM_x">, </span> <span class="NLM_fpage">1259</span><span class="NLM_x">–</span> <span class="NLM_lpage">1269</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=9588894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A280%3ADyaK1c3kvVejug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=1998&pages=1259-1269&author=L.+G.+Kindblomauthor=H.+E.+Remottiauthor=F.+Aldenborgauthor=J.+M.+Meis-Kindblom&title=Gastrointestinal+pacemaker+cell+tumor+%28GIPACT%29%3A+gastrointestinal+stromal+tumors+show+phenotypic+characteristics+of+the+interstitial+cells+of+Cajal"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal</span></div><div class="casAuthors">Kindblom L G; Remotti H E; Aldenborg F; Meis-Kindblom J M</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of pathology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1259-69</span>
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    </div><div class="casAbstract">The interstitial cells of Cajal (ICC) form a complex cell network within the gastrointestinal tract wall where they function as a pacemaker system.  Expression of the kit proto-oncogene is essential for the development of this system.  The aim of our study was to examine the hypothesis that gastrointestinal stromal tumors differentiate toward cells with an ICC phenotype.  Ultrastructurally, 58 stromal tumors were characterized and found to share many features with ICC.  Seventy-eight stromal tumors were immunophenotyped, particularly with regard to the kit receptor.  All 78 tumors revealed strong, homogeneous immunoreactivity for the kit receptor as did ICC of adjacent and control gastrointestinal walls.  Focal hyperplasia and hypertrophy of kit receptor positive cells were also observed in the gastrointestinal wall adjacent to the tumors.  CD34 immunoreactivity observed in interstitial cells surrounding Auerbach's ganglia suggests that a subpopulation of ICC is CD34 positive and may explain why 56 of 78 stromal tumors were CD34 positive.  Thirty control tumors, including gastrointestinal leiomyomas and leiomyosarcomas, were all negative for the kit receptor.  We conclude that gastrointestinal stromal tumors show striking morphological and immunophenotypic similarities with ICC and that they may originate from stem cells that differentiate toward a pacemaker cell phenotype.  We propose that the noncommittal name "gastrointestinal stromal tumor" be replaced by gastrointestinal pacemaker cell tumor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTo1_gLlQJ49LesJRIHUP1ofW6udTcc2eYUEoUr2l9yLrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c3kvVejug%253D%253D&md5=fb5342253954593446205c2ea24b21e3</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKindblom%26aufirst%3DL.%2BG.%26aulast%3DRemotti%26aufirst%3DH.%2BE.%26aulast%3DAldenborg%26aufirst%3DF.%26aulast%3DMeis-Kindblom%26aufirst%3DJ.%2BM.%26atitle%3DGastrointestinal%2520pacemaker%2520cell%2520tumor%2520%2528GIPACT%2529%253A%2520gastrointestinal%2520stromal%2520tumors%2520show%2520phenotypic%2520characteristics%2520of%2520the%2520interstitial%2520cells%2520of%2520Cajal%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D1998%26volume%3D152%26spage%3D1259%26epage%3D1269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Miettinen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasota, J.</span><span> </span><span class="NLM_article-title">Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis</span> <span class="citation_source-journal">Virchows Arch.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">438</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span><span class="refDoi"> DOI: 10.1007/s004280000338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1007%2Fs004280000338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=11213830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlt1Kquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=438&publication_year=2001&pages=1-12&author=M.+Miettinenauthor=J.+Lasota&title=Gastrointestinal+stromal+tumors-definition%2C+clinical%2C+histological%2C+immunohistochemical%2C+and+molecular+genetic+features+and+differential+diagnosis&doi=10.1007%2Fs004280000338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis</span></div><div class="casAuthors">Miettinen, Markku; Lasota, Jerzy</div><div class="citationInfo"><span class="NLM_cas:title">Virchows Archiv</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">438</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">VARCEM</span>;
        ISSN:<span class="NLM_cas:issn">0945-6317</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A review with 81 refs.  Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal (GI) tract.  They are defined here as KIT (CD117, stem cell factor receptor)-pos. mesenchymal spindle cell or epithelioid neoplasms primary in the GI tract, omentum, and mesentery.  GISTs typically present in older individuals and are most common in the stomach (60-70%), followed by small intestine (20-25%), colon and rectum (5%), and esophagus (<5%).  Benign tumors outnumber the malignant ones by a wide margin.  Approx. 70% of GISTs are pos. for CD34, 20-30% are pos. for smooth muscle actin (SMA), 10% are pos. for S100 protein and <5% are pos. for desmin.  The expression of CD34 and SMA is often reciprocal.  GISTs commonly have activating mutations in exon 11 (or rarely exon 9 and exon 13) of the KIT gene that encodes a tyrosine kinase receptor for the growth factor named stem cell factor or mast cell growth factor.  Ligand-independent activation of KIT appears to be a strong candidate for mol. pathogenesis of GISTs, and it may be a target for future treatment for such tumors.  Other genetic changes in GISTs discovered using comparative genomic hybridization include losses in 14q and 22q in both benign and malignant GISTs and occurrence in various gains predominantly in malignant GISTs.  GISTs have phenotypic similarities with the interstitial cells of Cajal and, therefore, a histogenetic origin from these cells has been suggested.  An alternative possibility, origin of pluripotential stem cells, is also possible; this is supported by the same origin of Cajal cells and smooth muscle and by the common SMA expression in GISTs.  GISTs differ clin. and pathogenetically from true leiomyosarcomas (very rare in the GI tract) and leiomyomas.  The latter occur in the GI tract, predominantly in the esophagus (intramural tumors) and the colon and rectum (muscularis mucosae tumors).  They also differ from schwannomas that are benign S100-pos. spindle cell tumors usually presenting in the stomach.  GI autonomic nerve tumors (GANTs) are probably a subset of GIST.  Other mesenchymal tumors that have to be sepd. from GISTs include inflammatory myofibroblastic tumors in children, desmoid, and dedifferentiated liposarcoma.  Angiosarcomas and metastatic melanomas, both of which are often KIT-pos., should not be confused with GISTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeixqNq3cd-7Vg90H21EOLACvtfcHk0ljQKjqBrUGyTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlt1Kquw%253D%253D&md5=d2600b6aa118b36339ace603c1c9b87f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs004280000338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs004280000338%26sid%3Dliteratum%253Aachs%26aulast%3DMiettinen%26aufirst%3DM.%26aulast%3DLasota%26aufirst%3DJ.%26atitle%3DGastrointestinal%2520stromal%2520tumors-definition%252C%2520clinical%252C%2520histological%252C%2520immunohistochemical%252C%2520and%2520molecular%2520genetic%2520features%2520and%2520differential%2520diagnosis%26jtitle%3DVirchows%2520Arch.%26date%3D2001%26volume%3D438%26spage%3D1%26epage%3D12%26doi%3D10.1007%2Fs004280000338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Chi, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, B. T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, Y.</span><span> </span><span class="NLM_article-title">All-trans retinoic acid inhibits KIT activity and induces apoptosis in gastrointestinal stromal tumor GIST-T1 cell line by affecting on the expression of survivin and Bax protein</span> <span class="citation_source-journal">J. Exp. Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="refDoi"> DOI: 10.1186/1756-9966-29-165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1186%2F1756-9966-29-165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=21159206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1amsLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=165&author=H.+T.+Chiauthor=B.+T.+K.+Lyauthor=T.+Taguchiauthor=T.+Watanabeauthor=Y.+Sato&title=All-trans+retinoic+acid+inhibits+KIT+activity+and+induces+apoptosis+in+gastrointestinal+stromal+tumor+GIST-T1+cell+line+by+affecting+on+the+expression+of+survivin+and+Bax+protein&doi=10.1186%2F1756-9966-29-165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">All-trans retinoic acid inhibits KIT activity and induces apoptosis in gastrointestinal stromal tumor GIST-T1 cell line by affecting on the expression of survivin and Bax protein</span></div><div class="casAuthors">Chi, Hoang Thanh; Ly, Bui Thi Kim; Taguchi, Takahiro; Watanabe, Toshiki; Sato, Yuko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental & Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">165</span>CODEN:
                <span class="NLM_cas:coden">JECRDN</span>;
        ISSN:<span class="NLM_cas:issn">1756-9966</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Imatinib, a selective tyrosine kinase inhibitor, has been used as a std. first-line therapy for irresectable and metastasized gastrointestinal stromal tumor (GIST) patients.  Unfortunately, most patients responding to imatinib will eventually exhibit imatinib-resistance, the cause of which is not fully understood.  The serious clin. problem of imatinib-resistance demands alternative therapeutic strategy.  This study was conducted to investigate the effect of all-trans retinoic acid (ATRA) on GIST cell lines.  Methods: Cell proliferation was detd. by trypan blue dye exclusion test.  Western blot anal. was performed to test the expression of activated KIT, its downstream proteins, and apoptosis assocd. proteins.  The cytotoxic interactions of imatinib with ATRA were evaluated using the isobologram of Steel and Peckham.  Results and Conclusion: In this work, for the first time we have demonstrated that ATRA affected on cell proliferation of GIST-T1 and GIST-882 cell line through inhibition of cell growth in a dose dependent manner and induced apoptosis.  High dose of ATRA induced morphol. change in GIST-T1 cells, rounded-up cells, and activated the caspase-3 protein.  In further examn., we found that the ATRA-induced apoptosis in GIST-T1 cells was accompanied by the down-regulated expression of survivin and up-regulated expression of Bax protein.  Moreover, ATRA suppressed the activity of KIT protein in GIST-T1 cells and its downstream signal, AKT activity, but not MAPK activity.  We also have demonstrated that combination of ATRA with imatinib showed additive effect by isobologram, suggesting that the combination of ATRA and imatinib may be a novel potential therapeutic option for GIST treatment.  Furthermore, the scracht assay result suggested that ATRA was a potential reagent to prevent the invasion or metastasis of GIST cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW9YTHTs48TrVg90H21EOLACvtfcHk0ljQKjqBrUGyTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1amsLbM&md5=64cb1aaa71fe79e1a76448253a98cbb8</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1186%2F1756-9966-29-165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-9966-29-165%26sid%3Dliteratum%253Aachs%26aulast%3DChi%26aufirst%3DH.%2BT.%26aulast%3DLy%26aufirst%3DB.%2BT.%2BK.%26aulast%3DTaguchi%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DY.%26atitle%3DAll-trans%2520retinoic%2520acid%2520inhibits%2520KIT%2520activity%2520and%2520induces%2520apoptosis%2520in%2520gastrointestinal%2520stromal%2520tumor%2520GIST-T1%2520cell%2520line%2520by%2520affecting%2520on%2520the%2520expression%2520of%2520survivin%2520and%2520Bax%2520protein%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D29%26spage%3D165%26doi%3D10.1186%2F1756-9966-29-165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Wit, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grabellus, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antoch, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niebel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erhard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebeling, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taeger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flasshove, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schutte, J.</span><span> </span><span class="NLM_article-title">Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">325</span><span class="refDoi"> DOI: 10.1002/ijc.21164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1002%2Fijc.21164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=15900603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVygsrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2005&pages=316-325&author=S.+Bauerauthor=J.+T.+Hartmannauthor=M.+de+Witauthor=H.+Langauthor=F.+Grabellusauthor=G.+Antochauthor=W.+Niebelauthor=J.+Erhardauthor=P.+Ebelingauthor=M.+Zethauthor=G.+Taegerauthor=S.+Seeberauthor=M.+Flasshoveauthor=J.+Schutte&title=Resection+of+residual+disease+in+patients+with+metastatic+gastrointestinal+stromal+tumors+responding+to+treatment+with+imatinib&doi=10.1002%2Fijc.21164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib</span></div><div class="casAuthors">Bauer, Sebastian; Hartmann, Joerg Thomas; de Wit, Maike; Lang, Hauke; Grabellus, Florian; Antoch, Gerald; Niebel, Wolfgang; Erhard, Jochen; Ebeling, Peter; Zeth, Matthias; Taeger, Georg; Seeber, Siegfried; Flasshove, Michael; Schuette, Jochen</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">316-325</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract.  Long-term survival of patients with metastatic disease has only been obsd. in patients with completely resected disease.  Recently, the tyrosine kinase inhibitor imatinib has been found to yield responses in the majority of patients with metastatic GIST suggesting improved resectability in responding patients.  Combined treatment approaches including resective surgery after imatinib treatment in patients with advanced metastatic disease have rarely been explored.  We report a series of 90 patients with metastatic GIST in whom treatment with imatinib enabled 12 patients with mostly recurrent and extensive disease to be considered for resection of residual disease.  In 11 of these patients, complete resection could be achieved.  Viable tumor cells were found in all but one resected specimens suggesting that despite favorable radiol. or clin. responses, imatinib is unlikely to induce pathol. complete responses.  Until more mature data from prospective trials are available, these data suggest that an early aggressive surgical approach should be considered for all patients with metastatic GIST.  Further trials investigating a combined surgical and pre/postoperative treatment with imatinib in patients with advanced metastatic GIST are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0hhkvmyGH07Vg90H21EOLACvtfcHk0lheCtOWV9BtsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVygsrfK&md5=dfb19559fd3ce59612d2e83f03452d88</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fijc.21164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.21164%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DHartmann%26aufirst%3DJ.%2BT.%26aulast%3Dde%2BWit%26aufirst%3DM.%26aulast%3DLang%26aufirst%3DH.%26aulast%3DGrabellus%26aufirst%3DF.%26aulast%3DAntoch%26aufirst%3DG.%26aulast%3DNiebel%26aufirst%3DW.%26aulast%3DErhard%26aufirst%3DJ.%26aulast%3DEbeling%26aufirst%3DP.%26aulast%3DZeth%26aufirst%3DM.%26aulast%3DTaeger%26aufirst%3DG.%26aulast%3DSeeber%26aufirst%3DS.%26aulast%3DFlasshove%26aufirst%3DM.%26aulast%3DSchutte%26aufirst%3DJ.%26atitle%3DResection%2520of%2520residual%2520disease%2520in%2520patients%2520with%2520metastatic%2520gastrointestinal%2520stromal%2520tumors%2520responding%2520to%2520treatment%2520with%2520imatinib%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2005%26volume%3D117%26spage%3D316%26epage%3D325%26doi%3D10.1002%2Fijc.21164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">DeMatteo, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mudan, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodruff, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, M. F.</span><span> </span><span class="NLM_article-title">Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival</span> <span class="citation_source-journal">Ann. Surg.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">231</span><span class="NLM_x">, </span> <span class="NLM_fpage">51</span><span class="NLM_x">–</span> <span class="NLM_lpage">58</span><span class="refDoi"> DOI: 10.1097/00000658-200001000-00008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1097%2F00000658-200001000-00008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2000&pages=51-58&author=R.+P.+DeMatteoauthor=J.+J.+Lewisauthor=D.+Leungauthor=S.+S.+Mudanauthor=J.+M.+Woodruffauthor=M.+F.+Brennan&title=Two+hundred+gastrointestinal+stromal+tumors%3A+recurrence+patterns+and+prognostic+factors+for+survival&doi=10.1097%2F00000658-200001000-00008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1097%2F00000658-200001000-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000658-200001000-00008%26sid%3Dliteratum%253Aachs%26aulast%3DDeMatteo%26aufirst%3DR.%2BP.%26aulast%3DLewis%26aufirst%3DJ.%2BJ.%26aulast%3DLeung%26aufirst%3DD.%26aulast%3DMudan%26aufirst%3DS.%2BS.%26aulast%3DWoodruff%26aufirst%3DJ.%2BM.%26aulast%3DBrennan%26aufirst%3DM.%2BF.%26atitle%3DTwo%2520hundred%2520gastrointestinal%2520stromal%2520tumors%253A%2520recurrence%2520patterns%2520and%2520prognostic%2520factors%2520for%2520survival%26jtitle%3DAnn.%2520Surg.%26date%3D2000%26volume%3D231%26spage%3D51%26epage%3D58%26doi%3D10.1097%2F00000658-200001000-00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vehtari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riihimaki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steigen, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brabec, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plank, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirilli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braconi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnusson, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linke, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sufliarsky, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Federico, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonasson, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dei Tos, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutkowski, P.</span><span> </span><span class="NLM_article-title">Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">265</span><span class="NLM_x">–</span> <span class="NLM_lpage">274</span><span class="refDoi"> DOI: 10.1016/S1470-2045(11)70299-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1016%2FS1470-2045%2811%2970299-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=22153892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A280%3ADC%252BC383nsFeksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=265-274&author=H.+Joensuuauthor=A.+Vehtariauthor=J.+Riihimakiauthor=T.+Nishidaauthor=S.+E.+Steigenauthor=P.+Brabecauthor=L.+Plankauthor=B.+Nilssonauthor=C.+Cirilliauthor=C.+Braconiauthor=A.+Bordoniauthor=M.+K.+Magnussonauthor=Z.+Linkeauthor=J.+Sufliarskyauthor=M.+Federicoauthor=J.+G.+Jonassonauthor=A.+P.+Dei+Tosauthor=P.+Rutkowski&title=Risk+of+recurrence+of+gastrointestinal+stromal+tumour+after+surgery%3A+an+analysis+of+pooled+population-based+cohorts&doi=10.1016%2FS1470-2045%2811%2970299-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts</span></div><div class="casAuthors">Joensuu Heikki; Vehtari Aki; Riihimaki Jaakko; Nishida Toshirou; Steigen Sonja E; Brabec Peter; Plank Lukas; Nilsson Bengt; Cirilli Claudia; Braconi Chiara; Bordoni Andrea; Magnusson Magnus K; Linke Zdenek; Sufliarsky Jozef; Federico Massimo; Jonasson Jon G; Dei Tos Angelo Paolo; Rutkowski Piotr</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">265-74</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The risk of recurrence of gastrointestinal stromal tumour (GIST) after surgery needs to be estimated when considering adjuvant systemic therapy.  We assessed prognostic factors of patients with operable GIST, to compare widely used risk-stratification schemes and to develop a new method for risk estimation.  METHODS:  Population-based cohorts of patients diagnosed with operable GIST, who were not given adjuvant therapy, were identified from the literature.  Data from ten series and 2560 patients were pooled.  Risk of tumour recurrence was stratified using the National Institute of Health (NIH) consensus criteria, the modified consensus criteria, and the Armed Forces Institute of Pathology (AFIP) criteria.  Prognostic factors were examined using proportional hazards and non-linear models.  The results were validated in an independent centre-based cohort consisting of 920 patients with GIST.  FINDINGS:  Estimated 15-year recurrence-free survival (RFS) after surgery was 59·9% (95% CI 56·2-63·6); few recurrences occurred after the first 10 years of follow-up.  Large tumour size, high mitosis count, non-gastric location, presence of rupture, and male sex were independent adverse prognostic factors.  In receiver operating characteristics curve analysis of 10-year RFS, the NIH consensus criteria, modified consensus criteria, and AFIP criteria resulted in an area under the curve (AUC) of 0·79 (95% CI 0·76-0·81), 0·78 (0·75-0·80), and 0·82 (0·80-0·85), respectively.  The modified consensus criteria identified a single high-risk group.  Since tumour size and mitosis count had a non-linear association with the risk of GIST recurrence, novel prognostic contour maps were generated using non-linear modelling of tumour size and mitosis count, and taking into account tumour site and rupture.  The non-linear model accurately predicted the risk of recurrence (AUC 0·88, 0·86-0·90).  INTERPRETATION:  The risk-stratification schemes assessed identify patients who are likely to be cured by surgery alone.  Although the modified NIH classification is the best criteria to identify a single high-risk group for consideration of adjuvant therapy, the prognostic contour maps resulting from non-linear modelling are appropriate for estimation of individualised outcomes.  FUNDING:  Academy of Finland, Cancer Society of Finland, Sigrid Juselius Foundation and Helsinki University Research Funds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1mbEPz33jqZSWdIdmEou5fW6udTcc2ea4BojeXoqZk7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383nsFeksw%253D%253D&md5=75b9c93788a2286ff5896236d1e16df7</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2811%2970299-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252811%252970299-6%26sid%3Dliteratum%253Aachs%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DVehtari%26aufirst%3DA.%26aulast%3DRiihimaki%26aufirst%3DJ.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DSteigen%26aufirst%3DS.%2BE.%26aulast%3DBrabec%26aufirst%3DP.%26aulast%3DPlank%26aufirst%3DL.%26aulast%3DNilsson%26aufirst%3DB.%26aulast%3DCirilli%26aufirst%3DC.%26aulast%3DBraconi%26aufirst%3DC.%26aulast%3DBordoni%26aufirst%3DA.%26aulast%3DMagnusson%26aufirst%3DM.%2BK.%26aulast%3DLinke%26aufirst%3DZ.%26aulast%3DSufliarsky%26aufirst%3DJ.%26aulast%3DFederico%26aufirst%3DM.%26aulast%3DJonasson%26aufirst%3DJ.%2BG.%26aulast%3DDei%2BTos%26aufirst%3DA.%2BP.%26aulast%3DRutkowski%26aufirst%3DP.%26atitle%3DRisk%2520of%2520recurrence%2520of%2520gastrointestinal%2520stromal%2520tumour%2520after%2520surgery%253A%2520an%2520analysis%2520of%2520pooled%2520population-based%2520cohorts%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D265%26epage%3D274%26doi%3D10.1016%2FS1470-2045%2811%2970299-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrijevic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silberman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G.</span><span> </span><span class="NLM_article-title">Management of malignant gastrointestinal stromal tumours</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">655</span><span class="NLM_x">–</span> <span class="NLM_lpage">664</span><span class="refDoi"> DOI: 10.1016/S1470-2045(02)00899-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1016%2FS1470-2045%2802%2900899-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=12424067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD38Xotlygs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=655-664&author=H.+Joensuuauthor=C.+Fletcherauthor=S.+Dimitrijevicauthor=S.+Silbermanauthor=P.+Robertsauthor=G.+Demetri&title=Management+of+malignant+gastrointestinal+stromal+tumours&doi=10.1016%2FS1470-2045%2802%2900899-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Management of malignant gastrointestinal stromal tumors</span></div><div class="casAuthors">Joensuu, Heikki; Fletcher, Christopher; Dimitrijevic, Sasa; Silberman, Sandra; Roberts, Peter; Demetri, George</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">655-664</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Lancet Publishing Group</span>)
        </div><div class="casAbstract">A review.  Gastrointestinal stromal tumors (GISTs) are the most common form of mesenchymal tumor of the gastrointestinal tract.  Clin., they range from small indolent tumors curable with surgery alone to aggressive cancers.  Making a distinction between an indolent and a malignant GIST is unreliable with conventional histopathol. techniques.  The presence of metastases at the time of diagnosis confirms malignancy, but all GISTs should be regarded as having malignant potential.  GISTs characteristically express the KIT protein, a transmembrane tyrosine kinase receptor for stem-cell factor.  Most GISTs have a mutation in the KIT proto-oncogene that translates into a gain-of-function constitutive activation of the KIT kinase.  KIT activation seems to be an early tumor-promoting event in pathogenesis.  Commonly, malignant GISTs show high-level primary resistance to conventional chemotherapy.  Imatinib mesylate is an orally administered selective inhibitor of certain tyrosine kinases including KIT.  Most patients with advanced malignant GISTs achieve clin. benefit and significant antitumor responses with imatinib mesylate.  Responses have been durable, and most patients tolerate the drug well at clin. EDs.  Imatinib mesylate is the first effective systemic therapy for advanced GIST.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRQYYGGZ5FlrVg90H21EOLACvtfcHk0lh5mkbeOtTi7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xotlygs7Y%253D&md5=50b1bd67556b6ab83ae6b37bceb59d6c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2802%2900899-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252802%252900899-9%26sid%3Dliteratum%253Aachs%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DFletcher%26aufirst%3DC.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DSilberman%26aufirst%3DS.%26aulast%3DRoberts%26aufirst%3DP.%26aulast%3DDemetri%26aufirst%3DG.%26atitle%3DManagement%2520of%2520malignant%2520gastrointestinal%2520stromal%2520tumours%26jtitle%3DLancet%2520Oncol.%26date%3D2002%26volume%3D3%26spage%3D655%26epage%3D664%26doi%3D10.1016%2FS1470-2045%2802%2900899-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Rammohan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sathyanesan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajendran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitchaimuthu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perumal, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srinivasan, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramasamy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palaniappan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Govindan, M.</span><span> </span><span class="NLM_article-title">A gist of gastrointestinal stromal tumors: a review</span> <span class="citation_source-journal">World J. Gastrointest. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">102</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span><span class="refDoi"> DOI: 10.4251/wjgo.v5.i6.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.4251%2Fwjgo.v5.i6.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=23847717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A280%3ADC%252BC3sfgt1Kntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=102-112&author=A.+Rammohanauthor=J.+Sathyanesanauthor=K.+Rajendranauthor=A.+Pitchaimuthuauthor=S.+K.+Perumalauthor=U.+Srinivasanauthor=R.+Ramasamyauthor=R.+Palaniappanauthor=M.+Govindan&title=A+gist+of+gastrointestinal+stromal+tumors%3A+a+review&doi=10.4251%2Fwjgo.v5.i6.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A gist of gastrointestinal stromal tumors: A review</span></div><div class="casAuthors">Rammohan Ashwin; Sathyanesan Jeswanth; Rajendran Kamalakannan; Pitchaimuthu Anbalagan; Perumal Senthil-Kumar; Srinivasan Up; Ramasamy Ravi; Palaniappan Ravichandran; Govindan Manoharan</div><div class="citationInfo"><span class="NLM_cas:title">World journal of gastrointestinal oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">102-12</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Gastrointestinal stromal tumors (GISTs) have been recognized as a biologically distinctive tumor type, different from smooth muscle and neural tumors of the gastrointestinal tract (GIT).  They constitute the majority of gastrointestinal mesenchymal tumors of the GIT and are known to be refractory to conventional chemotherapy or radiation.  They are defined and diagnosed by the expression of a proto-oncogene protein detected by immunohistochemistry which serves as a crucial diagnostic and therapeutic target.  The identification of these mutations has resulted in a better understanding of their oncogenic mechanisms.  The remarkable antitumor effects of the molecular inhibitor imatinib have necessitated accurate diagnosis of GIST and their distinction from other gastrointestinal mesenchymal tumors.  Both traditional and minimally invasive surgery are used to remove these tumors with minimal morbidity and excellent perioperative outcomes.  The revolutionary use of specific, molecularly-targeted therapies, such as imatinib mesylate, reduces the frequency of disease recurrence when used as an adjuvant following complete resection.  Neoadjuvant treatment with these agents appears to stabilize disease in the majority of patients and may reduce the extent of surgical resection required for subsequent complete tumor removal.  The important interplay between the molecular genetics of GIST and responses to targeted therapeutics serves as a model for the study of targeted therapies in other solid tumors.  This review summarizes our current knowledge and recent advances regarding the histogenesis, pathology, molecular biology, the basis for the novel targeted cancer therapy and current evidence based management of these unique tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-JVCNzFLbmg8IxFYvehhofW6udTcc2eYfSGL-9t4DpLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfgt1Kntg%253D%253D&md5=4999d3f458d9fbbc1a43cfb6caa50dca</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.4251%2Fwjgo.v5.i6.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4251%252Fwjgo.v5.i6.102%26sid%3Dliteratum%253Aachs%26aulast%3DRammohan%26aufirst%3DA.%26aulast%3DSathyanesan%26aufirst%3DJ.%26aulast%3DRajendran%26aufirst%3DK.%26aulast%3DPitchaimuthu%26aufirst%3DA.%26aulast%3DPerumal%26aufirst%3DS.%2BK.%26aulast%3DSrinivasan%26aufirst%3DU.%26aulast%3DRamasamy%26aufirst%3DR.%26aulast%3DPalaniappan%26aufirst%3DR.%26aulast%3DGovindan%26aufirst%3DM.%26atitle%3DA%2520gist%2520of%2520gastrointestinal%2520stromal%2520tumors%253A%2520a%2520review%26jtitle%3DWorld%2520J.%2520Gastrointest.%2520Oncol.%26date%3D2013%26volume%3D5%26spage%3D102%26epage%3D112%26doi%3D10.4251%2Fwjgo.v5.i6.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rubin, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span> </span><span class="NLM_article-title">Gastrointestinal stromal tumour</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">369</span><span class="NLM_x">, </span> <span class="NLM_fpage">1731</span><span class="NLM_x">–</span> <span class="NLM_lpage">1741</span><span class="refDoi"> DOI: 10.1016/S0140-6736(07)60780-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1016%2FS0140-6736%2807%2960780-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=17512858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlsFertrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2007&pages=1731-1741&author=B.+P.+Rubinauthor=M.+C.+Heinrichauthor=C.+L.+Corless&title=Gastrointestinal+stromal+tumour&doi=10.1016%2FS0140-6736%2807%2960780-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal stromal tumor</span></div><div class="casAuthors">Rubin, Brian P.; Heinrich, Michael C.; Corless, Christopher L.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">9574</span>),
    <span class="NLM_cas:pages">1731-1741</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Gastrointestinal stromal tumors are the most common mesenchymal neoplasm of the gastrointestinal tract and are highly resistant to conventional chemotherapy and radiotherapy.  Such tumors usually have activating mutations in either KIT (75-80%) or PDGFRA (5-10%), two closely related receptor tyrosine kinases.  These mutations lead to ligand-independent activation and signal transduction mediated by constitutively activated KIT or PDGFRA.  Targeting these activated proteins with imatinib mesylate, a small-mol. kinase inhibitor, has proven useful in the treatment of recurrent or metastatic gastrointestinal stromal tumors and is now being tested as an adjuvant or neoadjuvant.  However, resistance to imatinib is a growing problem and other targeted therapeutics such as sunitinib are available.  The important interplay between the mol. genetics of gastrointestinal stromal tumor and responses to targeted therapeutics serves as a model for the study of targeted therapies in other solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNtDxolv4iBrVg90H21EOLACvtfcHk0lh5mkbeOtTi7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlsFertrk%253D&md5=9a9d1fc97239da0bb0cfa8edb925524b</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2807%2960780-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252807%252960780-6%26sid%3Dliteratum%253Aachs%26aulast%3DRubin%26aufirst%3DB.%2BP.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26atitle%3DGastrointestinal%2520stromal%2520tumour%26jtitle%3DLancet%26date%3D2007%26volume%3D369%26spage%3D1731%26epage%3D1741%26doi%3D10.1016%2FS0140-6736%2807%2960780-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Miettinen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasota, J.</span><span> </span><span class="NLM_article-title">Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis</span> <span class="citation_source-journal">Arch. Pathol. Lab. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">70</span><span class="NLM_x">–</span> <span class="NLM_lpage">83</span><span class="refDoi"> DOI: 10.1053/j.semdp.2006.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1053%2Fj.semdp.2006.09.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2006&pages=70-83&author=M.+Miettinenauthor=J.+Lasota&title=Gastrointestinal+stromal+tumors%3A+review+on+morphology%2C+molecular+pathology%2C+prognosis%2C+and+differential+diagnosis&doi=10.1053%2Fj.semdp.2006.09.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1053%2Fj.semdp.2006.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.semdp.2006.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DMiettinen%26aufirst%3DM.%26aulast%3DLasota%26aufirst%3DJ.%26atitle%3DGastrointestinal%2520stromal%2520tumors%253A%2520review%2520on%2520morphology%252C%2520molecular%2520pathology%252C%2520prognosis%252C%2520and%2520differential%2520diagnosis%26jtitle%3DArch.%2520Pathol.%2520Lab.%2520Med.%26date%3D2006%26volume%3D23%26spage%3D70%26epage%3D83%26doi%3D10.1053%2Fj.semdp.2006.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGreevey, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Abbeele, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiese, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silberman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrijevic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4342</span><span class="NLM_x">–</span> <span class="NLM_lpage">4349</span><span class="refDoi"> DOI: 10.1200/JCO.2003.04.190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1200%2FJCO.2003.04.190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=14645423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVWqu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=4342-4349&author=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=G.+D.+Demetriauthor=C.+D.+Blankeauthor=M.+von+Mehrenauthor=H.+Joensuuauthor=L.+S.+McGreeveyauthor=C.+J.+Chenauthor=A.+D.+Van+den+Abbeeleauthor=B.+J.+Drukerauthor=B.+Kieseauthor=B.+Eisenbergauthor=P.+J.+Robertsauthor=S.+Singerauthor=C.+D.+M.+Fletcherauthor=S.+Silbermanauthor=S.+Dimitrijevicauthor=J.+A.+Fletcher&title=Kinase+mutations+and+imatinib+response+in+patients+with+metastatic+gastrointestinal+stromal+tumor&doi=10.1200%2FJCO.2003.04.190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor</span></div><div class="casAuthors">Heinrich, Michael C.; Corless, Christopher L.; Demetri, George D.; Blanke, Charles D.; von Mehren, Margaret; Joensuu, Heikki; McGreevey, Laura S.; Chen, Chang-Jie; Van den Abbeele, Annick D.; Druker, Brian J.; Kiese, Beate; Eisenberg, Burton; Roberts, Peter J.; Singer, Samuel; Fletcher, Christopher D. M.; Silberman, Sandra; Dimitrijevic, Sasa; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4342-4349</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Most gastrointestinal stromal tumors (GISTs) express constitutively activated mutant isoforms of KIT or kinase platelet-derived growth factor receptor alpha (PDGFRA) that are potential therapeutic targets for imatinib mesylate.  The relationship between mutations in these kinases and clin. response to imatinib was examd. in a group of patients with advanced GIST.  Patients and Methods: GISTs from 127 patients enrolled onto a phase II clin. study of imatinib were examd. for mutations of KIT or PDGFRA.  Mutation types were correlated with clin. outcome.  Results: Activating mutations of KIT or PDGFRA were found in 112 (88.2%) and six (4.7%) GISTs, resp.  Most KIT mutations involved exon 9 (n = 23) or exon 11 (n = 85).  All KIT mutant isoforms, but only a subset of PDGFRA mutant isoforms, were sensitive to imatinib, in vitro.  In patients with GISTs harboring exon 11 KIT mutations, the partial response rate (PR) was 83.5%, whereas patients with tumors contg. an exon 9 KIT mutation or no detectable mutation of KIT or PDGFRA had PR rates of 47.8% (P = .0006) and 0.0% (P < .0001), resp.  Patients whose tumors contained exon 11 KIT mutations had a longer event-free and overall survival than those whose tumors expressed either exon 9 KIT mutations or had no detectable kinase mutation.  Conclusion: Activating mutations of KIT or PDGFRA are found in the vast majority of GISTs, and the mutational status of these oncoproteins is predictive of clin. response to imatinib.  PDGFRA mutations can explain response and sensitivity to imatinib in some GISTs lacking KIT mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquHal4hZZoc7Vg90H21EOLACvtfcHk0lhtmnY43iHJiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVWqu7Y%253D&md5=cbfd753460bdf0005c3bd93f12df98dc</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1200%2FJCO.2003.04.190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2003.04.190%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DMcGreevey%26aufirst%3DL.%2BS.%26aulast%3DChen%26aufirst%3DC.%2BJ.%26aulast%3DVan%2Bden%2BAbbeele%26aufirst%3DA.%2BD.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DKiese%26aufirst%3DB.%26aulast%3DEisenberg%26aufirst%3DB.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%2BM.%26aulast%3DSilberman%26aufirst%3DS.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DKinase%2520mutations%2520and%2520imatinib%2520response%2520in%2520patients%2520with%2520metastatic%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2003%26volume%3D21%26spage%3D4342%26epage%3D4349%26doi%3D10.1200%2FJCO.2003.04.190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lasota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miettinen, M.</span><span> </span><span class="NLM_article-title">Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours</span> <span class="citation_source-journal">Histopathology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">–</span> <span class="NLM_lpage">266</span><span class="refDoi"> DOI: 10.1111/j.1365-2559.2008.02977.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1111%2Fj.1365-2559.2008.02977.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2008&pages=245-266&author=J.+Lasotaauthor=M.+Miettinen&title=Clinical+significance+of+oncogenic+KIT+and+PDGFRA+mutations+in+gastrointestinal+stromal+tumours&doi=10.1111%2Fj.1365-2559.2008.02977.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2559.2008.02977.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2559.2008.02977.x%26sid%3Dliteratum%253Aachs%26aulast%3DLasota%26aufirst%3DJ.%26aulast%3DMiettinen%26aufirst%3DM.%26atitle%3DClinical%2520significance%2520of%2520oncogenic%2520KIT%2520and%2520PDGFRA%2520mutations%2520in%2520gastrointestinal%2520stromal%2520tumours%26jtitle%3DHistopathology%26date%3D2008%26volume%3D53%26spage%3D245%26epage%3D266%26doi%3D10.1111%2Fj.1365-2559.2008.02977.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hirota, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isozaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishiguro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tunio, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuzawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanakura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinomura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, Y.</span><span> </span><span class="NLM_article-title">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">577</span><span class="NLM_x">–</span> <span class="NLM_lpage">580</span><span class="refDoi"> DOI: 10.1126/science.279.5350.577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1126%2Fscience.279.5350.577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=9438854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADyaK1cXotVyhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1998&pages=577-580&author=S.+Hirotaauthor=K.+Isozakiauthor=Y.+Moriyamaauthor=K.+Hashimotoauthor=T.+Nishidaauthor=S.+Ishiguroauthor=K.+Kawanoauthor=M.+Hanadaauthor=A.+Kurataauthor=M.+Takedaauthor=G.+M.+Tunioauthor=Y.+Matsuzawaauthor=Y.+Kanakuraauthor=Y.+Shinomuraauthor=Y.+Kitamura&title=Gain-of-function+mutations+of+c-kit+in+human+gastrointestinal+stromal+tumors&doi=10.1126%2Fscience.279.5350.577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</span></div><div class="casAuthors">Hirota, Seiichi; Isozaki, Koji; Moriyama, Yasuhiro; Hashimoto, Koji; Nishida, Toshirou; Ishiguro, Shingo; Kawano, Kiyoshi; Hanada, Masato; Kurata, Akihiko; Takeda, Masashi; Muhammad Tunio, Ghulam; Matsuzawa, Yuji; Kanakura, Yuzuru; Shinomura, Yasuhisa; Kitamura, Yukihiko</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">5350</span>),
    <span class="NLM_cas:pages">577-580</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the human digestive tract, but their mol. etiol. and cellular origin are unknown.  Sequencing of c-kit complementary DNA, which encodes a proto-oncogenic receptor tyrosine kinase (KIT), from five GISTs revealed mutations in the region between the transmembrane and tyrosine kinase domains.  All of the corresponding mutant KIT proteins were constitutively activated without the KIT ligand, stem cell factor (SCF).  Stable transfection of the mutant c-kit complementary DNAs induced malignant transformation of Ba/F3 murine lymphoid cells, suggesting that the mutations contribute to tumor development.  GISTs may originate from the interstitial cells of Cajal (ICCs) because the development of ICCs is dependent on the SCF-KIT interaction and because, like GISTs, these cells express both KIT and CD34.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLlGnWQ79KELVg90H21EOLACvtfcHk0lhtmnY43iHJiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotVyhsw%253D%253D&md5=b66b6b8a389b064f73fba13ca84e8650</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1126%2Fscience.279.5350.577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.279.5350.577%26sid%3Dliteratum%253Aachs%26aulast%3DHirota%26aufirst%3DS.%26aulast%3DIsozaki%26aufirst%3DK.%26aulast%3DMoriyama%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DK.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DIshiguro%26aufirst%3DS.%26aulast%3DKawano%26aufirst%3DK.%26aulast%3DHanada%26aufirst%3DM.%26aulast%3DKurata%26aufirst%3DA.%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DTunio%26aufirst%3DG.%2BM.%26aulast%3DMatsuzawa%26aufirst%3DY.%26aulast%3DKanakura%26aufirst%3DY.%26aulast%3DShinomura%26aufirst%3DY.%26aulast%3DKitamura%26aufirst%3DY.%26atitle%3DGain-of-function%2520mutations%2520of%2520c-kit%2520in%2520human%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DScience%26date%3D1998%26volume%3D279%26spage%3D577%26epage%3D580%26doi%3D10.1126%2Fscience.279.5350.577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duensing, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGreevey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Town, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">PDGFRA activating mutations in gastrointestinal stromal tumors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">708</span><span class="NLM_x">–</span> <span class="NLM_lpage">710</span><span class="refDoi"> DOI: 10.1126/science.1079666</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1126%2Fscience.1079666" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2003&pages=708-710&author=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=A.+Duensingauthor=L.+McGreeveyauthor=C.+J.+Chenauthor=N.+Josephauthor=S.+Singerauthor=D.+J.+Griffithauthor=A.+Haleyauthor=A.+Townauthor=G.+D.+Demetriauthor=C.+D.+M.+Fletcherauthor=J.+A.+Fletcher&title=PDGFRA+activating+mutations+in+gastrointestinal+stromal+tumors&doi=10.1126%2Fscience.1079666"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.1126%2Fscience.1079666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1079666%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DDuensing%26aufirst%3DA.%26aulast%3DMcGreevey%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DC.%2BJ.%26aulast%3DJoseph%26aufirst%3DN.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DGriffith%26aufirst%3DD.%2BJ.%26aulast%3DHaley%26aufirst%3DA.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%2BM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DPDGFRA%2520activating%2520mutations%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DScience%26date%3D2003%26volume%3D299%26spage%3D708%26epage%3D710%26doi%3D10.1126%2Fscience.1079666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarlomo-Rikala, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tervahartiala, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuveson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silberman, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrijevic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span> </span><span class="NLM_article-title">Effect of the tyrosine inhibitor STI571 in a patient with a metastatis gastrointestinal stromal tumor</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x">, </span> <span class="NLM_fpage">1052</span><span class="NLM_x">–</span> <span class="NLM_lpage">1056</span><span class="refDoi"> DOI: 10.1056/NEJM200104053441404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1056%2FNEJM200104053441404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=11287975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A280%3ADC%252BD3M3gvVekuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2001&pages=1052-1056&author=H.+Joensuuauthor=P.+J.+Robertsauthor=M.+Sarlomo-Rikalaauthor=L.+C.+Anderssonauthor=P.+Tervahartialaauthor=D.+Tuvesonauthor=S.+L.+Silbermanauthor=R.+Capdevilleauthor=S.+Dimitrijevicauthor=B.+Drukerauthor=G.+D.+Demetri&title=Effect+of+the+tyrosine+inhibitor+STI571+in+a+patient+with+a+metastatis+gastrointestinal+stromal+tumor&doi=10.1056%2FNEJM200104053441404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor</span></div><div class="casAuthors">Joensuu H; Roberts P J; Sarlomo-Rikala M; Andersson L C; Tervahartiala P; Tuveson D; Silberman S; Capdeville R; Dimitrijevic S; Druker B; Demetri G D</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1052-6</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYZ86Vmj15i5otVjB3IRIyfW6udTcc2eae1cOs1uH_-7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M3gvVekuw%253D%253D&md5=d361debf544b136b28889449118225e3</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1056%2FNEJM200104053441404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200104053441404%26sid%3Dliteratum%253Aachs%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DSarlomo-Rikala%26aufirst%3DM.%26aulast%3DAndersson%26aufirst%3DL.%2BC.%26aulast%3DTervahartiala%26aufirst%3DP.%26aulast%3DTuveson%26aufirst%3DD.%26aulast%3DSilberman%26aufirst%3DS.%2BL.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DDruker%26aufirst%3DB.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DEffect%2520of%2520the%2520tyrosine%2520inhibitor%2520STI571%2520in%2520a%2520patient%2520with%2520a%2520metastatis%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D344%26spage%3D1052%26epage%3D1056%26doi%3D10.1056%2FNEJM200104053441404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Abbeele, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuveson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janicek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silberman, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiese, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrijevic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, K.</span><span> </span><span class="NLM_article-title">Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">347</span><span class="NLM_x">, </span> <span class="NLM_fpage">472</span><span class="NLM_x">–</span> <span class="NLM_lpage">480</span><span class="refDoi"> DOI: 10.1056/NEJMoa020461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1056%2FNEJMoa020461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=12181401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtV2nt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2002&pages=472-480&author=G.+D.+Demetriauthor=M.+von+Mehrenauthor=C.+D.+Blankeauthor=A.+D.+Van+den+Abbeeleauthor=B.+Eisenbergauthor=P.+J.+Robertsauthor=M.+C.+Heinrichauthor=D.+A.+Tuvesonauthor=S.+Singerauthor=M.+Janicekauthor=J.+A.+Fletcherauthor=S.+G.+Silvermanauthor=S.+L.+Silbermanauthor=R.+Capdevilleauthor=B.+Kieseauthor=B.+Pengauthor=S.+Dimitrijevicauthor=B.+J.+Drukerauthor=C.+Corlessauthor=C.+D.+M.+Fletcherauthor=K.+Joensuu&title=Efficacy+and+safety+of+imatinib+mesylate+in+advanced+gastrointestinal+stromal+tumors&doi=10.1056%2FNEJMoa020461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors</span></div><div class="casAuthors">Demetri, George D.; von Mehren, Margaret; Blanke, Charles D.; Van den Abbeele, Annick D.; Eisenberg, Burton; Roberts, Peter J.; Heinrich, Michael C.; Tuveson, David A.; Singer, Samuel; Janicek, Milos; Fletcher, Jonathan A.; Silverman, Stuart G.; Silberman, Sandra L.; Capdeville, Renaud; Kiese, Beate; Peng, Bin; Dimitrijevic, Sasa; Druker, Brian J.; Corless, Christopher; Fletcher, Christopher D. M.; Joensuu, Heikki</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">472-480</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Constitutive activation of KIT receptor tyrosine kinase is crit. in the pathogenesis of gastrointestinal stromal tumors.  Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclin. models and preliminary clin. studies to have activity against such tumors.  We conducted an open-label, randomized, multicenter trial to evaluate the activity of imatinib in patients with advanced gastrointestinal stromal tumor.  We assessed antitumor response and the safety and tolerability of the drug.  Pharmacokinetics were assessed in a subgroup of patients.  A total of 147 patients were randomly assigned to receive 400 mg or 600 mg of imatinib daily.  Overall, 79 patients (53.7 percent) had a partial response, 41 patients (27.9 percent) had stable disease, and for tech. reasons, response could not be evaluated in 7 patients (4.8 percent).  No patient had a complete response to the treatment.  The median duration of response had not been reached after a median follow-up of 24 wk after the onset of response.  Early resistance to imatinib was noted in 20 patients (13.6 percent).  Therapy was well tolerated, although mild-to-moderate edema, diarrhea, and fatigue were common.  Gastrointestinal or intraabdominal hemorrhage occurred in approx. 5 percent of patients.  There were no significant differences in toxic effects or response between the two doses.  Imatinib was well absorbed, with pharmacokinetics similar to those reported in patients with chronic myeloid leukemia.  Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor.  Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVE0HpuuKXXrVg90H21EOLACvtfcHk0lhGzfbocDEFpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtV2nt7s%253D&md5=95c9ea076dd2b0e053ae2061cb3f5d24</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa020461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa020461%26sid%3Dliteratum%253Aachs%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DVan%2Bden%2BAbbeele%26aufirst%3DA.%2BD.%26aulast%3DEisenberg%26aufirst%3DB.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DJanicek%26aufirst%3DM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DSilverman%26aufirst%3DS.%2BG.%26aulast%3DSilberman%26aufirst%3DS.%2BL.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DKiese%26aufirst%3DB.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DCorless%26aufirst%3DC.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%2BM.%26aulast%3DJoensuu%26aufirst%3DK.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520imatinib%2520mesylate%2520in%2520advanced%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2002%26volume%3D347%26spage%3D472%26epage%3D480%26doi%3D10.1056%2FNEJMoa020461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Beham, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghadimi, B. M.</span><span> </span><span class="NLM_article-title">Gastrointestinal stromal tumors</span> <span class="citation_source-journal">Int. J. Colorectal. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">689</span><span class="NLM_x">–</span> <span class="NLM_lpage">700</span><span class="refDoi"> DOI: 10.1007/s00384-011-1353-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1007%2Fs00384-011-1353-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=22124674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A280%3ADC%252BC38zotFeisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2012&pages=689-700&author=A.+W.+Behamauthor=I.+M.+Schaeferauthor=P.+Schulerauthor=S.+Cameronauthor=B.+M.+Ghadimi&title=Gastrointestinal+stromal+tumors&doi=10.1007%2Fs00384-011-1353-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal stromal tumors</span></div><div class="casAuthors">Beham Alexander W; Schaefer Inga-Marie; Schuler Philipp; Cameron Silke; Ghadimi B Michael</div><div class="citationInfo"><span class="NLM_cas:title">International journal of colorectal disease</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">689-700</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  The gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the intestinal tract, known to be refractory to conventional chemotherapy or radiation.  Its pathogenesis is defined by mutations within the KIT and PDGFRA gene, which constitutively activate KIT and PDGFRA oncoproteins, and serve as crucial diagnostic and therapeutic targets.  DISCUSSION:  Besides surgery, therapy with imatinib mesylate, which inhibits KIT kinase activity, represents the other cornerstone for the treatment of GIST.  Still, the only curative option for GIST is given after complete surgical removal even in a metastatic setting, but recurrence is common, and the risk can be defined by surgical factors like incomplete resection, intraperitoneal rupture, or bleeding and tumor associated factors like tumor size, mitotic index, or localization.  CONCLUSION:  Consequently, adjuvant therapy with imatinib mesylate or other tyrosine kinase inhibitors is recommended for high-risk patients after complete resection.  For unresectable and advanced GIST, a partial response or stable disease can be achieved in about 80% of patients with imatinib mesylate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS9xNFEc0G2FhLDWw4HIq2sfW6udTcc2eZ3-3lzlOG4Hbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38zotFeisw%253D%253D&md5=ff8081bd813d5c0ee9de419f5cc2c1e0</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs00384-011-1353-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00384-011-1353-y%26sid%3Dliteratum%253Aachs%26aulast%3DBeham%26aufirst%3DA.%2BW.%26aulast%3DSchaefer%26aufirst%3DI.%2BM.%26aulast%3DSchuler%26aufirst%3DP.%26aulast%3DCameron%26aufirst%3DS.%26aulast%3DGhadimi%26aufirst%3DB.%2BM.%26atitle%3DGastrointestinal%2520stromal%2520tumors%26jtitle%3DInt.%2520J.%2520Colorectal.%2520Dis.%26date%3D2012%26volume%3D27%26spage%3D689%26epage%3D700%26doi%3D10.1007%2Fs00384-011-1353-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalcberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeCesne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichardt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blay, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Issels, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Oosterom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogendoorn, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Glabbeke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertulli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I.</span><span> </span><span class="NLM_article-title">Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">1127</span><span class="NLM_x">–</span> <span class="NLM_lpage">1134</span><span class="refDoi"> DOI: 10.1016/S0140-6736(04)17098-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1016%2FS0140-6736%2804%2917098-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2004&pages=1127-1134&author=J.+Verweijauthor=P.+G.+Casaliauthor=J.+Zalcbergauthor=A.+LeCesneauthor=P.+Reichardtauthor=J.+Y.+Blayauthor=R.+Isselsauthor=A.+van+Oosteromauthor=P.+C.+Hogendoornauthor=M.+Van+Glabbekeauthor=R.+Bertulliauthor=I.+Judson&title=Progression-free+survival+in+gastrointestinal+stromal+tumours+with+high-dose+imatinib%3A+randomised+trial&doi=10.1016%2FS0140-6736%2804%2917098-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2804%2917098-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252804%252917098-0%26sid%3Dliteratum%253Aachs%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3DZalcberg%26aufirst%3DJ.%26aulast%3DLeCesne%26aufirst%3DA.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DIssels%26aufirst%3DR.%26aulast%3Dvan%2BOosterom%26aufirst%3DA.%26aulast%3DHogendoorn%26aufirst%3DP.%2BC.%26aulast%3DVan%2BGlabbeke%26aufirst%3DM.%26aulast%3DBertulli%26aufirst%3DR.%26aulast%3DJudson%26aufirst%3DI.%26atitle%3DProgression-free%2520survival%2520in%2520gastrointestinal%2520stromal%2520tumours%2520with%2520high-dose%2520imatinib%253A%2520randomised%2520trial%26jtitle%3DLancet%26date%3D2004%26volume%3D364%26spage%3D1127%26epage%3D1134%26doi%3D10.1016%2FS0140-6736%2804%2917098-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Antonescu, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besmer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arkun, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hom, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koryotowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leversha, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desantis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMatteo, R. P.</span><span> </span><span class="NLM_article-title">Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">4182</span><span class="NLM_x">–</span> <span class="NLM_lpage">4190</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-2245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1158%2F1078-0432.CCR-04-2245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=15930355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1GksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=4182-4190&author=C.+R.+Antonescuauthor=P.+Besmerauthor=T.+Guoauthor=K.+Arkunauthor=G.+Homauthor=B.+Koryotowskiauthor=M.+A.+Levershaauthor=P.+D.+Jeffreyauthor=D.+Desantisauthor=S.+Singerauthor=M.+F.+Brennanauthor=R.+G.+Makiauthor=R.+P.+DeMatteo&title=Acquired+resistance+to+imatinib+in+gastrointestinal+stromal+tumor+occurs+through+secondary+gene+mutation&doi=10.1158%2F1078-0432.CCR-04-2245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation</span></div><div class="casAuthors">Antonescu, Cristina R.; Besmer, Peter; Guo, Tianhua; Arkun, Knarik; Hom, Glory; Koryotowski, Beata; Leversha, Margaret A.; Jeffrey, Philip D.; Desantis, Diann; Singer, Samuel; Brennan, Murray F.; Maki, Robert G.; DeMatteo, Ronald P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4182-4190</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GIST) have an activating mutation in either KIT or PDGFRA.  Imatinib is a selective tyrosine kinase inhibitor and achieves a partial response or stable disease in about 80% of patients with metastatic GIST.  It is now clear that some patients with GIST develop resistance to imatinib during chronic therapy.  To identify the mechanism of resistance, we studied 31 patients with GIST who were treated with imatinib and then underwent surgical resection.  There were 13 patients who were nonresistant to imatinib, 3 with primary resistance, and 15 with acquired resistance after initial benefit from the drug.  There were no secondary mutations in KIT or PDGFRA in the nonresistant or primary resistance groups.  In contrast, secondary mutations were found in 7 of 15 (46%) patients with acquired resistance, each of whom had a primary mutation in KIT exon 11.  Most secondary mutations were located in KIT exon 17.  KIT phosphorylation was heterogeneous and did not correlate with clin. response to imatinib or mutation status.  That acquired resistance to imatinib in GIST commonly occurs via secondary gene mutation in the KIT kinase domain has implications for strategies to delay or prevent imatinib resistance and to employ newer targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOQf6NfYqwnrVg90H21EOLACvtfcHk0lgsnkNOj5YWgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1GksLw%253D&md5=f0f8000b2c362c7d1dcc74a2a7aaa067</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-2245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-2245%26sid%3Dliteratum%253Aachs%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26aulast%3DBesmer%26aufirst%3DP.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DArkun%26aufirst%3DK.%26aulast%3DHom%26aufirst%3DG.%26aulast%3DKoryotowski%26aufirst%3DB.%26aulast%3DLeversha%26aufirst%3DM.%2BA.%26aulast%3DJeffrey%26aufirst%3DP.%2BD.%26aulast%3DDesantis%26aufirst%3DD.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DBrennan%26aufirst%3DM.%2BF.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DDeMatteo%26aufirst%3DR.%2BP.%26atitle%3DAcquired%2520resistance%2520to%2520imatinib%2520in%2520gastrointestinal%2520stromal%2520tumor%2520occurs%2520through%2520secondary%2520gene%2520mutation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D4182%26epage%3D4190%26doi%3D10.1158%2F1078-0432.CCR-04-2245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Debiec-Rychter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cools, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumez, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciot, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mentens, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vranckx, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasag, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prenen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roesel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagemeijer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Oosterom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marynen, P.</span><span> </span><span class="NLM_article-title">Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x">, </span> <span class="NLM_fpage">270</span><span class="NLM_x">–</span> <span class="NLM_lpage">279</span><span class="refDoi"> DOI: 10.1053/j.gastro.2004.11.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1053%2Fj.gastro.2004.11.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2005&pages=270-279&author=M.+Debiec-Rychterauthor=J.+Coolsauthor=H.+Dumezauthor=R.+Sciotauthor=M.+Stulauthor=N.+Mentensauthor=H.+Vranckxauthor=B.+Wasagauthor=H.+Prenenauthor=J.+Roeselauthor=A.+Hagemeijerauthor=A.+Van+Oosteromauthor=P.+Marynen&title=Mechanisms+of+resistance+to+imatinib+mesylate+in+gastrointestinal+stromal+tumors+and+activity+of+the+PKC412+inhibitor+against+imatinib-resistant+mutants&doi=10.1053%2Fj.gastro.2004.11.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2004.11.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2004.11.020%26sid%3Dliteratum%253Aachs%26aulast%3DDebiec-Rychter%26aufirst%3DM.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DDumez%26aufirst%3DH.%26aulast%3DSciot%26aufirst%3DR.%26aulast%3DStul%26aufirst%3DM.%26aulast%3DMentens%26aufirst%3DN.%26aulast%3DVranckx%26aufirst%3DH.%26aulast%3DWasag%26aufirst%3DB.%26aulast%3DPrenen%26aufirst%3DH.%26aulast%3DRoesel%26aufirst%3DJ.%26aulast%3DHagemeijer%26aufirst%3DA.%26aulast%3DVan%2BOosterom%26aufirst%3DA.%26aulast%3DMarynen%26aufirst%3DP.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520imatinib%2520mesylate%2520in%2520gastrointestinal%2520stromal%2520tumors%2520and%2520activity%2520of%2520the%2520PKC412%2520inhibitor%2520against%2520imatinib-resistant%2520mutants%26jtitle%3DGastroenterology%26date%3D2005%26volume%3D128%26spage%3D270%26epage%3D279%26doi%3D10.1053%2Fj.gastro.2004.11.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandau, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDougall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">Molecular correlates of imatinib resistance in gastrointestinal stromal tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4764</span><span class="NLM_x">–</span> <span class="NLM_lpage">4774</span><span class="refDoi"> DOI: 10.1200/JCO.2006.06.2265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1200%2FJCO.2006.06.2265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=16954519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFynsrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=4764-4774&author=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=C.+D.+Blankeauthor=G.+D.+Demetriauthor=H.+Joensuuauthor=P.+J.+Robertsauthor=B.+L.+Eisenbergauthor=M.+von+Mehrenauthor=C.+D.+Fletcherauthor=K.+Sandauauthor=K.+McDougallauthor=W.+B.+Ouauthor=C.+J.+Chenauthor=J.+A.+Fletcher&title=Molecular+correlates+of+imatinib+resistance+in+gastrointestinal+stromal+tumors&doi=10.1200%2FJCO.2006.06.2265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15cR"><div class="casContent"><span class="casTitleNuber">15c</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular correlates of imatinib resistance in gastrointestinal stromal tumors</span></div><div class="casAuthors">Heinrich, Michael C.; Corless, Christopher L.; Blanke, Charles D.; Demetri, George D.; Joensuu, Heikki; Roberts, Peter J.; Eisenberg, Burton L.; von Mehren, Margaret; Fletcher, Christopher D. M.; Sandau, Katrin; McDougall, Karen; Ou, Wen-bin; Chen, Chang-Jie; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">4764-4774</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Gastrointestinal stromal tumors (GISTs) commonly harbor oncogenic mutations of the KIT or platelet-derived growth factor alpha (PDGFRA) kinases, which are targets for imatinib.  In clin. studies, 75% to 90% of patients with advanced GISTs experience clin. benefit from imatinib.  However, imatinib resistance is an increasing clin. problem.  Patients and Methods One hundred forty-seven patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clin. study of imatinib.  Specimens from pretreatment and/or imatinib-resistant tumors were analyzed to identify mol. correlates of imatinib resistance.  Secondary kinase mutations of KIT or PDGFRA that were identified in imatinib-resistant GISTs were biochem. profiled for imatinib sensitivity.  Results Mol. studies were performed using specimens from 10 patients with primary and 33 patients with secondary resistance.  Imatinib-resistant tumors had levels of activated KIT that were similar to or greater than those typically found in untreated GISTs.  Secondary kinase mutations were rare in GISTs with primary resistance but frequently found in GISTs with secondary resistance (10% v 67%, P = .002).  Evidence for clonal evolution and/or polyclonal secondary kinase mutations was seen in three (18.8%) of 16 patients.  Secondary kinase mutations were nonrandomly distributed and were assocd. with decreased imatinib sensitivity compared with typical KIT exon 11 mutations.  Using RNAi technol., we demonstrated that imatinib-resistant GIST cells remain dependent on KIT kinase activity for activation of crit. downstream signaling pathways.  Conclusion Different mol. mechanisms are responsible for primary and secondary imatinib resistance in GISTs.  These findings have implications for future approaches to the growing problem of imatinib resistance in patients with advanced GISTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw_n35sjCddLVg90H21EOLACvtfcHk0lgsnkNOj5YWgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFynsrrN&md5=25f7b94dd02d55c2fb56cea499cb7ab8</span></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.06.2265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.06.2265%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DEisenberg%26aufirst%3DB.%2BL.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DSandau%26aufirst%3DK.%26aulast%3DMcDougall%26aufirst%3DK.%26aulast%3DOu%26aufirst%3DW.%2BB.%26aulast%3DChen%26aufirst%3DC.%2BJ.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DMolecular%2520correlates%2520of%2520imatinib%2520resistance%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D4764%26epage%3D4774%26doi%3D10.1200%2FJCO.2006.06.2265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Gajiwala, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiNitto, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">English, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greig, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacques, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lunney, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quenzer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmett, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span> </span><span class="NLM_article-title">KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">1542</span><span class="NLM_x">–</span> <span class="NLM_lpage">1547</span><span class="refDoi"> DOI: 10.1073/pnas.0812413106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1073%2Fpnas.0812413106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=19164557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=1542-1547&author=K.+S.+Gajiwalaauthor=J.+C.+Wuauthor=J.+Christensenauthor=G.+D.+Deshmukhauthor=W.+Diehlauthor=J.+P.+DiNittoauthor=J.+M.+Englishauthor=M.+J.+Greigauthor=Y.+A.+Heauthor=S.+L.+Jacquesauthor=E.+A.+Lunneyauthor=M.+McTigueauthor=D.+Molinaauthor=T.+Quenzerauthor=P.+A.+Wellsauthor=X.+Yuauthor=Y.+Zhangauthor=A.+Zouauthor=M.+R.+Emmettauthor=A.+G.+Marshallauthor=H.+M.+Zhangauthor=G.+D.+Demetri&title=KIT+kinase+mutants+show+unique+mechanisms+of+drug+resistance+to+imatinib+and+sunitinib+in+gastrointestinal+stromal+tumor+patients&doi=10.1073%2Fpnas.0812413106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients</span></div><div class="casAuthors">Gajiwala, Ketan S.; Wu, Joe C.; Christensen, James; Deshmukh, Gayatri D.; Diehl, Wade; DiNitto, Jonathan P.; English, Jessie M.; Greig, Michael J.; He, You-Ai; Jacques, Suzanne L.; Lunney, Elizabeth A.; McTigue, Michele; Molina, Dave; Quenzer, Terri; Wells, Peter A.; Yu, Xiu; Zhang, Yan; Zou, Aihua; Emmett, Mark R.; Marshall, Alan G.; Zhang, Hui-Min; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1542-1547</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GISTs) exhibit aberrant activation of the receptor tyrosine kinase (RTK) KIT.  The efficacy of the inhibitors imatinib mesylate and sunitinib malate in GIST patients has been linked to their inhibition of these mutant KIT proteins.  However, patients on imatinib can acquire secondary KIT mutations that render the protein insensitive to the inhibitor.  Sunitinib has shown efficacy against certain imatinib-resistant mutants, although a subset that resides in the activation loop, including D816H/V, remains resistant.  Biochem. and structural studies were undertaken to det. the mol. basis of sunitinib resistance.  Our results show that sunitinib targets the autoinhibited conformation of WT KIT and that the D816H mutant undergoes a shift in conformational equil. toward the active state.  These findings provide a structural and enzymol. explanation for the resistance profile obsd. with the KIT inhibitors.  Prospectively, they have implications for understanding oncogenic kinase mutants and for circumventing drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkwFxa-p-iWbVg90H21EOLACvtfcHk0lgyvaH_lIUxPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D&md5=dd226c914c6f9a258426c0f4984a5258</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0812413106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0812413106%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DDeshmukh%26aufirst%3DG.%2BD.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DDiNitto%26aufirst%3DJ.%2BP.%26aulast%3DEnglish%26aufirst%3DJ.%2BM.%26aulast%3DGreig%26aufirst%3DM.%2BJ.%26aulast%3DHe%26aufirst%3DY.%2BA.%26aulast%3DJacques%26aufirst%3DS.%2BL.%26aulast%3DLunney%26aufirst%3DE.%2BA.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DMolina%26aufirst%3DD.%26aulast%3DQuenzer%26aufirst%3DT.%26aulast%3DWells%26aufirst%3DP.%2BA.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DA.%26aulast%3DEmmett%26aufirst%3DM.%2BR.%26aulast%3DMarshall%26aufirst%3DA.%2BG.%26aulast%3DZhang%26aufirst%3DH.%2BM.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DKIT%2520kinase%2520mutants%2520show%2520unique%2520mechanisms%2520of%2520drug%2520resistance%2520to%2520imatinib%2520and%2520sunitinib%2520in%2520gastrointestinal%2520stromal%2520tumor%2520patients%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26spage%3D1542%26epage%3D1547%26doi%3D10.1073%2Fpnas.0812413106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Tamborini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pricl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negri, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagonigro, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miselli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greco, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gronchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fermeglia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carbone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierotti, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilotti, S.</span><span> </span><span class="NLM_article-title">Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">6140</span><span class="NLM_x">–</span> <span class="NLM_lpage">6146</span><span class="refDoi"> DOI: 10.1038/sj.onc.1209639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1038%2Fsj.onc.1209639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=16751810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVGgsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=6140-6146&author=E.+Tamboriniauthor=S.+Priclauthor=T.+Negriauthor=M.+S.+Lagonigroauthor=F.+Miselliauthor=A.+Grecoauthor=A.+Gronchiauthor=P.+G.+Casaliauthor=M.+Ferroneauthor=M.+Fermegliaauthor=A.+Carboneauthor=M.+A.+Pierottiauthor=S.+Pilotti&title=Functional+analyses+and+molecular+modeling+of+two+c-Kit+mutations+responsible+for+imatinib+secondary+resistance+in+GIST+patients&doi=10.1038%2Fsj.onc.1209639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients</span></div><div class="casAuthors">Tamborini, E.; Pricl, S.; Negri, T.; Lagonigro, M. S.; Miselli, F.; Greco, A.; Gronchi, A.; Casali, P. G.; Ferrone, M.; Fermeglia, M.; Carbone, A.; Pierotti, M. A.; Pilotti, S.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">6140-6146</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Imatinib-acquired resistance related to the presence of secondary point mutations has become a frequent event in gastrointestinal stromal tumors.  Here, transient transfection expts. with plasmids carrying two different KIT-acquired point mutations were performed along with immunopptn. of total protein exts., derived from imatinib-treated and untreated cells.  The mol. mechanics/Poisson Boltzmann surface area computational techniques were applied to study the interactions of the wild-type and mutated receptors with imatinib at the mol. level.  Biochem. analyses showed KIT phosphorylation in cells transfected with vectors carrying the specific mutant genes.  Imatinib treatment demonstrated that T670I was insensitive to the drug at all the applied concns., whereas V654A was inhibited by 6 μM of imatinib.  The modeling of the mutated receptors revealed that both substitutions affect imatinib-binding site, but to a different extent: T670I substantially modifies the binding pocket, whereas V654A induces only relatively confined structural changes.  We demonstrated that T670I and V654A cause indeed imatinib-acquired resistance and that the former is more resistant to imatinib than the latter.  The application of mol. simulations allowed us to quantify the interactions between the mutated receptors and imatinib, and to propose a mol. rationale for this type of drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrozOoPwE9hbVg90H21EOLACvtfcHk0lgyvaH_lIUxPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVGgsr7E&md5=03f253028385fd9244a94d9b6bcce077</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1209639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1209639%26sid%3Dliteratum%253Aachs%26aulast%3DTamborini%26aufirst%3DE.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DNegri%26aufirst%3DT.%26aulast%3DLagonigro%26aufirst%3DM.%2BS.%26aulast%3DMiselli%26aufirst%3DF.%26aulast%3DGreco%26aufirst%3DA.%26aulast%3DGronchi%26aufirst%3DA.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3DFerrone%26aufirst%3DM.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DCarbone%26aufirst%3DA.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26aulast%3DPilotti%26aufirst%3DS.%26atitle%3DFunctional%2520analyses%2520and%2520molecular%2520modeling%2520of%2520two%2520c-Kit%2520mutations%2520responsible%2520for%2520imatinib%2520secondary%2520resistance%2520in%2520GIST%2520patients%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26spage%3D6140%26epage%3D6146%26doi%3D10.1038%2Fsj.onc.1209639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tamborini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonadiman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greco, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albertini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negri, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gronchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertulli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colecchia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierotti, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilotti, S.</span><span> </span><span class="NLM_article-title">A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x">, </span> <span class="NLM_fpage">294</span><span class="NLM_x">–</span> <span class="NLM_lpage">299</span><span class="refDoi"> DOI: 10.1053/j.gastro.2004.02.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1053%2Fj.gastro.2004.02.021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2004&pages=294-299&author=E.+Tamboriniauthor=L.+Bonadimanauthor=A.+Grecoauthor=V.+Albertiniauthor=T.+Negriauthor=A.+Gronchiauthor=R.+Bertulliauthor=M.+Colecchiaauthor=P.+G.+Casaliauthor=M.+A.+Pierottiauthor=S.+Pilotti&title=A+new+mutation+in+the+KIT+ATP+pocket+causes+acquired+resistance+to+imatinib+in+a+gastrointestinal+stromal+tumor+patient&doi=10.1053%2Fj.gastro.2004.02.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2004.02.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2004.02.021%26sid%3Dliteratum%253Aachs%26aulast%3DTamborini%26aufirst%3DE.%26aulast%3DBonadiman%26aufirst%3DL.%26aulast%3DGreco%26aufirst%3DA.%26aulast%3DAlbertini%26aufirst%3DV.%26aulast%3DNegri%26aufirst%3DT.%26aulast%3DGronchi%26aufirst%3DA.%26aulast%3DBertulli%26aufirst%3DR.%26aulast%3DColecchia%26aufirst%3DM.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26aulast%3DPilotti%26aufirst%3DS.%26atitle%3DA%2520new%2520mutation%2520in%2520the%2520KIT%2520ATP%2520pocket%2520causes%2520acquired%2520resistance%2520to%2520imatinib%2520in%2520a%2520gastrointestinal%2520stromal%2520tumor%2520patient%26jtitle%3DGastroenterology%26date%3D2004%26volume%3D127%26spage%3D294%26epage%3D299%26doi%3D10.1053%2Fj.gastro.2004.02.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Wardelmann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merkelbach-Bruse, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauls, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schildhaus, H. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinicke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speidel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietsch, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buettner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pink, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichardt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohenberger, P.</span><span> </span><span class="NLM_article-title">Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1743</span><span class="NLM_x">–</span> <span class="NLM_lpage">1749</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-1211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1158%2F1078-0432.CCR-05-1211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=16551858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD28Xis1Cjs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=1743-1749&author=E.+Wardelmannauthor=S.+Merkelbach-Bruseauthor=K.+Paulsauthor=N.+Thomasauthor=H.+U.+Schildhausauthor=T.+Heinickeauthor=N.+Speidelauthor=T.+Pietschauthor=R.+Buettnerauthor=D.+Pinkauthor=P.+Reichardtauthor=P.+Hohenberger&title=Polyclonal+evolution+of+multiple+secondary+KIT+mutations+in+gastrointestinal+stromal+tumors+under+treatment+with+imatinib+mesylate&doi=10.1158%2F1078-0432.CCR-05-1211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate</span></div><div class="casAuthors">Wardelmann, Eva; Merkelbach-Bruse, Sabine; Pauls, Katharina; Thomas, Nadja; Schildhaus, Hans-Ulrich; Heinicke, Thomas; Speidel, Nicola; Pietsch, Torsten; Buettner, Reinhard; Pink, Daniel; Reichardt, Peter; Hohenberger, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1743-1749</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Gastrointestinal stromal tumors (GIST) are characterized by a strong KIT receptor activation most often resulting from KIT mutations.  In a smaller subgroup of tumors without KIT mutations, analogous activating mutations are found in the platelet-derived growth factor receptor α (PDGFRα) gene.  Both PDGFRα and KIT receptors are targets of the tyrosine kinase inhibitor imatinib (Glivec) which has improved the treatment of advanced GISTs significantly.  However, a subgroup of tumors show a secondary progress under therapy with imatinib after initial response.  One possible mechanism of secondary resistance is the development of newly acquired KIT mutations.  In the present study, we evaluated the frequency of such secondary KIT mutations in a series of GIST patients in which tumor tissue was resected under treatment.  We examd. one to seven different tumor areas in 32 cases (total of 104 samples) and found up to four newly acquired KIT mutations in 14 patients (43.8%).  These were always located in exons encoding the first or second tyrosine kinase domain (exon 13, 14, or 17).  Mutations were found only in a subset of samples analyzed from each case whereas others retained the wild-type sequence in the same region.  There was never more than one new mutation in the same sample.  Consistent with a secondary clonal evolution, the primary mutation was always detectable in all samples from each tumor.  According to our results, the identification of newly acquired KIT mutations in addn. to the primary mutation is dependent on the no. of tissue samples analyzed and has high implications for further therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovhLaWTAFjP7Vg90H21EOLACvtfcHk0lhyL8cB-UJYRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xis1Cjs7Y%253D&md5=e39c95f452672224e49e8c5515b139c1</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-1211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-1211%26sid%3Dliteratum%253Aachs%26aulast%3DWardelmann%26aufirst%3DE.%26aulast%3DMerkelbach-Bruse%26aufirst%3DS.%26aulast%3DPauls%26aufirst%3DK.%26aulast%3DThomas%26aufirst%3DN.%26aulast%3DSchildhaus%26aufirst%3DH.%2BU.%26aulast%3DHeinicke%26aufirst%3DT.%26aulast%3DSpeidel%26aufirst%3DN.%26aulast%3DPietsch%26aufirst%3DT.%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DPink%26aufirst%3DD.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DHohenberger%26aufirst%3DP.%26atitle%3DPolyclonal%2520evolution%2520of%2520multiple%2520secondary%2520KIT%2520mutations%2520in%2520gastrointestinal%2520stromal%2520tumors%2520under%2520treatment%2520with%2520imatinib%2520mesylate%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D1743%26epage%3D1749%26doi%3D10.1158%2F1078-0432.CCR-05-1211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Town, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGreevey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiraga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bainbridge, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span> </span><span class="NLM_article-title">PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5357</span><span class="NLM_x">–</span> <span class="NLM_lpage">5364</span><span class="refDoi"> DOI: 10.1200/JCO.2005.14.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1200%2FJCO.2005.14.068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=15928335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpslOrtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=5357-5364&author=C.+L.+Corlessauthor=A.+Schroederauthor=D.+Griffithauthor=A.+Townauthor=L.+McGreeveyauthor=P.+Harrellauthor=S.+Shiragaauthor=T.+Bainbridgeauthor=J.+Morichauthor=M.+C.+Heinrich&title=PDGFRA+mutations+in+gastrointestinal+stromal+tumors%3A+frequency%2C+spectrum+and+in+vitro+sensitivity+to+imatinib&doi=10.1200%2FJCO.2005.14.068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib</span></div><div class="casAuthors">Corless, Christopher L.; Schroeder, Arin; Griffith, Diana; Town, Ajia; McGreevey, Laura; Harrell, Patina; Shiraga, Sharon; Bainbridge, Troy; Morich, Jason; Heinrich, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5357-5364</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Gastrointestinal stromal tumors (GISTs) commonly harbor oncogenic mutations of the KIT tyrosine kinase, which is a target for the kinase inhibitor imatinib.  A subset of GISTs, however, contains mutations in the homologous kinase platelet derived growth factor receptor alpha (PDGFRA), and the most common of these mutations is resistant to imatinib in vitro.  Little is known of the other types of PDGFRA mutations that occur in GISTs.  Materials and Methods: We detd. the KIT and PDGFRA mutation status of 1,105 unique GISTs using a combination of denaturing high-performance liq. chromatog. and direct sequencing.  Results: There were 80 tumors (7.2%) with a PDGFRA mutation: 66 in exon 18, 11 in exon 12, and three in exon 14.  Transient expression of representative PDGFRA isoforms in CHO cells revealed imatinib sensitivity of exon 12 mutations (SPDHE566-571R and insertion ER561-562) and an exon 14 substitution (N659K).  However, most isoforms with a substitution involving codon D842 in exon 18 (D842V, RD841-842KI, DI842-843IM) were resistant to the drug, with the exception of D842Y.  Interestingly, other mutations in exon 18 (D846Y, N848K, Y849K and HDSN845-848P) were all imatinib sensitive.  Proliferation studies with BA/F3 cell lines stably expressing selected PDGFRA mutant isoforms supported these findings.  Conclusion: Including our cases, there are 289 reported PDGFRA-mutant GISTs, of which 181 (62.6%) had the imatinib-resistant substitution D842V.  However, our findings suggest that more than one third of GISTs with PDGFRA mutations may respond to imatinib and that mutation screening may be helpful in the management of these tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnkomzycGeSbVg90H21EOLACvtfcHk0lhyL8cB-UJYRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpslOrtLY%253D&md5=f93f7152a982366acd714cef3207ff2f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.14.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.14.068%26sid%3Dliteratum%253Aachs%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DSchroeder%26aufirst%3DA.%26aulast%3DGriffith%26aufirst%3DD.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DMcGreevey%26aufirst%3DL.%26aulast%3DHarrell%26aufirst%3DP.%26aulast%3DShiraga%26aufirst%3DS.%26aulast%3DBainbridge%26aufirst%3DT.%26aulast%3DMorich%26aufirst%3DJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26atitle%3DPDGFRA%2520mutations%2520in%2520gastrointestinal%2520stromal%2520tumors%253A%2520frequency%252C%2520spectrum%2520and%2520in%2520vitro%2520sensitivity%2520to%2520imatinib%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D5357%26epage%3D5364%26doi%3D10.1200%2FJCO.2005.14.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Oosterom, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackstein, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bello, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span> </span><span class="NLM_article-title">Effcacy and safety of sunitinib in patients with advanced astrointestinal stromal tumour after failure of imatinib: a randomised controlled trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">368</span><span class="NLM_x">, </span> <span class="NLM_fpage">1329</span><span class="NLM_x">–</span> <span class="NLM_lpage">1338</span><span class="refDoi"> DOI: 10.1016/S0140-6736(06)69446-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1016%2FS0140-6736%2806%2969446-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2006&pages=1329-1338&author=G.+D.+Demetriauthor=A.+T.+van+Oosteromauthor=C.+R.+Garrettauthor=M.+E.+Blacksteinauthor=M.+H.+Shahauthor=J.+Verweijauthor=G.+McArthurauthor=I.+R.+Judsonauthor=M.+C.+Heinrichauthor=J.+A.+Morganauthor=J.+Desaiauthor=C.+D.+Fletcherauthor=S.+Georgeauthor=C.+L.+Belloauthor=X.+Huangauthor=C.+M.+Baumauthor=P.+G.+Casali&title=Effcacy+and+safety+of+sunitinib+in+patients+with+advanced+astrointestinal+stromal+tumour+after+failure+of+imatinib%3A+a+randomised+controlled+trial&doi=10.1016%2FS0140-6736%2806%2969446-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2806%2969446-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252806%252969446-4%26sid%3Dliteratum%253Aachs%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3Dvan%2BOosterom%26aufirst%3DA.%2BT.%26aulast%3DGarrett%26aufirst%3DC.%2BR.%26aulast%3DBlackstein%26aufirst%3DM.%2BE.%26aulast%3DShah%26aufirst%3DM.%2BH.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DMcArthur%26aufirst%3DG.%26aulast%3DJudson%26aufirst%3DI.%2BR.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DMorgan%26aufirst%3DJ.%2BA.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DBello%26aufirst%3DC.%2BL.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DBaum%26aufirst%3DC.%2BM.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26atitle%3DEffcacy%2520and%2520safety%2520of%2520sunitinib%2520in%2520patients%2520with%2520advanced%2520astrointestinal%2520stromal%2520tumour%2520after%2520failure%2520of%2520imatinib%253A%2520a%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2006%26volume%3D368%26spage%3D1329%26epage%3D1338%26doi%3D10.1016%2FS0140-6736%2806%2969446-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichardt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blay, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutkowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelderblom, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohenberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leahy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badalamenti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackstein, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Cesne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schöffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kappeler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuss, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span> </span><span class="NLM_article-title">GRID Study investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">381</span><span class="NLM_x">, </span> <span class="NLM_fpage">295</span><span class="NLM_x">–</span> <span class="NLM_lpage">302</span><span class="refDoi"> DOI: 10.1016/S0140-6736(12)61857-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1016%2FS0140-6736%2812%2961857-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2013&pages=295-302&author=G.+D.+Demetriauthor=P.+Reichardtauthor=Y.+K.+Kangauthor=J.+Y.+Blayauthor=P.+Rutkowskiauthor=H.+Gelderblomauthor=P.+Hohenbergerauthor=M.+Leahyauthor=M.+von+Mehrenauthor=H.+Joensuuauthor=G.+Badalamentiauthor=M.+Blacksteinauthor=A.+Le+Cesneauthor=P.+Sch%C3%B6ffskiauthor=R.+G.+Makiauthor=S.+Bauerauthor=B.+B.+Nguyenauthor=J.+M.+Xuauthor=T.+Nishidaauthor=J.+Chungauthor=C.+Kappelerauthor=I.+Kussauthor=D.+Laurentauthor=P.+G.+Casali&title=GRID+Study+investigators.+Efficacy+and+safety+of+regorafenib+for+advanced+gastrointestinal+stromal+tumours+after+failure+of+imatinib+and+sunitinib+%28GRID%29%3A+an+international%2C+multicentre%2C+randomised%2C+placebo-controlled%2C+phase+3+trial&doi=10.1016%2FS0140-6736%2812%2961857-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2961857-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252961857-1%26sid%3Dliteratum%253Aachs%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DKang%26aufirst%3DY.%2BK.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DGelderblom%26aufirst%3DH.%26aulast%3DHohenberger%26aufirst%3DP.%26aulast%3DLeahy%26aufirst%3DM.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DBadalamenti%26aufirst%3DG.%26aulast%3DBlackstein%26aufirst%3DM.%26aulast%3DLe%2BCesne%26aufirst%3DA.%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DB.%2BB.%26aulast%3DXu%26aufirst%3DJ.%2BM.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DChung%26aufirst%3DJ.%26aulast%3DKappeler%26aufirst%3DC.%26aulast%3DKuss%26aufirst%3DI.%26aulast%3DLaurent%26aufirst%3DD.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26atitle%3DGRID%2520Study%2520investigators.%2520Efficacy%2520and%2520safety%2520of%2520regorafenib%2520for%2520advanced%2520gastrointestinal%2520stromal%2520tumours%2520after%2520failure%2520of%2520imatinib%2520and%2520sunitinib%2520%2528GRID%2529%253A%2520an%2520international%252C%2520multicentre%252C%2520randomised%252C%2520placebo-controlled%252C%2520phase%25203%2520trial%26jtitle%3DLancet%26date%3D2013%26volume%3D381%26spage%3D295%26epage%3D302%26doi%3D10.1016%2FS0140-6736%2812%2961857-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitenstein, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntly, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall-Meyers, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callahan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammed, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span><span class="refDoi"> DOI: 10.1016/j.ccr.2005.01.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1016%2Fj.ccr.2005.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=15710326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=129-141&author=E.+Weisbergauthor=P.+W.+Manleyauthor=W.+Breitensteinauthor=J.+Bruggenauthor=S.+W.+Cowan-Jacobauthor=A.+Rayauthor=B.+Huntlyauthor=D.+Fabbroauthor=G.+Fendrichauthor=E.+Hall-Meyersauthor=A.+L.+Kungauthor=J.+Mestanauthor=G.+Q.+Daleyauthor=L.+Callahanauthor=L.+Catleyauthor=C.+Cavazzaauthor=A.+Mohammedauthor=D.+Neubergauthor=R.+D.+Wrightauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Characterization+of+AMN107%2C+a+selective+inhibitor+of+native+and+mutant+Bcr-Abl&doi=10.1016%2Fj.ccr.2005.01.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span></div><div class="casAuthors">Weisberg, Ellen; Manley, Paul W.; Breitenstein, Werner; Brueggen, Josef; Cowan-Jacob, Sandra W.; Ray, Arghya; Huntly, Brian; Fabbro, Doriano; Fendrich, Gabriele; Hall-Meyers, Elizabeth; Kung, Andrew L.; Mestan, Juergen; Daley, George Q.; Callahan, Linda; Catley, Laurie; Cavazza, Cara; Mohammed, Azam; Neuberg, Donna; Wright, Renee D.; Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-141</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-pos. (Ph+) acute lymphoblastic leukemia (ALL).  We describe a novel selective inhibitor of Bcr-Abl, AMN107 (IC50 < 30 nM), which is significantly more potent than imatinib, and active against a no. of imatinib-resistant Bcr-Abl mutants.  Crystallog. anal. of Abl-AMN107 complexes provides a structural explanation for the differential activity of AMN107 and imatinib against imatinib-resistant Bcr-Abl.  Consistent with its in vitro and pharmacokinetic profile, AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models.  AMN107 is a promising new inhibitor for the therapy of CML and Ph+ ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow6QF3qX2uO7Vg90H21EOLACvtfcHk0lh6CTaQXVgjuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D&md5=d28e1a54b982951f8d3e6ef1d2d3b2eb</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DBreitenstein%26aufirst%3DW.%26aulast%3DBruggen%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DHuntly%26aufirst%3DB.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DHall-Meyers%26aufirst%3DE.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DCallahan%26aufirst%3DL.%26aulast%3DCatley%26aufirst%3DL.%26aulast%3DCavazza%26aufirst%3DC.%26aulast%3DMohammed%26aufirst%3DA.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DWright%26aufirst%3DR.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DCharacterization%2520of%2520AMN107%252C%2520a%2520selective%2520inhibitor%2520of%2520native%2520and%2520mutant%2520Bcr-Abl%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D129%26epage%3D141%26doi%3D10.1016%2Fj.ccr.2005.01.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Adenis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blay, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bui-Nguyen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouche, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertucci, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isambert, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bompas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaigneau, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domont, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray-Coquard, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blesius, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Tine, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bulusu, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubreuil, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansfield, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moussy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermine, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Cesne, A.</span><span> </span><span class="NLM_article-title">Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1762</span><span class="NLM_x">–</span> <span class="NLM_lpage">1769</span><span class="refDoi"> DOI: 10.1093/annonc/mdu237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1093%2Fannonc%2Fmdu237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=25122671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FhsFagtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=1762-1769&author=A.+Adenisauthor=J.+Y.+Blayauthor=B.+Bui-Nguyenauthor=O.+Boucheauthor=F.+Bertucciauthor=N.+Isambertauthor=E.+Bompasauthor=L.+Chaigneauauthor=J.+Domontauthor=I.+Ray-Coquardauthor=A.+Blesiusauthor=B.+A.+Van+Tineauthor=V.+R.+Bulusuauthor=P.+Dubreuilauthor=C.+D.+Mansfieldauthor=Y.+Acinauthor=A.+Moussyauthor=O.+Hermineauthor=A.+Le+Cesne&title=Masitinib+in+advanced+gastrointestinal+stromal+tumor+%28GIST%29+after+failure+of+imatinib%3A+a+randomized+controlled+open-label+trial&doi=10.1093%2Fannonc%2Fmdu237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial</span></div><div class="casAuthors">Adenis A; Blay J-Y; Ray-Coquard I; Bui-Nguyen B; Bouche O; Bertucci F; Isambert N; Bompas E; Chaigneau L; Domont J; Blesius A; Le Cesne A; Van Tine B A; Bulusu V R; Dubreuil P; Mansfield C D; Acin Y; Moussy A; Hermine O</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1762-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Masitinib is a highly selective tyrosine kinase inhibitor with activity against the main oncogenic drivers of gastrointestinal stromal tumor (GIST).  Masitinib was evaluated in patients with advanced GIST after imatinib failure or intolerance.  PATIENTS AND METHODS:  Prospective, multicenter, randomized, open-label trial.  Patients with inoperable, advanced imatinib-resistant GIST were randomized (1 : 1) to receive masitinib (12 mg/kg/day) or sunitinib (50 mg/day 4-weeks-on/2-weeks-off) until progression, intolerance, or refusal.  Primary efficacy analysis was noncomparative, testing whether masitinib attained a median progression-free survival (PFS) (blind centrally reviewed RECIST) threshold of >3 months according to the lower bound of the 90% unilateral confidence interval (CI).  Secondary analyses on overall survival (OS) and PFS were comparative with results presented according to a two-sided 95% CI.  RESULTS:  Forty-four patients were randomized to receive masitinib (n = 23) or sunitinib (n = 21).  Median follow-up was 14 months.  Patients receiving masitinib experienced less toxicity than those receiving sunitinib, with significantly lower occurrence of severe adverse events (52% versus 91%, respectively, P = 0.008).  Median PFS (central RECIST) for the noncomparative primary analysis in the masitinib treatment arm was 3.71 months (90% CI 3.65).  Secondary analyses showed that median OS was significantly longer for patients receiving masitinib followed by post-progression addition of sunitinib when compared against patients treated directly with sunitinib in second-line [hazard ratio (HR) = 0.27, 95% CI 0.09-0.85, P = 0.016].  This improvement was sustainable as evidenced by 26-month follow-up OS data (HR = 0.40, 95% CI 0.16-0.96, P = 0.033); an additional 12.4 months survival advantage being reported for the masitinib treatment arm.  Risk of progression while under treatment with masitinib was in the same range as for sunitinib (HR = 1.1, 95% CI 0.6-2.2, P = 0.833).  CONCLUSIONS:  Primary efficacy analysis ensured the masitinib treatment arm could satisfy a prespecified PFS threshold.  Secondary efficacy analysis showed that masitinib followed by the standard of care generated a statistically significant survival benefit over standard of care.  Encouraging median OS and safety data from this well-controlled and appropriately designed randomized trial indicate a positive benefit-risk ratio.  Further development of masitinib in imatinib-resistant/intolerant patients with advanced GIST is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSxkpR-5bcD_eb6AVA-44PTfW6udTcc2ebAc7aSCAQFh7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FhsFagtA%253D%253D&md5=a2aae8942a25c3f43682342282f40402</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdu237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdu237%26sid%3Dliteratum%253Aachs%26aulast%3DAdenis%26aufirst%3DA.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DBui-Nguyen%26aufirst%3DB.%26aulast%3DBouche%26aufirst%3DO.%26aulast%3DBertucci%26aufirst%3DF.%26aulast%3DIsambert%26aufirst%3DN.%26aulast%3DBompas%26aufirst%3DE.%26aulast%3DChaigneau%26aufirst%3DL.%26aulast%3DDomont%26aufirst%3DJ.%26aulast%3DRay-Coquard%26aufirst%3DI.%26aulast%3DBlesius%26aufirst%3DA.%26aulast%3DVan%2BTine%26aufirst%3DB.%2BA.%26aulast%3DBulusu%26aufirst%3DV.%2BR.%26aulast%3DDubreuil%26aufirst%3DP.%26aulast%3DMansfield%26aufirst%3DC.%2BD.%26aulast%3DAcin%26aufirst%3DY.%26aulast%3DMoussy%26aufirst%3DA.%26aulast%3DHermine%26aufirst%3DO.%26aulast%3DLe%2BCesne%26aufirst%3DA.%26atitle%3DMasitinib%2520in%2520advanced%2520gastrointestinal%2520stromal%2520tumor%2520%2528GIST%2529%2520after%2520failure%2520of%2520imatinib%253A%2520a%2520randomized%2520controlled%2520open-label%2520trial%26jtitle%3DAnn.%2520Oncol.%26date%3D2014%26volume%3D25%26spage%3D1762%26epage%3D1769%26doi%3D10.1093%2Fannonc%2Fmdu237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Trudel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reece, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A. K.</span><span> </span><span class="NLM_article-title">Chir-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t (4;14) multiple myeloma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2941</span><span class="NLM_x">–</span> <span class="NLM_lpage">2948</span><span class="refDoi"> DOI: 10.1182/blood-2004-10-3913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1182%2Fblood-2004-10-3913" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=2941-2948&author=S.+Trudelauthor=Z.+H.+Liauthor=E.+Weiauthor=M.+Wiesmannauthor=H.+Changauthor=C.+Chenauthor=D.+Reeceauthor=C.+Heiseauthor=A.+K.+Stewart&title=Chir-258%2C+a+novel%2C+multitargeted+tyrosine+kinase+inhibitor+for+the+potential+treatment+of+t+%284%3B14%29+multiple+myeloma&doi=10.1182%2Fblood-2004-10-3913"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1182%2Fblood-2004-10-3913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2004-10-3913%26sid%3Dliteratum%253Aachs%26aulast%3DTrudel%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DZ.%2BH.%26aulast%3DWei%26aufirst%3DE.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DReece%26aufirst%3DD.%26aulast%3DHeise%26aufirst%3DC.%26aulast%3DStewart%26aufirst%3DA.%2BK.%26atitle%3DChir-258%252C%2520a%2520novel%252C%2520multitargeted%2520tyrosine%2520kinase%2520inhibitor%2520for%2520the%2520potential%2520treatment%2520of%2520t%2520%25284%253B14%2529%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2005%26volume%3D105%26spage%3D2941%26epage%3D2948%26doi%3D10.1182%2Fblood-2004-10-3913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Van Glabbeke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Cesne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichardt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Issels, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Oosterom, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blay, J. Y.</span><span> </span><span class="NLM_article-title">Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European organisation for research and treatment of cancer, the Italian sarcoma group, and the Australasian gastro-intestinal trials group (EORTC-ISG-AGITG)</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">2277</span><span class="NLM_x">–</span> <span class="NLM_lpage">2285</span><span class="refDoi"> DOI: 10.1016/j.ejca.2006.03.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1016%2Fj.ejca.2006.03.029" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2006&pages=2277-2285&author=M.+Van+Glabbekeauthor=J.+Verweijauthor=P.+G.+Casaliauthor=J.+Simesauthor=A.+Le+Cesneauthor=P.+Reichardtauthor=R.+Isselsauthor=I.+R.+Judsonauthor=A.+T.+van+Oosteromauthor=J.+Y.+Blay&title=Predicting+toxicities+for+patients+with+advanced+gastrointestinal+stromal+tumours+treated+with+imatinib%3A+a+study+of+the+European+organisation+for+research+and+treatment+of+cancer%2C+the+Italian+sarcoma+group%2C+and+the+Australasian+gastro-intestinal+trials+group+%28EORTC-ISG-AGITG%29&doi=10.1016%2Fj.ejca.2006.03.029"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2006.03.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2006.03.029%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BGlabbeke%26aufirst%3DM.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3DSimes%26aufirst%3DJ.%26aulast%3DLe%2BCesne%26aufirst%3DA.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DIssels%26aufirst%3DR.%26aulast%3DJudson%26aufirst%3DI.%2BR.%26aulast%3Dvan%2BOosterom%26aufirst%3DA.%2BT.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26atitle%3DPredicting%2520toxicities%2520for%2520patients%2520with%2520advanced%2520gastrointestinal%2520stromal%2520tumours%2520treated%2520with%2520imatinib%253A%2520a%2520study%2520of%2520the%2520European%2520organisation%2520for%2520research%2520and%2520treatment%2520of%2520cancer%252C%2520the%2520Italian%2520sarcoma%2520group%252C%2520and%2520the%2520Australasian%2520gastro-intestinal%2520trials%2520group%2520%2528EORTC-ISG-AGITG%2529%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2006%26volume%3D42%26spage%3D2277%26epage%3D2285%26doi%3D10.1016%2Fj.ejca.2006.03.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Ben Ami, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, M. D.</span><span> </span><span class="NLM_article-title">A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumours</span> <span class="citation_source-journal">Expert Opin. Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">571</span><span class="NLM_x">–</span> <span class="NLM_lpage">578</span><span class="refDoi"> DOI: 10.1517/14740338.2016.1152258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1517%2F14740338.2016.1152258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=26865352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BC28XjsVGgtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=571-578&author=E.+Ben+Amiauthor=M.+D.+Demetri&title=A+safety+evaluation+of+imatinib+mesylate+in+the+treatment+of+gastrointestinal+stromal+tumours&doi=10.1517%2F14740338.2016.1152258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor</span></div><div class="casAuthors">Ben Ami, Eytan; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">571-578</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : For the last 15 years, imatinib mesylate has been the first line treatment of choice for advanced (metastatic) GIST.: This review describes key efficacy data on imatinib for the treatment of GIST, and focuses on safety and tolerability of imatinib, with emphasis on common adverse events management and long term toxicity profile.: Imatinib has been the std. of care for metastatic GIST and probably will continue to be so for the next few years.  Still, despite dramatic responses initially, imatinib drug resistance continues to be the major factor for treatment discontinuation.  The toxicity profile of imatinib has been well characterized, and although the majority of patients experience an adverse event during treatment with imatinib, these side effects are usually mild and manageable, with the majority of patients continuing treatment uninterruptedly.  Early concerns regarding imatinib related cardiotoxicity in GIST have not been confirmed in large prospective randomized trials, with reports indicating a low incidence of approx. 0.2%-0.4%.  Future strategies for treatment of imatinib resistant GIST will probably include novel tyrosine kinase inhibitors, combination therapies or immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrum_xmjNop4LVg90H21EOLACvtfcHk0li_ZlxQiemd2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjsVGgtr8%253D&md5=8bae948198bf58e410d1f51d5b67d08b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1517%2F14740338.2016.1152258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.2016.1152258%26sid%3Dliteratum%253Aachs%26aulast%3DBen%2BAmi%26aufirst%3DE.%26aulast%3DDemetri%26aufirst%3DM.%2BD.%26atitle%3DA%2520safety%2520evaluation%2520of%2520imatinib%2520mesylate%2520in%2520the%2520treatment%2520of%2520gastrointestinal%2520stromal%2520tumours%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2016%26volume%3D15%26spage%3D571%26epage%3D578%26doi%3D10.1517%2F14740338.2016.1152258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Motzer, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutson, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomczak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelson, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukowski, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oudard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negrier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szczylik, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pili, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjarnason, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-del-Muro, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solska, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilding, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figlin, R. A.</span><span> </span><span class="NLM_article-title">Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">3584</span><span class="NLM_x">–</span> <span class="NLM_lpage">3590</span><span class="refDoi"> DOI: 10.1200/JCO.2008.20.1293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1200%2FJCO.2008.20.1293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=19487381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOnu7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=3584-3590&author=R.+J.+Motzerauthor=T.+E.+Hutsonauthor=P.+Tomczakauthor=M.+D.+Michaelsonauthor=R.+M.+Bukowskiauthor=S.+Oudardauthor=S.+Negrierauthor=C.+Szczylikauthor=R.+Piliauthor=G.+A.+Bjarnasonauthor=X.+Garcia-del-Muroauthor=J.+A.+Sosmanauthor=E.+Solskaauthor=G.+Wildingauthor=J.+A.+Thompsonauthor=S.+T.+Kimauthor=I.+Chenauthor=X.+Huangauthor=R.+A.+Figlin&title=Overall+survival+and+updated+results+for+sunitinib+compared+with+interferon+alfa+in+patients+with+metastatic+renal+cell+carcinoma&doi=10.1200%2FJCO.2008.20.1293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma</span></div><div class="casAuthors">Motzer, Robert J.; Hutson, Thomas E.; Tomczak, Piotr; Michaelson, Dror; Bukowski, Ronald M.; Oudard, Stephane; Negrier, Sylvie; Szczylik, Cezary; Pili, Roberto; Bjarnason, Georg A.; Garcia-del-Muro, Xavier; Sosman, Jeffrey A.; Solska, Ewa; Wilding, George; Thompson, John A.; Kim, Sindy T.; Chen, Isan; Huang, Xin; Figlin, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3584-3590</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-α) in progression-free survival (primary end point) as first-line treatment for metastatic renal cell carcinoma (RCC).  Final survival analyses and updated results are reported.  750 Treatment-naive patients with metastatic clear cell RCC were randomly assigned to sunitinib 50 mg orally once daily on a 4 wk on, 2 wk off dosing schedule or to IFN-α 9 MU s.c. three times weekly.  Overall survival was compared by two-sided log-rank and Wilcoxon tests.  Progression-free survival, response, and safety end points were assessed with updated follow-up.  Median overall survival was greater in the sunitinib group than in the IFN-α group (26.4 v 21.8 mo, resp.; hazard ratio [HR] = 0.821; 95% CI, 0.673 to 1.001; P = .051) per the primary anal. of unstratified log-rank test (P = .013 per unstratified Wilcoxon test).  By stratified log-rank test, the HR was 0.818 (95% CI, 0.669 to 0.999; P = .049).  Within the IFN-α group, 33% of patients received sunitinib, and 32% received other vascular endothelial growth factor-signaling inhibitors after discontinuation from the trial.  Median progression-free survival was 11 mo for sunitinib compared with 5 mo for IFN-α (P < .001).  Objective response rate was 47% for sunitinib compared with 12% for IFN-α (P < .001).  The most commonly reported sunitinib-related grade 3 adverse events included hypertension (12%), fatigue (11%), diarrhea (9%), and hand-foot syndrome (9%).  Sunitinib demonstrates longer overall survival compared with IFN-α plus improvement in response and progression-free survival in the first-line treatment of patients with metastatic RCC.  The overall survival highlights an improved prognosis in patients with RCC in the era of targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH-pepRkwehbVg90H21EOLACvtfcHk0li_ZlxQiemd2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOnu7nI&md5=69c3d4feceab003cc6faca799d813668</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.20.1293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.20.1293%26sid%3Dliteratum%253Aachs%26aulast%3DMotzer%26aufirst%3DR.%2BJ.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DTomczak%26aufirst%3DP.%26aulast%3DMichaelson%26aufirst%3DM.%2BD.%26aulast%3DBukowski%26aufirst%3DR.%2BM.%26aulast%3DOudard%26aufirst%3DS.%26aulast%3DNegrier%26aufirst%3DS.%26aulast%3DSzczylik%26aufirst%3DC.%26aulast%3DPili%26aufirst%3DR.%26aulast%3DBjarnason%26aufirst%3DG.%2BA.%26aulast%3DGarcia-del-Muro%26aufirst%3DX.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DSolska%26aufirst%3DE.%26aulast%3DWilding%26aufirst%3DG.%26aulast%3DThompson%26aufirst%3DJ.%2BA.%26aulast%3DKim%26aufirst%3DS.%2BT.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DFiglin%26aufirst%3DR.%2BA.%26atitle%3DOverall%2520survival%2520and%2520updated%2520results%2520for%2520sunitinib%2520compared%2520with%2520interferon%2520alfa%2520in%2520patients%2520with%2520metastatic%2520renal%2520cell%2520carcinoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D3584%26epage%3D3590%26doi%3D10.1200%2FJCO.2008.20.1293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Dai, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartandi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, Z. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albert, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bousquet, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunha, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaser, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcotte, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moskey, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoll, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tapang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelides, M. R.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-(4-(3-amino-1<i>H</i>-indazol-4-yl)phenyl)-<i>N′</i>-(2-fluoro-5-methyl phenyl) urea (ABT-869), a 3-amino indazole-based orally active multitargeted receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1584</span><span class="NLM_x">–</span> <span class="NLM_lpage">1597</span><span class="refDoi"> DOI: 10.1021/jm061280h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061280h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1584-1597&author=Y.+J.+Daiauthor=K.+Hartandiauthor=Z.+Q.+Jiauthor=A.+A.+Ahmedauthor=D.+H.+Albertauthor=J.+L.+Bauchauthor=J.+J.+Bouskaauthor=P.+F.+Bousquetauthor=G.+A.+Cunhaauthor=K.+B.+Glaserauthor=C.+M.+Harrisauthor=D.+Hickmanauthor=J.+Guoauthor=J.+L.+Liauthor=P.+A.+Marcotteauthor=K.+C.+Marshauthor=M.+D.+Moskeyauthor=R.+L.+Martinauthor=A.+M.+Olsonauthor=D.+J.+Osterlingauthor=L.+J.+Peaseauthor=N.+B.+Soniauthor=K.+D.+Stewartauthor=V.+S.+Stollauthor=P.+Tapangauthor=D.+R.+Reuterauthor=S.+K.+Davidsenauthor=M.+R.+Michaelides&title=Discovery+of+N-%284-%283-amino-1H-indazol-4-yl%29phenyl%29-N%E2%80%B2-%282-fluoro-5-methyl+phenyl%29+urea+%28ABT-869%29%2C+a+3-amino+indazole-based+orally+active+multitargeted+receptor+tyrosine+kinase+inhibitor&doi=10.1021%2Fjm061280h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm061280h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061280h%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DY.%2BJ.%26aulast%3DHartandi%26aufirst%3DK.%26aulast%3DJi%26aufirst%3DZ.%2BQ.%26aulast%3DAhmed%26aufirst%3DA.%2BA.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DBauch%26aufirst%3DJ.%2BL.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DBousquet%26aufirst%3DP.%2BF.%26aulast%3DCunha%26aufirst%3DG.%2BA.%26aulast%3DGlaser%26aufirst%3DK.%2BB.%26aulast%3DHarris%26aufirst%3DC.%2BM.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%2BL.%26aulast%3DMarcotte%26aufirst%3DP.%2BA.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DMoskey%26aufirst%3DM.%2BD.%26aulast%3DMartin%26aufirst%3DR.%2BL.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DPease%26aufirst%3DL.%2BJ.%26aulast%3DSoni%26aufirst%3DN.%2BB.%26aulast%3DStewart%26aufirst%3DK.%2BD.%26aulast%3DStoll%26aufirst%3DV.%2BS.%26aulast%3DTapang%26aufirst%3DP.%26aulast%3DReuter%26aufirst%3DD.%2BR.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26atitle%3DDiscovery%2520of%2520N-%25284-%25283-amino-1H-indazol-4-yl%2529phenyl%2529-N%25E2%2580%25B2-%25282-fluoro-5-methyl%2520phenyl%2529%2520urea%2520%2528ABT-869%2529%252C%2520a%25203-amino%2520indazole-based%2520orally%2520active%2520multitargeted%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1584%26epage%3D1597%26doi%3D10.1021%2Fjm061280h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Albert, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tapang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magoc, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, R. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bousquet, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghoreishi-Haack, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukofzer, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stavropoulos, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartandi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niquette, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCall, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donawho, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcotte, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaser, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelides, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span> </span><span class="NLM_article-title">Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">995</span><span class="NLM_x">–</span> <span class="NLM_lpage">1006</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-05-0410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1158%2F1535-7163.MCT-05-0410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=16648571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvFCkt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=995-1006&author=D.+H.+Albertauthor=P.+Tapangauthor=T.+J.+Magocauthor=L.+J.+Peaseauthor=D.+R.+Reuterauthor=R.+Q.+Weiauthor=J.+L.+Liauthor=J.+Guoauthor=P.+F.+Bousquetauthor=N.+S.+Ghoreishi-Haackauthor=B.+Wangauthor=G.+T.+Bukofzerauthor=Y.+C.+Wangauthor=J.+A.+Stavropoulosauthor=K.+Hartandiauthor=A.+L.+Niquetteauthor=N.+Soniauthor=E.+F.+Johnsonauthor=J.+O.+McCallauthor=J.+J.+Bouskaauthor=Y.+Luoauthor=C.+K.+Donawhoauthor=Y.+Daiauthor=P.+A.+Marcotteauthor=K.+B.+Glaserauthor=M.+R.+Michaelidesauthor=S.+K.+Davidsen&title=Preclinical+activity+of+ABT-869%2C+a+multitargeted+receptor+tyrosine+kinase+inhibitor&doi=10.1158%2F1535-7163.MCT-05-0410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor</span></div><div class="casAuthors">Albert, Daniel H.; Tapang, Paul; Magoc, Terrance J.; Pease, Lori J.; Reuter, David R.; Wei, Ru-Qi; Li, Junling; Guo, Jun; Bousquet, Peter F.; Ghoreishi-Haack, Nayereh S.; Wang, Baole; Bukofzer, Gail T.; Wang, Yi-Chun; Stavropoulos, Jason A.; Hartandi, Kresna; Niquette, Amanda L.; Soni, Nirupama; Johnson, Eric F.; McCall, J. Owen; Bouska, Jennifer J.; Luo, Yanping; Donawho, Cherrie K.; Dai, Yujia; Marcotte, Patrick A.; Glaser, Keith B.; Michaelides, Michael R.; Davidsen, Steven K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">995-1006</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">ABT-869 is a structurally novel, receptor tyrosine kinase (RTK) inhibitor that is a potent inhibitor of members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor families (e.g., KDR IC50 = 4 nmol/L) but has much less activity (IC50s > 1 μmol/L) against unrelated RTKs, sol. tyrosine kinases, or serine/threonine kinases.  The inhibition profile of ABT-869 is evident in cellular assays of RTK phosphorylation (IC50 = 2, 4, and 7 nmol/L for PDGFR-β, KDR, and CSF-1R, resp.) and VEGF-stimulated proliferation (IC50 = 0.2 nmol/L for human endothelial cells).  ABT-869 is not a general antiproliferative agent because, in most cancer cells, >1,000-fold higher concns. of ABT-869 are required for inhibition of proliferation.  However, ABT-869 exhibits potent antiproliferative and apoptotic effects on cancer cells whose proliferation is dependent on mutant kinases, such as FLT3.  In vivo ABT-869 is effective orally in the mechanism-based murine models of VEGF-induced uterine edema (ED50 = 0.5 mg/kg) and corneal angiogenesis (>50% inhibition, 15 mg/kg).  In tumor growth studies, ABT-869 exhibits efficacy in human fibrosarcoma and breast, colon, and small cell lung carcinoma xenograft models (ED50 = 1.5-5 mg/kg, twice daily) and is also effective (>50% inhibition) in orthotopic breast and glioma models.  Redn. in tumor size and tumor regression was obsd. in epidermoid carcinoma and leukemia xenograft models, resp.  In combination, ABT-869 produced at least additive effects when given with cytotoxic therapies.  Based on pharmacokinetic anal. from tumor growth studies, efficacy correlated more strongly with time over a threshold value (cellular KDR IC50 cor. for blood plasma protein binding = 0.08 μg/mL, ≥7 h) than with plasma area under the curve or Cmax.  These results support clin. assessment of ABT-869 as a therapeutic agent for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkn2KBvMa4wrVg90H21EOLACvtfcHk0lhwQO7g4vmw-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvFCkt7g%253D&md5=a5a60b591b4da7a3c589f1618d9cffb9</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0410%26sid%3Dliteratum%253Aachs%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DTapang%26aufirst%3DP.%26aulast%3DMagoc%26aufirst%3DT.%2BJ.%26aulast%3DPease%26aufirst%3DL.%2BJ.%26aulast%3DReuter%26aufirst%3DD.%2BR.%26aulast%3DWei%26aufirst%3DR.%2BQ.%26aulast%3DLi%26aufirst%3DJ.%2BL.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DBousquet%26aufirst%3DP.%2BF.%26aulast%3DGhoreishi-Haack%26aufirst%3DN.%2BS.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DBukofzer%26aufirst%3DG.%2BT.%26aulast%3DWang%26aufirst%3DY.%2BC.%26aulast%3DStavropoulos%26aufirst%3DJ.%2BA.%26aulast%3DHartandi%26aufirst%3DK.%26aulast%3DNiquette%26aufirst%3DA.%2BL.%26aulast%3DSoni%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DMcCall%26aufirst%3DJ.%2BO.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DMarcotte%26aufirst%3DP.%2BA.%26aulast%3DGlaser%26aufirst%3DK.%2BB.%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26atitle%3DPreclinical%2520activity%2520of%2520ABT-869%252C%2520a%2520multitargeted%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D995%26epage%3D1006%26doi%3D10.1158%2F1535-7163.MCT-05-0410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Melnick, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sipes, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunderson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarnes, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matzen, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beigi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harig, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asatryan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saadat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downs, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldwell, J. S.</span><span> </span><span class="NLM_article-title">An efficient rapid system for profiling the cellular activities of molecular libraries</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">3153</span><span class="NLM_x">–</span> <span class="NLM_lpage">3158</span><span class="refDoi"> DOI: 10.1073/pnas.0511292103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1073%2Fpnas.0511292103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=16492761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD28XksF2ktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=3153-3158&author=J.+S.+Melnickauthor=J.+Janesauthor=S.+Kimauthor=J.+Y.+Changauthor=D.+G.+Sipesauthor=D.+Gundersonauthor=L.+Jarnesauthor=J.+T.+Matzenauthor=M.+E.+Garciaauthor=T.+L.+Hoodauthor=R.+Beigiauthor=G.+Xiaauthor=R.+A.+Harigauthor=H.+Asatryanauthor=S.+F.+Yanauthor=Y.+Y.+Zhouauthor=X.+J.+Guauthor=A.+Saadatauthor=V.+Zhouauthor=F.+J.+Kingauthor=C.+M.+Shawauthor=A.+I.+Suauthor=R.+Downsauthor=N.+S.+Grayauthor=P.+G.+Schultzauthor=M.+Warmuthauthor=J.+S.+Caldwell&title=An+efficient+rapid+system+for+profiling+the+cellular+activities+of+molecular+libraries&doi=10.1073%2Fpnas.0511292103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">An efficient rapid system for profiling the cellular activities of molecular libraries</span></div><div class="casAuthors">Melnick, Jonathan S.; Janes, Jeff; Kim, Sungjoon; Chang, Jim Y.; Sipes, Daniel G.; Gunderson, Drew; Jarnes, Laura; Matzen, Jason T.; Garcia, Michael E.; Hood, Tami L.; Beigi, Ronak; Xia, Gang; Harig, Richard A.; Asatryan, Hayk; Yan, S. Frank; Zhou, Yingyao; Gu, Xiang-Ju; Saadat, Alham; Zhou, Vicki; King, Frederick J.; Shaw, Christopher M.; Su, Andrew I.; Downs, Robert; Gray, Nathanael S.; Schultz, Peter G.; Warmuth, Markus; Caldwell, Jeremy S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3153-3158</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Rapid quant. methods for characterizing small mols., peptides, proteins, or RNAs in a broad array of cellular assays would allow one to discover new biol. activities assocd. with these mols. and also provide a more comprehensive profile of drug candidates early in the drug development process.  Here the authors describe a robotic system, termed the automated compd. profiler, capable of both propagating a large no. of cell lines in parallel and assaying large collections of mols. simultaneously against a matrix of cellular assays in a highly reproducible manner.  To illustrate its utility, the authors have characterized a set of 1400 kinase inhibitors in a panel of 35 activated tyrosine-kinase-dependent cellular assays in dose-response format in a single expt.  Anal. of the resulting multidimensional dataset revealed subclusters of both inhibitors and kinases with closely correlated activities.  The approach also identified activities for the p38 inhibitor BIRB796 and the dual src/abl inhibitor BMS-354825 and exposed the expected side activities for Glivec/STI571, including cellular inhibition of c-kit and platelet-derived growth factor receptor.  This methodol. provides a powerful tool for unraveling the cellular biol. and mol. pharmacol. of both naturally occurring and synthetic chem. diversity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQNvyk_cSNMrVg90H21EOLACvtfcHk0li6yGzfju5rRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksF2ktr0%253D&md5=df174db38f600f27bfba3d8363e68ce1</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0511292103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0511292103%26sid%3Dliteratum%253Aachs%26aulast%3DMelnick%26aufirst%3DJ.%2BS.%26aulast%3DJanes%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DJ.%2BY.%26aulast%3DSipes%26aufirst%3DD.%2BG.%26aulast%3DGunderson%26aufirst%3DD.%26aulast%3DJarnes%26aufirst%3DL.%26aulast%3DMatzen%26aufirst%3DJ.%2BT.%26aulast%3DGarcia%26aufirst%3DM.%2BE.%26aulast%3DHood%26aufirst%3DT.%2BL.%26aulast%3DBeigi%26aufirst%3DR.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DHarig%26aufirst%3DR.%2BA.%26aulast%3DAsatryan%26aufirst%3DH.%26aulast%3DYan%26aufirst%3DS.%2BF.%26aulast%3DZhou%26aufirst%3DY.%2BY.%26aulast%3DGu%26aufirst%3DX.%2BJ.%26aulast%3DSaadat%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DV.%26aulast%3DKing%26aufirst%3DF.%2BJ.%26aulast%3DShaw%26aufirst%3DC.%2BM.%26aulast%3DSu%26aufirst%3DA.%2BI.%26aulast%3DDowns%26aufirst%3DR.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DCaldwell%26aufirst%3DJ.%2BS.%26atitle%3DAn%2520efficient%2520rapid%2520system%2520for%2520profiling%2520the%2520cellular%2520activities%2520of%2520molecular%2520libraries%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D3153%26epage%3D3158%26doi%3D10.1073%2Fpnas.0511292103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Neuhann, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merkelbach-Bruse, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klink, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellinger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffkes, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardelmann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schildhaus, H. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tinschert, S.</span><span> </span><span class="NLM_article-title">A novel germline KIT mutation (p. L576P) in a family presenting with juvenile onset of multiple gastrointestinal stromal tumors, skin hyperpigmentations, and esophageal stenosis</span> <span class="citation_source-journal">Am. J. Surg. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">898</span><span class="NLM_x">–</span> <span class="NLM_lpage">905</span><span class="refDoi"> DOI: 10.1097/PAS.0b013e31827bc071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1097%2FPAS.0b013e31827bc071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=23598963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A280%3ADC%252BC3srmtl2ltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2013&pages=898-905&author=T.+M.+Neuhannauthor=V.+Mansmannauthor=S.+Merkelbach-Bruseauthor=B.+Klinkauthor=A.+Hellingerauthor=H.+G.+Hoffkesauthor=E.+Wardelmannauthor=H.+U.+Schildhausauthor=S.+Tinschert&title=A+novel+germline+KIT+mutation+%28p.+L576P%29+in+a+family+presenting+with+juvenile+onset+of+multiple+gastrointestinal+stromal+tumors%2C+skin+hyperpigmentations%2C+and+esophageal+stenosis&doi=10.1097%2FPAS.0b013e31827bc071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">A novel germline KIT mutation (p.L576P) in a family presenting with juvenile onset of multiple gastrointestinal stromal tumors, skin hyperpigmentations, and esophageal stenosis</span></div><div class="casAuthors">Neuhann Teresa M; Mansmann Veit; Merkelbach-Bruse Sabine; Klink Barbara; Hellinger Achim; Hoffkes Heinz-Gert; Wardelmann Eva; Schildhaus Hans-Ulrich; Tinschert Sigrid</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of surgical pathology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">898-905</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Familial gastrointestinal stromal tumor (GIST) syndrome is a rare autosomal dominant genetic disorder.  We report on a kindred in which 3 family members carry a germline mutation (c.1727T>C, p.L576P) in exon 11 of the KIT gene.  This mutation was not reported so far in familial GISTs.  Apart from multiple GISTs in 2 of the mutation carriers, all of them had multiple hyperpigmented skin macules and a history of achalasia-like stenosis of the esophagus in early childhood.  In the index patient >100 tumors and a diffuse Cajal cell hyperplasia of the small bowel occurred.  Sequencing of DNA extracted from tumor tissue of one of his GISTs revealed the KIT mutation in exon 11 (c.1727T>C).  By array comparative genomic hybridization whole chromosomal gains 3, 5, 7, 9, 12, 15, and 18 were detected.  In addition, we could identify a gain on chromosome 4, spanning the KIT gene.  Together with the family described here, 24 unrelated cases with proven germline mutations in KIT have been reported.  In these families the diagnosis was established from the age of 30 years onwards.  Because in 1 patient reported here the GIST was a coincidental finding at the age of 15 years, the tumors might occur at a very young age and remain unnoticed until they-either due to increasing size, ulceration, or malignant progression-become symptomatic.  Therefore, we propose to start screening patients with known KIT mutations from a younger age.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSptAqgP-IBkTjk2McQZ6XmfW6udTcc2ebXJYuMoNbR9rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srmtl2ltA%253D%253D&md5=ea12361159e68b86d038eb1afcd07be4</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1097%2FPAS.0b013e31827bc071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FPAS.0b013e31827bc071%26sid%3Dliteratum%253Aachs%26aulast%3DNeuhann%26aufirst%3DT.%2BM.%26aulast%3DMansmann%26aufirst%3DV.%26aulast%3DMerkelbach-Bruse%26aufirst%3DS.%26aulast%3DKlink%26aufirst%3DB.%26aulast%3DHellinger%26aufirst%3DA.%26aulast%3DHoffkes%26aufirst%3DH.%2BG.%26aulast%3DWardelmann%26aufirst%3DE.%26aulast%3DSchildhaus%26aufirst%3DH.%2BU.%26aulast%3DTinschert%26aufirst%3DS.%26atitle%3DA%2520novel%2520germline%2520KIT%2520mutation%2520%2528p.%2520L576P%2529%2520in%2520a%2520family%2520presenting%2520with%2520juvenile%2520onset%2520of%2520multiple%2520gastrointestinal%2520stromal%2520tumors%252C%2520skin%2520hyperpigmentations%252C%2520and%2520esophageal%2520stenosis%26jtitle%3DAm.%2520J.%2520Surg.%2520Pathol.%26date%3D2013%26volume%3D37%26spage%3D898%26epage%3D905%26doi%3D10.1097%2FPAS.0b013e31827bc071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Garner, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gozgit, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anjum, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vodala, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrock, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eilers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ketzer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohlmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span> </span><span class="NLM_article-title">Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5745</span><span class="NLM_x">–</span> <span class="NLM_lpage">5755</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-1397</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1158%2F1078-0432.CCR-14-1397" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=25239608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGgsL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=5745-5755&author=A.+P.+Garnerauthor=J.+M.+Gozgitauthor=R.+Anjumauthor=S.+Vodalaauthor=A.+Schrockauthor=T.+J.+Zhouauthor=C.+Serranoauthor=G.+Eilersauthor=M.+J.+Zhuauthor=J.+Ketzerauthor=S.+Wardwellauthor=Y.+Y.+Ningauthor=Y.+Songauthor=A.+Kohlmannauthor=F.+Wangauthor=T.+Clacksonauthor=M.+C.+Heinrichauthor=J.+A.+Fletcherauthor=S.+Bauerauthor=V.+M.+Rivera&title=Ponatinib+inhibits+polyclonal+drug-resistant+KIT+oncoproteins+and+shows+therapeutic+potential+in+heavily+pretreated+gastrointestinal+stromal+tumor+%28GIST%29+patients&doi=10.1158%2F1078-0432.CCR-14-1397"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients</span></div><div class="casAuthors">Garner, Andrew P.; Gozgit, Joseph M.; Anjum, Rana; Vodala, Sadanand; Schrock, Alexa; Zhou, Tianjun; Serrano, Cesar; Eilers, Grant; Zhu, Meijun; Ketzer, Julia; Wardwell, Scott; Ning, Yaoyu; Song, Youngchul; Kohlmann, Anna; Wang, Frank; Clackson, Tim; Heinrich, Michael C.; Fletcher, Jonathan A.; Bauer, Sebastian; Rivera, Victor M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5745-5755</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: KIT is the major oncogenic driver of gastrointestinal stromal tumors (GIST).  Imatinib, sunitinib, and regorafenib are approved therapies; however, efficacy is often limited by the acquisition of polyclonal secondary resistance mutations in KIT, with those located in the activation (A) loop (exons 17/18) being particularly problematic.  Here, we explore the KIT-inhibitory activity of ponatinib in preclin. models and describe initial characterization of its activity in patients with GIST.  Exptl. Design: The cellular and in vivo activities of ponatinib, imatinib, sunitinib, and regorafenib against mutant KIT were evaluated using an accelerated mutagenesis assay and a panel of engineered and GIST-derived cell lines.  The ponatinib-KIT costructure was also detd.  The clin. activity of ponatinib was examd. in three patients with GIST previously treated with all three FDA-approved agents.  Results: In engineered and GIST-derived cell lines, ponatinib potently inhibited KIT exon 11 primary mutants and a range of secondary mutants, including those within the A-loop.  Ponatinib also induced regression in engineered and GIST-derived tumor models contg. these secondary mutations.  In a mutagenesis screen, 40 nmol/L ponatinib was sufficient to suppress outgrowth of all secondary mutants except V654A, which was suppressed at 80 nmol/L.  This inhibitory profile could be rationalized on the basis of structural analyses.  Ponatinib (30 mg daily) displayed encouraging clin. activity in two of three patients with GIST.  Conclusion:Ponatinib possesses potent activity against most major clin. relevant KIT mutants and has demonstrated preliminary evidence of activity in patients with refractory GIST.  These data strongly support further evaluation of ponatinib in patients with GIST.  Clin Cancer Res; 20(22); 5745-55. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTGG18CSl3XLVg90H21EOLACvtfcHk0ljYXr8XRoIMcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGgsL7E&md5=7537e45f37546f9e0cb799bdf05ed847</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1397%26sid%3Dliteratum%253Aachs%26aulast%3DGarner%26aufirst%3DA.%2BP.%26aulast%3DGozgit%26aufirst%3DJ.%2BM.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DVodala%26aufirst%3DS.%26aulast%3DSchrock%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DT.%2BJ.%26aulast%3DSerrano%26aufirst%3DC.%26aulast%3DEilers%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DM.%2BJ.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%2BY.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DKohlmann%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26atitle%3DPonatinib%2520inhibits%2520polyclonal%2520drug-resistant%2520KIT%2520oncoproteins%2520and%2520shows%2520therapeutic%2520potential%2520in%2520heavily%2520pretreated%2520gastrointestinal%2520stromal%2520tumor%2520%2528GIST%2529%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D5745%26epage%3D5755%26doi%3D10.1158%2F1078-0432.CCR-14-1397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Taguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonobe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyonaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamasaki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimaru, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuri, K.</span><span> </span><span class="NLM_article-title">Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stromal tumor</span> <span class="citation_source-journal">Lab. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">663</span><span class="NLM_x">–</span> <span class="NLM_lpage">665</span><span class="refDoi"> DOI: 10.1038/labinvest.3780461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1038%2Flabinvest.3780461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=12004007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A280%3ADC%252BD383msVOjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2002&pages=663-665&author=T.+Taguchiauthor=H.+Sonobeauthor=S.+Toyonagaauthor=I.+Yamasakiauthor=T.+Shuinauthor=A.+Takanoauthor=K.+Arakiauthor=K.+Akimaruauthor=K.+Yuri&title=Conventional+and+molecular+cytogenetic+characterization+of+a+new+human+cell+line%2C+GIST-T1%2C+established+from+gastrointestinal+stromal+tumor&doi=10.1038%2Flabinvest.3780461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stromal tumor</span></div><div class="casAuthors">Taguchi Takahiro; Sonobe Hiroshi; Toyonaga Shin-ichi; Yamasaki Ichiro; Shuin Taro; Takano Atsushi; Araki Keijiro; Akimaru Kunihiro; Yuri Kazunari</div><div class="citationInfo"><span class="NLM_cas:title">Laboratory investigation; a journal of technical methods and pathology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">663-5</span>
        ISSN:<span class="NLM_cas:issn">0023-6837</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfLoSxovx6e8RAV4D_Ins_fW6udTcc2eYBDCxziBarKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD383msVOjsg%253D%253D&md5=2a397ed59d4b02cde55eb3253dc2cb13</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Flabinvest.3780461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Flabinvest.3780461%26sid%3Dliteratum%253Aachs%26aulast%3DTaguchi%26aufirst%3DT.%26aulast%3DSonobe%26aufirst%3DH.%26aulast%3DToyonaga%26aufirst%3DS.%26aulast%3DYamasaki%26aufirst%3DI.%26aulast%3DShuin%26aufirst%3DT.%26aulast%3DTakano%26aufirst%3DA.%26aulast%3DAraki%26aufirst%3DK.%26aulast%3DAkimaru%26aufirst%3DK.%26aulast%3DYuri%26aufirst%3DK.%26atitle%3DConventional%2520and%2520molecular%2520cytogenetic%2520characterization%2520of%2520a%2520new%2520human%2520cell%2520line%252C%2520GIST-T1%252C%2520established%2520from%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DLab.%2520Invest.%26date%3D2002%26volume%3D82%26spage%3D663%26epage%3D665%26doi%3D10.1038%2Flabinvest.3780461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Tuveson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willis, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacks, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span> </span><span class="NLM_article-title">STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5054</span><span class="NLM_x">–</span> <span class="NLM_lpage">5058</span><span class="refDoi"> DOI: 10.1038/sj.onc.1204704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1038%2Fsj.onc.1204704" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2001&pages=5054-5058&author=D.+A.+Tuvesonauthor=N.+A.+Willisauthor=T.+Jacksauthor=J.+D.+Griffinauthor=S.+Singerauthor=C.+D.+M.+Fletcherauthor=J.+A.+Fletcherauthor=G.+D.+Demetri&title=STI571+inactivation+of+the+gastrointestinal+stromal+tumor+c-KIT+oncoprotein%3A+biological+and+clinical+implications&doi=10.1038%2Fsj.onc.1204704"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1204704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1204704%26sid%3Dliteratum%253Aachs%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26aulast%3DWillis%26aufirst%3DN.%2BA.%26aulast%3DJacks%26aufirst%3DT.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%2BM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DSTI571%2520inactivation%2520of%2520the%2520gastrointestinal%2520stromal%2520tumor%2520c-KIT%2520oncoprotein%253A%2520biological%2520and%2520clinical%2520implications%26jtitle%3DOncogene%26date%3D2001%26volume%3D20%26spage%3D5054%26epage%3D5058%26doi%3D10.1038%2Fsj.onc.1204704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Falkenhorst, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grunewald, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muhlenberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marino-Enriquez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treckmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Podleska, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span> </span><span class="NLM_article-title">Inhibitor of apoptosis proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib</span> <span class="citation_source-journal">OncoTarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">41390</span><span class="NLM_x">–</span> <span class="NLM_lpage">41403</span><span class="refDoi"> DOI: 10.18632/oncotarget.9159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.18632%2Foncotarget.9159" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=41390-41403&author=J.+Falkenhorstauthor=S.+Grunewaldauthor=T.+Muhlenbergauthor=A.+Marino-Enriquezauthor=A.+C.+Reisauthor=C.+Corlessauthor=M.+Heinrichauthor=J.+Treckmannauthor=L.+E.+Podleskaauthor=M.+Schulerauthor=J.+A.+Fletcherauthor=S.+Bauer&title=Inhibitor+of+apoptosis+proteins+%28IAPs%29+are+commonly+dysregulated+in+GIST+and+can+be+pharmacologically+targeted+to+enhance+the+pro-apoptotic+activity+of+imatinib&doi=10.18632%2Foncotarget.9159"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.9159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.9159%26sid%3Dliteratum%253Aachs%26aulast%3DFalkenhorst%26aufirst%3DJ.%26aulast%3DGrunewald%26aufirst%3DS.%26aulast%3DMuhlenberg%26aufirst%3DT.%26aulast%3DMarino-Enriquez%26aufirst%3DA.%26aulast%3DReis%26aufirst%3DA.%2BC.%26aulast%3DCorless%26aufirst%3DC.%26aulast%3DHeinrich%26aufirst%3DM.%26aulast%3DTreckmann%26aufirst%3DJ.%26aulast%3DPodleska%26aufirst%3DL.%2BE.%26aulast%3DSchuler%26aufirst%3DM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DBauer%26aufirst%3DS.%26atitle%3DInhibitor%2520of%2520apoptosis%2520proteins%2520%2528IAPs%2529%2520are%2520commonly%2520dysregulated%2520in%2520GIST%2520and%2520can%2520be%2520pharmacologically%2520targeted%2520to%2520enhance%2520the%2520pro-apoptotic%2520activity%2520of%2520imatinib%26jtitle%3DOncoTarget%26date%3D2016%26volume%3D7%26spage%3D41390%26epage%3D41403%26doi%3D10.18632%2Foncotarget.9159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelias, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.+M.+Leliasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0ljbxa1Ws8Wv7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DLelias%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Tong, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span> </span><span class="NLM_article-title">Establishment of platform for screening insulin-like growth factor-1 receptor inhibitors and evaluation of novel inhibitors</span> <span class="citation_source-journal">Acta Pharmacol. Sin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">930</span><span class="NLM_x">–</span> <span class="NLM_lpage">938</span><span class="refDoi"> DOI: 10.1038/aps.2011.23</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1038%2Faps.2011.23" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=930-938&author=L.+J.+Tongauthor=H.+Xieauthor=T.+Pengauthor=X.+F.+Liuauthor=X.+L.+Xinauthor=X.+Huangauthor=X.+M.+Chenauthor=H.+Y.+Liuauthor=H.+L.+Liauthor=M.+Y.+Gengauthor=M.+Yinauthor=J.+Ding&title=Establishment+of+platform+for+screening+insulin-like+growth+factor-1+receptor+inhibitors+and+evaluation+of+novel+inhibitors&doi=10.1038%2Faps.2011.23"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Faps.2011.23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2011.23%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DL.%2BJ.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DX.%2BF.%26aulast%3DXin%26aufirst%3DX.%2BL.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%2BM.%26aulast%3DLiu%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DH.%2BL.%26aulast%3DGeng%26aufirst%3DM.%2BY.%26aulast%3DYin%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26atitle%3DEstablishment%2520of%2520platform%2520for%2520screening%2520insulin-like%2520growth%2520factor-1%2520receptor%2520inhibitors%2520and%2520evaluation%2520of%2520novel%2520inhibitors%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2011%26volume%3D32%26spage%3D930%26epage%3D938%26doi%3D10.1038%2Faps.2011.23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Fischer, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeller, R.</span><span> </span><span class="NLM_article-title">Hematoxylin and eosin staining of tissue and cell sections</span> <span class="citation_source-journal">Cold Spring Harbor Protoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">4986</span><span class="refDoi"> DOI: 10.1101/pdb.prot4986</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1101%2Fpdb.prot4986" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=4986&author=A.+H.+Fischerauthor=K.+A.+Jacobsonauthor=J.+Roseauthor=R.+Zeller&title=Hematoxylin+and+eosin+staining+of+tissue+and+cell+sections&doi=10.1101%2Fpdb.prot4986"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1101%2Fpdb.prot4986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fpdb.prot4986%26sid%3Dliteratum%253Aachs%26aulast%3DFischer%26aufirst%3DA.%2BH.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DRose%26aufirst%3DJ.%26aulast%3DZeller%26aufirst%3DR.%26atitle%3DHematoxylin%2520and%2520eosin%2520staining%2520of%2520tissue%2520and%2520cell%2520sections%26jtitle%3DCold%2520Spring%2520Harbor%2520Protoc.%26date%3D2008%26volume%3D3%26spage%3D4986%26doi%3D10.1101%2Fpdb.prot4986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9a','cit9b'],'ref10':['cit10'],'ref11':['cit11a','cit11b','cit11c'],'ref12':['cit12a','cit12b'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15a','cit15b','cit15c'],'ref16':['cit16'],'ref17':['cit17a','cit17b'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 6 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ting  Guo</span>, <span class="hlFld-ContribAuthor ">Shutao  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (4)
                                     , 600-620. <a href="https://doi.org/10.1002/cmdc.202000658" title="DOI URL">https://doi.org/10.1002/cmdc.202000658</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000658%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDiscovery%252Bof%252BMultitargeted%252BTyrosine%252BKinase%252BInhibitors%252Bas%252BAnticancer%252BAgents%26aulast%3DGuo%26aufirst%3DTing%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D4%26spage%3D600%26epage%3D620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Natalia A.  Elkina</span>, <span class="hlFld-ContribAuthor ">Yanina V.  Burgart</span>, <span class="hlFld-ContribAuthor ">Evgeny V.  Shchegolkov</span>, <span class="hlFld-ContribAuthor ">Olga P.  Krasnykh</span>, <span class="hlFld-ContribAuthor ">Vera V.  Maslova</span>, <span class="hlFld-ContribAuthor ">Galina A.  Triandafilova</span>, <span class="hlFld-ContribAuthor ">Sergey S.  Solodnikov</span>, <span class="hlFld-ContribAuthor ">Anna A.  Muryleva</span>, <span class="hlFld-ContribAuthor ">Maria A.  Misiurina</span>, <span class="hlFld-ContribAuthor ">Alexander V.  Slita</span>, <span class="hlFld-ContribAuthor ">Vladimir V.  Zarubaev</span>, <span class="hlFld-ContribAuthor ">Victor I.  Saloutin</span>. </span><span class="cited-content_cbyCitation_article-title">Competitive routes to cyclizations of polyfluoroalkyl-containing 2-tolylhydrazinylidene-1,3-diketones with 3-aminopyrazoles into bioactive pyrazoloazines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Fluorine Chemistry</span><span> <strong>2020,</strong> <em>240 </em>, 109648. <a href="https://doi.org/10.1016/j.jfluchem.2020.109648" title="DOI URL">https://doi.org/10.1016/j.jfluchem.2020.109648</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jfluchem.2020.109648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jfluchem.2020.109648%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Fluorine%2520Chemistry%26atitle%3DCompetitive%252Broutes%252Bto%252Bcyclizations%252Bof%252Bpolyfluoroalkyl-containing%252B2-tolylhydrazinylidene-1%25252C3-diketones%252Bwith%252B3-aminopyrazoles%252Binto%252Bbioactive%252Bpyrazoloazines%26aulast%3DElkina%26aufirst%3DNatalia%2BA.%26date%3D2020%26volume%3D240%26spage%3D109648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Seketoulie  Keretsu</span>, <span class="hlFld-ContribAuthor ">Suparna  Ghosh</span>, <span class="hlFld-ContribAuthor ">Seung Joo  Cho</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Modeling Study of c-KIT/PDGFRα Dual Inhibitors for the Treatment of Gastrointestinal Stromal Tumors. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (21)
                                     , 8232. <a href="https://doi.org/10.3390/ijms21218232" title="DOI URL">https://doi.org/10.3390/ijms21218232</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21218232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21218232%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DMolecular%252BModeling%252BStudy%252Bof%252Bc-KIT%25252FPDGFR%2525CE%2525B1%252BDual%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BGastrointestinal%252BStromal%252BTumors%26aulast%3DKeretsu%26aufirst%3DSeketoulie%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D21%26spage%3D8232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hairui  Wu</span>, <span class="hlFld-ContribAuthor ">Xi  Gu</span>, <span class="hlFld-ContribAuthor ">Jinling  Li</span>, <span class="hlFld-ContribAuthor ">Mingxing  Wang</span>, <span class="hlFld-ContribAuthor ">Yanchun  Li</span>, <span class="hlFld-ContribAuthor ">Lei  Yuan</span>, <span class="hlFld-ContribAuthor ">Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Enlong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of potential platelet-derived growth factor receptor α inhibitors by computational screening and binding simulations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2020,</strong> <em>96 </em>, 107527. <a href="https://doi.org/10.1016/j.jmgm.2019.107527" title="DOI URL">https://doi.org/10.1016/j.jmgm.2019.107527</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2019.107527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2019.107527%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DIdentification%252Bof%252Bpotential%252Bplatelet-derived%252Bgrowth%252Bfactor%252Breceptor%252B%2525CE%2525B1%252Binhibitors%252Bby%252Bcomputational%252Bscreening%252Band%252Bbinding%252Bsimulations%26aulast%3DWu%26aufirst%3DHairui%26date%3D2020%26volume%3D96%26spage%3D107527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fatima  Arshad</span>, <span class="hlFld-ContribAuthor ">Mohemmed Faraz  Khan</span>, <span class="hlFld-ContribAuthor ">Wasim  Akhtar</span>, <span class="hlFld-ContribAuthor ">Mohammad Mumtaz  Alam</span>, <span class="hlFld-ContribAuthor ">Lalit Mohan  Nainwal</span>, <span class="hlFld-ContribAuthor ">Sumit Kumar  Kaushik</span>, <span class="hlFld-ContribAuthor ">Mymoona  Akhter</span>, <span class="hlFld-ContribAuthor ">Suhel  Parvez</span>, <span class="hlFld-ContribAuthor ">Syed Misbahul  Hasan</span>, <span class="hlFld-ContribAuthor ">Mohammad  Shaquiquzzaman</span>. </span><span class="cited-content_cbyCitation_article-title">Revealing quinquennial anticancer journey of morpholine: A SAR based review. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>167 </em>, 324-356. <a href="https://doi.org/10.1016/j.ejmech.2019.02.015" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.02.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.02.015%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRevealing%252Bquinquennial%252Banticancer%252Bjourney%252Bof%252Bmorpholine%25253A%252BA%252BSAR%252Bbased%252Breview%26aulast%3DArshad%26aufirst%3DFatima%26date%3D2019%26volume%3D167%26spage%3D324%26epage%3D356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhi-Hao  Shi</span>, <span class="hlFld-ContribAuthor ">Feng-Tao  Liu</span>, <span class="hlFld-ContribAuthor ">Hao-Zhong  Tian</span>, <span class="hlFld-ContribAuthor ">Yan-Min  Zhang</span>, <span class="hlFld-ContribAuthor ">Nian-Guang  Li</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and structure-activity relationship of diaryl-ureas with novel isoxazol[3,4-b]pyridine-3-amino-structure as multi-target inhibitors against receptor tyrosine kinase. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (16)
                                     , 4735-4744. <a href="https://doi.org/10.1016/j.bmc.2018.08.013" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.08.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.08.013%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bstructure-activity%252Brelationship%252Bof%252Bdiaryl-ureas%252Bwith%252Bnovel%252Bisoxazol%25255B3%25252C4-b%25255Dpyridine-3-amino-structure%252Bas%252Bmulti-target%252Binhibitors%252Bagainst%252Breceptor%252Btyrosine%252Bkinase%26aulast%3DShi%26aufirst%3DZhi-Hao%26date%3D2018%26volume%3D26%26issue%3D16%26spage%3D4735%26epage%3D4744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00468&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0001.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of representative nonselective c-KIT/PDGFRα kinase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00468&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic illustration of the discovery of selective potent dual c-KIT/PDGFRα inhibitor <b>31</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00468&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0007.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Intermediate <b>67a</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00468&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaH, THF, reflux, 15 h; (b) N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O, CH<sub>3</sub>HSO<sub>3</sub>, 80 °C, overnight.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0008.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>8</b>–<b>17</b> and <b>20</b>–<b>27<sup>a</sup></b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00468&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) for <b>68a</b>, EtOH, reflux, 4 h; (b) for <b>68b</b>, DMF, reflux, 4 h; (c) Pd/C, H<sub>2</sub>, MeOH, rt, 5 h; (d) R<sup>2</sup>NCO or R<sup>2</sup>NSO, Et<sub>3</sub>N, DMSO, rt, overnight; (e) for <b>70a</b>, DDQ, BSTFA, chlorobenzene, reflux, overnight; (f) for <b>70b</b>, DDQ, BSTFA, 1,4-dioxane, reflux, overnight; (g) SnCl<sub>2</sub>, EtOH, reflux, overnight; (h) BPOD, 110 °C, overnight; (i) N<sub>2</sub>, Zn, N<sub>2</sub>H<sub>4</sub>·H<sub>2</sub>O, THF, reflux, 5 h.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0009.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>18</b>,<b>19</b> and <b>41</b>–<b>65</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00468&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (Boc)<sub>2</sub>O, DMPA, THF, rt, 1 h; (b) N<sub>2</sub>, NBS, BPO, CCl<sub>4</sub>, reflux, 20 h; (c) H<sub>2</sub>O, 1,4-dioxane, reflux, overnight; (d) R<sup>2</sup>NCO, Et<sub>3</sub>N, DMSO, rt, overnight; (e) R<sup>2</sup>NH<sub>2</sub>, CDI, Et<sub>3</sub>N, DMSO, rt, overnight.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0010.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>28</b>–<b>40</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00468&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Pd/C, H<sub>2</sub>, MeOH, rt, overnight; (b) (1) pyridine, DMF, phenyl chloroformate, rt, 3 h, (2) 1,4-dioxane, reflux, overnight.</p></p></figure><figure data-id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Antiproliferative effect of <b>31</b> against a variety of TEL-c-KIT/PDGFRα -BaF3 isogenic cells. (Note: no comparison for GI<sub>50</sub> > 10 μM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00468&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Kinome wide selectivity profiling of <b>31</b>. (A) KinomeScan profiling of compound <b>31</b> at a concentration of 1 μM against 468 kinases and mutants. (B) Kinases mutants that remained activity less than 1% of control in the presence of 1 μM <b>31</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00468&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Antitumor efficacy of compound <b>31</b> in GIST-T1 xenograft model. Female nu/nu mice harboring established GIST-T1 tumor xenografts were treated with <b>31</b> at 25 and 100 mg/kg/d or vehicle or with <b>1</b> at 100 mg/kg/d. Daily IP injection was initiated when GIST-T1 tumors had reached a volume of 100–200 mm<sup>3</sup>. Each group contained five animals. The data are expressed as the mean ± SEM (A) body weight and (B) tumor size measurements from GIST-T1 xenograft mice after <b>31</b> or <b>1</b> administration. Initial body weight and tumor size were set as 100%. (C) Comparison of the final tumor volume in each group after 28-day treatment period with <b>31</b> or <b>1</b>; ns, <i>p</i> > 0.05, *<i>p</i> < 0.05, ***<i>p</i> < 0.001. (D) Representative photographs of tumors in each group after <b>31</b> or <b>1</b> treatment. (E) Immunohistochemical staining assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00468&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/medium/jm-2017-00468y_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0006.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Antitumor efficacy of compound <b>31</b> in BaF3-TEL-cKIT-T670I xenograft model. Female nu/nu mice harboring established BaF3-TEL-cKIT-T670I tumor xenografts were treated with <b>31</b> at 25 and 100 mg/kg/d or vehicle or with <b>1</b> at 100 mg/kg/d. Daily IP injection was initiated when BaF3-TEL-cKIT-T670I tumors had reached a volume of 100–200 mm<sup>3</sup>. Each group contained five animals. The data are expressed as the mean ± SEM (A) body weight and (B) tumor size measurements from BaF3-TEL-cKIT-T670I xenograft mice after <b>31</b> or <b>1</b> administration. Initial body weight and tumor size were set as 100%. (C) Comparison of the final tumor volume in each group after 11-day treatment period with <b>31</b> or <b>1</b>; ns, <i>p</i> > 0.05, *<i>p</i> < 0.05. (D) Western blot analysis with antibodies specific to the indicated proteins from tumor lysates prepared from the BaF3-TEL-cKIT-T670I tumor xenografts upon the completion of the indicated treatments. (E) Immunohistochemical staining assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00468/20170616/images/large/jm-2017-00468y_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00468&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i104">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11670" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11670" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 38 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Kindblom, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remotti, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldenborg, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meis-Kindblom, J. M.</span><span> </span><span class="NLM_article-title">Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">152</span><span class="NLM_x">, </span> <span class="NLM_fpage">1259</span><span class="NLM_x">–</span> <span class="NLM_lpage">1269</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=9588894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A280%3ADyaK1c3kvVejug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=1998&pages=1259-1269&author=L.+G.+Kindblomauthor=H.+E.+Remottiauthor=F.+Aldenborgauthor=J.+M.+Meis-Kindblom&title=Gastrointestinal+pacemaker+cell+tumor+%28GIPACT%29%3A+gastrointestinal+stromal+tumors+show+phenotypic+characteristics+of+the+interstitial+cells+of+Cajal"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal</span></div><div class="casAuthors">Kindblom L G; Remotti H E; Aldenborg F; Meis-Kindblom J M</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of pathology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1259-69</span>
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    </div><div class="casAbstract">The interstitial cells of Cajal (ICC) form a complex cell network within the gastrointestinal tract wall where they function as a pacemaker system.  Expression of the kit proto-oncogene is essential for the development of this system.  The aim of our study was to examine the hypothesis that gastrointestinal stromal tumors differentiate toward cells with an ICC phenotype.  Ultrastructurally, 58 stromal tumors were characterized and found to share many features with ICC.  Seventy-eight stromal tumors were immunophenotyped, particularly with regard to the kit receptor.  All 78 tumors revealed strong, homogeneous immunoreactivity for the kit receptor as did ICC of adjacent and control gastrointestinal walls.  Focal hyperplasia and hypertrophy of kit receptor positive cells were also observed in the gastrointestinal wall adjacent to the tumors.  CD34 immunoreactivity observed in interstitial cells surrounding Auerbach's ganglia suggests that a subpopulation of ICC is CD34 positive and may explain why 56 of 78 stromal tumors were CD34 positive.  Thirty control tumors, including gastrointestinal leiomyomas and leiomyosarcomas, were all negative for the kit receptor.  We conclude that gastrointestinal stromal tumors show striking morphological and immunophenotypic similarities with ICC and that they may originate from stem cells that differentiate toward a pacemaker cell phenotype.  We propose that the noncommittal name "gastrointestinal stromal tumor" be replaced by gastrointestinal pacemaker cell tumor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTo1_gLlQJ49LesJRIHUP1ofW6udTcc2eatC0MLVGfyXrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c3kvVejug%253D%253D&md5=fb5342253954593446205c2ea24b21e3</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKindblom%26aufirst%3DL.%2BG.%26aulast%3DRemotti%26aufirst%3DH.%2BE.%26aulast%3DAldenborg%26aufirst%3DF.%26aulast%3DMeis-Kindblom%26aufirst%3DJ.%2BM.%26atitle%3DGastrointestinal%2520pacemaker%2520cell%2520tumor%2520%2528GIPACT%2529%253A%2520gastrointestinal%2520stromal%2520tumors%2520show%2520phenotypic%2520characteristics%2520of%2520the%2520interstitial%2520cells%2520of%2520Cajal%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D1998%26volume%3D152%26spage%3D1259%26epage%3D1269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Miettinen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasota, J.</span><span> </span><span class="NLM_article-title">Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis</span> <span class="citation_source-journal">Virchows Arch.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">438</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span><span class="refDoi"> DOI: 10.1007/s004280000338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1007%2Fs004280000338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=11213830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlt1Kquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=438&publication_year=2001&pages=1-12&author=M.+Miettinenauthor=J.+Lasota&title=Gastrointestinal+stromal+tumors-definition%2C+clinical%2C+histological%2C+immunohistochemical%2C+and+molecular+genetic+features+and+differential+diagnosis&doi=10.1007%2Fs004280000338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis</span></div><div class="casAuthors">Miettinen, Markku; Lasota, Jerzy</div><div class="citationInfo"><span class="NLM_cas:title">Virchows Archiv</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">438</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">VARCEM</span>;
        ISSN:<span class="NLM_cas:issn">0945-6317</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A review with 81 refs.  Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal (GI) tract.  They are defined here as KIT (CD117, stem cell factor receptor)-pos. mesenchymal spindle cell or epithelioid neoplasms primary in the GI tract, omentum, and mesentery.  GISTs typically present in older individuals and are most common in the stomach (60-70%), followed by small intestine (20-25%), colon and rectum (5%), and esophagus (<5%).  Benign tumors outnumber the malignant ones by a wide margin.  Approx. 70% of GISTs are pos. for CD34, 20-30% are pos. for smooth muscle actin (SMA), 10% are pos. for S100 protein and <5% are pos. for desmin.  The expression of CD34 and SMA is often reciprocal.  GISTs commonly have activating mutations in exon 11 (or rarely exon 9 and exon 13) of the KIT gene that encodes a tyrosine kinase receptor for the growth factor named stem cell factor or mast cell growth factor.  Ligand-independent activation of KIT appears to be a strong candidate for mol. pathogenesis of GISTs, and it may be a target for future treatment for such tumors.  Other genetic changes in GISTs discovered using comparative genomic hybridization include losses in 14q and 22q in both benign and malignant GISTs and occurrence in various gains predominantly in malignant GISTs.  GISTs have phenotypic similarities with the interstitial cells of Cajal and, therefore, a histogenetic origin from these cells has been suggested.  An alternative possibility, origin of pluripotential stem cells, is also possible; this is supported by the same origin of Cajal cells and smooth muscle and by the common SMA expression in GISTs.  GISTs differ clin. and pathogenetically from true leiomyosarcomas (very rare in the GI tract) and leiomyomas.  The latter occur in the GI tract, predominantly in the esophagus (intramural tumors) and the colon and rectum (muscularis mucosae tumors).  They also differ from schwannomas that are benign S100-pos. spindle cell tumors usually presenting in the stomach.  GI autonomic nerve tumors (GANTs) are probably a subset of GIST.  Other mesenchymal tumors that have to be sepd. from GISTs include inflammatory myofibroblastic tumors in children, desmoid, and dedifferentiated liposarcoma.  Angiosarcomas and metastatic melanomas, both of which are often KIT-pos., should not be confused with GISTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeixqNq3cd-7Vg90H21EOLACvtfcHk0li6_hzS9fJBCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlt1Kquw%253D%253D&md5=d2600b6aa118b36339ace603c1c9b87f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs004280000338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs004280000338%26sid%3Dliteratum%253Aachs%26aulast%3DMiettinen%26aufirst%3DM.%26aulast%3DLasota%26aufirst%3DJ.%26atitle%3DGastrointestinal%2520stromal%2520tumors-definition%252C%2520clinical%252C%2520histological%252C%2520immunohistochemical%252C%2520and%2520molecular%2520genetic%2520features%2520and%2520differential%2520diagnosis%26jtitle%3DVirchows%2520Arch.%26date%3D2001%26volume%3D438%26spage%3D1%26epage%3D12%26doi%3D10.1007%2Fs004280000338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Chi, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ly, B. T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, Y.</span><span> </span><span class="NLM_article-title">All-trans retinoic acid inhibits KIT activity and induces apoptosis in gastrointestinal stromal tumor GIST-T1 cell line by affecting on the expression of survivin and Bax protein</span> <span class="citation_source-journal">J. Exp. Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="refDoi"> DOI: 10.1186/1756-9966-29-165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1186%2F1756-9966-29-165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=21159206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1amsLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=165&author=H.+T.+Chiauthor=B.+T.+K.+Lyauthor=T.+Taguchiauthor=T.+Watanabeauthor=Y.+Sato&title=All-trans+retinoic+acid+inhibits+KIT+activity+and+induces+apoptosis+in+gastrointestinal+stromal+tumor+GIST-T1+cell+line+by+affecting+on+the+expression+of+survivin+and+Bax+protein&doi=10.1186%2F1756-9966-29-165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">All-trans retinoic acid inhibits KIT activity and induces apoptosis in gastrointestinal stromal tumor GIST-T1 cell line by affecting on the expression of survivin and Bax protein</span></div><div class="casAuthors">Chi, Hoang Thanh; Ly, Bui Thi Kim; Taguchi, Takahiro; Watanabe, Toshiki; Sato, Yuko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental & Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">165</span>CODEN:
                <span class="NLM_cas:coden">JECRDN</span>;
        ISSN:<span class="NLM_cas:issn">1756-9966</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Imatinib, a selective tyrosine kinase inhibitor, has been used as a std. first-line therapy for irresectable and metastasized gastrointestinal stromal tumor (GIST) patients.  Unfortunately, most patients responding to imatinib will eventually exhibit imatinib-resistance, the cause of which is not fully understood.  The serious clin. problem of imatinib-resistance demands alternative therapeutic strategy.  This study was conducted to investigate the effect of all-trans retinoic acid (ATRA) on GIST cell lines.  Methods: Cell proliferation was detd. by trypan blue dye exclusion test.  Western blot anal. was performed to test the expression of activated KIT, its downstream proteins, and apoptosis assocd. proteins.  The cytotoxic interactions of imatinib with ATRA were evaluated using the isobologram of Steel and Peckham.  Results and Conclusion: In this work, for the first time we have demonstrated that ATRA affected on cell proliferation of GIST-T1 and GIST-882 cell line through inhibition of cell growth in a dose dependent manner and induced apoptosis.  High dose of ATRA induced morphol. change in GIST-T1 cells, rounded-up cells, and activated the caspase-3 protein.  In further examn., we found that the ATRA-induced apoptosis in GIST-T1 cells was accompanied by the down-regulated expression of survivin and up-regulated expression of Bax protein.  Moreover, ATRA suppressed the activity of KIT protein in GIST-T1 cells and its downstream signal, AKT activity, but not MAPK activity.  We also have demonstrated that combination of ATRA with imatinib showed additive effect by isobologram, suggesting that the combination of ATRA and imatinib may be a novel potential therapeutic option for GIST treatment.  Furthermore, the scracht assay result suggested that ATRA was a potential reagent to prevent the invasion or metastasis of GIST cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW9YTHTs48TrVg90H21EOLACvtfcHk0lgDG1-bWFnnvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1amsLbM&md5=64cb1aaa71fe79e1a76448253a98cbb8</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1186%2F1756-9966-29-165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-9966-29-165%26sid%3Dliteratum%253Aachs%26aulast%3DChi%26aufirst%3DH.%2BT.%26aulast%3DLy%26aufirst%3DB.%2BT.%2BK.%26aulast%3DTaguchi%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DY.%26atitle%3DAll-trans%2520retinoic%2520acid%2520inhibits%2520KIT%2520activity%2520and%2520induces%2520apoptosis%2520in%2520gastrointestinal%2520stromal%2520tumor%2520GIST-T1%2520cell%2520line%2520by%2520affecting%2520on%2520the%2520expression%2520of%2520survivin%2520and%2520Bax%2520protein%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D29%26spage%3D165%26doi%3D10.1186%2F1756-9966-29-165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Wit, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grabellus, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antoch, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niebel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erhard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebeling, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taeger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flasshove, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schutte, J.</span><span> </span><span class="NLM_article-title">Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">316</span><span class="NLM_x">–</span> <span class="NLM_lpage">325</span><span class="refDoi"> DOI: 10.1002/ijc.21164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1002%2Fijc.21164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=15900603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVygsrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2005&pages=316-325&author=S.+Bauerauthor=J.+T.+Hartmannauthor=M.+de+Witauthor=H.+Langauthor=F.+Grabellusauthor=G.+Antochauthor=W.+Niebelauthor=J.+Erhardauthor=P.+Ebelingauthor=M.+Zethauthor=G.+Taegerauthor=S.+Seeberauthor=M.+Flasshoveauthor=J.+Schutte&title=Resection+of+residual+disease+in+patients+with+metastatic+gastrointestinal+stromal+tumors+responding+to+treatment+with+imatinib&doi=10.1002%2Fijc.21164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib</span></div><div class="casAuthors">Bauer, Sebastian; Hartmann, Joerg Thomas; de Wit, Maike; Lang, Hauke; Grabellus, Florian; Antoch, Gerald; Niebel, Wolfgang; Erhard, Jochen; Ebeling, Peter; Zeth, Matthias; Taeger, Georg; Seeber, Siegfried; Flasshove, Michael; Schuette, Jochen</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">316-325</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract.  Long-term survival of patients with metastatic disease has only been obsd. in patients with completely resected disease.  Recently, the tyrosine kinase inhibitor imatinib has been found to yield responses in the majority of patients with metastatic GIST suggesting improved resectability in responding patients.  Combined treatment approaches including resective surgery after imatinib treatment in patients with advanced metastatic disease have rarely been explored.  We report a series of 90 patients with metastatic GIST in whom treatment with imatinib enabled 12 patients with mostly recurrent and extensive disease to be considered for resection of residual disease.  In 11 of these patients, complete resection could be achieved.  Viable tumor cells were found in all but one resected specimens suggesting that despite favorable radiol. or clin. responses, imatinib is unlikely to induce pathol. complete responses.  Until more mature data from prospective trials are available, these data suggest that an early aggressive surgical approach should be considered for all patients with metastatic GIST.  Further trials investigating a combined surgical and pre/postoperative treatment with imatinib in patients with advanced metastatic GIST are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0hhkvmyGH07Vg90H21EOLACvtfcHk0lgDG1-bWFnnvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVygsrfK&md5=dfb19559fd3ce59612d2e83f03452d88</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fijc.21164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.21164%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DHartmann%26aufirst%3DJ.%2BT.%26aulast%3Dde%2BWit%26aufirst%3DM.%26aulast%3DLang%26aufirst%3DH.%26aulast%3DGrabellus%26aufirst%3DF.%26aulast%3DAntoch%26aufirst%3DG.%26aulast%3DNiebel%26aufirst%3DW.%26aulast%3DErhard%26aufirst%3DJ.%26aulast%3DEbeling%26aufirst%3DP.%26aulast%3DZeth%26aufirst%3DM.%26aulast%3DTaeger%26aufirst%3DG.%26aulast%3DSeeber%26aufirst%3DS.%26aulast%3DFlasshove%26aufirst%3DM.%26aulast%3DSchutte%26aufirst%3DJ.%26atitle%3DResection%2520of%2520residual%2520disease%2520in%2520patients%2520with%2520metastatic%2520gastrointestinal%2520stromal%2520tumors%2520responding%2520to%2520treatment%2520with%2520imatinib%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2005%26volume%3D117%26spage%3D316%26epage%3D325%26doi%3D10.1002%2Fijc.21164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">DeMatteo, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mudan, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodruff, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, M. F.</span><span> </span><span class="NLM_article-title">Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival</span> <span class="citation_source-journal">Ann. Surg.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">231</span><span class="NLM_x">, </span> <span class="NLM_fpage">51</span><span class="NLM_x">–</span> <span class="NLM_lpage">58</span><span class="refDoi"> DOI: 10.1097/00000658-200001000-00008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1097%2F00000658-200001000-00008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2000&pages=51-58&author=R.+P.+DeMatteoauthor=J.+J.+Lewisauthor=D.+Leungauthor=S.+S.+Mudanauthor=J.+M.+Woodruffauthor=M.+F.+Brennan&title=Two+hundred+gastrointestinal+stromal+tumors%3A+recurrence+patterns+and+prognostic+factors+for+survival&doi=10.1097%2F00000658-200001000-00008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1097%2F00000658-200001000-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000658-200001000-00008%26sid%3Dliteratum%253Aachs%26aulast%3DDeMatteo%26aufirst%3DR.%2BP.%26aulast%3DLewis%26aufirst%3DJ.%2BJ.%26aulast%3DLeung%26aufirst%3DD.%26aulast%3DMudan%26aufirst%3DS.%2BS.%26aulast%3DWoodruff%26aufirst%3DJ.%2BM.%26aulast%3DBrennan%26aufirst%3DM.%2BF.%26atitle%3DTwo%2520hundred%2520gastrointestinal%2520stromal%2520tumors%253A%2520recurrence%2520patterns%2520and%2520prognostic%2520factors%2520for%2520survival%26jtitle%3DAnn.%2520Surg.%26date%3D2000%26volume%3D231%26spage%3D51%26epage%3D58%26doi%3D10.1097%2F00000658-200001000-00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vehtari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riihimaki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steigen, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brabec, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plank, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirilli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braconi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnusson, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linke, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sufliarsky, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Federico, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonasson, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dei Tos, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutkowski, P.</span><span> </span><span class="NLM_article-title">Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">265</span><span class="NLM_x">–</span> <span class="NLM_lpage">274</span><span class="refDoi"> DOI: 10.1016/S1470-2045(11)70299-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1016%2FS1470-2045%2811%2970299-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=22153892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A280%3ADC%252BC383nsFeksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=265-274&author=H.+Joensuuauthor=A.+Vehtariauthor=J.+Riihimakiauthor=T.+Nishidaauthor=S.+E.+Steigenauthor=P.+Brabecauthor=L.+Plankauthor=B.+Nilssonauthor=C.+Cirilliauthor=C.+Braconiauthor=A.+Bordoniauthor=M.+K.+Magnussonauthor=Z.+Linkeauthor=J.+Sufliarskyauthor=M.+Federicoauthor=J.+G.+Jonassonauthor=A.+P.+Dei+Tosauthor=P.+Rutkowski&title=Risk+of+recurrence+of+gastrointestinal+stromal+tumour+after+surgery%3A+an+analysis+of+pooled+population-based+cohorts&doi=10.1016%2FS1470-2045%2811%2970299-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts</span></div><div class="casAuthors">Joensuu Heikki; Vehtari Aki; Riihimaki Jaakko; Nishida Toshirou; Steigen Sonja E; Brabec Peter; Plank Lukas; Nilsson Bengt; Cirilli Claudia; Braconi Chiara; Bordoni Andrea; Magnusson Magnus K; Linke Zdenek; Sufliarsky Jozef; Federico Massimo; Jonasson Jon G; Dei Tos Angelo Paolo; Rutkowski Piotr</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">265-74</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The risk of recurrence of gastrointestinal stromal tumour (GIST) after surgery needs to be estimated when considering adjuvant systemic therapy.  We assessed prognostic factors of patients with operable GIST, to compare widely used risk-stratification schemes and to develop a new method for risk estimation.  METHODS:  Population-based cohorts of patients diagnosed with operable GIST, who were not given adjuvant therapy, were identified from the literature.  Data from ten series and 2560 patients were pooled.  Risk of tumour recurrence was stratified using the National Institute of Health (NIH) consensus criteria, the modified consensus criteria, and the Armed Forces Institute of Pathology (AFIP) criteria.  Prognostic factors were examined using proportional hazards and non-linear models.  The results were validated in an independent centre-based cohort consisting of 920 patients with GIST.  FINDINGS:  Estimated 15-year recurrence-free survival (RFS) after surgery was 59·9% (95% CI 56·2-63·6); few recurrences occurred after the first 10 years of follow-up.  Large tumour size, high mitosis count, non-gastric location, presence of rupture, and male sex were independent adverse prognostic factors.  In receiver operating characteristics curve analysis of 10-year RFS, the NIH consensus criteria, modified consensus criteria, and AFIP criteria resulted in an area under the curve (AUC) of 0·79 (95% CI 0·76-0·81), 0·78 (0·75-0·80), and 0·82 (0·80-0·85), respectively.  The modified consensus criteria identified a single high-risk group.  Since tumour size and mitosis count had a non-linear association with the risk of GIST recurrence, novel prognostic contour maps were generated using non-linear modelling of tumour size and mitosis count, and taking into account tumour site and rupture.  The non-linear model accurately predicted the risk of recurrence (AUC 0·88, 0·86-0·90).  INTERPRETATION:  The risk-stratification schemes assessed identify patients who are likely to be cured by surgery alone.  Although the modified NIH classification is the best criteria to identify a single high-risk group for consideration of adjuvant therapy, the prognostic contour maps resulting from non-linear modelling are appropriate for estimation of individualised outcomes.  FUNDING:  Academy of Finland, Cancer Society of Finland, Sigrid Juselius Foundation and Helsinki University Research Funds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1mbEPz33jqZSWdIdmEou5fW6udTcc2eYqBa3KJjDQWLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383nsFeksw%253D%253D&md5=75b9c93788a2286ff5896236d1e16df7</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2811%2970299-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252811%252970299-6%26sid%3Dliteratum%253Aachs%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DVehtari%26aufirst%3DA.%26aulast%3DRiihimaki%26aufirst%3DJ.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DSteigen%26aufirst%3DS.%2BE.%26aulast%3DBrabec%26aufirst%3DP.%26aulast%3DPlank%26aufirst%3DL.%26aulast%3DNilsson%26aufirst%3DB.%26aulast%3DCirilli%26aufirst%3DC.%26aulast%3DBraconi%26aufirst%3DC.%26aulast%3DBordoni%26aufirst%3DA.%26aulast%3DMagnusson%26aufirst%3DM.%2BK.%26aulast%3DLinke%26aufirst%3DZ.%26aulast%3DSufliarsky%26aufirst%3DJ.%26aulast%3DFederico%26aufirst%3DM.%26aulast%3DJonasson%26aufirst%3DJ.%2BG.%26aulast%3DDei%2BTos%26aufirst%3DA.%2BP.%26aulast%3DRutkowski%26aufirst%3DP.%26atitle%3DRisk%2520of%2520recurrence%2520of%2520gastrointestinal%2520stromal%2520tumour%2520after%2520surgery%253A%2520an%2520analysis%2520of%2520pooled%2520population-based%2520cohorts%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D265%26epage%3D274%26doi%3D10.1016%2FS1470-2045%2811%2970299-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrijevic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silberman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G.</span><span> </span><span class="NLM_article-title">Management of malignant gastrointestinal stromal tumours</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">655</span><span class="NLM_x">–</span> <span class="NLM_lpage">664</span><span class="refDoi"> DOI: 10.1016/S1470-2045(02)00899-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1016%2FS1470-2045%2802%2900899-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=12424067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD38Xotlygs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=655-664&author=H.+Joensuuauthor=C.+Fletcherauthor=S.+Dimitrijevicauthor=S.+Silbermanauthor=P.+Robertsauthor=G.+Demetri&title=Management+of+malignant+gastrointestinal+stromal+tumours&doi=10.1016%2FS1470-2045%2802%2900899-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Management of malignant gastrointestinal stromal tumors</span></div><div class="casAuthors">Joensuu, Heikki; Fletcher, Christopher; Dimitrijevic, Sasa; Silberman, Sandra; Roberts, Peter; Demetri, George</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">655-664</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Lancet Publishing Group</span>)
        </div><div class="casAbstract">A review.  Gastrointestinal stromal tumors (GISTs) are the most common form of mesenchymal tumor of the gastrointestinal tract.  Clin., they range from small indolent tumors curable with surgery alone to aggressive cancers.  Making a distinction between an indolent and a malignant GIST is unreliable with conventional histopathol. techniques.  The presence of metastases at the time of diagnosis confirms malignancy, but all GISTs should be regarded as having malignant potential.  GISTs characteristically express the KIT protein, a transmembrane tyrosine kinase receptor for stem-cell factor.  Most GISTs have a mutation in the KIT proto-oncogene that translates into a gain-of-function constitutive activation of the KIT kinase.  KIT activation seems to be an early tumor-promoting event in pathogenesis.  Commonly, malignant GISTs show high-level primary resistance to conventional chemotherapy.  Imatinib mesylate is an orally administered selective inhibitor of certain tyrosine kinases including KIT.  Most patients with advanced malignant GISTs achieve clin. benefit and significant antitumor responses with imatinib mesylate.  Responses have been durable, and most patients tolerate the drug well at clin. EDs.  Imatinib mesylate is the first effective systemic therapy for advanced GIST.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRQYYGGZ5FlrVg90H21EOLACvtfcHk0lhUu-GI72bS8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xotlygs7Y%253D&md5=50b1bd67556b6ab83ae6b37bceb59d6c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2802%2900899-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252802%252900899-9%26sid%3Dliteratum%253Aachs%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DFletcher%26aufirst%3DC.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DSilberman%26aufirst%3DS.%26aulast%3DRoberts%26aufirst%3DP.%26aulast%3DDemetri%26aufirst%3DG.%26atitle%3DManagement%2520of%2520malignant%2520gastrointestinal%2520stromal%2520tumours%26jtitle%3DLancet%2520Oncol.%26date%3D2002%26volume%3D3%26spage%3D655%26epage%3D664%26doi%3D10.1016%2FS1470-2045%2802%2900899-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Rammohan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sathyanesan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajendran, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitchaimuthu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perumal, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srinivasan, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramasamy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palaniappan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Govindan, M.</span><span> </span><span class="NLM_article-title">A gist of gastrointestinal stromal tumors: a review</span> <span class="citation_source-journal">World J. Gastrointest. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">102</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span><span class="refDoi"> DOI: 10.4251/wjgo.v5.i6.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.4251%2Fwjgo.v5.i6.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=23847717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A280%3ADC%252BC3sfgt1Kntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=102-112&author=A.+Rammohanauthor=J.+Sathyanesanauthor=K.+Rajendranauthor=A.+Pitchaimuthuauthor=S.+K.+Perumalauthor=U.+Srinivasanauthor=R.+Ramasamyauthor=R.+Palaniappanauthor=M.+Govindan&title=A+gist+of+gastrointestinal+stromal+tumors%3A+a+review&doi=10.4251%2Fwjgo.v5.i6.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A gist of gastrointestinal stromal tumors: A review</span></div><div class="casAuthors">Rammohan Ashwin; Sathyanesan Jeswanth; Rajendran Kamalakannan; Pitchaimuthu Anbalagan; Perumal Senthil-Kumar; Srinivasan Up; Ramasamy Ravi; Palaniappan Ravichandran; Govindan Manoharan</div><div class="citationInfo"><span class="NLM_cas:title">World journal of gastrointestinal oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">102-12</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Gastrointestinal stromal tumors (GISTs) have been recognized as a biologically distinctive tumor type, different from smooth muscle and neural tumors of the gastrointestinal tract (GIT).  They constitute the majority of gastrointestinal mesenchymal tumors of the GIT and are known to be refractory to conventional chemotherapy or radiation.  They are defined and diagnosed by the expression of a proto-oncogene protein detected by immunohistochemistry which serves as a crucial diagnostic and therapeutic target.  The identification of these mutations has resulted in a better understanding of their oncogenic mechanisms.  The remarkable antitumor effects of the molecular inhibitor imatinib have necessitated accurate diagnosis of GIST and their distinction from other gastrointestinal mesenchymal tumors.  Both traditional and minimally invasive surgery are used to remove these tumors with minimal morbidity and excellent perioperative outcomes.  The revolutionary use of specific, molecularly-targeted therapies, such as imatinib mesylate, reduces the frequency of disease recurrence when used as an adjuvant following complete resection.  Neoadjuvant treatment with these agents appears to stabilize disease in the majority of patients and may reduce the extent of surgical resection required for subsequent complete tumor removal.  The important interplay between the molecular genetics of GIST and responses to targeted therapeutics serves as a model for the study of targeted therapies in other solid tumors.  This review summarizes our current knowledge and recent advances regarding the histogenesis, pathology, molecular biology, the basis for the novel targeted cancer therapy and current evidence based management of these unique tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-JVCNzFLbmg8IxFYvehhofW6udTcc2eYqBa3KJjDQWLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfgt1Kntg%253D%253D&md5=4999d3f458d9fbbc1a43cfb6caa50dca</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.4251%2Fwjgo.v5.i6.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4251%252Fwjgo.v5.i6.102%26sid%3Dliteratum%253Aachs%26aulast%3DRammohan%26aufirst%3DA.%26aulast%3DSathyanesan%26aufirst%3DJ.%26aulast%3DRajendran%26aufirst%3DK.%26aulast%3DPitchaimuthu%26aufirst%3DA.%26aulast%3DPerumal%26aufirst%3DS.%2BK.%26aulast%3DSrinivasan%26aufirst%3DU.%26aulast%3DRamasamy%26aufirst%3DR.%26aulast%3DPalaniappan%26aufirst%3DR.%26aulast%3DGovindan%26aufirst%3DM.%26atitle%3DA%2520gist%2520of%2520gastrointestinal%2520stromal%2520tumors%253A%2520a%2520review%26jtitle%3DWorld%2520J.%2520Gastrointest.%2520Oncol.%26date%3D2013%26volume%3D5%26spage%3D102%26epage%3D112%26doi%3D10.4251%2Fwjgo.v5.i6.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rubin, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span> </span><span class="NLM_article-title">Gastrointestinal stromal tumour</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">369</span><span class="NLM_x">, </span> <span class="NLM_fpage">1731</span><span class="NLM_x">–</span> <span class="NLM_lpage">1741</span><span class="refDoi"> DOI: 10.1016/S0140-6736(07)60780-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1016%2FS0140-6736%2807%2960780-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=17512858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlsFertrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2007&pages=1731-1741&author=B.+P.+Rubinauthor=M.+C.+Heinrichauthor=C.+L.+Corless&title=Gastrointestinal+stromal+tumour&doi=10.1016%2FS0140-6736%2807%2960780-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal stromal tumor</span></div><div class="casAuthors">Rubin, Brian P.; Heinrich, Michael C.; Corless, Christopher L.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">9574</span>),
    <span class="NLM_cas:pages">1731-1741</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Gastrointestinal stromal tumors are the most common mesenchymal neoplasm of the gastrointestinal tract and are highly resistant to conventional chemotherapy and radiotherapy.  Such tumors usually have activating mutations in either KIT (75-80%) or PDGFRA (5-10%), two closely related receptor tyrosine kinases.  These mutations lead to ligand-independent activation and signal transduction mediated by constitutively activated KIT or PDGFRA.  Targeting these activated proteins with imatinib mesylate, a small-mol. kinase inhibitor, has proven useful in the treatment of recurrent or metastatic gastrointestinal stromal tumors and is now being tested as an adjuvant or neoadjuvant.  However, resistance to imatinib is a growing problem and other targeted therapeutics such as sunitinib are available.  The important interplay between the mol. genetics of gastrointestinal stromal tumor and responses to targeted therapeutics serves as a model for the study of targeted therapies in other solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNtDxolv4iBrVg90H21EOLACvtfcHk0ljE3gjzIUq8yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlsFertrk%253D&md5=9a9d1fc97239da0bb0cfa8edb925524b</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2807%2960780-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252807%252960780-6%26sid%3Dliteratum%253Aachs%26aulast%3DRubin%26aufirst%3DB.%2BP.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26atitle%3DGastrointestinal%2520stromal%2520tumour%26jtitle%3DLancet%26date%3D2007%26volume%3D369%26spage%3D1731%26epage%3D1741%26doi%3D10.1016%2FS0140-6736%2807%2960780-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Miettinen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasota, J.</span><span> </span><span class="NLM_article-title">Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis</span> <span class="citation_source-journal">Arch. Pathol. Lab. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">70</span><span class="NLM_x">–</span> <span class="NLM_lpage">83</span><span class="refDoi"> DOI: 10.1053/j.semdp.2006.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1053%2Fj.semdp.2006.09.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2006&pages=70-83&author=M.+Miettinenauthor=J.+Lasota&title=Gastrointestinal+stromal+tumors%3A+review+on+morphology%2C+molecular+pathology%2C+prognosis%2C+and+differential+diagnosis&doi=10.1053%2Fj.semdp.2006.09.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1053%2Fj.semdp.2006.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.semdp.2006.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DMiettinen%26aufirst%3DM.%26aulast%3DLasota%26aufirst%3DJ.%26atitle%3DGastrointestinal%2520stromal%2520tumors%253A%2520review%2520on%2520morphology%252C%2520molecular%2520pathology%252C%2520prognosis%252C%2520and%2520differential%2520diagnosis%26jtitle%3DArch.%2520Pathol.%2520Lab.%2520Med.%26date%3D2006%26volume%3D23%26spage%3D70%26epage%3D83%26doi%3D10.1053%2Fj.semdp.2006.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGreevey, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Abbeele, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiese, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silberman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrijevic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4342</span><span class="NLM_x">–</span> <span class="NLM_lpage">4349</span><span class="refDoi"> DOI: 10.1200/JCO.2003.04.190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1200%2FJCO.2003.04.190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=14645423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVWqu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=4342-4349&author=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=G.+D.+Demetriauthor=C.+D.+Blankeauthor=M.+von+Mehrenauthor=H.+Joensuuauthor=L.+S.+McGreeveyauthor=C.+J.+Chenauthor=A.+D.+Van+den+Abbeeleauthor=B.+J.+Drukerauthor=B.+Kieseauthor=B.+Eisenbergauthor=P.+J.+Robertsauthor=S.+Singerauthor=C.+D.+M.+Fletcherauthor=S.+Silbermanauthor=S.+Dimitrijevicauthor=J.+A.+Fletcher&title=Kinase+mutations+and+imatinib+response+in+patients+with+metastatic+gastrointestinal+stromal+tumor&doi=10.1200%2FJCO.2003.04.190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor</span></div><div class="casAuthors">Heinrich, Michael C.; Corless, Christopher L.; Demetri, George D.; Blanke, Charles D.; von Mehren, Margaret; Joensuu, Heikki; McGreevey, Laura S.; Chen, Chang-Jie; Van den Abbeele, Annick D.; Druker, Brian J.; Kiese, Beate; Eisenberg, Burton; Roberts, Peter J.; Singer, Samuel; Fletcher, Christopher D. M.; Silberman, Sandra; Dimitrijevic, Sasa; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4342-4349</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Most gastrointestinal stromal tumors (GISTs) express constitutively activated mutant isoforms of KIT or kinase platelet-derived growth factor receptor alpha (PDGFRA) that are potential therapeutic targets for imatinib mesylate.  The relationship between mutations in these kinases and clin. response to imatinib was examd. in a group of patients with advanced GIST.  Patients and Methods: GISTs from 127 patients enrolled onto a phase II clin. study of imatinib were examd. for mutations of KIT or PDGFRA.  Mutation types were correlated with clin. outcome.  Results: Activating mutations of KIT or PDGFRA were found in 112 (88.2%) and six (4.7%) GISTs, resp.  Most KIT mutations involved exon 9 (n = 23) or exon 11 (n = 85).  All KIT mutant isoforms, but only a subset of PDGFRA mutant isoforms, were sensitive to imatinib, in vitro.  In patients with GISTs harboring exon 11 KIT mutations, the partial response rate (PR) was 83.5%, whereas patients with tumors contg. an exon 9 KIT mutation or no detectable mutation of KIT or PDGFRA had PR rates of 47.8% (P = .0006) and 0.0% (P < .0001), resp.  Patients whose tumors contained exon 11 KIT mutations had a longer event-free and overall survival than those whose tumors expressed either exon 9 KIT mutations or had no detectable kinase mutation.  Conclusion: Activating mutations of KIT or PDGFRA are found in the vast majority of GISTs, and the mutational status of these oncoproteins is predictive of clin. response to imatinib.  PDGFRA mutations can explain response and sensitivity to imatinib in some GISTs lacking KIT mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquHal4hZZoc7Vg90H21EOLACvtfcHk0ljE3gjzIUq8yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVWqu7Y%253D&md5=cbfd753460bdf0005c3bd93f12df98dc</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1200%2FJCO.2003.04.190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2003.04.190%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DMcGreevey%26aufirst%3DL.%2BS.%26aulast%3DChen%26aufirst%3DC.%2BJ.%26aulast%3DVan%2Bden%2BAbbeele%26aufirst%3DA.%2BD.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DKiese%26aufirst%3DB.%26aulast%3DEisenberg%26aufirst%3DB.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%2BM.%26aulast%3DSilberman%26aufirst%3DS.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DKinase%2520mutations%2520and%2520imatinib%2520response%2520in%2520patients%2520with%2520metastatic%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2003%26volume%3D21%26spage%3D4342%26epage%3D4349%26doi%3D10.1200%2FJCO.2003.04.190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lasota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miettinen, M.</span><span> </span><span class="NLM_article-title">Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours</span> <span class="citation_source-journal">Histopathology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">–</span> <span class="NLM_lpage">266</span><span class="refDoi"> DOI: 10.1111/j.1365-2559.2008.02977.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1111%2Fj.1365-2559.2008.02977.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2008&pages=245-266&author=J.+Lasotaauthor=M.+Miettinen&title=Clinical+significance+of+oncogenic+KIT+and+PDGFRA+mutations+in+gastrointestinal+stromal+tumours&doi=10.1111%2Fj.1365-2559.2008.02977.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2559.2008.02977.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2559.2008.02977.x%26sid%3Dliteratum%253Aachs%26aulast%3DLasota%26aufirst%3DJ.%26aulast%3DMiettinen%26aufirst%3DM.%26atitle%3DClinical%2520significance%2520of%2520oncogenic%2520KIT%2520and%2520PDGFRA%2520mutations%2520in%2520gastrointestinal%2520stromal%2520tumours%26jtitle%3DHistopathology%26date%3D2008%26volume%3D53%26spage%3D245%26epage%3D266%26doi%3D10.1111%2Fj.1365-2559.2008.02977.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hirota, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isozaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishiguro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tunio, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuzawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanakura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinomura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, Y.</span><span> </span><span class="NLM_article-title">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">577</span><span class="NLM_x">–</span> <span class="NLM_lpage">580</span><span class="refDoi"> DOI: 10.1126/science.279.5350.577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1126%2Fscience.279.5350.577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=9438854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADyaK1cXotVyhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1998&pages=577-580&author=S.+Hirotaauthor=K.+Isozakiauthor=Y.+Moriyamaauthor=K.+Hashimotoauthor=T.+Nishidaauthor=S.+Ishiguroauthor=K.+Kawanoauthor=M.+Hanadaauthor=A.+Kurataauthor=M.+Takedaauthor=G.+M.+Tunioauthor=Y.+Matsuzawaauthor=Y.+Kanakuraauthor=Y.+Shinomuraauthor=Y.+Kitamura&title=Gain-of-function+mutations+of+c-kit+in+human+gastrointestinal+stromal+tumors&doi=10.1126%2Fscience.279.5350.577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</span></div><div class="casAuthors">Hirota, Seiichi; Isozaki, Koji; Moriyama, Yasuhiro; Hashimoto, Koji; Nishida, Toshirou; Ishiguro, Shingo; Kawano, Kiyoshi; Hanada, Masato; Kurata, Akihiko; Takeda, Masashi; Muhammad Tunio, Ghulam; Matsuzawa, Yuji; Kanakura, Yuzuru; Shinomura, Yasuhisa; Kitamura, Yukihiko</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">5350</span>),
    <span class="NLM_cas:pages">577-580</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the human digestive tract, but their mol. etiol. and cellular origin are unknown.  Sequencing of c-kit complementary DNA, which encodes a proto-oncogenic receptor tyrosine kinase (KIT), from five GISTs revealed mutations in the region between the transmembrane and tyrosine kinase domains.  All of the corresponding mutant KIT proteins were constitutively activated without the KIT ligand, stem cell factor (SCF).  Stable transfection of the mutant c-kit complementary DNAs induced malignant transformation of Ba/F3 murine lymphoid cells, suggesting that the mutations contribute to tumor development.  GISTs may originate from the interstitial cells of Cajal (ICCs) because the development of ICCs is dependent on the SCF-KIT interaction and because, like GISTs, these cells express both KIT and CD34.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLlGnWQ79KELVg90H21EOLACvtfcHk0liKN3DHkt1g4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotVyhsw%253D%253D&md5=b66b6b8a389b064f73fba13ca84e8650</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1126%2Fscience.279.5350.577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.279.5350.577%26sid%3Dliteratum%253Aachs%26aulast%3DHirota%26aufirst%3DS.%26aulast%3DIsozaki%26aufirst%3DK.%26aulast%3DMoriyama%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DK.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DIshiguro%26aufirst%3DS.%26aulast%3DKawano%26aufirst%3DK.%26aulast%3DHanada%26aufirst%3DM.%26aulast%3DKurata%26aufirst%3DA.%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DTunio%26aufirst%3DG.%2BM.%26aulast%3DMatsuzawa%26aufirst%3DY.%26aulast%3DKanakura%26aufirst%3DY.%26aulast%3DShinomura%26aufirst%3DY.%26aulast%3DKitamura%26aufirst%3DY.%26atitle%3DGain-of-function%2520mutations%2520of%2520c-kit%2520in%2520human%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DScience%26date%3D1998%26volume%3D279%26spage%3D577%26epage%3D580%26doi%3D10.1126%2Fscience.279.5350.577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duensing, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGreevey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Town, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">PDGFRA activating mutations in gastrointestinal stromal tumors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">708</span><span class="NLM_x">–</span> <span class="NLM_lpage">710</span><span class="refDoi"> DOI: 10.1126/science.1079666</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1126%2Fscience.1079666" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2003&pages=708-710&author=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=A.+Duensingauthor=L.+McGreeveyauthor=C.+J.+Chenauthor=N.+Josephauthor=S.+Singerauthor=D.+J.+Griffithauthor=A.+Haleyauthor=A.+Townauthor=G.+D.+Demetriauthor=C.+D.+M.+Fletcherauthor=J.+A.+Fletcher&title=PDGFRA+activating+mutations+in+gastrointestinal+stromal+tumors&doi=10.1126%2Fscience.1079666"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.1126%2Fscience.1079666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1079666%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DDuensing%26aufirst%3DA.%26aulast%3DMcGreevey%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DC.%2BJ.%26aulast%3DJoseph%26aufirst%3DN.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DGriffith%26aufirst%3DD.%2BJ.%26aulast%3DHaley%26aufirst%3DA.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%2BM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DPDGFRA%2520activating%2520mutations%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DScience%26date%3D2003%26volume%3D299%26spage%3D708%26epage%3D710%26doi%3D10.1126%2Fscience.1079666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarlomo-Rikala, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tervahartiala, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuveson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silberman, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrijevic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span> </span><span class="NLM_article-title">Effect of the tyrosine inhibitor STI571 in a patient with a metastatis gastrointestinal stromal tumor</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x">, </span> <span class="NLM_fpage">1052</span><span class="NLM_x">–</span> <span class="NLM_lpage">1056</span><span class="refDoi"> DOI: 10.1056/NEJM200104053441404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1056%2FNEJM200104053441404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=11287975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A280%3ADC%252BD3M3gvVekuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2001&pages=1052-1056&author=H.+Joensuuauthor=P.+J.+Robertsauthor=M.+Sarlomo-Rikalaauthor=L.+C.+Anderssonauthor=P.+Tervahartialaauthor=D.+Tuvesonauthor=S.+L.+Silbermanauthor=R.+Capdevilleauthor=S.+Dimitrijevicauthor=B.+Drukerauthor=G.+D.+Demetri&title=Effect+of+the+tyrosine+inhibitor+STI571+in+a+patient+with+a+metastatis+gastrointestinal+stromal+tumor&doi=10.1056%2FNEJM200104053441404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor</span></div><div class="casAuthors">Joensuu H; Roberts P J; Sarlomo-Rikala M; Andersson L C; Tervahartiala P; Tuveson D; Silberman S; Capdeville R; Dimitrijevic S; Druker B; Demetri G D</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1052-6</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYZ86Vmj15i5otVjB3IRIyfW6udTcc2ebGhASAdDgASbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M3gvVekuw%253D%253D&md5=d361debf544b136b28889449118225e3</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1056%2FNEJM200104053441404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200104053441404%26sid%3Dliteratum%253Aachs%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DSarlomo-Rikala%26aufirst%3DM.%26aulast%3DAndersson%26aufirst%3DL.%2BC.%26aulast%3DTervahartiala%26aufirst%3DP.%26aulast%3DTuveson%26aufirst%3DD.%26aulast%3DSilberman%26aufirst%3DS.%2BL.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DDruker%26aufirst%3DB.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DEffect%2520of%2520the%2520tyrosine%2520inhibitor%2520STI571%2520in%2520a%2520patient%2520with%2520a%2520metastatis%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D344%26spage%3D1052%26epage%3D1056%26doi%3D10.1056%2FNEJM200104053441404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Abbeele, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuveson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janicek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silberman, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiese, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrijevic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, K.</span><span> </span><span class="NLM_article-title">Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">347</span><span class="NLM_x">, </span> <span class="NLM_fpage">472</span><span class="NLM_x">–</span> <span class="NLM_lpage">480</span><span class="refDoi"> DOI: 10.1056/NEJMoa020461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1056%2FNEJMoa020461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=12181401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtV2nt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2002&pages=472-480&author=G.+D.+Demetriauthor=M.+von+Mehrenauthor=C.+D.+Blankeauthor=A.+D.+Van+den+Abbeeleauthor=B.+Eisenbergauthor=P.+J.+Robertsauthor=M.+C.+Heinrichauthor=D.+A.+Tuvesonauthor=S.+Singerauthor=M.+Janicekauthor=J.+A.+Fletcherauthor=S.+G.+Silvermanauthor=S.+L.+Silbermanauthor=R.+Capdevilleauthor=B.+Kieseauthor=B.+Pengauthor=S.+Dimitrijevicauthor=B.+J.+Drukerauthor=C.+Corlessauthor=C.+D.+M.+Fletcherauthor=K.+Joensuu&title=Efficacy+and+safety+of+imatinib+mesylate+in+advanced+gastrointestinal+stromal+tumors&doi=10.1056%2FNEJMoa020461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors</span></div><div class="casAuthors">Demetri, George D.; von Mehren, Margaret; Blanke, Charles D.; Van den Abbeele, Annick D.; Eisenberg, Burton; Roberts, Peter J.; Heinrich, Michael C.; Tuveson, David A.; Singer, Samuel; Janicek, Milos; Fletcher, Jonathan A.; Silverman, Stuart G.; Silberman, Sandra L.; Capdeville, Renaud; Kiese, Beate; Peng, Bin; Dimitrijevic, Sasa; Druker, Brian J.; Corless, Christopher; Fletcher, Christopher D. M.; Joensuu, Heikki</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">472-480</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Constitutive activation of KIT receptor tyrosine kinase is crit. in the pathogenesis of gastrointestinal stromal tumors.  Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclin. models and preliminary clin. studies to have activity against such tumors.  We conducted an open-label, randomized, multicenter trial to evaluate the activity of imatinib in patients with advanced gastrointestinal stromal tumor.  We assessed antitumor response and the safety and tolerability of the drug.  Pharmacokinetics were assessed in a subgroup of patients.  A total of 147 patients were randomly assigned to receive 400 mg or 600 mg of imatinib daily.  Overall, 79 patients (53.7 percent) had a partial response, 41 patients (27.9 percent) had stable disease, and for tech. reasons, response could not be evaluated in 7 patients (4.8 percent).  No patient had a complete response to the treatment.  The median duration of response had not been reached after a median follow-up of 24 wk after the onset of response.  Early resistance to imatinib was noted in 20 patients (13.6 percent).  Therapy was well tolerated, although mild-to-moderate edema, diarrhea, and fatigue were common.  Gastrointestinal or intraabdominal hemorrhage occurred in approx. 5 percent of patients.  There were no significant differences in toxic effects or response between the two doses.  Imatinib was well absorbed, with pharmacokinetics similar to those reported in patients with chronic myeloid leukemia.  Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor.  Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVE0HpuuKXXrVg90H21EOLACvtfcHk0liXwrpfXC4WMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtV2nt7s%253D&md5=95c9ea076dd2b0e053ae2061cb3f5d24</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa020461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa020461%26sid%3Dliteratum%253Aachs%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DVan%2Bden%2BAbbeele%26aufirst%3DA.%2BD.%26aulast%3DEisenberg%26aufirst%3DB.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DJanicek%26aufirst%3DM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DSilverman%26aufirst%3DS.%2BG.%26aulast%3DSilberman%26aufirst%3DS.%2BL.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DKiese%26aufirst%3DB.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DCorless%26aufirst%3DC.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%2BM.%26aulast%3DJoensuu%26aufirst%3DK.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520imatinib%2520mesylate%2520in%2520advanced%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2002%26volume%3D347%26spage%3D472%26epage%3D480%26doi%3D10.1056%2FNEJMoa020461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Beham, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghadimi, B. M.</span><span> </span><span class="NLM_article-title">Gastrointestinal stromal tumors</span> <span class="citation_source-journal">Int. J. Colorectal. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">689</span><span class="NLM_x">–</span> <span class="NLM_lpage">700</span><span class="refDoi"> DOI: 10.1007/s00384-011-1353-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1007%2Fs00384-011-1353-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=22124674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A280%3ADC%252BC38zotFeisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2012&pages=689-700&author=A.+W.+Behamauthor=I.+M.+Schaeferauthor=P.+Schulerauthor=S.+Cameronauthor=B.+M.+Ghadimi&title=Gastrointestinal+stromal+tumors&doi=10.1007%2Fs00384-011-1353-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal stromal tumors</span></div><div class="casAuthors">Beham Alexander W; Schaefer Inga-Marie; Schuler Philipp; Cameron Silke; Ghadimi B Michael</div><div class="citationInfo"><span class="NLM_cas:title">International journal of colorectal disease</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">689-700</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  The gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the intestinal tract, known to be refractory to conventional chemotherapy or radiation.  Its pathogenesis is defined by mutations within the KIT and PDGFRA gene, which constitutively activate KIT and PDGFRA oncoproteins, and serve as crucial diagnostic and therapeutic targets.  DISCUSSION:  Besides surgery, therapy with imatinib mesylate, which inhibits KIT kinase activity, represents the other cornerstone for the treatment of GIST.  Still, the only curative option for GIST is given after complete surgical removal even in a metastatic setting, but recurrence is common, and the risk can be defined by surgical factors like incomplete resection, intraperitoneal rupture, or bleeding and tumor associated factors like tumor size, mitotic index, or localization.  CONCLUSION:  Consequently, adjuvant therapy with imatinib mesylate or other tyrosine kinase inhibitors is recommended for high-risk patients after complete resection.  For unresectable and advanced GIST, a partial response or stable disease can be achieved in about 80% of patients with imatinib mesylate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS9xNFEc0G2FhLDWw4HIq2sfW6udTcc2eYwBP86plYF_rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38zotFeisw%253D%253D&md5=ff8081bd813d5c0ee9de419f5cc2c1e0</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs00384-011-1353-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00384-011-1353-y%26sid%3Dliteratum%253Aachs%26aulast%3DBeham%26aufirst%3DA.%2BW.%26aulast%3DSchaefer%26aufirst%3DI.%2BM.%26aulast%3DSchuler%26aufirst%3DP.%26aulast%3DCameron%26aufirst%3DS.%26aulast%3DGhadimi%26aufirst%3DB.%2BM.%26atitle%3DGastrointestinal%2520stromal%2520tumors%26jtitle%3DInt.%2520J.%2520Colorectal.%2520Dis.%26date%3D2012%26volume%3D27%26spage%3D689%26epage%3D700%26doi%3D10.1007%2Fs00384-011-1353-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalcberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeCesne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichardt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blay, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Issels, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Oosterom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogendoorn, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Glabbeke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertulli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I.</span><span> </span><span class="NLM_article-title">Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">1127</span><span class="NLM_x">–</span> <span class="NLM_lpage">1134</span><span class="refDoi"> DOI: 10.1016/S0140-6736(04)17098-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1016%2FS0140-6736%2804%2917098-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2004&pages=1127-1134&author=J.+Verweijauthor=P.+G.+Casaliauthor=J.+Zalcbergauthor=A.+LeCesneauthor=P.+Reichardtauthor=J.+Y.+Blayauthor=R.+Isselsauthor=A.+van+Oosteromauthor=P.+C.+Hogendoornauthor=M.+Van+Glabbekeauthor=R.+Bertulliauthor=I.+Judson&title=Progression-free+survival+in+gastrointestinal+stromal+tumours+with+high-dose+imatinib%3A+randomised+trial&doi=10.1016%2FS0140-6736%2804%2917098-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2804%2917098-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252804%252917098-0%26sid%3Dliteratum%253Aachs%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3DZalcberg%26aufirst%3DJ.%26aulast%3DLeCesne%26aufirst%3DA.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DIssels%26aufirst%3DR.%26aulast%3Dvan%2BOosterom%26aufirst%3DA.%26aulast%3DHogendoorn%26aufirst%3DP.%2BC.%26aulast%3DVan%2BGlabbeke%26aufirst%3DM.%26aulast%3DBertulli%26aufirst%3DR.%26aulast%3DJudson%26aufirst%3DI.%26atitle%3DProgression-free%2520survival%2520in%2520gastrointestinal%2520stromal%2520tumours%2520with%2520high-dose%2520imatinib%253A%2520randomised%2520trial%26jtitle%3DLancet%26date%3D2004%26volume%3D364%26spage%3D1127%26epage%3D1134%26doi%3D10.1016%2FS0140-6736%2804%2917098-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Antonescu, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besmer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arkun, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hom, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koryotowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leversha, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desantis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMatteo, R. P.</span><span> </span><span class="NLM_article-title">Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">4182</span><span class="NLM_x">–</span> <span class="NLM_lpage">4190</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-2245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1158%2F1078-0432.CCR-04-2245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=15930355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1GksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=4182-4190&author=C.+R.+Antonescuauthor=P.+Besmerauthor=T.+Guoauthor=K.+Arkunauthor=G.+Homauthor=B.+Koryotowskiauthor=M.+A.+Levershaauthor=P.+D.+Jeffreyauthor=D.+Desantisauthor=S.+Singerauthor=M.+F.+Brennanauthor=R.+G.+Makiauthor=R.+P.+DeMatteo&title=Acquired+resistance+to+imatinib+in+gastrointestinal+stromal+tumor+occurs+through+secondary+gene+mutation&doi=10.1158%2F1078-0432.CCR-04-2245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation</span></div><div class="casAuthors">Antonescu, Cristina R.; Besmer, Peter; Guo, Tianhua; Arkun, Knarik; Hom, Glory; Koryotowski, Beata; Leversha, Margaret A.; Jeffrey, Philip D.; Desantis, Diann; Singer, Samuel; Brennan, Murray F.; Maki, Robert G.; DeMatteo, Ronald P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4182-4190</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GIST) have an activating mutation in either KIT or PDGFRA.  Imatinib is a selective tyrosine kinase inhibitor and achieves a partial response or stable disease in about 80% of patients with metastatic GIST.  It is now clear that some patients with GIST develop resistance to imatinib during chronic therapy.  To identify the mechanism of resistance, we studied 31 patients with GIST who were treated with imatinib and then underwent surgical resection.  There were 13 patients who were nonresistant to imatinib, 3 with primary resistance, and 15 with acquired resistance after initial benefit from the drug.  There were no secondary mutations in KIT or PDGFRA in the nonresistant or primary resistance groups.  In contrast, secondary mutations were found in 7 of 15 (46%) patients with acquired resistance, each of whom had a primary mutation in KIT exon 11.  Most secondary mutations were located in KIT exon 17.  KIT phosphorylation was heterogeneous and did not correlate with clin. response to imatinib or mutation status.  That acquired resistance to imatinib in GIST commonly occurs via secondary gene mutation in the KIT kinase domain has implications for strategies to delay or prevent imatinib resistance and to employ newer targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOQf6NfYqwnrVg90H21EOLACvtfcHk0li5tusebdHklA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1GksLw%253D&md5=f0f8000b2c362c7d1dcc74a2a7aaa067</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-2245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-2245%26sid%3Dliteratum%253Aachs%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26aulast%3DBesmer%26aufirst%3DP.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DArkun%26aufirst%3DK.%26aulast%3DHom%26aufirst%3DG.%26aulast%3DKoryotowski%26aufirst%3DB.%26aulast%3DLeversha%26aufirst%3DM.%2BA.%26aulast%3DJeffrey%26aufirst%3DP.%2BD.%26aulast%3DDesantis%26aufirst%3DD.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DBrennan%26aufirst%3DM.%2BF.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DDeMatteo%26aufirst%3DR.%2BP.%26atitle%3DAcquired%2520resistance%2520to%2520imatinib%2520in%2520gastrointestinal%2520stromal%2520tumor%2520occurs%2520through%2520secondary%2520gene%2520mutation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D4182%26epage%3D4190%26doi%3D10.1158%2F1078-0432.CCR-04-2245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Debiec-Rychter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cools, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumez, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciot, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mentens, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vranckx, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasag, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prenen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roesel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagemeijer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Oosterom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marynen, P.</span><span> </span><span class="NLM_article-title">Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x">, </span> <span class="NLM_fpage">270</span><span class="NLM_x">–</span> <span class="NLM_lpage">279</span><span class="refDoi"> DOI: 10.1053/j.gastro.2004.11.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1053%2Fj.gastro.2004.11.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2005&pages=270-279&author=M.+Debiec-Rychterauthor=J.+Coolsauthor=H.+Dumezauthor=R.+Sciotauthor=M.+Stulauthor=N.+Mentensauthor=H.+Vranckxauthor=B.+Wasagauthor=H.+Prenenauthor=J.+Roeselauthor=A.+Hagemeijerauthor=A.+Van+Oosteromauthor=P.+Marynen&title=Mechanisms+of+resistance+to+imatinib+mesylate+in+gastrointestinal+stromal+tumors+and+activity+of+the+PKC412+inhibitor+against+imatinib-resistant+mutants&doi=10.1053%2Fj.gastro.2004.11.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2004.11.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2004.11.020%26sid%3Dliteratum%253Aachs%26aulast%3DDebiec-Rychter%26aufirst%3DM.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DDumez%26aufirst%3DH.%26aulast%3DSciot%26aufirst%3DR.%26aulast%3DStul%26aufirst%3DM.%26aulast%3DMentens%26aufirst%3DN.%26aulast%3DVranckx%26aufirst%3DH.%26aulast%3DWasag%26aufirst%3DB.%26aulast%3DPrenen%26aufirst%3DH.%26aulast%3DRoesel%26aufirst%3DJ.%26aulast%3DHagemeijer%26aufirst%3DA.%26aulast%3DVan%2BOosterom%26aufirst%3DA.%26aulast%3DMarynen%26aufirst%3DP.%26atitle%3DMechanisms%2520of%2520resistance%2520to%2520imatinib%2520mesylate%2520in%2520gastrointestinal%2520stromal%2520tumors%2520and%2520activity%2520of%2520the%2520PKC412%2520inhibitor%2520against%2520imatinib-resistant%2520mutants%26jtitle%3DGastroenterology%26date%3D2005%26volume%3D128%26spage%3D270%26epage%3D279%26doi%3D10.1053%2Fj.gastro.2004.11.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandau, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDougall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">Molecular correlates of imatinib resistance in gastrointestinal stromal tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4764</span><span class="NLM_x">–</span> <span class="NLM_lpage">4774</span><span class="refDoi"> DOI: 10.1200/JCO.2006.06.2265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1200%2FJCO.2006.06.2265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=16954519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFynsrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=4764-4774&author=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=C.+D.+Blankeauthor=G.+D.+Demetriauthor=H.+Joensuuauthor=P.+J.+Robertsauthor=B.+L.+Eisenbergauthor=M.+von+Mehrenauthor=C.+D.+Fletcherauthor=K.+Sandauauthor=K.+McDougallauthor=W.+B.+Ouauthor=C.+J.+Chenauthor=J.+A.+Fletcher&title=Molecular+correlates+of+imatinib+resistance+in+gastrointestinal+stromal+tumors&doi=10.1200%2FJCO.2006.06.2265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15cR"><div class="casContent"><span class="casTitleNuber">15c</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular correlates of imatinib resistance in gastrointestinal stromal tumors</span></div><div class="casAuthors">Heinrich, Michael C.; Corless, Christopher L.; Blanke, Charles D.; Demetri, George D.; Joensuu, Heikki; Roberts, Peter J.; Eisenberg, Burton L.; von Mehren, Margaret; Fletcher, Christopher D. M.; Sandau, Katrin; McDougall, Karen; Ou, Wen-bin; Chen, Chang-Jie; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">4764-4774</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Gastrointestinal stromal tumors (GISTs) commonly harbor oncogenic mutations of the KIT or platelet-derived growth factor alpha (PDGFRA) kinases, which are targets for imatinib.  In clin. studies, 75% to 90% of patients with advanced GISTs experience clin. benefit from imatinib.  However, imatinib resistance is an increasing clin. problem.  Patients and Methods One hundred forty-seven patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clin. study of imatinib.  Specimens from pretreatment and/or imatinib-resistant tumors were analyzed to identify mol. correlates of imatinib resistance.  Secondary kinase mutations of KIT or PDGFRA that were identified in imatinib-resistant GISTs were biochem. profiled for imatinib sensitivity.  Results Mol. studies were performed using specimens from 10 patients with primary and 33 patients with secondary resistance.  Imatinib-resistant tumors had levels of activated KIT that were similar to or greater than those typically found in untreated GISTs.  Secondary kinase mutations were rare in GISTs with primary resistance but frequently found in GISTs with secondary resistance (10% v 67%, P = .002).  Evidence for clonal evolution and/or polyclonal secondary kinase mutations was seen in three (18.8%) of 16 patients.  Secondary kinase mutations were nonrandomly distributed and were assocd. with decreased imatinib sensitivity compared with typical KIT exon 11 mutations.  Using RNAi technol., we demonstrated that imatinib-resistant GIST cells remain dependent on KIT kinase activity for activation of crit. downstream signaling pathways.  Conclusion Different mol. mechanisms are responsible for primary and secondary imatinib resistance in GISTs.  These findings have implications for future approaches to the growing problem of imatinib resistance in patients with advanced GISTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw_n35sjCddLVg90H21EOLACvtfcHk0lgQ0ZGJHBwvkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFynsrrN&md5=25f7b94dd02d55c2fb56cea499cb7ab8</span></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.06.2265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.06.2265%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DEisenberg%26aufirst%3DB.%2BL.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DSandau%26aufirst%3DK.%26aulast%3DMcDougall%26aufirst%3DK.%26aulast%3DOu%26aufirst%3DW.%2BB.%26aulast%3DChen%26aufirst%3DC.%2BJ.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DMolecular%2520correlates%2520of%2520imatinib%2520resistance%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D4764%26epage%3D4774%26doi%3D10.1200%2FJCO.2006.06.2265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Gajiwala, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiNitto, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">English, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greig, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacques, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lunney, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quenzer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmett, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span> </span><span class="NLM_article-title">KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">1542</span><span class="NLM_x">–</span> <span class="NLM_lpage">1547</span><span class="refDoi"> DOI: 10.1073/pnas.0812413106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1073%2Fpnas.0812413106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=19164557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=1542-1547&author=K.+S.+Gajiwalaauthor=J.+C.+Wuauthor=J.+Christensenauthor=G.+D.+Deshmukhauthor=W.+Diehlauthor=J.+P.+DiNittoauthor=J.+M.+Englishauthor=M.+J.+Greigauthor=Y.+A.+Heauthor=S.+L.+Jacquesauthor=E.+A.+Lunneyauthor=M.+McTigueauthor=D.+Molinaauthor=T.+Quenzerauthor=P.+A.+Wellsauthor=X.+Yuauthor=Y.+Zhangauthor=A.+Zouauthor=M.+R.+Emmettauthor=A.+G.+Marshallauthor=H.+M.+Zhangauthor=G.+D.+Demetri&title=KIT+kinase+mutants+show+unique+mechanisms+of+drug+resistance+to+imatinib+and+sunitinib+in+gastrointestinal+stromal+tumor+patients&doi=10.1073%2Fpnas.0812413106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients</span></div><div class="casAuthors">Gajiwala, Ketan S.; Wu, Joe C.; Christensen, James; Deshmukh, Gayatri D.; Diehl, Wade; DiNitto, Jonathan P.; English, Jessie M.; Greig, Michael J.; He, You-Ai; Jacques, Suzanne L.; Lunney, Elizabeth A.; McTigue, Michele; Molina, Dave; Quenzer, Terri; Wells, Peter A.; Yu, Xiu; Zhang, Yan; Zou, Aihua; Emmett, Mark R.; Marshall, Alan G.; Zhang, Hui-Min; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1542-1547</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GISTs) exhibit aberrant activation of the receptor tyrosine kinase (RTK) KIT.  The efficacy of the inhibitors imatinib mesylate and sunitinib malate in GIST patients has been linked to their inhibition of these mutant KIT proteins.  However, patients on imatinib can acquire secondary KIT mutations that render the protein insensitive to the inhibitor.  Sunitinib has shown efficacy against certain imatinib-resistant mutants, although a subset that resides in the activation loop, including D816H/V, remains resistant.  Biochem. and structural studies were undertaken to det. the mol. basis of sunitinib resistance.  Our results show that sunitinib targets the autoinhibited conformation of WT KIT and that the D816H mutant undergoes a shift in conformational equil. toward the active state.  These findings provide a structural and enzymol. explanation for the resistance profile obsd. with the KIT inhibitors.  Prospectively, they have implications for understanding oncogenic kinase mutants and for circumventing drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkwFxa-p-iWbVg90H21EOLACvtfcHk0lgQ0ZGJHBwvkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D&md5=dd226c914c6f9a258426c0f4984a5258</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0812413106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0812413106%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DDeshmukh%26aufirst%3DG.%2BD.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DDiNitto%26aufirst%3DJ.%2BP.%26aulast%3DEnglish%26aufirst%3DJ.%2BM.%26aulast%3DGreig%26aufirst%3DM.%2BJ.%26aulast%3DHe%26aufirst%3DY.%2BA.%26aulast%3DJacques%26aufirst%3DS.%2BL.%26aulast%3DLunney%26aufirst%3DE.%2BA.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DMolina%26aufirst%3DD.%26aulast%3DQuenzer%26aufirst%3DT.%26aulast%3DWells%26aufirst%3DP.%2BA.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DA.%26aulast%3DEmmett%26aufirst%3DM.%2BR.%26aulast%3DMarshall%26aufirst%3DA.%2BG.%26aulast%3DZhang%26aufirst%3DH.%2BM.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DKIT%2520kinase%2520mutants%2520show%2520unique%2520mechanisms%2520of%2520drug%2520resistance%2520to%2520imatinib%2520and%2520sunitinib%2520in%2520gastrointestinal%2520stromal%2520tumor%2520patients%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26spage%3D1542%26epage%3D1547%26doi%3D10.1073%2Fpnas.0812413106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Tamborini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pricl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negri, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagonigro, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miselli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greco, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gronchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fermeglia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carbone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierotti, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilotti, S.</span><span> </span><span class="NLM_article-title">Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">6140</span><span class="NLM_x">–</span> <span class="NLM_lpage">6146</span><span class="refDoi"> DOI: 10.1038/sj.onc.1209639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1038%2Fsj.onc.1209639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=16751810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVGgsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=6140-6146&author=E.+Tamboriniauthor=S.+Priclauthor=T.+Negriauthor=M.+S.+Lagonigroauthor=F.+Miselliauthor=A.+Grecoauthor=A.+Gronchiauthor=P.+G.+Casaliauthor=M.+Ferroneauthor=M.+Fermegliaauthor=A.+Carboneauthor=M.+A.+Pierottiauthor=S.+Pilotti&title=Functional+analyses+and+molecular+modeling+of+two+c-Kit+mutations+responsible+for+imatinib+secondary+resistance+in+GIST+patients&doi=10.1038%2Fsj.onc.1209639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients</span></div><div class="casAuthors">Tamborini, E.; Pricl, S.; Negri, T.; Lagonigro, M. S.; Miselli, F.; Greco, A.; Gronchi, A.; Casali, P. G.; Ferrone, M.; Fermeglia, M.; Carbone, A.; Pierotti, M. A.; Pilotti, S.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">6140-6146</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Imatinib-acquired resistance related to the presence of secondary point mutations has become a frequent event in gastrointestinal stromal tumors.  Here, transient transfection expts. with plasmids carrying two different KIT-acquired point mutations were performed along with immunopptn. of total protein exts., derived from imatinib-treated and untreated cells.  The mol. mechanics/Poisson Boltzmann surface area computational techniques were applied to study the interactions of the wild-type and mutated receptors with imatinib at the mol. level.  Biochem. analyses showed KIT phosphorylation in cells transfected with vectors carrying the specific mutant genes.  Imatinib treatment demonstrated that T670I was insensitive to the drug at all the applied concns., whereas V654A was inhibited by 6 μM of imatinib.  The modeling of the mutated receptors revealed that both substitutions affect imatinib-binding site, but to a different extent: T670I substantially modifies the binding pocket, whereas V654A induces only relatively confined structural changes.  We demonstrated that T670I and V654A cause indeed imatinib-acquired resistance and that the former is more resistant to imatinib than the latter.  The application of mol. simulations allowed us to quantify the interactions between the mutated receptors and imatinib, and to propose a mol. rationale for this type of drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrozOoPwE9hbVg90H21EOLACvtfcHk0ljhTb76WKhLFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVGgsr7E&md5=03f253028385fd9244a94d9b6bcce077</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1209639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1209639%26sid%3Dliteratum%253Aachs%26aulast%3DTamborini%26aufirst%3DE.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DNegri%26aufirst%3DT.%26aulast%3DLagonigro%26aufirst%3DM.%2BS.%26aulast%3DMiselli%26aufirst%3DF.%26aulast%3DGreco%26aufirst%3DA.%26aulast%3DGronchi%26aufirst%3DA.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3DFerrone%26aufirst%3DM.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DCarbone%26aufirst%3DA.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26aulast%3DPilotti%26aufirst%3DS.%26atitle%3DFunctional%2520analyses%2520and%2520molecular%2520modeling%2520of%2520two%2520c-Kit%2520mutations%2520responsible%2520for%2520imatinib%2520secondary%2520resistance%2520in%2520GIST%2520patients%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26spage%3D6140%26epage%3D6146%26doi%3D10.1038%2Fsj.onc.1209639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tamborini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonadiman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greco, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albertini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negri, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gronchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertulli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colecchia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierotti, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilotti, S.</span><span> </span><span class="NLM_article-title">A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x">, </span> <span class="NLM_fpage">294</span><span class="NLM_x">–</span> <span class="NLM_lpage">299</span><span class="refDoi"> DOI: 10.1053/j.gastro.2004.02.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1053%2Fj.gastro.2004.02.021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2004&pages=294-299&author=E.+Tamboriniauthor=L.+Bonadimanauthor=A.+Grecoauthor=V.+Albertiniauthor=T.+Negriauthor=A.+Gronchiauthor=R.+Bertulliauthor=M.+Colecchiaauthor=P.+G.+Casaliauthor=M.+A.+Pierottiauthor=S.+Pilotti&title=A+new+mutation+in+the+KIT+ATP+pocket+causes+acquired+resistance+to+imatinib+in+a+gastrointestinal+stromal+tumor+patient&doi=10.1053%2Fj.gastro.2004.02.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2004.02.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2004.02.021%26sid%3Dliteratum%253Aachs%26aulast%3DTamborini%26aufirst%3DE.%26aulast%3DBonadiman%26aufirst%3DL.%26aulast%3DGreco%26aufirst%3DA.%26aulast%3DAlbertini%26aufirst%3DV.%26aulast%3DNegri%26aufirst%3DT.%26aulast%3DGronchi%26aufirst%3DA.%26aulast%3DBertulli%26aufirst%3DR.%26aulast%3DColecchia%26aufirst%3DM.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26aulast%3DPilotti%26aufirst%3DS.%26atitle%3DA%2520new%2520mutation%2520in%2520the%2520KIT%2520ATP%2520pocket%2520causes%2520acquired%2520resistance%2520to%2520imatinib%2520in%2520a%2520gastrointestinal%2520stromal%2520tumor%2520patient%26jtitle%3DGastroenterology%26date%3D2004%26volume%3D127%26spage%3D294%26epage%3D299%26doi%3D10.1053%2Fj.gastro.2004.02.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Wardelmann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merkelbach-Bruse, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauls, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schildhaus, H. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinicke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speidel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietsch, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buettner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pink, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichardt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohenberger, P.</span><span> </span><span class="NLM_article-title">Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1743</span><span class="NLM_x">–</span> <span class="NLM_lpage">1749</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-1211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1158%2F1078-0432.CCR-05-1211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=16551858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD28Xis1Cjs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=1743-1749&author=E.+Wardelmannauthor=S.+Merkelbach-Bruseauthor=K.+Paulsauthor=N.+Thomasauthor=H.+U.+Schildhausauthor=T.+Heinickeauthor=N.+Speidelauthor=T.+Pietschauthor=R.+Buettnerauthor=D.+Pinkauthor=P.+Reichardtauthor=P.+Hohenberger&title=Polyclonal+evolution+of+multiple+secondary+KIT+mutations+in+gastrointestinal+stromal+tumors+under+treatment+with+imatinib+mesylate&doi=10.1158%2F1078-0432.CCR-05-1211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate</span></div><div class="casAuthors">Wardelmann, Eva; Merkelbach-Bruse, Sabine; Pauls, Katharina; Thomas, Nadja; Schildhaus, Hans-Ulrich; Heinicke, Thomas; Speidel, Nicola; Pietsch, Torsten; Buettner, Reinhard; Pink, Daniel; Reichardt, Peter; Hohenberger, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1743-1749</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Gastrointestinal stromal tumors (GIST) are characterized by a strong KIT receptor activation most often resulting from KIT mutations.  In a smaller subgroup of tumors without KIT mutations, analogous activating mutations are found in the platelet-derived growth factor receptor α (PDGFRα) gene.  Both PDGFRα and KIT receptors are targets of the tyrosine kinase inhibitor imatinib (Glivec) which has improved the treatment of advanced GISTs significantly.  However, a subgroup of tumors show a secondary progress under therapy with imatinib after initial response.  One possible mechanism of secondary resistance is the development of newly acquired KIT mutations.  In the present study, we evaluated the frequency of such secondary KIT mutations in a series of GIST patients in which tumor tissue was resected under treatment.  We examd. one to seven different tumor areas in 32 cases (total of 104 samples) and found up to four newly acquired KIT mutations in 14 patients (43.8%).  These were always located in exons encoding the first or second tyrosine kinase domain (exon 13, 14, or 17).  Mutations were found only in a subset of samples analyzed from each case whereas others retained the wild-type sequence in the same region.  There was never more than one new mutation in the same sample.  Consistent with a secondary clonal evolution, the primary mutation was always detectable in all samples from each tumor.  According to our results, the identification of newly acquired KIT mutations in addn. to the primary mutation is dependent on the no. of tissue samples analyzed and has high implications for further therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovhLaWTAFjP7Vg90H21EOLACvtfcHk0ljhTb76WKhLFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xis1Cjs7Y%253D&md5=e39c95f452672224e49e8c5515b139c1</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-1211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-1211%26sid%3Dliteratum%253Aachs%26aulast%3DWardelmann%26aufirst%3DE.%26aulast%3DMerkelbach-Bruse%26aufirst%3DS.%26aulast%3DPauls%26aufirst%3DK.%26aulast%3DThomas%26aufirst%3DN.%26aulast%3DSchildhaus%26aufirst%3DH.%2BU.%26aulast%3DHeinicke%26aufirst%3DT.%26aulast%3DSpeidel%26aufirst%3DN.%26aulast%3DPietsch%26aufirst%3DT.%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DPink%26aufirst%3DD.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DHohenberger%26aufirst%3DP.%26atitle%3DPolyclonal%2520evolution%2520of%2520multiple%2520secondary%2520KIT%2520mutations%2520in%2520gastrointestinal%2520stromal%2520tumors%2520under%2520treatment%2520with%2520imatinib%2520mesylate%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D1743%26epage%3D1749%26doi%3D10.1158%2F1078-0432.CCR-05-1211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Town, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGreevey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiraga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bainbridge, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span> </span><span class="NLM_article-title">PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5357</span><span class="NLM_x">–</span> <span class="NLM_lpage">5364</span><span class="refDoi"> DOI: 10.1200/JCO.2005.14.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1200%2FJCO.2005.14.068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=15928335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpslOrtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=5357-5364&author=C.+L.+Corlessauthor=A.+Schroederauthor=D.+Griffithauthor=A.+Townauthor=L.+McGreeveyauthor=P.+Harrellauthor=S.+Shiragaauthor=T.+Bainbridgeauthor=J.+Morichauthor=M.+C.+Heinrich&title=PDGFRA+mutations+in+gastrointestinal+stromal+tumors%3A+frequency%2C+spectrum+and+in+vitro+sensitivity+to+imatinib&doi=10.1200%2FJCO.2005.14.068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib</span></div><div class="casAuthors">Corless, Christopher L.; Schroeder, Arin; Griffith, Diana; Town, Ajia; McGreevey, Laura; Harrell, Patina; Shiraga, Sharon; Bainbridge, Troy; Morich, Jason; Heinrich, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5357-5364</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Gastrointestinal stromal tumors (GISTs) commonly harbor oncogenic mutations of the KIT tyrosine kinase, which is a target for the kinase inhibitor imatinib.  A subset of GISTs, however, contains mutations in the homologous kinase platelet derived growth factor receptor alpha (PDGFRA), and the most common of these mutations is resistant to imatinib in vitro.  Little is known of the other types of PDGFRA mutations that occur in GISTs.  Materials and Methods: We detd. the KIT and PDGFRA mutation status of 1,105 unique GISTs using a combination of denaturing high-performance liq. chromatog. and direct sequencing.  Results: There were 80 tumors (7.2%) with a PDGFRA mutation: 66 in exon 18, 11 in exon 12, and three in exon 14.  Transient expression of representative PDGFRA isoforms in CHO cells revealed imatinib sensitivity of exon 12 mutations (SPDHE566-571R and insertion ER561-562) and an exon 14 substitution (N659K).  However, most isoforms with a substitution involving codon D842 in exon 18 (D842V, RD841-842KI, DI842-843IM) were resistant to the drug, with the exception of D842Y.  Interestingly, other mutations in exon 18 (D846Y, N848K, Y849K and HDSN845-848P) were all imatinib sensitive.  Proliferation studies with BA/F3 cell lines stably expressing selected PDGFRA mutant isoforms supported these findings.  Conclusion: Including our cases, there are 289 reported PDGFRA-mutant GISTs, of which 181 (62.6%) had the imatinib-resistant substitution D842V.  However, our findings suggest that more than one third of GISTs with PDGFRA mutations may respond to imatinib and that mutation screening may be helpful in the management of these tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnkomzycGeSbVg90H21EOLACvtfcHk0ljTzuWoyFfrhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpslOrtLY%253D&md5=f93f7152a982366acd714cef3207ff2f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.14.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.14.068%26sid%3Dliteratum%253Aachs%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DSchroeder%26aufirst%3DA.%26aulast%3DGriffith%26aufirst%3DD.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DMcGreevey%26aufirst%3DL.%26aulast%3DHarrell%26aufirst%3DP.%26aulast%3DShiraga%26aufirst%3DS.%26aulast%3DBainbridge%26aufirst%3DT.%26aulast%3DMorich%26aufirst%3DJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26atitle%3DPDGFRA%2520mutations%2520in%2520gastrointestinal%2520stromal%2520tumors%253A%2520frequency%252C%2520spectrum%2520and%2520in%2520vitro%2520sensitivity%2520to%2520imatinib%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D5357%26epage%3D5364%26doi%3D10.1200%2FJCO.2005.14.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Oosterom, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackstein, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bello, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span> </span><span class="NLM_article-title">Effcacy and safety of sunitinib in patients with advanced astrointestinal stromal tumour after failure of imatinib: a randomised controlled trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">368</span><span class="NLM_x">, </span> <span class="NLM_fpage">1329</span><span class="NLM_x">–</span> <span class="NLM_lpage">1338</span><span class="refDoi"> DOI: 10.1016/S0140-6736(06)69446-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1016%2FS0140-6736%2806%2969446-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2006&pages=1329-1338&author=G.+D.+Demetriauthor=A.+T.+van+Oosteromauthor=C.+R.+Garrettauthor=M.+E.+Blacksteinauthor=M.+H.+Shahauthor=J.+Verweijauthor=G.+McArthurauthor=I.+R.+Judsonauthor=M.+C.+Heinrichauthor=J.+A.+Morganauthor=J.+Desaiauthor=C.+D.+Fletcherauthor=S.+Georgeauthor=C.+L.+Belloauthor=X.+Huangauthor=C.+M.+Baumauthor=P.+G.+Casali&title=Effcacy+and+safety+of+sunitinib+in+patients+with+advanced+astrointestinal+stromal+tumour+after+failure+of+imatinib%3A+a+randomised+controlled+trial&doi=10.1016%2FS0140-6736%2806%2969446-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2806%2969446-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252806%252969446-4%26sid%3Dliteratum%253Aachs%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3Dvan%2BOosterom%26aufirst%3DA.%2BT.%26aulast%3DGarrett%26aufirst%3DC.%2BR.%26aulast%3DBlackstein%26aufirst%3DM.%2BE.%26aulast%3DShah%26aufirst%3DM.%2BH.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DMcArthur%26aufirst%3DG.%26aulast%3DJudson%26aufirst%3DI.%2BR.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DMorgan%26aufirst%3DJ.%2BA.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DBello%26aufirst%3DC.%2BL.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DBaum%26aufirst%3DC.%2BM.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26atitle%3DEffcacy%2520and%2520safety%2520of%2520sunitinib%2520in%2520patients%2520with%2520advanced%2520astrointestinal%2520stromal%2520tumour%2520after%2520failure%2520of%2520imatinib%253A%2520a%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2006%26volume%3D368%26spage%3D1329%26epage%3D1338%26doi%3D10.1016%2FS0140-6736%2806%2969446-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichardt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blay, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutkowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelderblom, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohenberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leahy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badalamenti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackstein, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Cesne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schöffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kappeler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuss, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span> </span><span class="NLM_article-title">GRID Study investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">381</span><span class="NLM_x">, </span> <span class="NLM_fpage">295</span><span class="NLM_x">–</span> <span class="NLM_lpage">302</span><span class="refDoi"> DOI: 10.1016/S0140-6736(12)61857-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1016%2FS0140-6736%2812%2961857-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2013&pages=295-302&author=G.+D.+Demetriauthor=P.+Reichardtauthor=Y.+K.+Kangauthor=J.+Y.+Blayauthor=P.+Rutkowskiauthor=H.+Gelderblomauthor=P.+Hohenbergerauthor=M.+Leahyauthor=M.+von+Mehrenauthor=H.+Joensuuauthor=G.+Badalamentiauthor=M.+Blacksteinauthor=A.+Le+Cesneauthor=P.+Sch%C3%B6ffskiauthor=R.+G.+Makiauthor=S.+Bauerauthor=B.+B.+Nguyenauthor=J.+M.+Xuauthor=T.+Nishidaauthor=J.+Chungauthor=C.+Kappelerauthor=I.+Kussauthor=D.+Laurentauthor=P.+G.+Casali&title=GRID+Study+investigators.+Efficacy+and+safety+of+regorafenib+for+advanced+gastrointestinal+stromal+tumours+after+failure+of+imatinib+and+sunitinib+%28GRID%29%3A+an+international%2C+multicentre%2C+randomised%2C+placebo-controlled%2C+phase+3+trial&doi=10.1016%2FS0140-6736%2812%2961857-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2961857-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252961857-1%26sid%3Dliteratum%253Aachs%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DKang%26aufirst%3DY.%2BK.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DGelderblom%26aufirst%3DH.%26aulast%3DHohenberger%26aufirst%3DP.%26aulast%3DLeahy%26aufirst%3DM.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DBadalamenti%26aufirst%3DG.%26aulast%3DBlackstein%26aufirst%3DM.%26aulast%3DLe%2BCesne%26aufirst%3DA.%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DB.%2BB.%26aulast%3DXu%26aufirst%3DJ.%2BM.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DChung%26aufirst%3DJ.%26aulast%3DKappeler%26aufirst%3DC.%26aulast%3DKuss%26aufirst%3DI.%26aulast%3DLaurent%26aufirst%3DD.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26atitle%3DGRID%2520Study%2520investigators.%2520Efficacy%2520and%2520safety%2520of%2520regorafenib%2520for%2520advanced%2520gastrointestinal%2520stromal%2520tumours%2520after%2520failure%2520of%2520imatinib%2520and%2520sunitinib%2520%2528GRID%2529%253A%2520an%2520international%252C%2520multicentre%252C%2520randomised%252C%2520placebo-controlled%252C%2520phase%25203%2520trial%26jtitle%3DLancet%26date%3D2013%26volume%3D381%26spage%3D295%26epage%3D302%26doi%3D10.1016%2FS0140-6736%2812%2961857-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitenstein, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntly, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall-Meyers, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callahan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammed, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span><span class="refDoi"> DOI: 10.1016/j.ccr.2005.01.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1016%2Fj.ccr.2005.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=15710326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=129-141&author=E.+Weisbergauthor=P.+W.+Manleyauthor=W.+Breitensteinauthor=J.+Bruggenauthor=S.+W.+Cowan-Jacobauthor=A.+Rayauthor=B.+Huntlyauthor=D.+Fabbroauthor=G.+Fendrichauthor=E.+Hall-Meyersauthor=A.+L.+Kungauthor=J.+Mestanauthor=G.+Q.+Daleyauthor=L.+Callahanauthor=L.+Catleyauthor=C.+Cavazzaauthor=A.+Mohammedauthor=D.+Neubergauthor=R.+D.+Wrightauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Characterization+of+AMN107%2C+a+selective+inhibitor+of+native+and+mutant+Bcr-Abl&doi=10.1016%2Fj.ccr.2005.01.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span></div><div class="casAuthors">Weisberg, Ellen; Manley, Paul W.; Breitenstein, Werner; Brueggen, Josef; Cowan-Jacob, Sandra W.; Ray, Arghya; Huntly, Brian; Fabbro, Doriano; Fendrich, Gabriele; Hall-Meyers, Elizabeth; Kung, Andrew L.; Mestan, Juergen; Daley, George Q.; Callahan, Linda; Catley, Laurie; Cavazza, Cara; Mohammed, Azam; Neuberg, Donna; Wright, Renee D.; Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-141</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-pos. (Ph+) acute lymphoblastic leukemia (ALL).  We describe a novel selective inhibitor of Bcr-Abl, AMN107 (IC50 < 30 nM), which is significantly more potent than imatinib, and active against a no. of imatinib-resistant Bcr-Abl mutants.  Crystallog. anal. of Abl-AMN107 complexes provides a structural explanation for the differential activity of AMN107 and imatinib against imatinib-resistant Bcr-Abl.  Consistent with its in vitro and pharmacokinetic profile, AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models.  AMN107 is a promising new inhibitor for the therapy of CML and Ph+ ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow6QF3qX2uO7Vg90H21EOLACvtfcHk0lgTK6lUSV-xWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D&md5=d28e1a54b982951f8d3e6ef1d2d3b2eb</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DBreitenstein%26aufirst%3DW.%26aulast%3DBruggen%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DHuntly%26aufirst%3DB.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DHall-Meyers%26aufirst%3DE.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DCallahan%26aufirst%3DL.%26aulast%3DCatley%26aufirst%3DL.%26aulast%3DCavazza%26aufirst%3DC.%26aulast%3DMohammed%26aufirst%3DA.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DWright%26aufirst%3DR.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DCharacterization%2520of%2520AMN107%252C%2520a%2520selective%2520inhibitor%2520of%2520native%2520and%2520mutant%2520Bcr-Abl%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D129%26epage%3D141%26doi%3D10.1016%2Fj.ccr.2005.01.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Adenis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blay, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bui-Nguyen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouche, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertucci, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isambert, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bompas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaigneau, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domont, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray-Coquard, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blesius, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Tine, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bulusu, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubreuil, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansfield, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moussy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermine, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Cesne, A.</span><span> </span><span class="NLM_article-title">Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1762</span><span class="NLM_x">–</span> <span class="NLM_lpage">1769</span><span class="refDoi"> DOI: 10.1093/annonc/mdu237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1093%2Fannonc%2Fmdu237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=25122671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FhsFagtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=1762-1769&author=A.+Adenisauthor=J.+Y.+Blayauthor=B.+Bui-Nguyenauthor=O.+Boucheauthor=F.+Bertucciauthor=N.+Isambertauthor=E.+Bompasauthor=L.+Chaigneauauthor=J.+Domontauthor=I.+Ray-Coquardauthor=A.+Blesiusauthor=B.+A.+Van+Tineauthor=V.+R.+Bulusuauthor=P.+Dubreuilauthor=C.+D.+Mansfieldauthor=Y.+Acinauthor=A.+Moussyauthor=O.+Hermineauthor=A.+Le+Cesne&title=Masitinib+in+advanced+gastrointestinal+stromal+tumor+%28GIST%29+after+failure+of+imatinib%3A+a+randomized+controlled+open-label+trial&doi=10.1093%2Fannonc%2Fmdu237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial</span></div><div class="casAuthors">Adenis A; Blay J-Y; Ray-Coquard I; Bui-Nguyen B; Bouche O; Bertucci F; Isambert N; Bompas E; Chaigneau L; Domont J; Blesius A; Le Cesne A; Van Tine B A; Bulusu V R; Dubreuil P; Mansfield C D; Acin Y; Moussy A; Hermine O</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1762-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Masitinib is a highly selective tyrosine kinase inhibitor with activity against the main oncogenic drivers of gastrointestinal stromal tumor (GIST).  Masitinib was evaluated in patients with advanced GIST after imatinib failure or intolerance.  PATIENTS AND METHODS:  Prospective, multicenter, randomized, open-label trial.  Patients with inoperable, advanced imatinib-resistant GIST were randomized (1 : 1) to receive masitinib (12 mg/kg/day) or sunitinib (50 mg/day 4-weeks-on/2-weeks-off) until progression, intolerance, or refusal.  Primary efficacy analysis was noncomparative, testing whether masitinib attained a median progression-free survival (PFS) (blind centrally reviewed RECIST) threshold of >3 months according to the lower bound of the 90% unilateral confidence interval (CI).  Secondary analyses on overall survival (OS) and PFS were comparative with results presented according to a two-sided 95% CI.  RESULTS:  Forty-four patients were randomized to receive masitinib (n = 23) or sunitinib (n = 21).  Median follow-up was 14 months.  Patients receiving masitinib experienced less toxicity than those receiving sunitinib, with significantly lower occurrence of severe adverse events (52% versus 91%, respectively, P = 0.008).  Median PFS (central RECIST) for the noncomparative primary analysis in the masitinib treatment arm was 3.71 months (90% CI 3.65).  Secondary analyses showed that median OS was significantly longer for patients receiving masitinib followed by post-progression addition of sunitinib when compared against patients treated directly with sunitinib in second-line [hazard ratio (HR) = 0.27, 95% CI 0.09-0.85, P = 0.016].  This improvement was sustainable as evidenced by 26-month follow-up OS data (HR = 0.40, 95% CI 0.16-0.96, P = 0.033); an additional 12.4 months survival advantage being reported for the masitinib treatment arm.  Risk of progression while under treatment with masitinib was in the same range as for sunitinib (HR = 1.1, 95% CI 0.6-2.2, P = 0.833).  CONCLUSIONS:  Primary efficacy analysis ensured the masitinib treatment arm could satisfy a prespecified PFS threshold.  Secondary efficacy analysis showed that masitinib followed by the standard of care generated a statistically significant survival benefit over standard of care.  Encouraging median OS and safety data from this well-controlled and appropriately designed randomized trial indicate a positive benefit-risk ratio.  Further development of masitinib in imatinib-resistant/intolerant patients with advanced GIST is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSxkpR-5bcD_eb6AVA-44PTfW6udTcc2eYbtCo3wgcNwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FhsFagtA%253D%253D&md5=a2aae8942a25c3f43682342282f40402</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdu237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdu237%26sid%3Dliteratum%253Aachs%26aulast%3DAdenis%26aufirst%3DA.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DBui-Nguyen%26aufirst%3DB.%26aulast%3DBouche%26aufirst%3DO.%26aulast%3DBertucci%26aufirst%3DF.%26aulast%3DIsambert%26aufirst%3DN.%26aulast%3DBompas%26aufirst%3DE.%26aulast%3DChaigneau%26aufirst%3DL.%26aulast%3DDomont%26aufirst%3DJ.%26aulast%3DRay-Coquard%26aufirst%3DI.%26aulast%3DBlesius%26aufirst%3DA.%26aulast%3DVan%2BTine%26aufirst%3DB.%2BA.%26aulast%3DBulusu%26aufirst%3DV.%2BR.%26aulast%3DDubreuil%26aufirst%3DP.%26aulast%3DMansfield%26aufirst%3DC.%2BD.%26aulast%3DAcin%26aufirst%3DY.%26aulast%3DMoussy%26aufirst%3DA.%26aulast%3DHermine%26aufirst%3DO.%26aulast%3DLe%2BCesne%26aufirst%3DA.%26atitle%3DMasitinib%2520in%2520advanced%2520gastrointestinal%2520stromal%2520tumor%2520%2528GIST%2529%2520after%2520failure%2520of%2520imatinib%253A%2520a%2520randomized%2520controlled%2520open-label%2520trial%26jtitle%3DAnn.%2520Oncol.%26date%3D2014%26volume%3D25%26spage%3D1762%26epage%3D1769%26doi%3D10.1093%2Fannonc%2Fmdu237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Trudel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reece, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A. K.</span><span> </span><span class="NLM_article-title">Chir-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t (4;14) multiple myeloma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2941</span><span class="NLM_x">–</span> <span class="NLM_lpage">2948</span><span class="refDoi"> DOI: 10.1182/blood-2004-10-3913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1182%2Fblood-2004-10-3913" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=2941-2948&author=S.+Trudelauthor=Z.+H.+Liauthor=E.+Weiauthor=M.+Wiesmannauthor=H.+Changauthor=C.+Chenauthor=D.+Reeceauthor=C.+Heiseauthor=A.+K.+Stewart&title=Chir-258%2C+a+novel%2C+multitargeted+tyrosine+kinase+inhibitor+for+the+potential+treatment+of+t+%284%3B14%29+multiple+myeloma&doi=10.1182%2Fblood-2004-10-3913"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1182%2Fblood-2004-10-3913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2004-10-3913%26sid%3Dliteratum%253Aachs%26aulast%3DTrudel%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DZ.%2BH.%26aulast%3DWei%26aufirst%3DE.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DReece%26aufirst%3DD.%26aulast%3DHeise%26aufirst%3DC.%26aulast%3DStewart%26aufirst%3DA.%2BK.%26atitle%3DChir-258%252C%2520a%2520novel%252C%2520multitargeted%2520tyrosine%2520kinase%2520inhibitor%2520for%2520the%2520potential%2520treatment%2520of%2520t%2520%25284%253B14%2529%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2005%26volume%3D105%26spage%3D2941%26epage%3D2948%26doi%3D10.1182%2Fblood-2004-10-3913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Van Glabbeke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Cesne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichardt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Issels, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Oosterom, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blay, J. Y.</span><span> </span><span class="NLM_article-title">Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European organisation for research and treatment of cancer, the Italian sarcoma group, and the Australasian gastro-intestinal trials group (EORTC-ISG-AGITG)</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">2277</span><span class="NLM_x">–</span> <span class="NLM_lpage">2285</span><span class="refDoi"> DOI: 10.1016/j.ejca.2006.03.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1016%2Fj.ejca.2006.03.029" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2006&pages=2277-2285&author=M.+Van+Glabbekeauthor=J.+Verweijauthor=P.+G.+Casaliauthor=J.+Simesauthor=A.+Le+Cesneauthor=P.+Reichardtauthor=R.+Isselsauthor=I.+R.+Judsonauthor=A.+T.+van+Oosteromauthor=J.+Y.+Blay&title=Predicting+toxicities+for+patients+with+advanced+gastrointestinal+stromal+tumours+treated+with+imatinib%3A+a+study+of+the+European+organisation+for+research+and+treatment+of+cancer%2C+the+Italian+sarcoma+group%2C+and+the+Australasian+gastro-intestinal+trials+group+%28EORTC-ISG-AGITG%29&doi=10.1016%2Fj.ejca.2006.03.029"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2006.03.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2006.03.029%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BGlabbeke%26aufirst%3DM.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3DSimes%26aufirst%3DJ.%26aulast%3DLe%2BCesne%26aufirst%3DA.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DIssels%26aufirst%3DR.%26aulast%3DJudson%26aufirst%3DI.%2BR.%26aulast%3Dvan%2BOosterom%26aufirst%3DA.%2BT.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26atitle%3DPredicting%2520toxicities%2520for%2520patients%2520with%2520advanced%2520gastrointestinal%2520stromal%2520tumours%2520treated%2520with%2520imatinib%253A%2520a%2520study%2520of%2520the%2520European%2520organisation%2520for%2520research%2520and%2520treatment%2520of%2520cancer%252C%2520the%2520Italian%2520sarcoma%2520group%252C%2520and%2520the%2520Australasian%2520gastro-intestinal%2520trials%2520group%2520%2528EORTC-ISG-AGITG%2529%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2006%26volume%3D42%26spage%3D2277%26epage%3D2285%26doi%3D10.1016%2Fj.ejca.2006.03.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Ben Ami, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, M. D.</span><span> </span><span class="NLM_article-title">A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumours</span> <span class="citation_source-journal">Expert Opin. Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">571</span><span class="NLM_x">–</span> <span class="NLM_lpage">578</span><span class="refDoi"> DOI: 10.1517/14740338.2016.1152258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1517%2F14740338.2016.1152258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=26865352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BC28XjsVGgtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=571-578&author=E.+Ben+Amiauthor=M.+D.+Demetri&title=A+safety+evaluation+of+imatinib+mesylate+in+the+treatment+of+gastrointestinal+stromal+tumours&doi=10.1517%2F14740338.2016.1152258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor</span></div><div class="casAuthors">Ben Ami, Eytan; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">571-578</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : For the last 15 years, imatinib mesylate has been the first line treatment of choice for advanced (metastatic) GIST.: This review describes key efficacy data on imatinib for the treatment of GIST, and focuses on safety and tolerability of imatinib, with emphasis on common adverse events management and long term toxicity profile.: Imatinib has been the std. of care for metastatic GIST and probably will continue to be so for the next few years.  Still, despite dramatic responses initially, imatinib drug resistance continues to be the major factor for treatment discontinuation.  The toxicity profile of imatinib has been well characterized, and although the majority of patients experience an adverse event during treatment with imatinib, these side effects are usually mild and manageable, with the majority of patients continuing treatment uninterruptedly.  Early concerns regarding imatinib related cardiotoxicity in GIST have not been confirmed in large prospective randomized trials, with reports indicating a low incidence of approx. 0.2%-0.4%.  Future strategies for treatment of imatinib resistant GIST will probably include novel tyrosine kinase inhibitors, combination therapies or immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrum_xmjNop4LVg90H21EOLACvtfcHk0ljlYA21waI3mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjsVGgtr8%253D&md5=8bae948198bf58e410d1f51d5b67d08b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1517%2F14740338.2016.1152258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.2016.1152258%26sid%3Dliteratum%253Aachs%26aulast%3DBen%2BAmi%26aufirst%3DE.%26aulast%3DDemetri%26aufirst%3DM.%2BD.%26atitle%3DA%2520safety%2520evaluation%2520of%2520imatinib%2520mesylate%2520in%2520the%2520treatment%2520of%2520gastrointestinal%2520stromal%2520tumours%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2016%26volume%3D15%26spage%3D571%26epage%3D578%26doi%3D10.1517%2F14740338.2016.1152258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Motzer, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutson, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomczak, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelson, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukowski, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oudard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negrier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szczylik, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pili, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjarnason, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-del-Muro, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solska, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilding, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figlin, R. A.</span><span> </span><span class="NLM_article-title">Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">3584</span><span class="NLM_x">–</span> <span class="NLM_lpage">3590</span><span class="refDoi"> DOI: 10.1200/JCO.2008.20.1293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1200%2FJCO.2008.20.1293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=19487381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOnu7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=3584-3590&author=R.+J.+Motzerauthor=T.+E.+Hutsonauthor=P.+Tomczakauthor=M.+D.+Michaelsonauthor=R.+M.+Bukowskiauthor=S.+Oudardauthor=S.+Negrierauthor=C.+Szczylikauthor=R.+Piliauthor=G.+A.+Bjarnasonauthor=X.+Garcia-del-Muroauthor=J.+A.+Sosmanauthor=E.+Solskaauthor=G.+Wildingauthor=J.+A.+Thompsonauthor=S.+T.+Kimauthor=I.+Chenauthor=X.+Huangauthor=R.+A.+Figlin&title=Overall+survival+and+updated+results+for+sunitinib+compared+with+interferon+alfa+in+patients+with+metastatic+renal+cell+carcinoma&doi=10.1200%2FJCO.2008.20.1293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma</span></div><div class="casAuthors">Motzer, Robert J.; Hutson, Thomas E.; Tomczak, Piotr; Michaelson, Dror; Bukowski, Ronald M.; Oudard, Stephane; Negrier, Sylvie; Szczylik, Cezary; Pili, Roberto; Bjarnason, Georg A.; Garcia-del-Muro, Xavier; Sosman, Jeffrey A.; Solska, Ewa; Wilding, George; Thompson, John A.; Kim, Sindy T.; Chen, Isan; Huang, Xin; Figlin, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3584-3590</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-α) in progression-free survival (primary end point) as first-line treatment for metastatic renal cell carcinoma (RCC).  Final survival analyses and updated results are reported.  750 Treatment-naive patients with metastatic clear cell RCC were randomly assigned to sunitinib 50 mg orally once daily on a 4 wk on, 2 wk off dosing schedule or to IFN-α 9 MU s.c. three times weekly.  Overall survival was compared by two-sided log-rank and Wilcoxon tests.  Progression-free survival, response, and safety end points were assessed with updated follow-up.  Median overall survival was greater in the sunitinib group than in the IFN-α group (26.4 v 21.8 mo, resp.; hazard ratio [HR] = 0.821; 95% CI, 0.673 to 1.001; P = .051) per the primary anal. of unstratified log-rank test (P = .013 per unstratified Wilcoxon test).  By stratified log-rank test, the HR was 0.818 (95% CI, 0.669 to 0.999; P = .049).  Within the IFN-α group, 33% of patients received sunitinib, and 32% received other vascular endothelial growth factor-signaling inhibitors after discontinuation from the trial.  Median progression-free survival was 11 mo for sunitinib compared with 5 mo for IFN-α (P < .001).  Objective response rate was 47% for sunitinib compared with 12% for IFN-α (P < .001).  The most commonly reported sunitinib-related grade 3 adverse events included hypertension (12%), fatigue (11%), diarrhea (9%), and hand-foot syndrome (9%).  Sunitinib demonstrates longer overall survival compared with IFN-α plus improvement in response and progression-free survival in the first-line treatment of patients with metastatic RCC.  The overall survival highlights an improved prognosis in patients with RCC in the era of targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH-pepRkwehbVg90H21EOLACvtfcHk0ljlYA21waI3mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOnu7nI&md5=69c3d4feceab003cc6faca799d813668</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.20.1293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.20.1293%26sid%3Dliteratum%253Aachs%26aulast%3DMotzer%26aufirst%3DR.%2BJ.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DTomczak%26aufirst%3DP.%26aulast%3DMichaelson%26aufirst%3DM.%2BD.%26aulast%3DBukowski%26aufirst%3DR.%2BM.%26aulast%3DOudard%26aufirst%3DS.%26aulast%3DNegrier%26aufirst%3DS.%26aulast%3DSzczylik%26aufirst%3DC.%26aulast%3DPili%26aufirst%3DR.%26aulast%3DBjarnason%26aufirst%3DG.%2BA.%26aulast%3DGarcia-del-Muro%26aufirst%3DX.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DSolska%26aufirst%3DE.%26aulast%3DWilding%26aufirst%3DG.%26aulast%3DThompson%26aufirst%3DJ.%2BA.%26aulast%3DKim%26aufirst%3DS.%2BT.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DFiglin%26aufirst%3DR.%2BA.%26atitle%3DOverall%2520survival%2520and%2520updated%2520results%2520for%2520sunitinib%2520compared%2520with%2520interferon%2520alfa%2520in%2520patients%2520with%2520metastatic%2520renal%2520cell%2520carcinoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D3584%26epage%3D3590%26doi%3D10.1200%2FJCO.2008.20.1293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Dai, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartandi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, Z. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albert, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bousquet, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunha, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaser, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcotte, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moskey, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoll, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tapang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelides, M. R.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-(4-(3-amino-1<i>H</i>-indazol-4-yl)phenyl)-<i>N′</i>-(2-fluoro-5-methyl phenyl) urea (ABT-869), a 3-amino indazole-based orally active multitargeted receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1584</span><span class="NLM_x">–</span> <span class="NLM_lpage">1597</span><span class="refDoi"> DOI: 10.1021/jm061280h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061280h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1584-1597&author=Y.+J.+Daiauthor=K.+Hartandiauthor=Z.+Q.+Jiauthor=A.+A.+Ahmedauthor=D.+H.+Albertauthor=J.+L.+Bauchauthor=J.+J.+Bouskaauthor=P.+F.+Bousquetauthor=G.+A.+Cunhaauthor=K.+B.+Glaserauthor=C.+M.+Harrisauthor=D.+Hickmanauthor=J.+Guoauthor=J.+L.+Liauthor=P.+A.+Marcotteauthor=K.+C.+Marshauthor=M.+D.+Moskeyauthor=R.+L.+Martinauthor=A.+M.+Olsonauthor=D.+J.+Osterlingauthor=L.+J.+Peaseauthor=N.+B.+Soniauthor=K.+D.+Stewartauthor=V.+S.+Stollauthor=P.+Tapangauthor=D.+R.+Reuterauthor=S.+K.+Davidsenauthor=M.+R.+Michaelides&title=Discovery+of+N-%284-%283-amino-1H-indazol-4-yl%29phenyl%29-N%E2%80%B2-%282-fluoro-5-methyl+phenyl%29+urea+%28ABT-869%29%2C+a+3-amino+indazole-based+orally+active+multitargeted+receptor+tyrosine+kinase+inhibitor&doi=10.1021%2Fjm061280h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm061280h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061280h%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DY.%2BJ.%26aulast%3DHartandi%26aufirst%3DK.%26aulast%3DJi%26aufirst%3DZ.%2BQ.%26aulast%3DAhmed%26aufirst%3DA.%2BA.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DBauch%26aufirst%3DJ.%2BL.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DBousquet%26aufirst%3DP.%2BF.%26aulast%3DCunha%26aufirst%3DG.%2BA.%26aulast%3DGlaser%26aufirst%3DK.%2BB.%26aulast%3DHarris%26aufirst%3DC.%2BM.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%2BL.%26aulast%3DMarcotte%26aufirst%3DP.%2BA.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DMoskey%26aufirst%3DM.%2BD.%26aulast%3DMartin%26aufirst%3DR.%2BL.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DPease%26aufirst%3DL.%2BJ.%26aulast%3DSoni%26aufirst%3DN.%2BB.%26aulast%3DStewart%26aufirst%3DK.%2BD.%26aulast%3DStoll%26aufirst%3DV.%2BS.%26aulast%3DTapang%26aufirst%3DP.%26aulast%3DReuter%26aufirst%3DD.%2BR.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26atitle%3DDiscovery%2520of%2520N-%25284-%25283-amino-1H-indazol-4-yl%2529phenyl%2529-N%25E2%2580%25B2-%25282-fluoro-5-methyl%2520phenyl%2529%2520urea%2520%2528ABT-869%2529%252C%2520a%25203-amino%2520indazole-based%2520orally%2520active%2520multitargeted%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1584%26epage%3D1597%26doi%3D10.1021%2Fjm061280h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Albert, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tapang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magoc, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pease, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, R. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bousquet, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghoreishi-Haack, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukofzer, G. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stavropoulos, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartandi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niquette, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCall, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donawho, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcotte, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaser, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelides, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidsen, S. K.</span><span> </span><span class="NLM_article-title">Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">995</span><span class="NLM_x">–</span> <span class="NLM_lpage">1006</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-05-0410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1158%2F1535-7163.MCT-05-0410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=16648571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvFCkt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=995-1006&author=D.+H.+Albertauthor=P.+Tapangauthor=T.+J.+Magocauthor=L.+J.+Peaseauthor=D.+R.+Reuterauthor=R.+Q.+Weiauthor=J.+L.+Liauthor=J.+Guoauthor=P.+F.+Bousquetauthor=N.+S.+Ghoreishi-Haackauthor=B.+Wangauthor=G.+T.+Bukofzerauthor=Y.+C.+Wangauthor=J.+A.+Stavropoulosauthor=K.+Hartandiauthor=A.+L.+Niquetteauthor=N.+Soniauthor=E.+F.+Johnsonauthor=J.+O.+McCallauthor=J.+J.+Bouskaauthor=Y.+Luoauthor=C.+K.+Donawhoauthor=Y.+Daiauthor=P.+A.+Marcotteauthor=K.+B.+Glaserauthor=M.+R.+Michaelidesauthor=S.+K.+Davidsen&title=Preclinical+activity+of+ABT-869%2C+a+multitargeted+receptor+tyrosine+kinase+inhibitor&doi=10.1158%2F1535-7163.MCT-05-0410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor</span></div><div class="casAuthors">Albert, Daniel H.; Tapang, Paul; Magoc, Terrance J.; Pease, Lori J.; Reuter, David R.; Wei, Ru-Qi; Li, Junling; Guo, Jun; Bousquet, Peter F.; Ghoreishi-Haack, Nayereh S.; Wang, Baole; Bukofzer, Gail T.; Wang, Yi-Chun; Stavropoulos, Jason A.; Hartandi, Kresna; Niquette, Amanda L.; Soni, Nirupama; Johnson, Eric F.; McCall, J. Owen; Bouska, Jennifer J.; Luo, Yanping; Donawho, Cherrie K.; Dai, Yujia; Marcotte, Patrick A.; Glaser, Keith B.; Michaelides, Michael R.; Davidsen, Steven K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">995-1006</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">ABT-869 is a structurally novel, receptor tyrosine kinase (RTK) inhibitor that is a potent inhibitor of members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor families (e.g., KDR IC50 = 4 nmol/L) but has much less activity (IC50s > 1 μmol/L) against unrelated RTKs, sol. tyrosine kinases, or serine/threonine kinases.  The inhibition profile of ABT-869 is evident in cellular assays of RTK phosphorylation (IC50 = 2, 4, and 7 nmol/L for PDGFR-β, KDR, and CSF-1R, resp.) and VEGF-stimulated proliferation (IC50 = 0.2 nmol/L for human endothelial cells).  ABT-869 is not a general antiproliferative agent because, in most cancer cells, >1,000-fold higher concns. of ABT-869 are required for inhibition of proliferation.  However, ABT-869 exhibits potent antiproliferative and apoptotic effects on cancer cells whose proliferation is dependent on mutant kinases, such as FLT3.  In vivo ABT-869 is effective orally in the mechanism-based murine models of VEGF-induced uterine edema (ED50 = 0.5 mg/kg) and corneal angiogenesis (>50% inhibition, 15 mg/kg).  In tumor growth studies, ABT-869 exhibits efficacy in human fibrosarcoma and breast, colon, and small cell lung carcinoma xenograft models (ED50 = 1.5-5 mg/kg, twice daily) and is also effective (>50% inhibition) in orthotopic breast and glioma models.  Redn. in tumor size and tumor regression was obsd. in epidermoid carcinoma and leukemia xenograft models, resp.  In combination, ABT-869 produced at least additive effects when given with cytotoxic therapies.  Based on pharmacokinetic anal. from tumor growth studies, efficacy correlated more strongly with time over a threshold value (cellular KDR IC50 cor. for blood plasma protein binding = 0.08 μg/mL, ≥7 h) than with plasma area under the curve or Cmax.  These results support clin. assessment of ABT-869 as a therapeutic agent for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkn2KBvMa4wrVg90H21EOLACvtfcHk0lj416xFxppdaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvFCkt7g%253D&md5=a5a60b591b4da7a3c589f1618d9cffb9</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0410%26sid%3Dliteratum%253Aachs%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DTapang%26aufirst%3DP.%26aulast%3DMagoc%26aufirst%3DT.%2BJ.%26aulast%3DPease%26aufirst%3DL.%2BJ.%26aulast%3DReuter%26aufirst%3DD.%2BR.%26aulast%3DWei%26aufirst%3DR.%2BQ.%26aulast%3DLi%26aufirst%3DJ.%2BL.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DBousquet%26aufirst%3DP.%2BF.%26aulast%3DGhoreishi-Haack%26aufirst%3DN.%2BS.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DBukofzer%26aufirst%3DG.%2BT.%26aulast%3DWang%26aufirst%3DY.%2BC.%26aulast%3DStavropoulos%26aufirst%3DJ.%2BA.%26aulast%3DHartandi%26aufirst%3DK.%26aulast%3DNiquette%26aufirst%3DA.%2BL.%26aulast%3DSoni%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DMcCall%26aufirst%3DJ.%2BO.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DMarcotte%26aufirst%3DP.%2BA.%26aulast%3DGlaser%26aufirst%3DK.%2BB.%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26aulast%3DDavidsen%26aufirst%3DS.%2BK.%26atitle%3DPreclinical%2520activity%2520of%2520ABT-869%252C%2520a%2520multitargeted%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D995%26epage%3D1006%26doi%3D10.1158%2F1535-7163.MCT-05-0410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Melnick, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sipes, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunderson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarnes, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matzen, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beigi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harig, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asatryan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saadat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downs, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldwell, J. S.</span><span> </span><span class="NLM_article-title">An efficient rapid system for profiling the cellular activities of molecular libraries</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">3153</span><span class="NLM_x">–</span> <span class="NLM_lpage">3158</span><span class="refDoi"> DOI: 10.1073/pnas.0511292103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1073%2Fpnas.0511292103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=16492761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD28XksF2ktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=3153-3158&author=J.+S.+Melnickauthor=J.+Janesauthor=S.+Kimauthor=J.+Y.+Changauthor=D.+G.+Sipesauthor=D.+Gundersonauthor=L.+Jarnesauthor=J.+T.+Matzenauthor=M.+E.+Garciaauthor=T.+L.+Hoodauthor=R.+Beigiauthor=G.+Xiaauthor=R.+A.+Harigauthor=H.+Asatryanauthor=S.+F.+Yanauthor=Y.+Y.+Zhouauthor=X.+J.+Guauthor=A.+Saadatauthor=V.+Zhouauthor=F.+J.+Kingauthor=C.+M.+Shawauthor=A.+I.+Suauthor=R.+Downsauthor=N.+S.+Grayauthor=P.+G.+Schultzauthor=M.+Warmuthauthor=J.+S.+Caldwell&title=An+efficient+rapid+system+for+profiling+the+cellular+activities+of+molecular+libraries&doi=10.1073%2Fpnas.0511292103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">An efficient rapid system for profiling the cellular activities of molecular libraries</span></div><div class="casAuthors">Melnick, Jonathan S.; Janes, Jeff; Kim, Sungjoon; Chang, Jim Y.; Sipes, Daniel G.; Gunderson, Drew; Jarnes, Laura; Matzen, Jason T.; Garcia, Michael E.; Hood, Tami L.; Beigi, Ronak; Xia, Gang; Harig, Richard A.; Asatryan, Hayk; Yan, S. Frank; Zhou, Yingyao; Gu, Xiang-Ju; Saadat, Alham; Zhou, Vicki; King, Frederick J.; Shaw, Christopher M.; Su, Andrew I.; Downs, Robert; Gray, Nathanael S.; Schultz, Peter G.; Warmuth, Markus; Caldwell, Jeremy S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3153-3158</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Rapid quant. methods for characterizing small mols., peptides, proteins, or RNAs in a broad array of cellular assays would allow one to discover new biol. activities assocd. with these mols. and also provide a more comprehensive profile of drug candidates early in the drug development process.  Here the authors describe a robotic system, termed the automated compd. profiler, capable of both propagating a large no. of cell lines in parallel and assaying large collections of mols. simultaneously against a matrix of cellular assays in a highly reproducible manner.  To illustrate its utility, the authors have characterized a set of 1400 kinase inhibitors in a panel of 35 activated tyrosine-kinase-dependent cellular assays in dose-response format in a single expt.  Anal. of the resulting multidimensional dataset revealed subclusters of both inhibitors and kinases with closely correlated activities.  The approach also identified activities for the p38 inhibitor BIRB796 and the dual src/abl inhibitor BMS-354825 and exposed the expected side activities for Glivec/STI571, including cellular inhibition of c-kit and platelet-derived growth factor receptor.  This methodol. provides a powerful tool for unraveling the cellular biol. and mol. pharmacol. of both naturally occurring and synthetic chem. diversity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQNvyk_cSNMrVg90H21EOLACvtfcHk0liXZol8cGO--w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksF2ktr0%253D&md5=df174db38f600f27bfba3d8363e68ce1</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0511292103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0511292103%26sid%3Dliteratum%253Aachs%26aulast%3DMelnick%26aufirst%3DJ.%2BS.%26aulast%3DJanes%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DJ.%2BY.%26aulast%3DSipes%26aufirst%3DD.%2BG.%26aulast%3DGunderson%26aufirst%3DD.%26aulast%3DJarnes%26aufirst%3DL.%26aulast%3DMatzen%26aufirst%3DJ.%2BT.%26aulast%3DGarcia%26aufirst%3DM.%2BE.%26aulast%3DHood%26aufirst%3DT.%2BL.%26aulast%3DBeigi%26aufirst%3DR.%26aulast%3DXia%26aufirst%3DG.%26aulast%3DHarig%26aufirst%3DR.%2BA.%26aulast%3DAsatryan%26aufirst%3DH.%26aulast%3DYan%26aufirst%3DS.%2BF.%26aulast%3DZhou%26aufirst%3DY.%2BY.%26aulast%3DGu%26aufirst%3DX.%2BJ.%26aulast%3DSaadat%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DV.%26aulast%3DKing%26aufirst%3DF.%2BJ.%26aulast%3DShaw%26aufirst%3DC.%2BM.%26aulast%3DSu%26aufirst%3DA.%2BI.%26aulast%3DDowns%26aufirst%3DR.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DCaldwell%26aufirst%3DJ.%2BS.%26atitle%3DAn%2520efficient%2520rapid%2520system%2520for%2520profiling%2520the%2520cellular%2520activities%2520of%2520molecular%2520libraries%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D3153%26epage%3D3158%26doi%3D10.1073%2Fpnas.0511292103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Neuhann, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansmann, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merkelbach-Bruse, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klink, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellinger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffkes, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardelmann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schildhaus, H. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tinschert, S.</span><span> </span><span class="NLM_article-title">A novel germline KIT mutation (p. L576P) in a family presenting with juvenile onset of multiple gastrointestinal stromal tumors, skin hyperpigmentations, and esophageal stenosis</span> <span class="citation_source-journal">Am. J. Surg. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">898</span><span class="NLM_x">–</span> <span class="NLM_lpage">905</span><span class="refDoi"> DOI: 10.1097/PAS.0b013e31827bc071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1097%2FPAS.0b013e31827bc071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=23598963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A280%3ADC%252BC3srmtl2ltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2013&pages=898-905&author=T.+M.+Neuhannauthor=V.+Mansmannauthor=S.+Merkelbach-Bruseauthor=B.+Klinkauthor=A.+Hellingerauthor=H.+G.+Hoffkesauthor=E.+Wardelmannauthor=H.+U.+Schildhausauthor=S.+Tinschert&title=A+novel+germline+KIT+mutation+%28p.+L576P%29+in+a+family+presenting+with+juvenile+onset+of+multiple+gastrointestinal+stromal+tumors%2C+skin+hyperpigmentations%2C+and+esophageal+stenosis&doi=10.1097%2FPAS.0b013e31827bc071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">A novel germline KIT mutation (p.L576P) in a family presenting with juvenile onset of multiple gastrointestinal stromal tumors, skin hyperpigmentations, and esophageal stenosis</span></div><div class="casAuthors">Neuhann Teresa M; Mansmann Veit; Merkelbach-Bruse Sabine; Klink Barbara; Hellinger Achim; Hoffkes Heinz-Gert; Wardelmann Eva; Schildhaus Hans-Ulrich; Tinschert Sigrid</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of surgical pathology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">898-905</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Familial gastrointestinal stromal tumor (GIST) syndrome is a rare autosomal dominant genetic disorder.  We report on a kindred in which 3 family members carry a germline mutation (c.1727T>C, p.L576P) in exon 11 of the KIT gene.  This mutation was not reported so far in familial GISTs.  Apart from multiple GISTs in 2 of the mutation carriers, all of them had multiple hyperpigmented skin macules and a history of achalasia-like stenosis of the esophagus in early childhood.  In the index patient >100 tumors and a diffuse Cajal cell hyperplasia of the small bowel occurred.  Sequencing of DNA extracted from tumor tissue of one of his GISTs revealed the KIT mutation in exon 11 (c.1727T>C).  By array comparative genomic hybridization whole chromosomal gains 3, 5, 7, 9, 12, 15, and 18 were detected.  In addition, we could identify a gain on chromosome 4, spanning the KIT gene.  Together with the family described here, 24 unrelated cases with proven germline mutations in KIT have been reported.  In these families the diagnosis was established from the age of 30 years onwards.  Because in 1 patient reported here the GIST was a coincidental finding at the age of 15 years, the tumors might occur at a very young age and remain unnoticed until they-either due to increasing size, ulceration, or malignant progression-become symptomatic.  Therefore, we propose to start screening patients with known KIT mutations from a younger age.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSptAqgP-IBkTjk2McQZ6XmfW6udTcc2eZKchHZmbsF6Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srmtl2ltA%253D%253D&md5=ea12361159e68b86d038eb1afcd07be4</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1097%2FPAS.0b013e31827bc071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FPAS.0b013e31827bc071%26sid%3Dliteratum%253Aachs%26aulast%3DNeuhann%26aufirst%3DT.%2BM.%26aulast%3DMansmann%26aufirst%3DV.%26aulast%3DMerkelbach-Bruse%26aufirst%3DS.%26aulast%3DKlink%26aufirst%3DB.%26aulast%3DHellinger%26aufirst%3DA.%26aulast%3DHoffkes%26aufirst%3DH.%2BG.%26aulast%3DWardelmann%26aufirst%3DE.%26aulast%3DSchildhaus%26aufirst%3DH.%2BU.%26aulast%3DTinschert%26aufirst%3DS.%26atitle%3DA%2520novel%2520germline%2520KIT%2520mutation%2520%2528p.%2520L576P%2529%2520in%2520a%2520family%2520presenting%2520with%2520juvenile%2520onset%2520of%2520multiple%2520gastrointestinal%2520stromal%2520tumors%252C%2520skin%2520hyperpigmentations%252C%2520and%2520esophageal%2520stenosis%26jtitle%3DAm.%2520J.%2520Surg.%2520Pathol.%26date%3D2013%26volume%3D37%26spage%3D898%26epage%3D905%26doi%3D10.1097%2FPAS.0b013e31827bc071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Garner, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gozgit, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anjum, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vodala, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrock, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eilers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ketzer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohlmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span> </span><span class="NLM_article-title">Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5745</span><span class="NLM_x">–</span> <span class="NLM_lpage">5755</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-1397</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1158%2F1078-0432.CCR-14-1397" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=25239608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGgsL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=5745-5755&author=A.+P.+Garnerauthor=J.+M.+Gozgitauthor=R.+Anjumauthor=S.+Vodalaauthor=A.+Schrockauthor=T.+J.+Zhouauthor=C.+Serranoauthor=G.+Eilersauthor=M.+J.+Zhuauthor=J.+Ketzerauthor=S.+Wardwellauthor=Y.+Y.+Ningauthor=Y.+Songauthor=A.+Kohlmannauthor=F.+Wangauthor=T.+Clacksonauthor=M.+C.+Heinrichauthor=J.+A.+Fletcherauthor=S.+Bauerauthor=V.+M.+Rivera&title=Ponatinib+inhibits+polyclonal+drug-resistant+KIT+oncoproteins+and+shows+therapeutic+potential+in+heavily+pretreated+gastrointestinal+stromal+tumor+%28GIST%29+patients&doi=10.1158%2F1078-0432.CCR-14-1397"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients</span></div><div class="casAuthors">Garner, Andrew P.; Gozgit, Joseph M.; Anjum, Rana; Vodala, Sadanand; Schrock, Alexa; Zhou, Tianjun; Serrano, Cesar; Eilers, Grant; Zhu, Meijun; Ketzer, Julia; Wardwell, Scott; Ning, Yaoyu; Song, Youngchul; Kohlmann, Anna; Wang, Frank; Clackson, Tim; Heinrich, Michael C.; Fletcher, Jonathan A.; Bauer, Sebastian; Rivera, Victor M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5745-5755</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: KIT is the major oncogenic driver of gastrointestinal stromal tumors (GIST).  Imatinib, sunitinib, and regorafenib are approved therapies; however, efficacy is often limited by the acquisition of polyclonal secondary resistance mutations in KIT, with those located in the activation (A) loop (exons 17/18) being particularly problematic.  Here, we explore the KIT-inhibitory activity of ponatinib in preclin. models and describe initial characterization of its activity in patients with GIST.  Exptl. Design: The cellular and in vivo activities of ponatinib, imatinib, sunitinib, and regorafenib against mutant KIT were evaluated using an accelerated mutagenesis assay and a panel of engineered and GIST-derived cell lines.  The ponatinib-KIT costructure was also detd.  The clin. activity of ponatinib was examd. in three patients with GIST previously treated with all three FDA-approved agents.  Results: In engineered and GIST-derived cell lines, ponatinib potently inhibited KIT exon 11 primary mutants and a range of secondary mutants, including those within the A-loop.  Ponatinib also induced regression in engineered and GIST-derived tumor models contg. these secondary mutations.  In a mutagenesis screen, 40 nmol/L ponatinib was sufficient to suppress outgrowth of all secondary mutants except V654A, which was suppressed at 80 nmol/L.  This inhibitory profile could be rationalized on the basis of structural analyses.  Ponatinib (30 mg daily) displayed encouraging clin. activity in two of three patients with GIST.  Conclusion:Ponatinib possesses potent activity against most major clin. relevant KIT mutants and has demonstrated preliminary evidence of activity in patients with refractory GIST.  These data strongly support further evaluation of ponatinib in patients with GIST.  Clin Cancer Res; 20(22); 5745-55. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTGG18CSl3XLVg90H21EOLACvtfcHk0lgdXl05jm_Yng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGgsL7E&md5=7537e45f37546f9e0cb799bdf05ed847</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1397%26sid%3Dliteratum%253Aachs%26aulast%3DGarner%26aufirst%3DA.%2BP.%26aulast%3DGozgit%26aufirst%3DJ.%2BM.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DVodala%26aufirst%3DS.%26aulast%3DSchrock%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DT.%2BJ.%26aulast%3DSerrano%26aufirst%3DC.%26aulast%3DEilers%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DM.%2BJ.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%2BY.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DKohlmann%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26atitle%3DPonatinib%2520inhibits%2520polyclonal%2520drug-resistant%2520KIT%2520oncoproteins%2520and%2520shows%2520therapeutic%2520potential%2520in%2520heavily%2520pretreated%2520gastrointestinal%2520stromal%2520tumor%2520%2528GIST%2529%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D5745%26epage%3D5755%26doi%3D10.1158%2F1078-0432.CCR-14-1397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Taguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonobe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyonaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamasaki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Araki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimaru, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuri, K.</span><span> </span><span class="NLM_article-title">Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stromal tumor</span> <span class="citation_source-journal">Lab. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">663</span><span class="NLM_x">–</span> <span class="NLM_lpage">665</span><span class="refDoi"> DOI: 10.1038/labinvest.3780461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1038%2Flabinvest.3780461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=12004007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A280%3ADC%252BD383msVOjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2002&pages=663-665&author=T.+Taguchiauthor=H.+Sonobeauthor=S.+Toyonagaauthor=I.+Yamasakiauthor=T.+Shuinauthor=A.+Takanoauthor=K.+Arakiauthor=K.+Akimaruauthor=K.+Yuri&title=Conventional+and+molecular+cytogenetic+characterization+of+a+new+human+cell+line%2C+GIST-T1%2C+established+from+gastrointestinal+stromal+tumor&doi=10.1038%2Flabinvest.3780461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stromal tumor</span></div><div class="casAuthors">Taguchi Takahiro; Sonobe Hiroshi; Toyonaga Shin-ichi; Yamasaki Ichiro; Shuin Taro; Takano Atsushi; Araki Keijiro; Akimaru Kunihiro; Yuri Kazunari</div><div class="citationInfo"><span class="NLM_cas:title">Laboratory investigation; a journal of technical methods and pathology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">663-5</span>
        ISSN:<span class="NLM_cas:issn">0023-6837</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfLoSxovx6e8RAV4D_Ins_fW6udTcc2eZKchHZmbsF6Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD383msVOjsg%253D%253D&md5=2a397ed59d4b02cde55eb3253dc2cb13</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Flabinvest.3780461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Flabinvest.3780461%26sid%3Dliteratum%253Aachs%26aulast%3DTaguchi%26aufirst%3DT.%26aulast%3DSonobe%26aufirst%3DH.%26aulast%3DToyonaga%26aufirst%3DS.%26aulast%3DYamasaki%26aufirst%3DI.%26aulast%3DShuin%26aufirst%3DT.%26aulast%3DTakano%26aufirst%3DA.%26aulast%3DAraki%26aufirst%3DK.%26aulast%3DAkimaru%26aufirst%3DK.%26aulast%3DYuri%26aufirst%3DK.%26atitle%3DConventional%2520and%2520molecular%2520cytogenetic%2520characterization%2520of%2520a%2520new%2520human%2520cell%2520line%252C%2520GIST-T1%252C%2520established%2520from%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DLab.%2520Invest.%26date%3D2002%26volume%3D82%26spage%3D663%26epage%3D665%26doi%3D10.1038%2Flabinvest.3780461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Tuveson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willis, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacks, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span> </span><span class="NLM_article-title">STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5054</span><span class="NLM_x">–</span> <span class="NLM_lpage">5058</span><span class="refDoi"> DOI: 10.1038/sj.onc.1204704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1038%2Fsj.onc.1204704" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2001&pages=5054-5058&author=D.+A.+Tuvesonauthor=N.+A.+Willisauthor=T.+Jacksauthor=J.+D.+Griffinauthor=S.+Singerauthor=C.+D.+M.+Fletcherauthor=J.+A.+Fletcherauthor=G.+D.+Demetri&title=STI571+inactivation+of+the+gastrointestinal+stromal+tumor+c-KIT+oncoprotein%3A+biological+and+clinical+implications&doi=10.1038%2Fsj.onc.1204704"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1204704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1204704%26sid%3Dliteratum%253Aachs%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26aulast%3DWillis%26aufirst%3DN.%2BA.%26aulast%3DJacks%26aufirst%3DT.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%2BM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DSTI571%2520inactivation%2520of%2520the%2520gastrointestinal%2520stromal%2520tumor%2520c-KIT%2520oncoprotein%253A%2520biological%2520and%2520clinical%2520implications%26jtitle%3DOncogene%26date%3D2001%26volume%3D20%26spage%3D5054%26epage%3D5058%26doi%3D10.1038%2Fsj.onc.1204704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Falkenhorst, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grunewald, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muhlenberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marino-Enriquez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treckmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Podleska, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span> </span><span class="NLM_article-title">Inhibitor of apoptosis proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib</span> <span class="citation_source-journal">OncoTarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">41390</span><span class="NLM_x">–</span> <span class="NLM_lpage">41403</span><span class="refDoi"> DOI: 10.18632/oncotarget.9159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.18632%2Foncotarget.9159" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=41390-41403&author=J.+Falkenhorstauthor=S.+Grunewaldauthor=T.+Muhlenbergauthor=A.+Marino-Enriquezauthor=A.+C.+Reisauthor=C.+Corlessauthor=M.+Heinrichauthor=J.+Treckmannauthor=L.+E.+Podleskaauthor=M.+Schulerauthor=J.+A.+Fletcherauthor=S.+Bauer&title=Inhibitor+of+apoptosis+proteins+%28IAPs%29+are+commonly+dysregulated+in+GIST+and+can+be+pharmacologically+targeted+to+enhance+the+pro-apoptotic+activity+of+imatinib&doi=10.18632%2Foncotarget.9159"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.9159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.9159%26sid%3Dliteratum%253Aachs%26aulast%3DFalkenhorst%26aufirst%3DJ.%26aulast%3DGrunewald%26aufirst%3DS.%26aulast%3DMuhlenberg%26aufirst%3DT.%26aulast%3DMarino-Enriquez%26aufirst%3DA.%26aulast%3DReis%26aufirst%3DA.%2BC.%26aulast%3DCorless%26aufirst%3DC.%26aulast%3DHeinrich%26aufirst%3DM.%26aulast%3DTreckmann%26aufirst%3DJ.%26aulast%3DPodleska%26aufirst%3DL.%2BE.%26aulast%3DSchuler%26aufirst%3DM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DBauer%26aufirst%3DS.%26atitle%3DInhibitor%2520of%2520apoptosis%2520proteins%2520%2528IAPs%2529%2520are%2520commonly%2520dysregulated%2520in%2520GIST%2520and%2520can%2520be%2520pharmacologically%2520targeted%2520to%2520enhance%2520the%2520pro-apoptotic%2520activity%2520of%2520imatinib%26jtitle%3DOncoTarget%26date%3D2016%26volume%3D7%26spage%3D41390%26epage%3D41403%26doi%3D10.18632%2Foncotarget.9159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelias, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.+M.+Leliasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0ljfHi0h2Sfi9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DLelias%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Tong, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span> </span><span class="NLM_article-title">Establishment of platform for screening insulin-like growth factor-1 receptor inhibitors and evaluation of novel inhibitors</span> <span class="citation_source-journal">Acta Pharmacol. Sin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">930</span><span class="NLM_x">–</span> <span class="NLM_lpage">938</span><span class="refDoi"> DOI: 10.1038/aps.2011.23</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1038%2Faps.2011.23" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=930-938&author=L.+J.+Tongauthor=H.+Xieauthor=T.+Pengauthor=X.+F.+Liuauthor=X.+L.+Xinauthor=X.+Huangauthor=X.+M.+Chenauthor=H.+Y.+Liuauthor=H.+L.+Liauthor=M.+Y.+Gengauthor=M.+Yinauthor=J.+Ding&title=Establishment+of+platform+for+screening+insulin-like+growth+factor-1+receptor+inhibitors+and+evaluation+of+novel+inhibitors&doi=10.1038%2Faps.2011.23"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Faps.2011.23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2011.23%26sid%3Dliteratum%253Aachs%26aulast%3DTong%26aufirst%3DL.%2BJ.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DX.%2BF.%26aulast%3DXin%26aufirst%3DX.%2BL.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%2BM.%26aulast%3DLiu%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DH.%2BL.%26aulast%3DGeng%26aufirst%3DM.%2BY.%26aulast%3DYin%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26atitle%3DEstablishment%2520of%2520platform%2520for%2520screening%2520insulin-like%2520growth%2520factor-1%2520receptor%2520inhibitors%2520and%2520evaluation%2520of%2520novel%2520inhibitors%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2011%26volume%3D32%26spage%3D930%26epage%3D938%26doi%3D10.1038%2Faps.2011.23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Fischer, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeller, R.</span><span> </span><span class="NLM_article-title">Hematoxylin and eosin staining of tissue and cell sections</span> <span class="citation_source-journal">Cold Spring Harbor Protoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">4986</span><span class="refDoi"> DOI: 10.1101/pdb.prot4986</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;key=10.1101%2Fpdb.prot4986" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=4986&author=A.+H.+Fischerauthor=K.+A.+Jacobsonauthor=J.+Roseauthor=R.+Zeller&title=Hematoxylin+and+eosin+staining+of+tissue+and+cell+sections&doi=10.1101%2Fpdb.prot4986"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1101%2Fpdb.prot4986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fpdb.prot4986%26sid%3Dliteratum%253Aachs%26aulast%3DFischer%26aufirst%3DA.%2BH.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DRose%26aufirst%3DJ.%26aulast%3DZeller%26aufirst%3DR.%26atitle%3DHematoxylin%2520and%2520eosin%2520staining%2520of%2520tissue%2520and%2520cell%2520sections%26jtitle%3DCold%2520Spring%2520Harbor%2520Protoc.%26date%3D2008%26volume%3D3%26spage%3D4986%26doi%3D10.1101%2Fpdb.prot4986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i99"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00468">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_14324"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00468">10.1021/acs.jmedchem.7b00468</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">HPLC reports for the purity check of compounds <b>8</b>–<b>65</b>, details of the synthetic procedures and structural characterizations of intermediates <b>66</b>–<b>78</b>, KinomeScan selectivity profiling data of compound <b>31</b>, in vitro metabolic stability assay, and methods of the hERG inhibition assay (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00468/suppl_file/jm7b00468_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of compounds <b>8</b>–<b>65</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00468/suppl_file/jm7b00468_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00468/suppl_file/jm7b00468_si_001.pdf">jm7b00468_si_001.pdf (307.13 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00468/suppl_file/jm7b00468_si_002.csv">jm7b00468_si_002.csv (3.43 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00468&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-12%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00468%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00468" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                8MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67998cf95b3d3d48","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
